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Abstract 
Introduction and Aims 
Epilepsy is a neurological disorder and is a heterogeneous condition both in terms of cause 
and prognosis.  Prognostic factors identify patients at varying degrees of risk for specific 
outcomes which facilitates treatment choice and aids patient counselling. 
 
Few prognostic models based on prospective cohorts or randomised controlled trial data 
have been published in epilepsy.  Patients with epilepsy can be loosely categorised as 
having had a first seizure, being newly diagnosed with epilepsy, having established epilepsy 
or frequent unremitting seizures despite optimum treatment.  This thesis concerns 
modelling prognostic factors for these patient groups, for outcomes including seizure 
recurrence, seizure remission and treatment failure. 
Methods 
Methods for modelling prognostic factors are discussed and applied to several examples 
including eligibility to drive following a first seizure and following withdrawal of treatment 
after a period of remission from seizures.  Internal and external model validation 
techniques are reviewed.  The latter is investigated further in a simulation study, the results 
of which are demonstrated in a motivating example.  Mixture modelling is introduced and 
assessed to better predict whether a patient would achieve remission from seizures 
immediately, at a later time point, or whether they may never achieve remission. 
Results 
Multivariable models identified a number of significant factors.  Future risk of a seizure was 
therefore obtained for various patient subgroups.  The models identified that the chance of 
a second seizure was below the risk threshold for driving, set by the DVLA, after six months, 
and the risk of a seizure following treatment withdrawal after a period of remission from 
seizures was below the risk threshold after three months.  
 
Selected models were found to be internally valid and the simulation study indicated that 
concordance and a variety of imputation methods for handling covariates missing from the 
validation dataset were useful approaches for external validation of prognostic models.  
Assessing these methods for a selected model indicated that the model was valid in 
independent datasets.  Mixture modelling techniques begin to show an improved 
prognostic model for the frequently reported outcome time to 12-month remission.   
Conclusions 
The models described within this thesis can be used to predict outcome for patients with 
first seizures or epilepsy aiding individual patient risk stratification and the design and 
analysis of future epilepsy trials.  Prognostic models are not commonly externally validated.  
A method of external validation in the presence of a missing covariate has been proposed 
and may facilitate validation of prognostic models making the evidence base more 
transparent and reliable and instil confidence in any significant findings. 
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Chapter 1: Introduction to 
Prognostic Factor Studies  
1.1 Introduction to Prognostic Factors for Epilepsy 
Epilepsy is a common neurological condition, with an estimated incidence of 50 per 
100,000 and prevalence of 5 to 10 per 1000 in the developed world. Between two and 
three percent of the population will be given a diagnosis of epilepsy at some time in their 
lives, the majority of whom will go into remission. However, up to 30% of those with 
epilepsy will fail to respond to monotherapy with standard antiepileptic drugs. 
Prognostic factors are defined as demographic, disease-specific, or co-morbid 
characteristics associated strongly enough with a condition's outcome to predict accurately 
the eventual development of those outcomes.   Prognostic factors can help to identify 
patients at different degrees of risk for specific outcomes, facilitate treatment choice and 
aid patient counselling.  Few prognostic models based on randomised controlled trial data 
or prospective cohorts have been published in epilepsy.   
Patients with epilepsy can be loosely categorised as having had a first seizure, being newly 
diagnosed with epilepsy – defined as at least two clinically unprovoked seizures, having 
established epilepsy, or frequent unremitting seizures despite optimum treatment.  
Prognostic models for time to treatment failure and time to 12 month remission for newly 
diagnosed patients are developed in Chapter 4.  In Chapter 5 a prognostic model for risk of 
seizure recurrence following a first ever seizure is developed and in Chapter 6 prognostic 
models are developed for risk of recurrence for patients who withdraw treatment following 
a period of remission and for patients who reinstate treatment following seizure 
recurrence after a period of remission.  The models in Chapter 5 and 6 are particularly 
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focussed on people with epilepsy who drive as the models influence the driving regulations 
regarding time off driving following a seizure or treatment withdrawal.  
Before prognostic models can be accepted into general practice they need to be validated.  
Internal validation – assessment of model validity for the setting where the development 
data originated from – is examined in Chapter 7 for the models developed in Chapter 4.  
External validation – assessment of model validity in other samples which are fully 
independent from the development data – is examined via a literature review and 
simulation study in Chapter 8, the results of which are applied to external validation of the 
model from Chapter 5 in Chapter 9. 
The internal validity of the model for remission in Chapter 4 is found to be poor at one 
year.  This may relate to the heterogeneity of outcome for epilepsy – some patients achieve 
remission immediately at 12 months while others may never achieve remission.  Therefore, 
it may be more appropriate to model the three distinct patient subgroups in one overall 
model for time to 12 month remission via a three-component mixture model.  This is the 
content of Chapter 10 which precedes an overview of the entire thesis together with 
suggestions for future research and clinical practice (Chapter 11). 
This chapter continues with a summary of prognostic factors studies including approaches 
to studying prognostic factors in section 1.3.1 and possible improvements that could be 
made to future prognostic factor studies (section 1.3.2).  This is followed by an overview of 
methods for modelling survival data including parametric methods, such as the accelerated 
failure time model (section 1.4.2.2) and the Cox proportional hazards model (section 
1.4.2.3), and nonparametric methods like neural networks (section 1.4.3.1) and hierarchical 
trees (section 1.4.3.2).  The chapter concludes with an overview of the thesis including a 
detailed summary of each chapter (section 1.5).  
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1.2 Introduction to Prognostic Factor Studies 
Prognostic factors are defined as demographic, disease-specific, or co-morbid 
characteristics associated strongly enough with a condition's outcome to predict accurately 
the eventual development of those outcomes [1].   Prognostic factors can help to identify 
patients at different degrees of risk for specific outcomes, facilitate treatment choice and 
aid patient counselling.  
When individual prospects for survival, or indeed any outcome, are highly variable, it is 
natural to look for possible explanations.  Knowledge of prognostic variables can aid in the 
understanding of a disease [2-4] and may lead to variation in treatment according to a 
patients’ predicted probability of survival [5-7].  Prognostic factor studies are described in 
section 1.3. 
In the medical literature, much emphasis has traditionally been given to the identification 
of predictors.  As of January 2007, over 60,000 papers had been published with the term 
“predictor” or “prognostic factor” [8].   Statistical models for prediction can be discerned 
into main classes: regression, classification, and neural networks.  These models are 
discussed in section 1.4. 
1.3 Prognostic Factor Studies 
The purpose of prognostic factor studies is to improve understanding of the disease 
process, improve the design and analysis of clinical trials and define risk groups based on 
prognosis.  In addition, prognostic factor studies can assist in comparing outcomes 
between treatment groups in non-randomised studies by allowing adjustment for case mix, 
predicting disease outcomes more accurately or parsimoniously and guiding clinical 
decision making, including treatment selection and patient counselling [9, 10].  
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When conducting and reporting prognostic factor studies, researchers should consider the 
approach to prognosis, explanatory or outcome prediction, and phase of investigation [11].  
Readers of health care research will then be better able to evaluate the goals and interpret, 
and appropriately use, the results of prognostic factor studies. 
Windeler observed that summaries of prognosis are not meaningful unless associated with 
a particular strategy for treatment and suggested that the greatest importance of 
prognostic factor studies is to aid decisions about treatment [12].  If the treatment received 
varies in relation to prognostic variables, then the study cannot deliver an unbiased and 
meaningful assessment of prognostic ability, unless the different treatments are equally 
effective - in which case, why vary the treatments?  Such variation in treatment may be 
quite common once there is evidence, usually non-systematic, that a variable is prognostic.  
Ideally therefore, prognostic variables should be evaluated either in a cohort of patients 
treated the same way or in a randomised trial [13, 14].   
Case-control and cross sectional studies may both be used to examine risk factors but these 
designs are much weaker [10].  This is because cross sectional studies are primarily used to 
determine prevalence and are also used to infer causation.  They do not provide an 
explanation for their findings.  Case-control studies determine the relative importance of a 
predictor variable in relation to the presence or absence of the disease.  They are 
retrospective and cannot therefore be used to calculate the relative risk.  The major 
problem with case-control studies are the familiar ones of confounding variables and bias.  
Case-control designs have, however, been shown to yield optimistic results for evaluations 
of diagnostic tests, a result that is likely to be relevant to prognostic studies [15].  This is 
because often, mild cases that are difficult to diagnose are omitted from case-control 
studies, causing an overestimation of sensitivity as well as specificity.  Also, diagnostic 
accuracy can be overestimated if the test is evaluated in a group of patients already known 
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to have the disease and a separate group of normal patients, rather than in a relevant 
clinical population [16].  This is obviously the scenario for a case-control study.  
1.3.1 Approaches to Prognostic Factor Studies 
Two approaches to prognostic factor studies have been identified by Hayden - explanatory 
analysis and outcome prediction [11].  Explanatory studies focus on the causal association 
between prognostic factors and an outcome, whereas outcome prediction studies focus on 
variables taken together to identify the combination of factors that is most strongly 
associated with outcome and can be used to stratify patients on an outcome, often to 
triage them into treatment programs. 
Altman and Lyman have also developed criteria for the design of a prognostic factor study 
[9].  According to this, primary and secondary hypotheses should be clearly stated, 
including any subgroup analyses planned in advance of the study.  Prognostic factors for 
which there is sufficient evidence to warrant further investigation based on previous 
studies, biological and clinical plausibility and relevance, and importance to the 
understanding or treatment of the disease should also be considered.   
Additionally, Altman and Lyman suggest that the study population should be defined with 
specific inclusion and exclusion criteria and methods to judge evaluability [9].  Patient 
treatment should be either standardised or assigned by randomisation and assays should 
be reproducible and be performed with knowledge of the clinical data and patient 
outcome.  The planned analysis, including proposed hypothesis testing on subgroups and 
anticipated interaction in advance of the study should also be specified as well as the key 
study features including the above information which should be fully detailed in a formal 
written protocol. 
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To develop an alternative framework for understanding prognosis, Hayden [11] adapted 
the work of Altman and Lyman [9] and integrated the discussion of causal understanding 
published by Goldthorpe [17].  She identified three phases of explanatory prognosis 
investigation.  The purpose of each phase can be described as exploration, confirmation 
[18], and development of understanding respectively.  To support all three phases, 
additional information can be obtained from clinical observations, basic science, descriptive 
studies, and other sources that may support the evidence on prognosis. 
Phase 1 studies identify associations between a number of potential prognostic factors and 
a health outcome and are the most common phase of prognostic investigation [11].  
Although this type of investigation is necessary to identify new factors, it provides the least 
conclusive information regarding the independence of a variable as a valid prognostic 
factor.  Phase 1 studies provide hypothesis-generating evidence indicative of a potential 
association between a prognostic factor and an outcome.  They are often recognisable by 
their objective statements that present broad exploratory aims.  Phase 1 studies do not 
focus on one specific prognostic factor rather the prognostic factor of interest is 
investigated as one of many factors assessed for their association with the outcome.  For 
this reason, most Phase 1 studies only discuss the findings for factors that are found to be 
statistically significant, regardless of clinical significance. 
Phase 1 investigations are appropriate when it is unclear which variables are important in 
predicting an outcome for a population [11].  However, it should be recognised that results 
from multiple studies in this exploratory phase of investigation often have widely varying 
results as spurious associations are common, and real effects are sometimes missed [9].  
Also, some associations are present in one population but not in another.  Further testing 
in a Phase 2 confirmatory investigation is required to confirm the results of a Phase 1 study. 
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Phase 2 studies test the independence of the association between a prognostic factor and 
the outcome of interest.  These studies aim to measure the independent effect of a 
prognostic factor while controlling for confounders [11].  Typical Phase 2 studies are 
recognisable by their objective statements that outline a specific prognostic factor of 
interest and aim to investigate the relationship between this variable and the outcome.  In 
Phase 2 studies, the importance shifts to assessing whether the factor independently adds 
to currently known prognostic factors. 
For a specific prognostic factor, the finding of a significant association in a study testing an 
independent association is a stronger finding than an association identified in the previous 
phase of investigation [11].  However, both Phase 1 and 2 studies are based on the often 
unrealistic assumption that the effect of the prognostic factor on the outcome is direct and 
isolated.  This may be inadequate to describe complex relationships for most conditions, 
and where the impact of factors may change over time. 
Phase 3 studies of prognosis attempt to describe the complexity of the prognostic 
pathways or processes.  These studies apply knowledge from the previous phases of study 
on independent associations and incorporate other knowledge from the field of study [11].  
Phase 3 explanatory studies start with an explicit theoretical framework that includes the 
prognostic construct of interest, variables that are thought to influence or modify the effect 
of that factor, variables that are thought to be intermediate or a mediator in the pathway 
toward the outcome, potential confounding variables, and the outcome of interest.  Phase 
3 explanatory studies provide evidence supportive of the mechanism or mechanisms of 
action of a prognostic factor on the outcome.  However, the strength of interpretation of 
Phase 3 explanatory studies depends on the strength of the theoretical framework and the 
extent to which existing knowledge about the disease or illness supports the study [11]. 
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Table 1 provides a summary of the phases of an exploratory prognostic factor investigation 
[11]. 
Table 1: Phases of an Exploratory Prognostic Factor Investigation 
Phase of 
Investigation 
Issue addressed for prognostic factor 
of interest
 
Interpretation of results for 
prognostic factor of interest 
Phase 1: 
Exploration of 
associations 
Measures the presence of a 
prognostic relationship between 
factor(s) and the outcome 
Provides hypothesis-generating 
evidence indicative of a potential 
association between a prognostic 
factor and outcome 
Phase 2: 
Testing independent 
associations 
Measures the strength of the 
prognostic relationship between a 
factor and the outcome while 
controlling for alternative 
explanations 
Provides evidence supportive of the 
independent effect of a prognostic 
factor 
Phase 3: 
Understanding and 
testing prognostic 
pathways 
Examines the role of the prognostic 
factor and the process by which it 
impacts the outcome 
Provides evidence supportive of the 
prognostic factor’s mechanism(s) of 
action on the outcome 
 
This framework differs from that of Altman and Lyman [9] in two ways.  Firstly, the two 
approaches of prognosis studies were distinguished between.  Secondly, cross-sectional 
studies were not included under the umbrella of prognosis which Altman and Lyman [9] 
described as “hypothesis generating” studies.  These studies provide information that may 
lead to testing in longitudinal studies.  However, without a longitudinal component they do 
not provide information on predictors of outcome over time [11]. 
Hayden has identified three specific areas where consideration of a framework of 
explanatory prognosis studies is important: defining the study objectives, presenting the 
study methods and data, and interpreting and applying the results of the study [11].  In 
terms of defining study objectives, investigators need to clearly identify the purpose of 
their study, to specify how their study will be used to improve health and health care, and 
to outline how their study will add to the existing knowledge in the area.  This means they 
must decide what approach, explanatory or outcome prediction, and what phase of 
investigation, is needed to advance the knowledge on a specific topic.  The extent of the 
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previous evidence, from prognosis research and other sources of information, will inform 
the study objectives about the phase of investigation [11].  A systematic and thoughtful 
review of literature is commonly required before funding for new randomised controlled 
trials is received, and is equally appropriate before planning and conducting new prognosis 
studies. 
The study design should follow directly from the prognosis study objectives.  For Phase 2 
and 3 explanatory studies, a clear presentation and rationale should be given to explain 
which confounders will be adjusted for in the analysis and why [19].  Study reports should 
give a clear and thoughtful presentation of what the current study adds to the available 
literature, the limitations of the research, and recommendations for future research.  Phase 
1 studies provide exploratory evidence regarding potential prognostic factors.  Further 
study, in the form of a Phase 2 study, would be needed to confirm the independent 
predictive effect of that factor while thoughtful planning and investigation of the 
prognostic pathway in a Phase 3 study is required to further understand how the 
prognostic factor affects the outcome.   
Interpretation of evidence from Phase 1 or 2 studies, without understanding a potential 
prognostic factor’s causal pathway may lead to inappropriate or harmful treatment 
recommendations or policy decisions.  A review, Phase 2, by Goldman [20] stated that 
studies had consistently shown that older patients had a higher risk of cardiac 
complications and in most studies age had been an independent predictive factor even 
after controlling for the severity of cardiac disease and combined conditions.   Two recent 
studies, Phase 3, of elderly patients suggested that such prevailing attitudes may lead to 
under-treatment or even inappropriate treatment of the elderly.  Maly [21] found a 
negative association between age and discussion of treatment options including surgery for 
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breast cancer by physicians while Ellis [22] advocated an aggressive surgical approach in 
elderly patients for cancer of the oesophagus and cardia. 
Interventions that are planned based on an understanding of how factors influence 
outcome, differences over time, dosage differences, or different contextual settings will 
allow optimisation of patient management.  For example, in patients with laryngeal 
carcinoma, breast carcinoma and carcinoma of the bladder, prognostic factors are used to 
select patients who are good candidates for organ preservation [23]. 
The explanatory framework presented can assist clinicians in their interpretation of the 
prognosis literature.  Researchers can also use the framework to plan innovative research 
programs based on theoretical models of prognostic pathways. 
1.3.2 Improvements to Prognostic Factor Studies 
The recently proposed REMARK consensus [24] is a step forward for the standardisation of 
the reporting of cancer prognostic marker studies.  No such guidelines currently exist for 
prognostic factor studies.   In general, authors should avoid highlighting only the significant 
associations and they should try to present, or at least alert readers to, all covariates that 
they considered a priori versus post hoc.  Additionally, journals should encourage the 
publication of well designed, executed and reported prognostic factor studies, regardless of 
the significant or non-significant findings.   
The development of collaborations and networks between investigators may be beneficial, 
if such networks focus also on minimising selective reporting and publication bias [25, 26].  
Transparency and public availability of protocols, data, analyses and results would also be 
helpful [25-27].  Funding groups should also realise that investigators should not be 
supported primarily for their ability to produce statistically significant results, but they 
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should reward novel ideas, rigorous design, implementation and transparent reporting of 
results, regardless of their statistical significance.   
1.4 Modelling Survival Data 
1.4.1 Introduction 
When the length of time taken for an event to occur is measured, the resulting data are 
known as time-to-event, or survival, data.  Often the event is death, hence the name of the 
method - survival analysis where the term survival usually means remaining event free.  In 
the medical setting the event might be discharge from hospital, weaning of a breast-fed 
infant, recurrence of tumour or remission from a disease and the time starting point might 
be time of diagnosis, time of surgery or time of entrance into the study. 
One problem with time-to-event data is that the event is often not observed on all 
subjects.  This might be because a person dropped out due to death or some other reason, 
or maybe the study ended before the event had occurred for an individual.  Although it is 
not known whether the event will happen, duration of follow-up for a person without the 
event being observed is known.  Individuals for whom the event is not observed are called 
censored.  Methods of analysis must be able to cope with censored values.   
Often a number of variables are observed at the commencement of a trial, and survival is 
related to the values of these variables; that is, the variables are prognostic.  Methods of 
analysis must be able to take account of the distribution of prognostic variables in the 
groups under study.  There are many ways to analyse time-to-event data, the most popular 
of which is the Cox proportional hazards model.  Alternatives include parametric methods, 
such as the accelerated failure time model, hierarchical trees and neural networks. 
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1.4.2 Parametric Methods 
A possible approach to the analysis of studies with survival time as the variable of interest 
is to postulate a distribution for survival time and to estimate the parameters of this 
distribution from the data.  This approach is usually applied by starting with a model for the 
death rate and determining the form of the resulting survival time distribution. 
The death rate will usually vary with time since entry to the study,  , and will be denoted 
    , referred to as the hazard function.  Suppose the probability density of survival time is 
     and the corresponding distribution function is     .  Then, since death rate is the rate 
at which deaths occur divided by the proportion of the population surviving, 
Equation 1 
     
    
      
 
    
    
 
where             is the proportion surviving and is referred to as the survivor 
function.  Therefore      and      can be specified in terms of      and the general 
solution is obtained by integrating Equation 1 with respect to   and noting that      is the 
derivative of     .  
In general, the hazard will depend on time and a family of models and may be written as  
Equation 2 
                 
    
where     is the matrix representation of the regression function             and 
      is the time-dependent part of the model [28].  The term       could represent any 
parametric function of   such as the exponential, Weibull or Gompertz.   
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Equation 2 is a regression model in terms of the covariates and is also referred to as a 
proportional hazards model since the hazards for different sets of covariates remain in the 
same proportion for all  .  Data can be analysed parametrically using Equation 2 provided 
that some particular form of       is assumed.  The parameters of       and also the 
regression coefficients, , would be estimated. 
1.4.2.1 Parametric Models 
1.4.2.1.1 Exponential 
The simplest model for the hazard function is to assume that it is constant over time.  The 
hazard of death at any time after the time origin of the study is then the same, irrespective 
of the time elapsed.  Under this model the hazard function may be written as        for 
     .  Thus, the corresponding survivor function is               and so the 
implied probability density function of the survival times is                for 
     .   
The exponential model is investigated in Chapter 10.  It is examined for its suitability to 
model time to 12 month remission for patients in The SANAD Trial (Chapter 4) who achieve 
remission but not immediately at 365 days. 
1.4.2.1.2 Weibull 
In practice, the assumption of a constant hazard function, or equivalently of exponentially 
distributed survival times, is rarely tenable.  A more general form of hazard function is such 
that               for      , a function that depends on two parameters   and  , 
which are both greater than zero.  In the particular case that    , the hazard function 
takes a constant value  , and the survival times have an exponential distribution.  For other 
values of  , the hazard function increases, for    , or decreases, for    , 
monotonically.  The shape of the hazard function depends on the value of   so   is known 
as the shape parameter while the parameter   is a scale parameter. 
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For this choice of hazard function, the survival function is given by               .  The 
corresponding probability density function is then                      for 
     . 
The Weibull model is investigated in Chapter 10.  It is examined for its suitability to model 
time to 12 month remission for patients in The SANAD Trial (Chapter 4) who achieve 
remission but not immediately at 365 days. 
1.4.2.1.3 Log-logistic 
One limitation of the Weibull hazard function is that it is a monotonic function of time.  
However, situations in which the hazard function changes direction can arise.  For example, 
following a heart transplantation, a patient faces an increasing hazard of death over the 
first ten days after transplant while the body adapts to the new organ.  The hazard then 
decreases with time as the patient recovers.  In situations such as this, a unimodal hazard 
function may be appropriate. 
A particular form of unimodal hazard is the function 
     
       
      
, 
for          .  This hazard function decreases monotonically if    , but if    , 
the hazard has a single mode.  The survivor function corresponding to the hazard function 
is given by 
             
  
, 
and the probability density function is 
     
       
        
 . 
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This is the density of a random variable   that has a log-logistic distribution with 
parameters   and  .  The distribution is so called because the variable      has a logistic 
distribution, a symmetric distribution whose probability density function is very similar to 
that of the normal distribution. 
The log-logistic model is investigated in Chapter 10.  It is examined for its suitability to 
model time to 12 month remission for patients in The SANAD Trial (Chapter 4) who achieve 
remission but not immediately at 365 days. 
1.4.2.1.4 Gompertz 
Although the Weibull model is the most widely used parametric model, the Gompertz has 
found application in demography and biological sciences.  Indeed the distribution was 
introduced by Gompertz in 1825 as a model for human mortality [29]. 
The hazard function of the Gompertz distribution is given by               for 
      and    .  In the particular case where    , the hazard function has a 
constant value   and the survival times then have an exponential distribution.  The 
parameter   determines the shape of the hazard function, positive values leading to a 
hazard function that increases with time.  Like the Weibull hazard function, the Gompertz 
hazard increases or decreases monotonically. 
The survivor function of the Gompertz distribution is given by          
 
 
            
and the corresponding density function is                  
 
 
           . 
The Gompertz distribution is included for completeness only.  It is not used within this 
thesis. 
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1.4.2.2 Accelerated Failure Time 
Another way of representing the effect of the covariates is to suppose that the distribution 
of survival time is changed by multiplying the time-scale by       
   , that is, that the 
logarithm of survival time is increased by   
  .  The effect of a predictor is to alter the rate 
at which a subject proceeds along the time axis (i.e. to accelerate the time to failure [30]).   
The hazard can then be written 
Equation 3 
                  
           
     
This is referred to as an accelerated failure time model.  For the exponential distribution, 
       , Equation 2 and Equation 3 are equivalent, with      , so the accelerated 
failure time model is also a proportional hazards model.  The same is true for the Weibull 
and Gompertz but in general the accelerated failure time model would not be a 
proportional hazards model [28]. 
The accelerated failure time model would have been used in Chapters 4, 5 and 6 if the 
proportional hazards assumption of the Cox model was found not to be valid for any of the 
developed prognostic models.  In this case the results would be compared to those from 
the accelerated failure time model to determine if the violation of the assumption affected 
the conclusion.  The developed models all satisfied the proportional hazards assumption so 
the accelerated failure time model was not required. 
1.4.2.3 Cox Proportional Hazards 
Since often an appropriate parametric form of       is unknown and, in any case, not of 
primary interest, it would be more convenient if it were unnecessary to substitute any 
particular form for       in Equation 2.  This was the approach introduced by Cox [31].  The 
model is then non-parametric with respect to time but parametric in terms of the 
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covariates.  Estimation of   and inferences are developed by considering the information 
supplied at each time that a death occurred. 
Consider a death occurring at time    and suppose that there were   
  subjects alive just 
before   , that the values of   for these subjects are         
  and that the subject that 
died is denoted, with no loss of generality, by the subscript 1.  The set of   
  subjects at risk 
is referred to as the risk set.  The risk of death at time    for each subject in the risk set is 
given by Equation 2.   
This does not supply absolute measures of risk but does supply the relative risks for each 
subject since, although       is unknown, it is the same for each subject [28].  Thus, the 
probability that the death observed at    was of the subject who did die at that time is 
   
         
          
 
where summation is over all members of the risk set.  Similar terms are derived for each 
time that a death occurred and are combined to form a likelihood. 
The Cox regression or proportional hazards model [31, 32] is the standard statistical tool 
used to analyse multiple prognostic factors.  The risk function for a patient with values 
             of the prognostic factors can be written as                 
                           where        denotes the hazard function of the 
event-free or overall survival time random variable   and       is the baseline hazard 
function representing the instantaneous risk of dying at time   given survival up to time   
for a patient with             .  Since this model can be re-expressed in the 
form     
     
     
               , the proportional hazards model may also be 
regarded as a linear model for the logarithm of the hazard ratio.  The estimated log-hazard 
ratios     can then be interpreted as estimated effects of the factors             .   
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If    is measured on a quantitative scale then           represents the increase or decrease 
in risk if    is increased by one unit.  If    is a binary covariate then           is the hazard 
ratio of the alternative category to the baseline category, which is assumed to be constant 
over the time range considered. 
Although the Cox model is non-parametric to the extent that no assumptions are made 
about the form of the baseline hazard, there are still a number of important assumptions 
that need to be assessed after a model has been fitted to an observed set of survival data.  
The first such assumption is non-informative censoring.  To satisfy this assumption the 
design of the underlying study must ensure that the mechanisms giving rise to censoring of 
individual subjects are not related to the probability of an event occurring.  For example, in 
clinical studies, care must be taken that continuation of follow-up does not depend on a 
participants’ medical condition.   
The second assumption of the Cox model is that of proportional hazards.  In a regression 
setting this means that the survival curves for two strata, determined by the particular 
choices of values for the variables, must have hazard functions that are proportional over 
time, i.e. constant relative hazard.  There are tests that can be applied to test 
proportionality. 
The Cox proportional hazard model is used in Chapters 4, 5, 6, 8, 9 and 10 to model time to 
event for various outcomes and various types of patients. 
1.4.3 Nonparametric Methods 
The nonparametric methods described in sections 1.4.3.1 and 1.4.3.2 are included for 
completeness only and are not used within this thesis. 
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1.4.3.1 Neural Networks 
Faraggi and Simon [33], and others [34-37], have proposed a neural network generalisation 
of the Cox regression model defined by                                    where 
                        
 
    
 
    and            are the values of the   
prognostic factors.   The weights                       can be estimated from the 
data via maximisation of the partial likelihood although other optimisation procedures are 
often used.  Although the problem of censoring is satisfactorily solved in this approach, 
there remain problems with potentially serious over-fitting of the data, especially if the 
number,  , of hidden units is large [38]. 
In general, feed-forward neural networks with one hidden layer are universal 
approximators [39] and can consequently approximate any function defined by the 
conditional probability that   is equal to one given   with arbitrary precision by increasing 
the number of hidden units.  This flexibility can however lead to serious over-fitting.  This 
can be compensated for by introducing some weight decay [40, 41], for example by adding 
a penalty term       
  
         
  
   
 
     to the log-likelihood [38].  The smoothness 
of the resulting function is then controlled by the decay parameter  . 
Another form of neural networks that have been applied to survival data are the so-called 
single time point models [42].  As they are identical to a logistic perceptron, otherwise 
known as a common logistic regression model, or a feed-forward neural network with a 
hidden layer, they correspond to fits of logistic regression models or their generalisations 
to survival data.  In practice, a single time point    is fixed and the network is trained to 
predict the survival probability.  The corresponding model is given by           
          
 
    , or its generalisation when introducing a hidden layer, where      
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denotes the logistic function,                   , and is called the activation 
function [43]. 
A common drawback of these naïve approaches is that they do not enable incorporation of 
censored observations in a straightforward manner, which is closely related to the fact that 
they are based on unconditional survival probabilities instead of conditional survival 
probabilities.  Neither omission of the censored observations, as suggested by Burke [44], 
nor treating censored observations as uncensored [43] are valid approaches but both 
instead are a serious source of bias.  De Laurentiis and Ravdin [42] and Ripley [41] propose 
to impute estimated conditional survival probabilities for the censored cases from a Cox 
regression model.  Further work is needed in this area. 
1.4.3.2 Hierarchical Trees 
Hierarchical trees are an approach for nonparametric modelling of the relationship 
between a response variable and several potential prognostic factors [45-49].  The idea of 
Classification And Regression Trees (CART), a synonym for different types of tree based 
analyses, is to construct subgroups that are internally as homogeneous as possible with 
regard to the outcome and externally as separated as possible.  Hence the method leads 
directly to prognostic subgroups defined by the potential prognostic factors and is achieved 
by a recursive tree building algorithm. 
The tree building algorithm produces a binary tree with a set of patients, a splitting rule, 
and the minimal   value, at each interior node.  For patients in the resulting final nodes, 
various statistics can be computed such as Kaplan-Meier estimates of event-free survival or 
hazard ratios with respect to specific references or combined groups. 
Unfortunately prognostic factors are usually measured on different scales meaning the 
number of possible partitions will be different [38].  Correction of   values and/or 
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restriction to a set of pre-specified cutpoints may be useful to overcome the problem that 
factors allowing more splits have a higher chance of being selected by the tree building 
algorithm.  Due to multiple testing, the algorithm may also be biased in favour of these 
factors over binary factors with prognostic relevance [38]. 
To improve the predictive ability of trees, stabilising methods based on resampling have 
been proposed [50-54].  However, the results are difficult to interpret which reduces their 
value for practical applications.   
1.4.4 Comparison of Methods 
Although traditional statistical methods such as Cox proportional hazards or logistic 
regression are easy to perform and routinely available in standard software packages, 
machine learning methods such as hierarchical trees and neural networks are thought to 
predict more accurately because of greater model-fitting flexibility [55]. 
Artificial neural networks are popularly used as universal non-linear inference models.  
However, they suffer from two major drawbacks.  The way they work is hidden because of 
the distributed nature of the representations they form [56], and this makes it difficult to 
interpret what they do.  Worse still, there are no clearly accepted models of generality 
which makes it difficult to demonstrate reliability when applied to future data. 
Cox proportional hazards models are well suited for regression modelling of survival data.  
They are simple to fit, can deal with time-varying regression coefficients as well as time-
dependent covariates and no assumption is made on the distribution of the lifetimes of the 
baseline population.  However, they are not flexible enough to deal with time-varying 
dynamics of covariate effects [57].  Additionally, the Cox model has the advantage over 
neural networks of providing some insight into which variables are most influential for 
 
 
22 
 
prognosis.  Nevertheless, it is likely that the assumptions required by the Cox model may 
not be satisfied in all datasets, justifying the use of neural networks in certain cases. 
Parametric regression models, such as the exponential, Weibull and Gompertz, may involve 
stronger distributional assumptions than it is suitable to make and inference procedures 
may not be sufficiently robust to departures from these assumptions [30].  This seems 
particularly to be the case in medical applications in which only limited experimentation in 
similar situations may have preceded the study in question or in which data are recorded 
by a number of individuals.  Parametric models are also less flexible than proportional 
hazard models [38].   
Although rank tests, encompassing accelerated failure time models, are derived with 
certain alternatives in mind for which optimum parametric procedures exist, they generally 
possess greater robustness than the corresponding parametric tests and are generally less 
sensitive to outliers [30].  In addition, for testing the null hypothesis, these tests generally 
involve only a small loss in efficiency compared to the parametric procedure when such a 
procedure is appropriate.  Unfortunately though, accelerated failure time models are 
difficult to extend to handle time-varying effects. 
1.5 Thesis Outline 
This chapter has considered prognostic factors studies and statistical models for prediction.  
The thesis continues with chapters on epilepsy, methods for identifying prognostic factors 
for epilepsy, prognostic modelling of time to treatment failure and time to 12 month 
remission for newly diagnosed patients, prognostic modelling of risk of recurrence for 
patients with a first seizure only, prognostic modelling of risk of recurrence for patient who 
withdraw their medication, validation methods for prognostic models and more 
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sophisticated mixture modelling methods.  Further descriptions of each chapter can be 
found in sections 1.5.1 to 1.5.10. 
1.5.1 Introduction to Epilepsy 
In Chapter 2, the condition of epilepsy will be summarised including descriptions of seizure 
types, such as simple partial seizures and absence seizures, and classifications, such as focal 
epilepsy or generalised epilepsy.  Methods of identification and diagnosis such as 
electroencephalogram (EEG) and magnetic resonance imaging (MRI) will also be outlined 
together with potential treatments including resective surgery, antiepileptic drug 
treatment and the ketogenic diet.   
The chapter will conclude with a literature review of prognostic factors studies in epilepsy 
which will highlight the dearth of such studies and provide justification for further research 
in this area.  The clinical background of epilepsy, described in this chapter, will inform the 
terminology and medical concepts used throughout my thesis (Chapters 4 to 11). 
1.5.2 Methods for Identifying Prognostic Factors for Epilepsy 
Chapter 3 will focus on generic methods of modelling prognostic factors.  Concepts such as 
handling continuous predictors by splines or fractional polynomial transformations will be 
considered as well as whether variable centring is appropriate, and if so, how it should be 
done.  Following on from this, model building and development will be considered 
including variable selection via sequential or all-subset strategies.  Methods for testing the 
proportional hazards assumption, required for the Cox model to be valid, will be outlined 
with particular interest in residuals.  Finally, a description of the use of competing risks 
analysis will be provided as such an analysis is required if patients can fail treatment for 
multiple reasons.  The chapter concludes with a section describing the chosen methods of 
analysis used in Chapters 4, 5 and 6. 
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1.5.3 Identifying Prognostic Factors for Epilepsy 
The work in Chapter 4 has been published in Lancet Neurology and I am first author.   
Using data from arm A of The SANAD Trial, multivariable models are produced for time to 
treatment failure, both overall and in the competing risks setting, and for time to 12 
months of remission.  In addition to presenting the models, risk estimates are calculated for 
various combinations of risk factors.  To aid the interpretation of these risk estimates by 
non-statisticians, forest-style plots are used to illustrate the heterogeneity of outcome for 
differing patient groups.   
Validation of these models is required and is the subject of subsequent chapters.  Internal 
validation is undertaken in Chapter 7 while the concept of external validation is examined 
in Chapter 8.  
1.5.4 Implications for Drivers with a First Seizure 
The work in Chapter 5 has been published in the British Medical Journal, together with an 
editorial, and I am again first author.   
Using data from the Multicentre study of Early epilepsy and Single Seizures (MESS), a 
prognostic model for the risk of a second seizure following a first ever seizure is developed.  
In an extension to the model, the time until the recurrence risk is below 20% is calculated 
for various combinations of risk factors to determine how long people with a first seizure 
should refrain from driving before their risk of a second seizure falls before the 
recommended risk level set by the U.K. based Driving and Vehicle Licensing Agency (DVLA). 
As a result of this work, the DVLA changed their guidelines concerning time off driving for 
patients with a first seizure. 
This model again needs to be validated.  External validation of this model is performed in 
Chapter 9. 
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1.5.5 Implications for Drivers who withdraw AED Treatment 
The work in Chapter 6 has been published in the Journal of Neurology, Neurosurgery and 
Psychiatry, and I am again first author. 
Using data from the Medical Research Council Antiepileptic Drug Withdrawal Study (MRC 
AEDWS) two prognostic models are developed.  The first considers time to seizure 
recurrence following treatment withdrawal while the second considers time to seizure 
recurrence following treatment reinstatement after seizure recurrence for patients 
withdrawing their antiepileptic drug medication.  In addition to the modelling presented, a 
literature review is described which identified three studies that provide additional 
information on risk of seizure recurrence following treatment withdrawal for patients in 
remission from seizures. 
1.5.6 Internal Validation of Prognostic Models 
Internal validation is necessary to assess the ability of models to predict outcome in 
settings where the development data originated from.  Methods of assessing model 
performance are outlined in Chapter 7, such as the    measure, together with methods of 
discrimination, via use of the  -statistic, and calibration, via plots.  Methods of internal 
validation are also considered including bootstrap resampling. 
The models derived in Chapter 4 using The SANAD Trial for time to treatment failure and 
time to 12 months of remission are validated internally in Chapter 7.  Both models show 
fairly good internal validity although there are signs of poor validity at one year for the 
remission model.  Reasons for this poor validity, together with an alternative way of 
modelling time to 12 month remission for patients with epilepsy, are described in Chapter 
10. 
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1.5.7 Externally Validating Prognostic Models – Simulation Study 
Chapter 8 begins with a literature review considering methods of external validation of 
prognostic models and methods used to handle covariates missing from the independent 
dataset used for validation - the validation dataset.  Discovering that very few prognostic 
models are externally validated, possibly due to a lack of guidelines on appropriate 
methods, Chapter 8 describes a detailed simulation study aimed at identifying methods of 
external validation and methods of handling covariates missing from the validation dataset.  
The so-called ‘imputation’ methods are derived from methods used to handle missing data 
within a covariate.  Three methods of external validation are examined – discrimination via 
the  -statistic, calibration via deviance, and prognostic separation via Royston and 
Sauerbrei’s method. 
The parameters used for the simulation study are based upon those derived in Chapter 4, 
from The SANAD Trial. 
1.5.8 Externally Validating Prognostic Models – Case Study 
Having examined methods of external validation, and methods for handling a covariate 
missing from the validation dataset in Chapter 8, Chapter 9 applies the methods to real 
data.  The model derived in Chapter 5 looking at risk of a second seizure following a first 
ever seizure, derived using the MESS data, is used as the development dataset.  Three 
independent datasets are used as validation data.  One of the validation datasets was 
collected in the U.K., one in Italy and one in Western Australia.   
The three methods of external validation considered in Chapter 8 are examined.  
Additionally, the Italian dataset is missing a covariate so the five imputation methods also 
described in Chapter 8 are tested on this dataset.  Using all these methods it is possible to 
decide if the MESS model from Chapter 5 is a clinically useful tool. 
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1.5.9 Prognostic Models for Remission – Mixture Modelling 
In Chapter 7 the internal validity of the model for time to 12 month remission, derived 
using The SANAD Trial in Chapter 4, was found to be fairly poor at one year.  This may be 
because of the heterogeneity of the remission outcome for patients with epilepsy – some 
patients will achieve 12 month remission immediately, some will achieve 12 month 
remission but not immediately, and some may never achieve remission. 
In Chapter 10, two types of mixture modelling are examined to handle the varying types of 
remission that a patient can achieve.  First, logistic regression is used to model immediate 
remission and survival analysis is used to examine time to 12 month remission conditional 
on not achieving it immediately.  Second, a three component mixture model is derived to 
model all three types of remission simultaneously. 
1.5.10 Conclusions and Further Work 
Chapter 11 uses the work of Chapters 2 to 10 to suggest recommendations for research 
and recommendations for practice.   
Recommendations for research can be split into model development and model validation.  
The main suggestions for model development include interpreting hazard ratios and 
confidence intervals for large numbers of interactions (Chapter 4), deriving a likelihood 
function for a mixture model and using it to obtain risk estimates (Chapter 10), and 
assessing model validation of a mixture model (Chapters 7-10).  The key ideas for model 
validation include assessing alternative scenario for external validation and handling a 
missing covariate (Chapter 8), assessing alternative methods of external validation (Chapter 
8), and producing a definition of plausibly related datasets (Chapter 8). 
Further research needs to include external validation of the models derived in Chapter 4 
using The SANAD Trial, and the combining of all four datasets examined in Chapter 9, to 
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give a more accurate estimate of recurrence risk as well as suggesting improved driving 
guidelines. 
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Chapter 2: Introduction to Epilepsy 
2.1 Introduction 
This chapter begins with an overview of epilepsy (section 2.1).  Various seizure types are 
then described (section 2.2) including those associated with focal epilepsies (section 2.2.1) 
and those with generalised epilepsies (section 2.2.2).  Section 2.3 then summarises 
frequent methods of investigation and diagnosis before moving on to look at treatment 
options in section 2.4.  
The impact of epilepsy on a person’s life is considered in section 2.5, especially with regards 
to driving (section 2.5.1) – following a seizure a person must refrain from driving.  This is 
true for all types of seizures, whether or not the person has a diagnosis of epilepsy or not.  
The issue of seizures and driving is considered in detail in Chapters 5 and 6.  The chapter 
concludes with a literature review aimed at identifying prognostic factor studies in epilepsy 
(section 2.6) before outlining the clinical motivation for the thesis (section 2.7). 
Epilepsy is one of the most common disorders of the brain [58].  It accounts for 1% of the 
global burden of disease, a figure equivalent to breast cancer in women and lung cancer in 
men [59].  Worldwide, epilepsy affects 50 million people [58], 80% of whom are in 
developing countries.  Within the United Kingdom, one in 131 people, approximately 
456,000, have epilepsy, making it the most common serious neurological condition [60].  
Every day in the UK, 75 people are diagnosed with epilepsy.   
The definition of epilepsy requires the occurrence of two unprovoked seizures [61] and is 
the tendency to have recurrent seizures due to abnormal electrical discharge from central 
nervous system neurons [62].  The estimated prevalence of epilepsy is 0.5% to 1% in the 
developed world [63] and the overall incidence of epilepsy is 40 to 70 cases per 100,000 
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per year in industrialised countries and 100 to 190 cases per 100,000 per year in resource-
poor countries [64].   
Although most people refer to ‘epilepsy’, it is more accurate to talk about ‘the epilepsies’ 
because epilepsy is a heterogeneous condition [58]; for example some types of epilepsy are 
associated with childhood onset while some will only start in later life.  Anyone can develop 
epilepsy and although males are slightly more likely to develop it than females it is not 
known why [65, 66].  Children and adults over the age of 60 are also more likely to develop 
epilepsy than young adults [67].   
Approximately three percent of the population will have epilepsy at some point in their 
lives [65] while 5% will have a single seizure at some time [68].  The majority of people with 
epilepsy will go into remission, however up to 30% will develop refractory, or drug-
resistant, epilepsy and continue to have seizures despite treatment with combinations of 
antiepileptic drugs [69, 70].  Only 52 per cent of people with epilepsy in the UK are seizure 
free [71] although it is estimated that 70 per cent could be seizure free with the right 
treatment [72].   
Sometimes the reason epilepsy develops is clear; it can be related to brain damage caused 
by surgery, a severe head injury, a stroke, or an infection of the brain, such as meningitis or 
encephalitis.  Very occasionally, the cause is a brain tumour.  For six out of ten people, 
there is no known structural cause [73], and for many of these the cause is thought to be 
genetic. 
2.2 Seizure Types  
Neurons, or specialised nerve cells, normally generate and transmit electrochemical 
impulses that act on other neurons, glands, and muscles to produce human thoughts, 
feelings, and actions.  In epilepsy, the normal pattern of neuronal activity becomes 
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disturbed, causing strange sensations, emotions, and behaviour, or sometimes convulsions, 
muscle spasms, and loss of consciousness.  During a seizure, neurons may fire as many as 
500 times a second, much faster than normal.  In some people, this happens only 
occasionally; for others, it may happen hundreds of times a day.  
Seizures can arise in any part of the cerebral cortex and patient experiences during a 
seizure will depend on where in the brain the seizure is happening.  There are around 40 
different types of seizure and a person may have more than one type [74].   
In 1981, the International League Against Epilepsy established standardised classifications 
and terminology for epileptic seizures [75] which provided a universal vocabulary that not 
only facilitated communication among clinicians, but also established a foundation for the 
performance of quantitative clinical and basic research on epilepsy.   There have been 
subsequent iterations of these classifications the last of which was published in 2010 [76].  
According to this, Figure 1 summarises possible symptoms according to seizure type. 
Seizures can be categorised according to which part, or parts, of the brain the epileptic 
activity starts in, and how widely and rapidly it spreads.  Partial seizures, also known as 
focal seizures, involve epileptic activity that starts in just one part of the brain.  Sometimes, 
epileptic activity that starts as a partial seizure can spread to the rest of the brain.  When 
this happens, the seizure is known as secondary generalised.  Conversely, in generalised 
seizures, the seizures involve both cerebral hemispheres from the onset. 
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Figure 1: Seizure map and brief summary of possible symptoms 
2.2.1 Focal Epilepsies 
Within the focal epilepsies, the epilepsy is classified according to the site of onset and the 
aetiology.  Regarding the site of onset, this is usually classified according to which lobe the 
seizure starts in.  The brain has four lobes - temporal, frontal, occipital or parietal, as shown 
in Figure 2.  Therefore, it may be possible to classify a patient as having complex partial 
seizures as part of a temporal lobe epilepsy. 
Regarding aetiology, there are three main categories; symptomatic where there is a known 
cause for a person’s epilepsy, such as a head injury; idiopathic epilepsy where, despite 
investigation, no apparent cause for the epilepsy can be found and a genetic aetiology is 
assumed; and cryptogenic epilepsy for which, like idiopathic epilepsy, no apparent cause 
can be found however, there is strong evidence to suggest that this type of epilepsy may be 
the result of brain damage.  For example, a patient with an epilepsy arising from a temporal 
lobe tumour would be considered as having a symptomatic temporal lobe epilepsy. 
Focal 
Simple 
Activity while person is 
alert 
Complex 
Activity with change in 
awareness 
Secondary generalised 
Activity begins in one area 
and spreads 
Primary Generalised 
Absence 
Staring and blinking 
Myoclonic 
Short jerking movements 
of parts of the body 
Tonic-clonic 
Going stiff and falling 
followed by convulsions 
Tonic 
Going stiff and falling but 
without convulsions 
Atonic 
Falling limply to the 
ground 
 
 
33 
 
Partial (focal) seizures can happen as a result of epileptic activity in any area of the brain, 
although the most common areas are the temporal lobes [73].  This is often as a result of 
mesial temporal sclerosis, the aetiology of which is poorly understood, or other pathologies 
such as head injury, or infection such as meningitis.  
Partial seizures are the most common type of seizures experienced by people with 
epilepsy.  Virtually any movement, sensory, or emotional symptom can occur as part of a 
partial seizure, including complex visual or auditory hallucinations.  There are three main 
categories of partial seizures: simple, complex and secondary generalised. 
 
Figure 2: The areas of the brain 
2.2.1.1 Simple or Complex Partial Seizures 
Partial seizures are subdivided into simple partial seizures and complex partial seizures.  
People who have simple partial seizures do not lose consciousness during the seizure.  
However, some people, although fully aware of what is going on, find they cannot speak or 
move until the seizure is over.  They remain awake and aware throughout.  Sometimes they 
can talk quite normally to other people during the seizure and they can usually remember 
exactly what happened to them while it is going on.  However, simple partial seizures can 
affect movement, emotion, sensations, and feelings in unusual and sometimes even 
frightening ways. 
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Complex partial seizures affect a larger area of the brain than simple partial seizures and 
they affect consciousness.  During a complex partial seizure, a person cannot interact 
normally with other people, is not in control of his or her movements, speech or actions, 
does not know what he or she is doing and cannot remember afterwards what happened 
during the seizure.  Although complex partial seizures can affect any area of the brain, they 
often take place in one of the brain's two temporal lobes.   
Although someone may appear to be conscious because he or she remains standing with 
eyes open and moving about, it will be an altered consciousness - a dreamlike, almost 
trancelike state.  A person may even be able to speak, but the words are unlikely to make 
sense and he or she will not be able to respond to others in an appropriate way. 
All seizures have a tendency to cluster.  This will, however, be more obvious for seizures 
that occur more frequently such as simple partial seizures and complex partial seizures. 
2.2.1.2 Secondary Generalised Seizures  
Partial seizures may be followed by a generalised seizure, called secondary generalisation, 
which causes loss of consciousness.  Secondary generalisation occurs when a partial seizure 
spreads and activates the entire cerebrum bilaterally.  Activation may occur so rapidly that 
the initial partial seizure is not clinically apparent or is very brief. 
2.2.2 Generalised Epilepsies 
A number of generalised epilepsies are recognised, and they are classified according to the 
seizure types the patient experiences, EEG changes and other characteristics such as 
learning disability.  The majority of the generalised epilepsies are classified as idiopathic 
and are believed to have a genetic aetiology.  Examples include childhood absence 
epilepsy, juvenile absence epilepsy, juvenile myoclonic epilepsy and generalised epilepsy 
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with tonic-clonic seizures on awaking.  The main primary generalised seizure types are 
absence, myoclonic, tonic-clonic, tonic and atonic. 
2.2.2.1 Absence Seizures  
Absence seizures mainly happen in childhood [77].  During an absence seizure, the child 
appears to be daydreaming or switching off.  However, in an absence seizure, the child 
cannot be woken up.  They are very briefly unconscious and unaware of what is happening 
around them.  Because most children tend to daydream at times, absences can be very 
hard to spot.  In some cases, children can be having hundreds of absence seizures a day.  
This prevents them from learning and fully taking part in school or family activities.  These 
children are missing out on tiny pieces of information.  For example, they might hear the 
first part of a sentence but not the end.  They may hear the instruction to go out and play, 
but not when to be back.  Because they might then not do what is expected of them, this 
may be mistaken for poor behaviour.  
2.2.2.2 Myoclonic Seizures 
Most people experience a sudden jerk as they are falling asleep.  Although this jerk is not 
epilepsy, it is similar to the jerks experienced by someone who has myoclonic seizures.  The 
term myoclonic comes from ‘myo’ meaning muscle, and ‘clonus’ meaning jerk.  Myoclonic 
seizures can affect the whole body, but are usually restricted to one or both arms and 
sometimes the head.  During the seizure, the person is not conscious, but the seizure is so 
brief that the person appears to remain fully conscious.  Myoclonic seizures may occur as a 
single seizure or a cluster of seizures.  
2.2.2.3 Tonic-Clonic Seizures  
This is the most common and widely recognised generalised seizure.  A tonic-clonic seizure 
affects both cerebral hemispheres from the onset.  There are two phases to this type of 
seizure: the ‘tonic’ phase followed by the ‘clonic’ phase.  In the tonic phase the person goes 
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stiff because all their body’s muscles contract, the person loses consciousness and falls to 
the floor and breathing patterns change with the result that there is less oxygen than 
normal in the lungs.   Because of this, the blood circulating in the body is less red than 
usual, causing the skin (particularly around the mouth and under the finger nails) to appear 
blue in colour.  This is called ‘cyanosis’.  The person may bite their tongue and the inside of 
their cheeks.  
After the tonic phase has passed, the clonic phase of the seizure begins.  The limbs jerk 
because now the muscles tighten and relax in turn.  After a further minute or so, the 
muscles relax and the person’s body goes limp.  Slowly they will regain consciousness, but 
may well be groggy or confused.  They will gradually return to normal but may not be able 
to remember anything for a while.  Very often, the person remains sleepy and may have a 
headache and aching limbs.  Recovery times differ from person to person.  
2.2.2.4 Tonic Seizures  
Tonic seizures result in all the muscles tightening.  The body stiffens and the person will fall 
over unless they are supported.  Tonic seizures usually last less than 20 seconds and most 
often happen during sleep.  
2.2.2.5 Atonic Seizures 
Atonic seizures are also called drop attacks or akinetic seizures.  In an atonic seizure, all 
muscle tone is lost and the person drops heavily to the ground.  The seizure is very brief 
and the person is not confused afterwards and is usually able to get up again straight away.  
However, because the person’s body usually falls forward in an atonic seizure, they are at 
risk of banging their head on furniture or other hard objects. 
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2.2.3 Status Epilepticus 
Status epilepticus is defined as a condition in which seizures occur so frequently that the 
patient does not fully recover from one seizure before having another.  Status epilepticus is 
also defined as a single prolonged seizure.  A seizure lasting more than five minutes – 
especially a tonic-clonic seizure in an older child or adult – should be considered status 
epilepticus.  
Status epilepticus is a medical emergency because the longer the seizure lasts the less likely 
it is to stop on its own.  It is also less likely to stop with emergency medicines.  Status 
epilepticus can lead to brain damage, or even death.  
Several types of status epilepticus exist depending on seizure type: tonic-clonic, simple 
partial, complex partial, and absence.  Tonic-clonic status epilepticus is the most common 
and most life-threatening type. 
2.3 Investigations and Diagnosis  
Diagnosis is mainly based on the description given of the seizure(s) and, if possible, an eye 
witness account.  There is no single test to determine if someone does or does not have 
epilepsy and frequently, when epilepsy begins, the tests are normal.   However, there are 
various hospital tests that can help clinicians make a diagnosis, although not everyone 
needs to have every test.   
In the first case a clinician will want to determine if a patient has had a seizure.  Answering 
this is almost entirely dependent upon getting a good description of the seizure(s).  The 
next question might involve determining if the seizures were focal or generalised.  An 
electroencephalogram (EEG) may be used to answer this.  Finally, the clinician will probably 
want to investigate why the person had a seizure.  The EEG can again help with this if it 
shows features of an idiopathic generalised epilepsy.  Magnetic Resonance Image (MRI) 
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brain scans can also help answer this question as they identify abnormalities that have 
caused the epilepsy.  These methods will be explained further in sections 2.3.1 and 2.3.2. 
2.3.1 Electroencephalogram  
The electroencephalogram, or EEG, gives clinicians information about the activity of the 
brain.  However an EEG only shows what is happening in the brain when the test is being 
done - it is not able to show what has already happened, or what is going to happen in the 
future.   
Although an EEG is localised, it integrates neuronal activity over a very large number of 
neurons which can make EEGs difficult to interpret.  Additionally, EEGs are reported in a 
qualitative way which makes it challenging to standardise reporting.  Typical examples of 
EEGs can be seen in Chapter 5. 
During an EEG, a technician places electrodes on the scalp which are then connected to the 
EEG machine that records the electrical signals in the brain.  During the EEG test, a person 
is asked to do things such as open and close their eyes, breathe deeply and look at flashing 
lights.  If seizures appear to be connected to sleep patterns, clinicians may suggest doing an 
EEG during sleep or after a period of sleep deprivation. 
Some people have an abnormal EEG but it does not necessarily mean they have epilepsy.  
Similarly, a normal EEG does not necessarily mean that someone does not have epilepsy. 
2.3.2 Magnetic Resonance Imaging 
The magnetic resonance imaging, or MRI, uses radio frequency waves and a magnetic field.  
It can show if there is a structural cause for the epilepsy. 
Most of the human body is comprised of water molecules comprising hydrogen and oxygen 
atoms.  Within the centre of each hydrogen atom is a particle called a proton.  These 
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protons are very sensitive to magnetic fields.  Therefore, when the magnets within the MRI 
scanner are switched on, the protons in the patient’s body are pulled towards the same 
direction.  Short bursts of radio waves to certain areas of the body pull the protons out of 
position.  As this happens, each proton transmits a radio signal that provides its exact 
location in the body.  The radio signals of millions of protons can be collected together and 
combined to create a detailed image of the inside of the body [78]. 
An MRI is not always used for people who have generalised seizures.  This is because 
generalised epilepsy is unlikely to be caused by damage to a part of the brain’s structure.  
In this situation the scan is unlikely to add anything to the diagnosis. 
2.4 Treatment  
The most common way epilepsy is treated is with antiepileptic drugs (AEDs).  AEDs do not 
cure epilepsy, but are designed to try and stop seizures happening.  AEDs make the brain 
more resistant to the spread of the abnormal electrical activity [79].  
There are many different AEDs available and the most appropriate drug is chosen based on 
the type of seizures and the person.  It is common practice to start the drug at a low 
dosage, referred to as a loading dose, with a gradual increase, to keep side effects to a 
minimum.  However, everyone is different, and some people find that they are particularly 
sensitive to a drug, even at low dosages.  
Wherever possible, clinicians treat epilepsy with one drug.  Where seizures prove difficult 
to control with one AED, more than one drug may be considered.  Different AEDs have 
different mechanisms of action and as a result of this, combining drugs, so called 
polytherapy or adjunct therapy, can often lead to improved seizure control.  
 
 
40 
 
Each AED has a recommended maintenance, or daily, dosage range that is very different, 
depending on the drug.  For example, 500 milligrams (mg) of lamotrigine is the 
recommended maximum dose [80], whereas for sodium valproate it is 2500 mg [81].  
However, this is only a guide for clinicians when prescribing, because some people may 
need dosages outside the usual range.  Common antiepileptic drugs can be seen in Table 2 
together with their abbreviation, year of introduction and primary indication [82].  The 
drugs listed here do not represent a comprehensive list of all antiepileptic drugs.  However, 
these are the drugs used in The SANAD Trial (Chapter 4) and the MESS study (Chapter 5). 
The length of time taken to gain control of the seizures varies from person to person.  The 
majority of people find the right AED and dosage very quickly.  However, for some people it 
can take a lot longer to find the right drug or drugs at the right dosage(s).  About 30% of 
people with epilepsy have epilepsy that is difficult to control with AEDs [69, 70]. 
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Table 2: Common Antiepileptic Drugs as used in SANAD and MESS 
Generic Drug 
Name 
Abbreviation 
Date of 
U.K. 
Licence 
Primary Indication 
Carbamazepine CBZ 1965 
Focal and secondary generalised tonic-clonic 
seizures, primary generalised tonic-clonic seizures 
Gabapentin GBP 1993 
Monotherapy and adjunctive treatment of focal 
seizures with or without secondary generalisation 
Lamotrigine LTG 1991 
Monotherapy and adjunctive treatment of focal 
seizures and generalised seizures including tonic-
clonic seizures; seizures associated with Lennox-
Gastaut syndrome; monotherapy of typical absence 
seizures in children 
Oxcarbazepine OXC 2000 
Monotherapy or adjunctive treatment of focal 
seizures with or without secondary generalised 
tonic-clonic seizures 
Phenytoin PHT 1938 All forms of epilepsy except absence seizures 
Topiramate TPM 1995 
Monotherapy and adjunctive treatment of 
generalised tonic-clonic seizures or focal seizures 
with or without secondary generalisation; adjunctive 
treatment of seizures associated with Lennox-
Gastaut syndrome 
Valproate VPS 1993 All forms of epilepsy 
 
 
 
42 
 
2.4.1 Non-Drug Treatments 
Most people with epilepsy take AEDs for their epilepsy and these can be very effective.  
Other treatments that are scientifically proven to work are surgery, vagus nerve stimulation 
and the ketogenic diet [79].  
2.4.1.1 Resective Surgery  
Only a small number of people with epilepsy are suitable for resective surgery.  Clinicians 
will usually consider surgery for epilepsy if a person is finding it difficult to get control of 
their seizures with AEDs.  This is most likely to be if a person has tried lots of different AEDs 
and taken a combination of more than one type.   
Surgery is not an option for everyone with epilepsy.  This may be because there is no 
obvious structural cause for the epilepsy, because the exact site of seizures cannot be 
identified, or because to operate would be too great a risk.  
2.4.1.2 Vagus Nerve Stimulation 
Vagus Nerve Stimulation, VNS, is a treatment for epilepsy where a small generator is 
implanted under the skin below the left collar bone.  This generator is connected to a lead 
with three coils at one end, which are wrapped around the vagus nerve in the left side of 
the neck [79].  The VNS stimulates the vagus nerve at intervals to reduce the frequency and 
intensity of seizures.  VNS doesn’t necessarily work straight away, taking from a couple of 
months to two years to see a noticeable reduction.  
Although it is rare for a person to become seizure free as a result of VNS, many people have 
fewer or less severe seizures and therefore report a better quality of life overall [83].  Some 
people experience no change in seizure control.  
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2.4.1.3 The Ketogenic Diet  
Since it was first used in the 1920s, this diet has been a controversial therapy for children 
with difficult to control epilepsy.  It can, however, be very good at controlling seizures [84, 
85].  Interest in the diet has grown again in recent years and it is achieving increasingly 
widespread use.  Although some children find the diet unpleasant and difficult to follow, 
other children manage it very well.  The ketogenic diet is high in fats, low in carbohydrates 
and adequate in protein.  
In the small number of studies done so far, it seems that the ketogenic diet could also be 
good at controlling seizures in adults [86].  The difficulty is that most adults find the diet 
unpleasant and too strict to keep to.  
2.5 Living with Epilepsy 
Having seizures, or being diagnosed with epilepsy, can affect people in different ways.  
Some people feel relieved to be given a name and treatment for their condition.  However, 
one of the biggest concerns for people with epilepsy is how it affects day to day life.    
Many people with epilepsy do lead full lives.  However, it is fairly common for people with 
epilepsy to find it hard to remember things as epileptic seizures can affect memory.  If 
there is damage to the brain that causes the epilepsy, this can also cause memory problems 
as may the antiepileptic medication itself.  Depression is also common which may be 
because of the epilepsy medication or the epilepsy itself.  However, someone with epilepsy 
may have to change things about their life that they did not want to and other people may 
treat a person differently because of their epilepsy. 
With the right support and relevant safety precautions, there is little that someone with 
epilepsy should need to avoid.  Many people with epilepsy have their seizures completely 
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controlled by antiepileptic medication and do not need to take any greater safety 
precautions than anyone else be it at home, or out and about.   
Most people with epilepsy can participate fully in school but at times, seizures or side 
effects of seizure medicine may interfere with schoolwork.  Additionally, having seizures 
may make it more difficult to find a job or to work at certain occupations.   
With the exception of the armed forces it is against the law for employers to discriminate 
against people with epilepsy.  However, if the epilepsy is not well controlled there will be 
some careers such as working at heights, becoming an airline pilot, train driver, policeman 
etc that are not appropriate.  
2.5.1 Epilepsy and Driving 
For people who have epilepsy or seizures, there are specific regulations about holding a 
driving license.  The regulations depend on the type of license held (Group 1, car drivers, or 
Group 2, HGV drivers), and when the person has seizures (as some people have seizures 
only while they are asleep).  There are additional regulations for individuals who have a 
single (one-off) seizure. 
For people who drive, one immediate effect of having a seizure is that they have to stop 
driving.  This is true for all types of seizures, whether or not the person has a diagnosis of 
epilepsy or not.  For many people this can have a big impact on their life, and be very 
difficult or upsetting. 
The effect of seizures on driving is further considered in Chapters 5 and 6. 
2.6 Prognostic Factor Studies in Epilepsy 
The choice of a first antiepileptic drug is arguably the most important decision that a 
patient with epilepsy will make as the majority of patients achieve seizure control on that 
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drug, possibly at the consequence of adverse effects.  It is thus important to have reliable 
evidence about the likely risk-benefit ratio of potential treatments to inform treatment 
choice.  For chronic conditions such as epilepsy this evidence will largely come from head 
to head randomised controlled trials in which long term outcomes have been assessed.  
Relatively few head to head trials have been undertaken in epilepsy with the majority of 
those that have been carried out being industry sponsored studies that have tended to 
recruit selected populations, make treatment comparisons that do not reflect every day 
treatment choices, and have patient follow-up that is typically less than 12 months such 
that long term seizure control outcomes cannot be assessed.  
The epilepsies are a heterogeneous group of disorders with varied outcome and a number 
of clinical factors have been shown to influence outcome.  In a search of the literature we 
found 54 studies that identified prognostic factors for epilepsy.  Studies of interest 
considered seizure outcomes for patients with either a single seizure only, with at least two 
seizures but newly diagnosed epilepsy, or patients with refractory epilepsy.  Refractory 
epilepsy was defined as per the study, or at least two years without seizure control despite 
at least two antiepileptic drugs at optimal dose either as monotherapy or polytherapy. 
28 studies considered prognostic factors for children with epilepsy.  Nine of these studies 
looked at prognostic factors for the risk of seizure recurrence after withdrawal of 
antiepileptic drugs.  The most frequently reported prognostic factors in these studies were 
aetiology, seizure type, age and EEG result [87-94].  Another 12 of the 28 studies 
considered prognostic factors for seizure outcomes, three of which focussed on particular 
seizure types with the most common factors being aetiology, seizure frequency, seizure 
type and neurological/mental retardation [95-103].  Three of the remaining studies in 
children considered remission in newly referred patients with the prognostic factor 
aetiology being recorded for all studies [104-106].  The final four studies in children 
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considered, in one case, remission after a second drug failure with prognostic factors 
seizure type and frequency [107], and three considered seizure outcome for medically 
intractable epilepsy with the common prognostic factor being history of status epilepticus 
[108, 109]. 
Eight studies focussed on seizure outcomes for either a specific seizure type or specific type 
of epilepsy.  Of these, three studies considered prognostic factors for patients with absence 
seizures with the most common factor being IQ level, also described as mental retardation 
[110-112], while two studies considered prognostic factors for patients with juvenile 
myoclonic seizures.  No prognostic factor was common to both studies [113, 114].  The 
other three studies focussed on either a specific epilepsy type or seizure type.  For patients 
with mesial temporal lobe epilepsy prognostic factors for febrile seizure history, mesial 
temporal sclerosis, age at onset and EEG result [115] were identified.  For symptomatic 
focal epilepsy prognostic factors seizure type, nocturnal seizures, history of status 
epilepticus and EEG result [116] were identified.  Finally, for complex partial epilepsy 
prognostic factors history of neonatal seizures, time between seizures, EEG result, and style 
of therapy (monotherapy or polytherapy) [117] were found to be significant. 
Six studies considered patients who were newly diagnosed with epilepsy.  In most cases 
there was little overlap in the identified prognostic factors, however number of seizures 
was identified by three studies [118-120].  Five studies looked at seizure outcomes for 
patients withdrawing their antiepileptic drug therapy.  Of these the most commonly 
reported prognostic factors were duration of remission and seizure type [121-123].   
Seven other studies identified prognostic factors for epilepsy, one of which was concerned 
with prognostic factors for intractability - aetiology, neurological development, seizure 
frequency, history of status epilepticus and effect of AED therapy [124].  Two other studies 
considered prognostic factors for long-term retention of treatment on either lamotrigine or 
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topiramate.  The factors for lamotrigine were seizure type and treatment [125] while for 
topiramate they were learning disability, age at onset, treatment history, style of treatment 
and dosage [126].  Seizure type was found to be a prognostic factor for seizure outcome in 
a study comparing phenytoin and valproate in adults [127].  The final three studies all 
looked at partial epilepsy and common prognostic factors for seizure outcomes in these 
were EEG result and seizure type [128-130]. 
2.7 Clinical Motivation 
Few prognostic models based on prospective cohorts or randomised controlled trial data 
have been published in epilepsy.  Those that have, include models from the National 
General Practice Survey of Epilepsy (NGPSE) [131], the MRC antiepileptic drug withdrawal 
study [119, 132] and the Multicentre study of early Epilepsy and Single Seizures (MESS) 
[133].  The NGPSE models identify patient characteristics that modify seizure recurrence 
while the MRC antiepileptic withdrawal study provides important predictors of risk of 
seizure recurrence with and without AED withdrawal for patients in remission from 
seizures.  However, many patients in NGPSE were not prescribed antiepileptic drugs.  For 
patients with single seizures and early epilepsy the MESS models predict the risk of seizure 
recurrence for the policies of immediate and delayed AED treatment. 
Although a number of clinical and population based studies have been undertaken to 
assess outcome and predictors of outcome in epilepsy, as shown in section 2.6, few 
predictive models have been published that can be used to predict an individual patient’s 
outcome in every day practice.  This may be due to the sample of patients studied, the 
specifics of the outcome considered or the size or design of the study.   Additionally no 
prognostic models represent an epilepsy cohort accrued at the start of treatment.   
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There is clearly a need for prognostic models in epilepsy not only for patients who have had 
a first seizure but also for patients who are attempting to achieve remission from seizures 
and for those wishing to withdraw from epilepsy treatment following a period of remission.   
Two prognostic models for patients with newly diagnosed epilepsy are presented in 
Chapter 4.  A prognostic model for the risk of seizure recurrence following a first ever 
seizure in the context of driving is developed in Chapter 5 while in Chapter 6, a model is 
developed for patients wishing to withdraw from treatment following a period of 
remission, again in the context of driving.  
Any prognostic model, which is to be implemented in general practice, needs to be 
validated both internally and externally.  Internal validation of models is addressed in 
Chapter 7 while external validation is considered via a simulation study and case study in 
Chapters 8 and 9 respectively.  Finally, more complex prognostic models, which combine 
patients at all stages of the condition simultaneously, are considered via mixture modelling 
in Chapter 10. 
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Chapter 3: Methods for Identifying 
Prognostic Factors for Epilepsy 
3.1 Introduction 
In order to fully investigate potential prognostic factors for patients with epilepsy, and thus 
develop an appropriate prognostic model, various techniques and methods need to be 
considered such as curve fitting, variable centring, model selection, assumption testing, 
treatment-covariate interactions and competing risks.  This chapter will provide an 
overview of this theory.  The methods described in this chapter will be used in subsequent 
chapters.  
Handling continuous predictors via splines and fractional polynomials will be examined in 
section 3.2.  In section 3.3 variable centring will be discussed while methods for model 
building and development will be presented in section 3.4.  Methods for testing the 
proportional hazards assumption for the Cox model will be addressed in section 3.5 before 
competing risks methods are described in section 3.6.  The chapter will conclude (section 
3.7) with a description of the methods used in Chapters 4, 5 and 6. 
3.2 Handling Continuous Predictors 
In the past, a linear function has been an acceptable model for data-dependent model 
building with continuous covariates.  This may not be appropriate in applications where the 
data contain strong evidence against linearity.  In these situations a cutpoint model may be 
used.  Since then, further guidance has been provided suggesting spline model fits or 
fractional polynomial transformations. 
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The cutpoint model (section 3.2.1) is included for completeness only.  Continuous 
predictors are investigated in Chapter 4 via fractional polynomial (section 3.2.3) 
transformations.  The knot positions from a potential spline model fit (section 3.2.2) are 
used to categorise the continuous predictors for presentation only, post analysis. 
3.2.1 Cutpoint Model 
In the cutpoint model, a change point is selected and then the dichotomised or categorical 
variable is used in a univariate analysis.  More specifically, denote the covariate of interest 
by  .  If this covariate has been measured on a quantitative scale, the proportional hazards 
[31] cutpoint model is defined as  
                             
where  
             
 
 
                   
denotes the hazard function of the event-free survival time random variable   [43].  The 
parameter           is referred to as the hazard ratio of observations and is estimated 
through             by maximising the corresponding partial likelihood [31] with given 
cutpoint  .    is usually unknown and hence a problem of model selection where the 
cutpoint   also has to be estimated from the data. 
A popular approach for this type of data-dependent categorization is the ‘minimum   
value’ method where, within a certain range of the distribution of  , called the selection 
interval, the cutpoint    is taken such that the   value for the comparison of observations 
below and above the cutpoint is a minimum [43].  This method, also referred to as the 
optimal cutpoint method, may lead to a severe overestimation of the absolute value of the 
log-hazard ratio, which is equivalent to an inflation of the type 1 error rate [134].  In order 
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to correct for the overestimation of the absolute value of the log-hazard ratio, Verweij 
[135] proposes shrinking the parameter estimates by a shrinkage factor,  .  In the cutpoint 
model the log-hazard ratio should then be estimated by             where    is based on 
the minimum   value method and   is the estimated shrinkage factor.  In a recent paper by 
Schumacher [136] several methods to estimate   were compared.   
As a somewhat ad hoc approach, the shrinkage factor can be obtained using the corrected 
P-value.  A second approach is based on cross-validation calibration with leave-one-out, 10-
fold or bootstrap cross-validation methods.  The final approach examined by Schumacher 
used a heuristic estimator described by van Houwelingen and Le Cessie [137]. 
Even with the correction via a shrinkage factor, the optimal cutpoint approach still has 
disadvantages; in particular, different studies will most likely yield different cutpoints, 
making comparisons across studies extremely difficult or even impossible.  Thus other 
approaches should be preferred. 
3.2.2 Spline Functions 
Using spline functions in regression models enables modelling of continuous covariates.   
For fitting functions of a single variable, the general principle is that the domain of a 
covariate is covered by knots and local polynomial pieces are anchored at these knots.  
Available techniques differ in the number of knots used, the approach for determining knot 
positions and in the way the parameters for the polynomial pieces are estimated [138].   
The simplest spline function is a linear spline function, a piecewise linear function.  Suppose 
that the  -axis is divided into intervals with endpoints at  ,  , and   called knots.  The 
linear spline function is given by                               
         where       
     
     
  [139].  
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Although the linear spline is simple and can approximate many common relationships, it is 
not smooth and will not fit highly curved functions well.  Alternatives include smoothing 
splines which place one knot at each unique covariate value and use a roughness penalty 
for parameter estimation.  With regression splines, only a small number of knots are used, 
with the advantage that parameter estimation can be performed by standard regression 
methods.  Regression splines can be extended by using a large number of knots combined 
with penalised parameter estimation [140] to make the exact knot position less important.  
Such procedures are closely related to smoothing splines and share the advantage that only 
a single smoothing parameter must be selected per covariate.   
Cubic polynomials have been found to have good properties with an ability to fit sharply 
curving shapes.  This ensures linearity in the tails of the distribution and thus avoids 
unrealistic end effects of the fitted functions.  However, Stone and Koo [141] have found 
that cubic splines do have a drawback in that they can be poorly behaved in the tails, that is 
before the first knot and after the last knot.  They cite advantages of constraining the 
function to be linear in the tails.  Their restricted cubic spline function has the additional 
advantage that only     parameters must be estimated, besides the intercept, as 
opposed to     parameters with the unrestricted cubic spline.   
The restricted cubic spline function with   knots         is given by [142]  
                             
where      and for          ,  
            
  
         
        
       
 
       
          
       
. 
Stone [143] found that the location of knots in a restricted cubic spline model is not very 
crucial in most situations.  The fit depends much more on the choice of  , the number of 
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knots.  Placing knots at fixed quantities, percentiles, of a predictor’s marginal distribution is 
a good approach in most datasets.  This ensures that enough points are available in each 
interval and also guards against letting outliers overly influence knot placement.  
Recommended equally spaced quantiles are shown in Table 3. 
Table 3: Recommended equally spaced quantiles for placement of between three and seven knots ( ) with 
restricted cubic spline models 
  Quantiles 
3 0.10 0.50 0.90     
4 0.05 0.35 0.65 0.95    
5 0.05 0.28 0.50 0.73 0.95   
6 0.05 0.23 0.41 0.59 0.77 0.95  
7 0.03 0.18 0.34 0.50 0.66 0.82 0.98 
 
Stone has found that more than five knots are seldom required in a restricted cubic spline 
model [143].  The principle decision is then between       or  .  For many datasets, 
    offers an adequate fit of the model and is a good compromise between flexibility 
and loss of precision caused by overfitting a small sample.  When the sample size is large 
(i.e.       with a continuous uncensored response variable),     is a good choice.  A 
linear spline and a cubic spline, each with five knots, can be seen in Figure 3. 
 
Figure 3: Linear spline and cubic spline with five knots (4 degrees of freedom) 
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3.2.3 Fractional Polynomials 
An approach to prognostic modelling of survival data that provides more flexibility than 
polynomials [144] while preserving the simplicity of the final model to an acceptable 
degree was originally developed by Royston and Altman [144] and is termed the fractional 
polynomial (FP) approach.  One, two or more power transformations of the form    are 
fitted, the exponent(s),  , being chosen from a small, preselected set 
                           where    is defined as     .  The set   includes the most 
commonly used power transformations and has the advantages of stabilising a function 
and enabling transportability to other settings. 
An integer suffix to FP denotes the degree of the fractional polynomial.  An FP1 
transformation of a positive argument     with power   is defined as    where     
while an FP1 function or model is defined as  
  
             
             
An FP2 transformation of   with powers          , or for       (‘repeated powers’) is 
the vector    with  
            
               
                   
  
while an FP2 function or model with parameter vector          
  and powers   is  
  
             
      
       
              
The constant,   , is optional and depends on the context.  For example, it is usually 
included in a normal-errors model, but not in the Cox regression model for survival data.  
There are eight FP1 functions and 36 FP2 functions comprising eight ‘repeated powers 
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functions’ where       and 28 combinations of each of the eight members of   where 
     .  More than two terms are rarely required in practical applications. 
The general definition of an FP  function with powers             is most easily 
written as a recurrence relation.  Let         and     .  Then 
  
                          
 
   
 
where        
             
                     
   for        . 
This extension of standard polynomials generates a considerable range of curve shapes 
while still preserving simplicity when compared to smoothing splines or other 
nonparametric techniques for example.   
3.2.3.1 Choice of Origin 
If non-positive values of   can occur, then a preliminary transformation of   to ensure 
positivity is needed.  Common cases are where   is a count, when          is 
traditionally used; where   is a positive random variable such as a physical quantity for 
which recorded values can be zero, due to imprecise measurement and/or rounding of 
observations; or where   is a difference or log ratio between two quantities.  A simple 
solution is to choose a non-zero origin   and work with             where      is 
the smallest observed, or smallest possible, value of  .  A possible choice of   is the 
rounding interval of the sample values of  , or the minimum increment between successive 
ordered sample values of   [144].  If   is a count, then a natural choice is     [145].   
3.2.3.2 Function Selection Procedure 
An obvious question to ask with FP modelling concerns how to select a suitable function for 
the data.  The approach of Royston and Sauerbrei [145] has been developed to answer the 
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question in terms of a closed test procedure.  In the following description of the functional 
selection procedure (FSP), a linear function is assumed as the default when   is either 
selected because of statistical significance or included in the model on a priori reasoning.  
The procedure runs as follows: 
1. Test the best FP2 model for   at the   significance level against the null model 
using four degrees of freedom.  If the test is not significant, stop, concluding that 
the effect of   is not significant at the   level.  Otherwise continue. 
2. Test the best FP2 for   against a straight line at the   level using three degrees of 
freedom.  If the test is not significant, stop, the final model being a straight line.  
Otherwise continue. 
3. Test the best FP2 for   against the best FP1 at the   level using two degrees of 
freedom.  If the test is not significant, the final model is FP1; otherwise the final 
model is FP2.  End of procedure. 
The test at step 1 is of overall association of the outcome with  .  The test at step 2 
examines the evidence for nonlinearity.  The test at step 3 chooses between a simpler or 
more complex nonlinear model.  Before applying the procedure, the user must decide on 
the nominal P-value,  , and on the degree  of the most complex FP model allowed. 
Holländer and Schumacher [146] showed, in a simulation study, that FSP preserves the 
family-wise type 1 error probability and generally ends up with a log-linear relationship if it 
is present. 
3.2.3.3 Multivariable Fractional Polynomial 
Sauerbrei and Royston [147] have extended the FP approach, proposing a model building 
strategy consisting of FP-transformations and selection of variables by backward 
elimination, called the multivariable FP approach (MFP).  It combines variable selection by 
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backward elimination with determination of functional form for continuous predictors by 
the FSP [10, 11]. 
The MFP algorithm investigates, in a systematic way, whether the effect of a continuous 
covariate is better modelled by a non-linear function from the class of fractional 
polynomials (FP) or by a linear function. 
3.2.3.4 Modelling Continuous Variables with a ‘Spike’ at Zero 
Royston et al. [148] describe a procedure to deal with the ‘spike’ at zero problem which 
commonly arises in epidemiology and other fields.  For example, a variable for number of 
cigarettes smoked per day will have a high number of zero responses.  General fractional 
polynomial (FP) methodology does not address the question of how to model the factor 
when there is such a spike at zero.  It is not always the case that the spike will represent 
genuine zero responses.  For example, in laboratory assays some samples will fall below the 
limit of detection.  In these cases zero-inflated mixtures are used such as the zero-inflated 
Poisson model [149].   
The definition of epilepsy requires two unprovoked seizures.  Therefore, in trials of newly 
diagnosed patients, there will be a higher number of patients with only two seizures.  This 
is particularly relevant to the SANAD dataset and in Chapter 4, FPs and FPs with a spike (at 
two) will be considered when modelling total number of seizures before randomisation. 
In the logistic regression setting, theoretical results [150, 151] suggest that a binary 
variable, say  , should be included in the model to represent exposure/non-exposure.  
However, the dose-response function for the exposed individuals still needs to be 
determined.  For univariate dose-response modelling, Royston and Sauerbrei [145] 
suggested a new approach to the problem by extending FP modelling to include  .  Their 
procedure comprises of two stages [148]: first, determine the best FP function when   is 
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included in the model; second, assess whether   or the FP component can be eliminated 
without harming the model fit. 
3.2.3.4.1 FSP-Spike Procedure 
Consider a model whose linear predictor,  , is given by 
   
     
                     
  
where    and    are powers from the standard set   of FP transformations.  The linear 
predictor   is an FP function of     where     and a constant     when    .  Thus   
is a discontinuous function of   with a possible jump at    .  The expression for   is 
equivalent to 
                     
             
where    
     
     
 , and 
                 
     
                  
 . 
The function selection procedure (FSP)-spike procedure for selecting a model has two 
stages.  In the first stage, the most complex model comprising   and                 is 
compared with the null model on 5 degrees of freedom.  If the test is significant, the steps 
of the FSP for selecting an FP function are followed, but with   always included in the 
model.  In the second stage, which is performed separately,  , and the remaining FP or 
linear component are each tested for removal from the model.  If both parts are significant, 
the final model includes both; if one or both parts are non-significant the one with the 
smaller deviance difference is removed.  In the latter case, the final model comprises either 
the binary dummy variable or the selected FP function.  If only the FP function is selected, 
the spike at zero plays no further part.  Since the selection of an FP function may be 
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affected by the presence of the binary dummy variable, the resulting model may differ 
from a standard FP analysis [148]. 
The decision to use a model including   as just described, or to work with the standard FP 
class, is best made on subject-matter grounds rather than by considering the fit of 
functions with or without  . 
3.2.3.4.2 Multivariable Case 
In reality it may be unrealistic to consider assessing the effect of an exposure with a spike 
at zero in univariate models; possible confounders may need to be considered.  The 
confounder model can easily be determined by using a variation - the multivariable FP 
(MFP) procedure [138, 145].  For variables with a spike at zero within MFP the standard FSP 
is replaced with the first stage of FSP-spike.  The second stage must be done separately for 
all spike variables after MFP has been completed. 
3.2.3.5 Hazard Ratios and Confidence Intervals 
To aid interpretation, it can be helpful to present continuous variables as categorised 
variables.  Having modelled the variable using an appropriate continuous model fit, hazard 
ratios and associated 95% confidence intervals may be calculated post hoc from the fitted 
FP model.   
Denote the centre of the baseline, reference, category as      where   is the variable of 
interest and    and    are the 1
st and 2nd FP2 transformations of the variable with 
coefficients    and    respectively.  Then, 
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The variance can be calculated as 
                         
   
 
 
               
   
 
 
                  
  
          
   
 , 
and thus a 95% confidence interval for the post hoc hazard ratios is           
                . 
In the case of FP1 transformations, the above equations are much simplified.  In addition, 
the log hazard ratios can obviously be varied to odds ratios. 
3.2.4 Comparison of Splines and Fractional Polynomials 
MFP and spline model-building procedures give roughly comparable multivariable models.  
Some of the weaker predictors may be included by one procedure but not by another, and 
estimated functions often show some differences.  In regions with sparse data the 
differences can be major, but where there is enough data the functions and their 
interpretation are similar.  If interest lies mainly in the simpler task of deriving a good 
predictor, the differences between the selection procedures become smaller.  
Results from MFP are more stable and easier to interpret and transfer to other 
environments while spline functions with large degrees of freedom produce many artefacts 
and spline functions cannot easily be written down.  However, if sample size is adequate, 
MFP and splines with small degrees of freedom give similar results.  Predictors are similar 
but there can be substantial differences when interest is in individual variables.  Differences 
may appear with weakly influential predictors and in regions with sparse data.  In general, 
transportability and general usefulness are more important than minor improvements in 
goodness of fit [145]. 
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3.3 Variable Centring 
Centring involves shifting the scale of a variable by subtracting a single value from all of the 
data points.  It is called centring because people often use the mean as the value they 
subtract, so the new mean is now at zero, but it does not have to be the mean.  In fact, 
there are many situations when a value other than the mean is most meaningful. 
There are mixed opinions on the value of centring.  Cronbach [152] suggests, ‘in regression 
analysis, always centre’ stating reasons such as increased relevance of the estimated 
regression coefficients and diminished multicollinearity.  If centring is done unnecessarily, 
the cost is minor.  Aiken and West [153] and Cohen et al [154] have described centring and 
the consequences of non-centred data while Glantz and Slinker [155] and Kromrey and 
Foster-Johnson [156] take the stand that centring does not usually change the statistical 
results, is necessary only in certain circumstances and can thus easily be avoided. 
All variables analysed in the thesis are centred.   This is particularly of relevance to the work 
in Chapters 4, 5, 6 and 10. 
3.3.1 Multicollinearity 
There are two sources of correlation between a predictor and an even power of the 
predictor, say between   and    [154].  The first is non-essential multicollinearity that 
exists merely due to the scaling, non-zero mean, of  .  The second is essential 
multicollinearity, correlation that exists because of any non-symmetry in the distribution of 
the original   variable.  Marquardt [157] refers to the problems of multicollinearity 
produced by non-centred variables as non-essential ill-conditioning, whereas those that 
exist because of actual relationships between variables in the population are referred to as 
essential ill-conditioning.   
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Problems with multicollinearity in least squares regression are well documented, 
particularly with multiple regression models containing both main effects and interaction 
terms [154] – in general for two factors   and  , if the effect of variable   on the outcome 
varies according to the level of variable  , there is said to be an interaction between   and 
 .   
Although the least squares estimates of the regression coefficients remain unbiased, as 
multicollinearity increases, the determinants of the independent variables covariance and 
correlation matrices approach zero and the standard errors of the coefficients increase.  
The resulting ill-conditioning yields coefficients, and an associated variance-covariance 
matrix, that are unstable.  Small changes due to measurement or rounding error may be 
magnified resulting in large changes in the coefficients and associated variance-covariance 
matrix.  In addition, when multicollinearity is present, slight sampling fluctuations in the 
estimates of the covariances can result in great variability in the values and signs of least 
squares estimates of the coefficients.  Finally, as a result of the increase in the expected 
distance between the vector of the least squares coefficient and the vector of true 
regression coefficients, estimates with excessively large values or unreasonable signs may 
result when extreme collinearity is present [156]. 
The problems of collinearity may be overcome in several ways.  In some situations the 
collinearity will have arisen purely as a computational problem and may be solved by 
alternative definitions of some of the variables.  For example, if both   and    are included 
as explanatory variables and all the values of   are positive, then   and    are likely to be 
highly correlated.  This can be overcome by redefining the quadratic term as        , 
which will reduce the correlation whilst leading to an equivalent regression [28].  If the 
multicollinearity is structural, it can often be dealt with by centring the measured 
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independent variables on their mean values before computing the power, e.g. squared, and 
interaction, cross-product, terms specified by the regression equation.   
3.3.2 Interpretation 
Lower order coefficients in higher order regression equations, regression equations 
containing terms of higher than order unity, only have meaningful interpretation if the 
variable has a meaningful zero.   For example, if some behaviour were predicted from a 
measure of motivation,  , and a seven point attitude scale,  , ranging from one to seven, 
the regression coefficient for   on   would be the slope of   on   at the value    , a 
value not even defined on the scale.  Similarly, if strength of athletes were produced from 
their height and weight, the regression coefficient predicting strength from height would 
represent the regression of strength on height for athletes weighing 0 pounds. 
There is a simple solution to making the value, zero, meaningful on any quantitative scale; 
centre the linear predictor.  Thus the regression of   on   at     becomes meaningful; it 
is the linear regression of   on   at the mean of the variable  .  To gain the benefits of 
interpretation of lower order terms, it is unnecessary to centre the criterion  .  This can be 
left in raw score form so that predicted scores will be in the metric of the observed 
criterion [154]. 
3.3.3 Discussion 
Cohen et al [154] strongly recommend the use and reporting of centred polynomial 
equations.  They suggest that doing so has no effect on the estimate of the highest order 
interaction in the regression equation and also yields two straightforward, meaningful 
interpretations of each first-order regression coefficient of predictors entered into the 
regression equation.  Firstly, the effects of the individual predictors at the mean of the 
sample and secondly, the average effects of each individual predictors across the range of 
the other variables.  Aiken and West [153] also recommend centring, this time for 
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computational reasons because the centred overall regression analysis provides regression 
coefficients for primary terms that may be informative.  
The main disadvantage of centring, however, is that the variables are no longer the natural 
variables of the problem.  If a predictor has a meaningful zero point, then one may wish to 
keep the predictor in non-centred form.  Centring also produces a puzzling effect.  When 
predictors are centred and entered into regression equations containing interactions, the 
regression coefficients for the first order effects are different numerically from those 
obtained by performing a regression analysis on the same data in raw score or non-centred 
form.  The regression coefficients do not change when predictors are centred in regression 
equations containing no interactions [154].  Differences between the non-centred 
equation, and the centred one get absorbed into the intercept [155], therefore, according 
to Glantz and Slinker [155], centring will only be beneficial if an intercept term is included 
in the model.   
Studies performed by Kromrey and Foster-Johnson [156] showed that regression equations 
obtained with centred and raw data were equivalent, results of hypothesis testing with 
either type of data were exactly the same and neither approach provided a viable vehicle 
for the interpretation of main effects in regression.  They therefore suggest ‘one might just 
as well not bother.’  There is, though, very little cost to unnecessary centring but the costs 
of not centring when it is necessary can be major [158] as using non-centred data in 
regression analysis, often leads to inconsistent and misleading results.  Thus it would 
always be better to centre in regression analyses. 
It can be argued that not centring represents a de facto decision that all ordinal variables 
be centred at zero, that all binary and categorical independent variables be coded 
somewhat arbitrarily, 1 and 0, and that one category, also often arbitrarily chosen, be used 
as the reference category.  This can lead to serious errors of statistical inference [158].   
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Kraemer and Blasey [158] recommend the following default approach to protect against 
most errors in statistical inference.  Each binary independent variable should be coded 
     and      while each ordinal independent variable should be centred with the 
median response.  Categorical independent variables should be ‘dummy coded’ as usual, 
but instead of coding each response as 1 and 0, the values       and      should be 
used where   is the number of categories.  As in the usual situation, one categorical 
‘dummy’ is omitted, but with the proposed centring it does not matter which one.  For 
example, for a three level variable, the traditional dummy coding may be as in the left hand 
side of Table 4 while the recommended coding with centring is as per the right hand side. 
Table 4: Alternatives for dummy coding of a three level categorical variable 
 
Traditional Coding Coding with Centring 
            
Baseline 0 0       
 
   
Level 1 1 0      
 
   
Level 2 0 1      
 
   
 
Requiring that centring always be done merely asks that what is done implicitly anyway be 
done explicitly and thoughtfully, which promotes better application and understanding of 
the results of regression analysis. 
3.4 Model Building and Development 
When developing regression models, data analysts are often faced with many predictor 
variables that may influence an outcome variable.  Often a practitioner’s task is to build a 
reliable regression model that fits the data well, is plausible, simple enough to be 
interpretable and useful in practice.  Model selection reduces to a decision to include or 
exclude each variable.  Many procedures for selecting variables have been proposed 
although often they do not lead to the same solution when applied to the same problem 
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and the ‘best’ way of selecting a multivariable model is still unresolved despite more than 
half a century of research.  It is generally agreed that subject matter knowledge, when 
available, should guide model building, however, such knowledge is often limited and data-
dependent model building is required [159]. 
If the number of independent variables is large, a parsimonious model is preferred, i.e. a 
subset of ‘important’ predictors whose regression coefficients    differ from 0.   There are 
two main types of strategies for variable selection to achieve such a model – sequential 
strategies and all-subsets strategies.  Sequential strategies, such as forward selection (FS), 
stepwise selection (StS) or backwards elimination (BE) procedures, are based on a 
sequence of tests of whether a given variable should be added to the current model or 
removed from it, or whether selection should stop.  A nominal significance level,  , for 
each of these tests is chosen in advance and largely determines how many variables will 
end up in the model.   
Mantel [160] and others [161, 162] argue strongly in favour of backward elimination over 
forward selection, especially when collinearity is present.  Forward selection starts by 
considering   univariate models, all of which underfit the data and have a large residual 
variance.  In contrast, backward elimination starts with the full model.  It is likely that some 
of the variables in the full model have no effect, but it is at least a reasonable starting 
point.  If collinearity between predictors is low, then forward selection and backward 
elimination frequently select the same model.   
Some computer programs use a stepwise strategy and combine it with Akaike’s 
Information Criterion (AIC) [163] or the Bayesian Information Criterion (BIC) [164] as 
selection criteria.  In all-subsets strategies, a model is selected by minimising an 
information criterion over the    available models with up to   variables.  For a given 
model, , the information criterion, IC, is of the form                  where   is the 
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maximised log likelihood of  ,        is the number of estimated parameters and   is a 
penalty constant.  The penalty constant     gives the AIC, independent of sample size.   
AIC is an index used in a number of areas as an aid to choosing between competing models.  
It is defined as 
        
where    is the maximized log-likelihood and  is the number of parameters in the model 
[165].  The index takes into account both the statistical goodness of fit and the number of 
parameters that have to be estimated to achieve this particular degree of fit, by imposing a 
penalty for increasing the number of parameters.  
BIC has a penalty constant        and therefore depends on the sample size.  For 
censored survival data, the sample size   may be replaced by the number of events [166].  
The penalty constant of      for BIC is larger than that of 2 for AIC, generally resulting in 
models with a smaller number of predictors.  This approach however, has major 
drawbacks, including the possibility of selecting models which omit important predictors 
[163]. 
Variable selection via AIC is implemented in Chapters 4, 5 and 6 to develop parsimonious 
multivariable models. 
3.4.1 Treatment-Covariate Interactions Methods 
Multivariable models need to be checked for interactions, including the relevant main 
effects [145].  Testing for binary by binary interactions can be done by standard methods 
such as the likelihood ratio test which may also be suitable for continuous by binary and 
continuous by continuous interactions.  Alternatives for these latter two combinations are 
available in the form of Multivariable Fractional Polynomial Interactions (MFPI). 
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Treatment-covariate interactions are considered in Chapter 4 via the likelihood ratio test 
(section 3.4.1.1) and multivariable fractional polynomial interactions (section 3.4.1.2). 
3.4.1.1 Likelihood Ratio Test 
In order to compare alternatives models, fitted to an observed set of survival data, a 
statistic that measures the extent to which the data are fitted by a particular model is 
required.  As the likelihood function summarises the information that the data contain 
about the unknown parameters in a given model, a suitable summary statistic is the value 
of the likelihood function when the parameters are replaced by their maximum likelihood 
estimates.  This is the maximised likelihood under an assumed model and can be computed 
from Equation 4 by replacing the  ’s by their maximum likelihood estimates under the 
model [167].       is the vector of covariates for the individual who dies at the  th ordered 
death time,     .  For a given set of data, the larger the value of the maximum likelihood, 
the better the agreement between the model and the observed data. 
Equation 4 
      
           
                   
 
   
 
It is more convenient to use minus twice the logarithm of the maximised likelihood in 
comparing alternative models.  If the maximised likelihood for a given model is denoted by 
  , the summary measure of agreement between the model and the data is        .     is 
the product of a series of conditional probabilities, so this statistics will be less than unity 
[167].  In consequence,        will always be positive, and for a given dataset, the smaller 
the value of       , the better the model. 
The statistic         cannot be used on its own as a measure of model adequacy as the 
value of   , and hence of        , is dependent upon the number of observations in the 
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dataset.  Thus if, after fitting a model to a set of data, additional data become available to 
which the fit of the model was the same as that to the original data, the value of         
for the enlarged dataset would be different from that of the original data [167].  
Accordingly the value of        is only useful when making comparisons between models 
fitted to the same data. 
3.4.1.2 Multivariable Fractional Polynomial Interactions 
Royston and Sauerbrei [168] proposed an extension of the MFP algorithm to investigate 
interactions between categorical and continuous covariates.  It is an extension of the MFP 
procedure for simultaneous selection of influential prognostic variables and the selection of 
the function form for a continuous covariate.  The multivariable fractional polynomial 
interaction, MFPI, algorithm models the prognostic effect of a continuous variable by FP2 
transformations within treatment groups, but under the constraint of the same powers.  It 
can be done in a univariate setting or by adjusting the model for other covariates.  The type 
1 error probability of MFPI is found to be close to its nominal value. 
Assume a covariate   has two levels coded 1 and 2.  The influence of the continuous 
covariate   on the estimated treatment effect is determined by                    
where              are the estimated functions for the prognostic effect of   in treatment 
group  .  A plot of      together with a point-wise confidence band is called a treatment-
effect plot. 
Let    be a continuous covariate and    be, for simplicity, a binary treatment variable, 
coded       and let   be a vector of potential prognostic factors.  With a pre-specified 
hypothesis,    is the only covariate to be investigated for interaction with   .  The 
relationship between the outcome and    is modelled by an FP with the same powers but 
different regression coefficients at each level of   .  A standard test of interaction is 
performed on regression coefficients at the final step.  To reduce possible confounding, 
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adjustment for   may be made.  Since    cannot belong to the adjustment model, a 
different model may be chosen for each    that is investigated.  The complete procedure is 
as follows: 
1. Apply the MFP algorithm to  , possibly including   , with a P-value threshold of  
  
for selecting variables and FP transformations.  Let    be the resulting covariate 
vector, called the adjustment model.     may include transformed variables in   
selected by the MFP algorithm.  If all variables in   are uninfluential, then    may 
even by empty. 
2. Find by maximum likelihood the best-fitting FP2 powers,          , for which   , 
with        , always adjusting for    and  
 .  Denote the FP2 transformations 
  
 
    
     
   . 
3. For groups       and powers    for      , define new predictors       
   if 
    , and       otherwise. 
4. The test of       interaction is a likelihood ratio test between the nested models 
                    
  and      
     
     .  The difference in deviance is compared 
with    on two degrees of freedom. 
5. If an interaction is not found, then    is regarded as a potential prognostic factor 
only.  To investigate if an FP2 function is still needed for   , the final model is 
chosen by repeating step 1, but including    as a potential prognostic factor. 
The reason why FP2 functions are fitted to   , rather than simpler functions, is to find the 
best-fitting specification from a flexible class.  In terms of bias or variance trade-off, 
increased variance incurred through the use of FP2 powers for    may be tolerated at the 
price of low bias.  To avoid excessive overfitting, leading to serious artefacts in the fitted 
functions, estimation of different powers in each treatment group is not considered.  An 
FP2 function with the same powers in each treatment group is already a flexible 
 
 
71 
 
specification.  When    is binary or categorical, the approach reduces to the usual approach 
of estimating and testing multiplicative interaction term(s), adjusting for   . 
Further refinements of the procedure are possible.  A less flexible option would involve use 
of linear functions.  Alternatively, FP1 functions could be used.  For greater flexibility it may 
be possible to allow the powers to be different in the treatment groups.  However, except 
in very large samples, the advantage of increased flexibility would probably be outweighed 
by the increased instability [145]. 
3.5 Testing the Proportional Hazards Assumption 
As mentioned previously, the Cox model relies on the proportional hazards assumption.  
Therefore the proportional hazards assumption will be investigated using log cumulative 
hazard plots and Schoenfeld residual plots.  The assumption will also be tested to see 
whether incorporating a time-dependent covariate effect indicates significant violations. 
If the proportional hazards assumption is found not to be valid, the results will be 
compared to those from the accelerated failure time model.  This will determine if the 
violation of the assumption affects the conclusion. 
The proportional hazards assumption is tested in Chapters 4, 5 and 6 via log cumulative 
hazard plots (section 3.5.1), the inclusion of time-dependent covariate effects (section 
3.5.2), and examination of Schoenfeld residuals (section 3.5.3.1).  Other types of residuals 
are included in this chapter for completeness only.  
3.5.1 Log Cumulative Hazard Plots 
A graphical approach for checking the proportional hazards assumption involves comparing 
log–log survival curves over different combinations of categories of variables being 
investigated.  Parallel curves indicate that the proportional hazards assumption is satisfied.  
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A log–log survival curve is a transformation of an estimated survival curve that results from 
taking the natural log of an estimated survival probability twice.  Mathematically, a log–log 
curve is written as          .  
Recall that the formula for the survival curve of the Cox model is  
            
         
 
    . 
The first time logs are taken the resulting expression is 
                     
 
               . 
Since        denotes a survival probability, its value for any   and any specification of the 
vector   will be some number between 0 and 1.  It follows that the natural log of any 
number between 0 and 1 is a negative number, so that the log of        as well as the log 
of       are both negative numbers.  Thus, when taking the second log, the log of 
             must be calculated.  
After some algebra, this expression can be rewritten as the sum of two terms, one of which 
is the linear sum of the      and the other is the log of the negative log of the baseline 
survival function.  Suppose two different specifications of the   vector are considered, 
corresponding to two different individuals,    and   .  Then the corresponding log–log 
curves for these individuals are given in Equation 5 [169]. 
Equation 5 
                       
 
   
              
                       
 
   
              
 
 
73 
 
Subtracting the second log–log curve from the first yields the expression shown in Equation 
6.  This expression is a linear sum of the differences in corresponding predictor values for 
the two individuals.  Note that the baseline survival function has dropped out, so that the 
difference in log–log curves involves an expression that does not involve time t. 
Equation 6 
                                           
 
   
 
Alternatively, using algebra, Equation 6 can be re-written by expressing the log–log survival 
curve for individual     as the log–log curve for individual     plus a linear sum term that is 
independent of  , as shown in Equation 7.  This says that if a Cox model is used and the 
estimated log–log survival curves for individuals are plotted on the same graph, the two 
plots will be approximately parallel.  The distance between the two curves is the linear 
expression involving the differences in predictor values, which does not involve time.  In 
general, if the vertical distance between two curves is constant, then the curves are 
considered parallel. 
Equation 7 
                                             
 
   
 
The parallelism of log–log survival plots for the Cox proportional hazards model provides a 
graphical approach for assessing the proportional hazards assumption.  That is, if a Cox 
model is appropriate for a given set of predictors, one should expect that empirical plots of 
log–log survival curves for different individuals will be approximately parallel. 
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3.5.2 Time-Dependent Covariate Effects 
When time-dependent variables are used to assess the proportional hazards assumption 
for a time-independent variable, the Cox model is extended to contain interaction terms 
involving the time independent variable being assessed and some function of time.  When 
assessing predictors one-at-a-time, the extended Cox model takes the general form shown 
in Equation 8 for the predictor  .  
Equation 8 
                           
One choice for the function      is simply      equal to  , so that the product term takes 
the form   .  Other choices for g(t) are also possible, for example, log t.  Using the above 
one-at-a-time model, the proportional hazards assumption is assessed by testing for the 
significance of the product term.  The null hypothesis is therefore    .  The test can be 
carried out using either a Wald statistic or a likelihood ratio statistic.  In either case, the test 
statistic has a chi-square distribution with one degree of freedom under the null 
hypothesis. 
3.5.3 Residuals for Cox regression model 
A goodness of fit testing approach is appealing because it provides a test statistic and p-
value for assessing the proportional hazards assumption for a given predictor of interest.  
Thus, the researcher can make a more objective decision using a statistical test than is 
typically possible when using a graphical approach.  Many goodness of fit testing 
procedures are based on residuals which are values that can be calculated for each 
individual in the study, and have known behaviour when the fitted model is satisfactory.  
Schoenfeld residuals, Martingale residuals and deviance residuals are the most popular. 
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3.5.3.1 Schoenfeld Residuals 
According to Collett [167], the Schoenfeld residuals are particularly useful in evaluating the 
assumption of the proportional hazards after fitting a Cox regression model.  Grambsch and 
Therneau [170] have shown that the expected value of the     scaled Schoenfeld residuals, 
for the     explanatory variable,   , in the model,     
 , is given by       
              
where       is taken to be a time-varying coefficient of   ,        is the value of the 
coefficient at the     death time,    and     is the estimated value of    in the fitted Cox 
regression model.  Consequently, a plot of the values of     
      against the death times 
should give information about the form of the time-dependent coefficient of   ,      .  In 
particular, a horizontal line will suggest that the coefficient of    is constant and the 
proportional hazards assumption is satisfied.  A smoothed curve can be superimposed onto 
this plot to aid interpretation.  This plot can also be supplemented by fitting a straight line, 
and formally testing if the slope of this line is zero.  However, this procedure has its 
limitations, since a slope that is not significantly different from zero may be found when 
there is, in fact, a non-linear relationship between the coefficient and time. 
3.5.3.2 Martingale Residuals 
Suppose that the     survival time is a censored observation,   
 , and let    be the actual, 
but unknown, survival time, so that      
 .  The Cox-Snell [171] residual for this individual, 
evaluated at the censored survival time, is then given by          
             
  , 
where      
   and       
   are the estimated cumulative hazard and survivor functions 
respectively for the     individual at the censored survival time.  Also, suppose that    is a 
censoring indicator which takes the value zero if the observed survival time of the     
individual is censored and unity if it is uncensored. 
Residuals,           , are known as Martingale residuals since they can be derived 
using Martingale methods.  They take values between    and unity with the residuals for 
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censored observations being negative.  In large samples, the Martingale residuals are 
uncorrelated with one another and have an expected value of zero.  They are not 
symmetrically distributed about zero which therefore makes plots based on the residuals 
difficult to interpret. 
3.5.3.3 Deviance Residuals 
The deviance residuals, which were introduced by Therneau et al [172], are more 
symmetrically distributed around zero than Martingale residuals.  They are defined by [167] 
                                   
    
where     is the Martingale residual for the  
   individual,    is the event indicator and the 
function        is the sign function - the function that takes the value    if its argument is 
positive and    if negative.  Thus          ensures that the deviance residuals have the 
same sign as the Martingale residuals. 
The deviance is a statistic that is used to summarise the extent to which the fit of a model 
of current interest deviates from that of a model which is a perfect fit to the data.  The 
statistic is given by                     where      is the maximised partial likelihood 
under the current model and     is the maximised partial likelihood under the full model.  
The deviance residuals are then such that       
 , so that observations that correspond 
to relatively large deviance residuals are those that are not well fitted by the model. 
An alternative way of viewing the deviance residuals is to consider them as Martingale 
residuals which have been transformed to produce values that are symmetric about zero 
when the fitted model is appropriate.  Although these residuals can be expected to be 
symmetrically distributed about zero when an appropriate model has been fitted, they do 
not necessarily sum to zero. 
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3.5.4 Comparison of Deviances 
Two disadvantages of the Martingale residuals are that they depend heavily on the 
observed survival time and require an estimate of the cumulative hazard function.  Both of 
these disadvantages are overcome in a residual proposed by Schoenfeld [173].  This 
residual differs from the Martingale residuals in one other important respect - there is not 
a single value of the residual for each individual, but a set of values, one for each 
explanatory variable included in the fitted Cox regression model.  While Martingale 
residuals are useful for assessing the correct functional form for the effect of a covariate, 
almost all of the available literature on testing the proportional hazards assumption uses 
Schoenfeld residuals.   
3.6 Competing Risks Methods 
When only one of several different types of event can occur, the probability of these events 
is referred to as competing risks.  In the epilepsy setting, treatment failure may arise as a 
result of either adverse events or inadequate seizure control.  Cumulative incidence 
analysis will be used to show the contribution to the treatment failure outcome across 
drugs while covariates will be tested by Gray’s method [174]. 
Many sources [169, 175] suggest that modelling competing risks survival data can be 
carried out using a Cox model.  The drawback of performing a survival analysis for each 
event type separately, where the other, competing, event types are treated as censored 
categories is the assumption that the competing risks are independent.  Cumulative 
incidence analysis makes no such assumption and allows the assessment of cause-specific 
withdrawal in the presence of other competing risks. 
Competing risks analyses are undertaken in Chapter 4 via cumulative incidence analysis 
(section 3.6.1) with examination of covariates by Fine and Gray’s method (section 3.6.2). 
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3.6.1 Cumulative Incidence Analysis 
The cumulative incidence curve estimates the marginal probability of an event and is 
therefore not estimated using a product-limit formulation.  The independence of 
competing risks is still required, when a proportional hazard model is used to obtain hazard 
ratio estimates for individual competing risks, as an intermediate step in the computation 
of a cumulative incidence curve.  This assumption will be satisfied whenever competing 
risks are mutually exclusive and events are non-recurrent; that is, one and only one event 
can occur at any one time and only once over time.  Irrespectively, the cumulative 
incidence curve has a meaningful interpretation in terms of treatment utility regardless of 
whether competing risks are independent [30, 169].   
To construct a cumulative incidence curve, first estimate the hazard at ordered time points 
   when the event of interest occurs.  This hazard estimate is simply the number of events 
that occur at    divided by the number at risk at   .  This can be written as  
        
   
    
where the    denotes the number of events for risk   at time    and    is the number of 
subjects at that time.  Thus, at any particular time, 
   
     is the estimated proportion of 
subjects failing from risk  .  
To be able to fail at time   , the subject must have survived the previous time when a 
failure occurred.  The probability of surviving the previous time      is denoted        , 
where      denotes the overall survival curve rather than the cause-specific survival curve 
     .  Overall survival must be considered here because the subject must have survived all 
other competing events.  The incidence of failing from event-type   at time    is then simply 
the probability of surviving the previous time period multiplied by        .  The cumulative 
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incidence at time    is then the cumulative sum up to time    of these incidence values over 
all event-type   failure times.   
3.6.2 Fine and Gray 
Fine and Gray [176] provide methodology for modelling the cumulative incidence curve 
with covariates using a proportional hazards assumption.  They refer to the cumulative 
incidence curves as sub-distribution functions.  The cumulative incidence curve models 
developed by Fine and Gray are analogous to the Cox model but, for any failure type, they 
model a cumulative incidence curve.  
Fine and Gray’s model is based on                     where   is the hazard of the 
subdistribution,    is the baseline hazard of the subdistribution,   is the vector of the 
covariates and   is the vector of the coefficients.  The form of the partial likelihood is 
similar to that used in the Cox model.  Written for just one covariate,  , the partial 
likelihood is given by Equation 9 [177] 
Equation 9 
      
        
                
 
   
 
where the product is taken over all   time points              where an event of 
interest was observed.   
There are two main differences between the partial likelihood for Fine and Gray’s model 
and that of the Cox model; the risk set    is defined in a different way and weights     are 
added.  The risk set is formed of those who did not experience an event by time   and of 
those who experienced a competing risk event by time  , 
                                                                    . 
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Thus those who experienced other types of events remain in the risk set all the time.  The 
weights are defined as  
    
      
              
 
where    is the Kaplan-Meier estimate of the survivor function of the censored distribution.  
The censoring distribution is defined by         where    is the time to the first event and 
   is 1 if no event is observed and 0 if any kind of event was observed.  At each time point 
where an event of interest occurred, indexed by  , the set of individuals at risk, indexed by 
 , includes those who did not have any type of event by time    as well as those who had a 
competing risks event before   .  The weight is 1 for the former and less than or equal to 1 
for the latter.  In this way those individuals experiencing a competing risk event do not 
participate fully in the partial likelihood: the further the time point,   , is from the time 
when the competing risk event occurred, the smaller the weight. 
To investigate the proportionality assumption for the competing risks regression, 
                 can be plotted against          .  Additionally, a time-dependent 
covariate may be included in the model, which tests whether the hazard ratio changes with 
time [177].   
3.7 Discussion 
Time to event outcomes will be summarised by Kaplan-Meier curves for each level of a 
categorical prognostic factor and compared overall using log-rank tests.  A Cox model for 
the prognostic factor effect will then be fitted using indicator variables for the levels of the 
categorical variable.  Univariate hazard ratios together with associated 95% confidence 
intervals for levels of each categorical prognostic factor will also be calculated.  Hazard 
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ratios together with their associated 95% confidence intervals will be calculated for any 
continuous variables.   
The hazard of each event in the multivariate setting will be assessed using a Cox 
proportional hazards regression model.  Best-fitting, parsimonious, multivariable models 
will be produced with backwards elimination by Akaike’s Information Criterion (AIC) [178]– 
the smaller the value of this statistic, the better the model [167].  Schoenfeld residual plots 
will be used to test the proportional hazards assumption. 
It is necessary to consider the effect of treatment in each case; to do this treatment will be 
forced to stay in the model.  I.e. it will be included as a variable and, irrespective of the 
backward elimination process, it will remain in the model.   
Potential prognostic factors may be investigated via implementation of methods for curve 
fitting, variable centring, model selection, assumption testing, treatment-covariate 
interactions and competing risks.  These methods will be employed in Chapter 4 to develop 
prognostic models for time to treatment failure and time to 12 months of remission for 
patients with epilepsy. 
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Chapter 4: Identifying Prognostic 
Factors for Epilepsy 
4.1  Introduction 
This chapter begins with an explanation of how it is possible to use The SANAD Trial data to 
investigate more than overall estimates of treatment effect (section 4.1).  In section 4.2 The 
SANAD Trial is described in detail (section 4.2.1) together with the prognostic modelling 
methods used (section 4.2.2).  A prognostic model for time to treatment failure can be seen 
in section 4.3.1 while a model for time to 12 month remission can be seen in section 4.3.3. 
The SANAD dataset will be further examined in Chapter 7 where the internal validation of 
the models presented in this chapter will be considered.  Additionally, a simulation study 
into methods of external validation will be considered in Chapter 8 and the SANAD dataset 
will be used to inform the simulations.  Finally, the SANAD dataset will also be considered 
in Chapter 10 where a more complex method of modelling time to 12 month remission will 
be considered. 
The work presented in this chapter has been published in Lancet Neurology and I am first 
author.  This is important research and has been discussed at various epilepsy meetings 
and conferences since its publication. 
The epilepsies represent a heterogeneous group of disorders and we recognise a number 
of differing seizure types [76] and epilepsy syndromes [179] with differing aetiologies, 
severity and age of onset.  While results from the Standard and New Antiepileptic Drug trial 
(SANAD) published so far [180, 181] provide overall estimates of treatment effect, SANAD 
recruited a large heterogeneous group of patients providing an opportunity to use 
prognostic modelling to investigate which clinical factors might influence outcome.  The 
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results will inform patient counselling about likely outcomes, treatment choices and the 
design of future monotherapy epilepsy trials. 
4.2 Methods 
4.2.1 SANAD 
SANAD [180] had two arms, A and B.  In the case of arm A, the recruited patients were 
those for whom clinicians considered carbamazepine the first line standard treatment, 89% 
of whom were classified with a focal epilepsy.  Patients were randomly allocated to 
treatment with carbamazepine, gabapentin, lamotrigine, oxcarbazepine or topiramate.  
Overall results indicated that lamotrigine was a potential first line treatment as it was 
significantly superior to carbamazepine for the outcome time to treatment failure 
(lamotrigine vs.  carbamazepine: HR 0.78 95% CI (0.63 to 0.97)), but similar to 
carbamazepine for time to 12 month remission.  Gabapentin and topiramate were 
identified as poor first line treatments, gabapentin due to lack of efficacy and topiramate 
due to both lack of efficacy and poor tolerability. 
The methods for the SANAD study have been published elsewhere [180].  In summary, 
patients were eligible for inclusion in the study if, in the previous year, they had a history of 
at least two clinically definite unprovoked epileptic seizures, they were at least five years 
old, and if the recruiting clinician deemed carbamazepine as opposed to valproate, to be 
the optimal standard treatment option in the case of arm A and valproate rather than 
carbamazepine to be the optimal in the case of arm B.  Patients generally had newly 
diagnosed and untreated epilepsy, but could also be recruited if they were taking a 
monotherapy drug that was not being investigated in SANAD (e.g.  phenytoin) with a 
change in drug indicated, or if they had previously been treated with an antiepileptic drug, 
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had had a seizure remission, but had a recurrence of seizures following antiepileptic drug 
withdrawal.   
Exclusion criteria included treatment contraindication, a history of progressive neurological 
disease or a history of only acute symptomatic seizures such as febrile seizures.  Patients 
were recruited to the trial between December 1st 1999 and August 31st 2004 and were 
followed-up, if possible, until between May 1st 2005 and August 31st 2005 although some 
follow-up data were obtained up to January 13th 2006.  Following enrolment by the 
recruiting physician and obtainment of informed consent, patients were allocated 
randomly to treatment.  Between December 1st 1999 and June 1st 2001 patients were 
allocated in a ratio of 1:1:1:1 to carbamazepine, gabapentin, lamotrigine, and topiramate in 
arm A, and 1:1:1 to valproate, lamotrigine and topiramate in arm B.   
From 1st June 2001 to 31st August 2004 an oxcarbazepine group was added to arm A of the 
trial and patients were randomly allocated in a ratio of 1:1:1:1:1 to carbamazepine, 
gabapentin, lamotrigine, oxcarbazepine or topiramate.  Randomisation was by a central 
telephone service via the minimisation method which was balanced across centre, gender 
and treatment history.  While the drug allocation was randomised, the dose and 
preparation was based on the clinicians’ usual practice aided by guidelines in the trial 
protocol.   
Baseline clinical information and demographic data such as neurological history, EEG, brain 
imaging results, seizure classification and epilepsy type were obtained for all randomised 
patients.  Where there was uncertainty between focal onset and generalised onset 
seizures, patients were recorded as having unclassified convulsive, or other unclassified, 
seizures.  Follow-up occurred at three, six and 12 months and successive yearly intervals 
from randomisation with additional visits as clinically indicated.  At each visit the 
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occurrence of seizures, adverse events, hospital admissions and antiepileptic drug 
treatment were recorded. 
There were two primary outcomes - time to treatment failure from randomisation and time 
to 12 month remission from randomisation.  Treatment failure can be split into two main 
categories; inadequate seizure control for which the randomised drug might be withdrawn 
or a second treatment added, or due to unacceptable adverse events.  Patients were 
categorised into these two main failure reasons as in the original SANAD analyses [180, 
181].  Patients categorised as failing due to inadequate seizure control included those citing 
inadequate seizure control as the only reason for treatment failure, those with both 
inadequate seizure control and unacceptable side effects, and those who died where the 
cause of death was related to epilepsy.  Patients were categorised as failing due to adverse 
events if they recorded unacceptable adverse events, withdrew treatment following a 
period of remission of less than 12 months where adverse events likely influenced the 
decision to withdraw treatment, and those withdrawing treatment due to pregnancy or 
planned pregnancy due to concerns about teratogenic effects.  Time to 12 month remission 
was defined as time from randomisation to 365 days of seizure freedom. 
4.2.2 Prognostic Modelling 
Analyses were undertaken using R version 2.9.2 [182] and SAS version 9 [183]. 
The aim of the prognostic modelling was to identify two sets of factors – one set that 
predict time to 12 month remission, and one set that predict time to treatment failure.  
Clinical consensus and knowledge from previous prognostic studies in epilepsy [119, 120] 
led to the following list of potential prognostic factors: gender, febrile seizure history, first 
degree relative with epilepsy, CT/MR scan result, treatment history, age, time from first 
seizure to randomisation, neurological insult (e.g.  hemiparesis), total number of seizures 
ever before randomisation, EEG result, seizure type and epilepsy type.  For the CT/MR 
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results, scans were classified as normal, abnormal and not done.  Patients were classified as 
having neurological insult if they had learning disabilities or neurological deficit.  EEGs were 
classified as normal, not done, non-specific abnormality and epileptiform abnormality 
(focal or generalised spikes or spike and slow wave activity). 
Seizure types were classified according to the International League Against Epilepsy seizure 
classification [76].  Epilepsy type was first classified as focal, generalised or unclassified.  In 
arm A, patients with a focal epilepsy were further classified as temporal lobe, frontal lobe, 
parietal lobe, occipital lobe, benign focal epilepsy, or focal epilepsy not localised.  For the 
regression modelling, due to small numbers of participants, occipital lobe, parietal lobe and 
benign focal epilepsy were combined in a group referred to as other.   
Modelling methods used are as outlined in detail in Chapter 3 but in summary variables 
associated with a higher chance of treatment failure and a higher chance of achieving 12 
month remission were determined after adjusting for multiple variables using Cox 
proportional hazards modelling methods.  As oxcarbazepine was only included in the 
randomisation after June 1st 2001 all analyses were stratified by randomisation period to 
account for the reduced patient numbers for this drug.  
Variables were centred to diminish multicollinearity [158] and tested via the likelihood 
ratio test [167].  Best-fitting, parsimonious, multivariable models were produced with 
backwards elimination with AIC – selection starts with the full model and eliminates 
predictors one at a time, at each step considering whether the criterion will be improved, 
smaller AIC, by adding back in a variable removed at a previous step [178].  From the 
multivariable model the probability of the event was calculated for combinations of risk 
factors.  The proportional hazards assumption was investigated using Schoenfeld residual 
plots [173] and incorporation of time-dependent covariate effects while the internal 
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validity was assessed by the concordance statistic which evaluates the discriminatory 
power and the predictive accuracy of nonlinear statistical models [184]. 
Assessment of the different reasons for treatment withdrawal requires a competing risks 
analysis which considers the probability of one of several different events occurring.  
Cumulative incidence analyses were undertaken to assess the probability of one of the two 
treatment failure events occurring (inadequate seizure control and unacceptable adverse 
events), with covariates tested by Gray’s method [174].  
Continuous variables were investigated using log, fractional polynomial and fractional 
polynomial with spike transformations [144, 145, 185, 186].  The results for the continuous 
variables are presented as post-hoc defined categorical variables with categories chosen 
according to knot positions for a spline model fit to the data [143] as described in Chapter 
3.  In the final model the variables were retained as continuous and presented as 
categorical variables on for ease of interpretation by non-statisticians.  
The variable for time from first seizure to randomisation includes extreme values.  A 
sensitivity analysis was performed which examined time to treatment failure and time to 
12 month remission in two scenarios.  First, time from first seizure to randomisation was 
included unchanged, and second the variable was reduced by excluding patients with 
extreme values (1% at either end of the range).  Patients with a seizure 18 days or less 
before randomisation and with a seizure over 41 years before randomisation were 
consequently examined to determine their impact on the analysis.   
An alternative scenario would involve regarding the extreme values as missing data and re-
estimating them via imputation.  However, recommended practice is to remove the 1% 
extreme values as this smoothly draws in the extreme tails [187].  Following this sensitivity 
analysis the 1% extreme values were removed therefore people with a time from first 
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seizure to randomisation in the first or last one percent of the variable were removed from 
the dataset – this applied to 34 patients (labelled ‘extremes’ in Figure 4). 
4.3 Results 
Figure 4 illustrates patient disposition for patients in arm A of SANAD.  1721 patients were 
recruited into the study, 44 of whom were excluded from the analyses as they were 
subsequently found not to have epilepsy.  Outcome data were available for 1664 patients 
who contributed to the analysis of time to treatment failure and 1644 who contributed to 
the analysis of time to 12 month remission.  Table 5 summarises the demographic details of 
the included patients; 55% of the patients were male, the median age was about 37 years, 
5% had a history of febrile seizures, 10% had a first degree relative with epilepsy and 82% 
were treatment naive.  The median time from first seizure to randomisation was 1.4 years, 
11% had history of neurological insult, the median number of seizures ever before 
randomisation was 12 and approximately 46% had abnormal EEG results.  An abnormal 
CT/MR result was seen in 26% while 32% had simple or complex partial seizures only, 58% 
had secondary generalised seizures and 10% uncertain seizures.  90% of patients were 
classified with focal epilepsy and 10% unclassified epilepsy.  Data were similar for time to 
12 month remission.  
  
 
 
90 
 
 
‘Extremes removed’ relates to the removal of patients with a time from first seizure to randomisation within 
the first or last one percent of the variable while ‘Generalised removed’ relates to removal of patients with 
generalised epilepsy type.  Percentages in final row are percentage of allocated patients with available data – 
93% of all randomised patients were available for analysis of time to treatment failure; 92% of all randomised 
patients were available for analysis of time to 12 month remission 
Figure 4: The SANAD Trial – arm A: Patient Disposition 
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Table 5: The SANAD trial – arm A: Baseline patient demographics 
 Treatment Failure Outcome 
 
CBZ 
(n=355) 
GBP 
(n=356) 
LTG 
(n=357) 
OXC 
(n=193) 
TPM 
(n=347) 
Total 
(n=1608) 
Gender: Male 196 (55) 197 (55) 199 (56) 102 (53) 193 (56) 887 (55) 
History of febrile seizures 24 (7) 15 (4) 22 (6) 7 (4) 13 (4) 81 (5) 
First degree relative with epilepsy 36 (10) 41 (12) 33 (9) 21 (11) 34 (10) 165 (10) 
Treatment history 
  Treatment naive 
  Taking non-SANAD AED  
  Seizures after remission 
 
290 (82) 
57 (16) 
8 (2) 
 
289 (81) 
56 (16) 
11 (3) 
 
292 (82) 
58 (16) 
7 (2) 
 
167 (87) 
23 (12) 
2 (1) 
 
282 (81) 
57 (16) 
9 (3) 
 
1320 (82) 
251 (16) 
37 (2) 
Age at randomisation in years, 
Median (IQR) 
 
38 (25 to 53) 
 
36 (24 to 50) 
 
34 (22 to 51) 
 
40 (27 to 56) 
 
37 (25 to 52) 
 
38 (24 to 52) 
Years from 1
st
 seizure to 
randomisation, Median (IQR) 
1.4 
(0.5 to 4.9) 
1.3 
(0.6 to 6.0) 
1.4 
(0.5 to 4.7) 
1.3 
(0.5 to 4.0) 
1.4 
(0.5 to 5.3) 
1.4 
(0.5 to 5.1) 
Neurological insult 42 (12) 41 (12) 41 (11) 16 (8) 43 (12) 113 (7) 
Number seizures ever before 
randomisation, Median (IQR) 
 
12 (4 to 75) 
 
14 (4 to 70) 
 
12 (4 to 60) 
 
11 (4 to 53) 
 
12 (4 to 100) 
 
12 (4 to 70) 
Seizure type 
  Simple or complex partial only 
  2° Generalised tonic-clonic 
  Uncertain 
 
122 (34) 
202 (57) 
31 (9) 
 
112 (31) 
209 (59) 
35 (10) 
 
105 (29) 
216 (61) 
36 (10) 
 
55 (28) 
117 (61) 
21 (11) 
 
116 (33) 
193 (56) 
38 (11) 
 
510 (32) 
937 (58) 
161 (10) 
Epilepsy type   
  Focal 
    Temporal 
    Frontal 
    Other 
    Not specified 
  Unclassified 
 
325 (92) 
150 (46) 
20 (6) 
20 (6) 
135 (42) 
30 (8) 
 
323 (91) 
120 (37) 
17 (5) 
28 (9) 
158 (49) 
33 (9) 
 
321 (90) 
107 (33) 
34 (11) 
17 (5) 
163 (51) 
36 (10) 
 
173 (90) 
56 (32) 
5 (3) 
13(8) 
99 (57) 
20 (10) 
 
311 (90) 
114 (37) 
31 (10) 
21 (6) 
145 (47) 
36 (10) 
 
1453 (90) 
547 (38) 
107 (7) 
99 (7) 
700 (48) 
155 (10) 
EEG results 
  Normal 
  Non-specific abnormality 
  Epileptiform abnormality 
  Not done 
 
150 (42) 
59 (17) 
113 (32) 
33 (9) 
 
177 (50) 
48 (13) 
100 (28) 
31 (9) 
 
169 (47) 
56 (16) 
100 (28) 
32 (9) 
 
84 (44) 
32 (17) 
54 (28) 
23 (12) 
 
144 (41) 
59 (17) 
104 (30) 
40 (12) 
 
724 (45) 
254 (16) 
471 (29) 
159 (10) 
CT/MR results 
  Normal 
  Abnormal 
  Not done 
 
205 (58) 
99 (28) 
51 (14) 
 
225 (63) 
82 (23) 
49 (14) 
 
207 (58) 
83 (23) 
67 (19) 
 
109 (56) 
53 (27) 
31 (16) 
 
188 (54) 
103 (30) 
56 (16) 
 
934 (58) 
420 (26) 
254 (16) 
Values in the table are actual number with percentages in brackets unless otherwise stated. 
 
4.3.1 Time to overall Treatment Failure 
Figure 5 shows the unadjusted time to treatment failure for the 1608 patients that 
contributed to the analysis.  Results for both the univariate and multivariable modelling are 
presented in Table 6.  In the univariate model the following factors were significantly  
associated (at the 5% level) with higher risk of treatment failure: gender, having an 
epileptiform EEG abnormality, being randomised to carbamazepine rather than to 
lamotrigine, treatment history, age, time from first seizure to randomisation, total number 
of seizures ever before randomisation, epilepsy type and seizure type. 
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Figure 5: The SANAD Trial – arm A: Unadjusted Kaplan-Meier curve for overall time to treatment failure (left) 
and cumulative incidence curves for time to treatment failure according to competing risks (right) 
 
For the treatment failure outcome, a HR > 1 indicates that treatment failure is more likely.  
The resulting parsimonious multivariable model included variables for gender, treatment 
history, age, total number of seizures ever before randomisation, EEG result, seizure type, 
focal epilepsy site of onset and treatment which was forced into the model.   
Treatment failure rates reduced as age increased and patients aged 10 years or under were 
significantly more likely to experience treatment failure.   Treatment failure rates increased 
as total number of seizures before randomisation increased and patients with less than or 
equal to two seizures before randomisation were significantly less likely to experience 
treatment failure.  Treatment failure was significantly (5% level) more likely in women than 
men (male vs.  female: HR 0.86 95% CI (0.75 to 0.99)), patients taking a non-SANAD 
antiepileptic drug immediately prior to randomisation rather than being treatment naive 
(non-SANAD vs.  naive: HR 1.27 95% CI (1.05 to 1.53)), patients with an epileptiform EEG 
abnormality rather than a normal EEG (abnormal vs.  normal: 1.26 95% CI (1.07 to 1.50)), 
patients with simple or complex partial seizures without secondary generalisation rather 
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than secondary generalised tonic-clonic seizures (secondary generalised vs.  simple or 
complex: HR 0.78 95% CI (0.66 to 0.91)), epilepsy that is not localised rather than temporal 
lobe epilepsy (not localised vs.  temporal: HR 1.25 95% CI (1.06 to 1.47)) and patients taking 
carbamazepine rather than lamotrigine (lamotrigine vs.  carbamazepine: HR 0.76 95% CI 
(0.61 to 0.95)).   
In order to illustrate the range of treatment failure rates predicted by the multivariable 
model, Figure 6 gives estimates of the proportion of patients having treatment failure 
events at 1 and 3 years after randomisation for patients treated with either carbamazepine 
or lamotrigine together with the associated 95% confidence intervals.  Patients were 
assumed to be treatment naive, have normal EEG results, simple or complex partial 
seizures and temporal lobe epilepsy.   
In general, based on the forest plots in Figure 6 and consequently a subset of the SANAD 
data, overall treatment failure rates are lowest in patients treated with lamotrigine.  There 
is a slight decrease in the risk of failure with an increase in age and men have a slightly 
lower chance of treatment failure than women.  There is also a very slight increase in the 
chance of treatment failure with an increase in total number of seizures ever before 
randomisation. 
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Table 6: The SANAD Trial – arm A: Univariate and Multivariable Hazard Ratios and Confidence Intervals for 
Overall Time to Treatment Failure 
 Hazard Ratio (95% CI) 
Prognostic Factor Comparison Univariate p-value Univariate Multivariable 
Gender 
Female 
Male 
0.01 
1.00 
0.82 (0.72 to 0.95) 
1.00 
0.86 (0.75 to 0.99) 
Febrile seizure 
history 
Absent 
Present 
0.78 
1.00 
1.05 (0.77 to 1.43) 
N/A 
First degree relative 
with epilepsy 
Absent 
Present 
0.15 
1.00 
1.18 (0.95 to 1.48) 
NA 
CT/MR scan result 
Normal 
Abnormal 
Not Done 
0.79 
1.00 
1.06 (0.90 to 1.24) 
1.01 (0.82 to 1.24) 
N/A 
Treatment history 
Treatment naive 
Seizures after remission 
Taking non-SANAD AEDs 
0.01 
1.00 
1.44 (0.93 to 2.24) 
1.32 (1.10 to 1.59) 
1.00 
1.35 (0.87 to 2.10) 
1.27 (1.05 to 1.53) 
Age (years) 
[Linear] 
≤10 
(10 to 24) 
(25 to 36) 
(37 to 49) 
(50 to 70) 
>71 
0.02 
1.00 
0.95 (0.92 to 0.99) 
0.89 (0.82 to 0.98) 
0.84 (0.73 to 0.97) 
0.78 (0.63 to 0.96) 
0.71 (0.54 to 0.94) 
1.00 
0.95 (0.91 to 0.99) 
0.88 (0.80 to 0.97) 
0.82 (0.71 to 0.96) 
0.76 (0.61 to 0.94) 
0.68 (0.51 to 0.91) 
Time from 1st 
seizure (months) 
[Log] 
≤2 
(2 to 5) 
(6 to 17) 
(18 to 59) 
(60 to 239) 
>240 
0.00 
1.00 
1.04 (1.01 to 1.06) 
1.07 (1.02 to 1.12) 
1.10 (1.03 to 1.18) 
1.11 (1.05 to 1.19) 
1.17 (1.05 to 1.30) 
N/A 
Neurological insult 
Absent 
Present 
0.67 
1.00 
1.05 (0.85 to 1.30) 
N/A 
Total number of 
seizures 
[Scale: 100, power: 
0] 
≤2 
(2 to 3) 
(4 to 11) 
(12 to 50) 
(51 to 299) 
>300 
0.00 
1.00 
1.03 (1.02 to 1.03) 
1.09 (1.07 to 1.12) 
1.19 (1.13 to 1.25) 
1.33 (1.23 to 1.44) 
1.61 (1.41 to 1.84) 
1.00 
1.02 (1.01 to 1.03) 
1.08 (1.05 to 1.11) 
1.17 (1.10 to 1.23) 
1.28 (1.17 to 1.40) 
1.52 (1.31 to 1.76) 
EEG results 
Normal 
Not done 
Non-specific abnormality 
Epileptiform abnormality 
0.02 
1.00 
1.22 (0.95 to 1.57) 
1.22 (0.99 to 1.49) 
1.27 (1.08 to 1.50) 
1.00 
1.25 (0.96 to 1.61) 
1.20 (0.98 to 1.47) 
1.26 (1.07 to 1.50) 
Epilepsy type 
Focal 
Unclassified 
0.02 
1.00 
0.74 (0.57 to 0.96) 
N/A 
Seizure type 
Simple or complex partial only 
2° Generalised tonic-clonic 
Uncertain 
0.00 
1.00 
0.77 (0.66 to 0.89) 
0.62 (0.47 to 0.81) 
1.00 
0.78 (0.66 to 0.91) 
0.33 (0.05 to 2.37) 
Focal epilepsy site 
of onset 
Temporal 
Not localised 
Frontal 
Other 
Unclassified 
0.13 
1.00 
1.04 (0.89 to 1.22) 
1.08 (0.81 to 1.45) 
0.87 (0.63 to 1.20) 
0.75 (0.57 to 0.99) 
1.00 
1.25 (1.06 to 1.47) 
1.18 (0.88 to 1.58) 
0.92 (0.66 to 1.28) 
2.69 (0.37 to 19.74) 
Treatment 
Carbamazepine 
Gabapentin 
Lamotrigine 
Oxcarbazepine 
Topiramate 
0.00 
1.00 
1.18 (0.96 to 1.45) 
0.75 (0.60 to 0.94) 
0.93 (0.71 to 1.22) 
1.21 (0.99 to 1.49) 
1.00 
1.23 (1.00 to 1.51) 
0.76 (0.61 to 0.95) 
0.94 (0.72 to 1.23) 
1.23 (1.00 to 1.52) 
Hazard ratio greater than 1 indicates that treatment failure is more likely in the alternative group than in the 
baseline group. 
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Risk Factors 
Patients with treatment failure at 
1 year 
% (95% CI) 
Patients with treatment failure at 3 
years 
% (95% CI) 
Age Gender Seizures Treatment Total Total 
10 M 2 CBZ 27 (21 to 35) 42 (33 to 52) 
10 F 2 CBZ 31 (24 to 39) 47 (37 to 58) 
10 M 2 LTG 21 (16 to 28) 34 (26 to 43) 
10 F 2 LTG 24 (18 to 31) 38 (30 to 48) 
10 M 10 CBZ 32 (25 to 40) 49 (40 to 59) 
10 F 10 CBZ 36 (29 to 45) 54 (45 to 64) 
10 M 10 LTG 25 (20 to 32) 40 (32 to 49) 
10 F 10 LTG 29 (22 to 36) 45 (36 to 54) 
40 M 2 CBZ 23 (18 to 30) 37 (30 to 46) 
40 F 2 CBZ 27 (21 to 34) 42 (34 to 51) 
40 M 2 LTG 18 (14 to 24) 30 (23 to 38) 
40 F 2 LTG 21 (16 to 27) 34 (26 to 42) 
40 M 10 CBZ 28 (23 to 34) 44 (36 to 52) 
40 F 10 CBZ 32 (26 to 39) 49 (41 to 57) 
40 M 10 LTG 22 (17 to 28) 35 (28 to 43) 
40 F 10 LTG 25 (20 to 31) 40 (32 to 48) 
75 M 2 CBZ 20 (15 to 26) 32 (25 to 41) 
75 F 2 CBZ 23 (17 to 30) 36 (28 to 45) 
75 M 2 LTG 15 (11 to 21) 25 (19 to 33) 
75 F 2 LTG 18 (13 to 24) 29 (22 to 37) 
75 M 10 CBZ 24 (19 to 30) 38 (30 to 47) 
75 F 10 CBZ 27 (21 to 34) 42 (34 to 52) 
75 M 10 LTG 19 (14 to 24) 30 (23 to 38) 
75 F 10 LTG 21 (16 to 28) 34 (27 to 43) 
 
 
Figure 6: The SANAD Trial – arm A: Combination of Risk Factors for Time to Treatment Failure  
(N.B. ‘Seizures’ is ‘Total Number of Seizures before randomisation’ variable) 
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4.3.2 Time to Treatment Failure due to Competing Risks 
Table 7: The SANAD Trial – arm A: Multivariable Hazard Ratios and Confidence Intervals for Time to 
Treatment Failure - Competing Risks Analysis: Full model (all variables) 
 Hazard Ratio (95% CI) 
Prognostic 
Factor 
Comparison Inadequate Seizure Control Unacceptable Adverse Events 
Gender 
Female 
Male  
1.00 
1.06 (0.85 to 1.31) 
1.00 
0.80 (0.66 to 0.98) 
Febrile 
seizure 
history 
Absent 
Present 
1.00 
0.90 (0.55 to 1.49) 
1.00 
1.09 (0.69 to 1.72) 
First degree 
relative  
Absent 
Present 
1.00 
0.88 (0.62 to 1.27) 
1.00 
1.26 (0.92 to 1.72) 
CT/MR scan 
result 
Normal 
Abnormal 
Not Done 
1.00 
1.38 (1.08 to 1.77) 
0.77 (0.55 to 1.08) 
1.00 
0.90 (0.70 to 1.15) 
1.16 (0.87 to 1.56) 
Treatment 
history 
Treatment naive 
Seizures after remission 
Taking non-SANAD AED 
1.00 
0.58 (0.22 to 1.50) 
1.76 (1.34 to 2.31) 
1.00 
1.77 (0.99 to 3.17) 
0.92 (0.68 to 1.23) 
Age (years) 
[Linear] 
≤10 
(10 to 24) 
(25 to 36) 
(37 to 49) 
(50 to 70) 
>71 
1.00 
0.84 (0.79 to 0.90) 
0.67 (0.57 to 0.78) 
0.54 (0.42 to 0.68) 
0.40 (0.29 to 0.57) 
0.29 (0.18 to 0.47) 
1.00 
1.06 (1.01 to 1.12) 
1.15 (1.01 to 1.31) 
1.24 (1.02 to 1.52) 
1.38 (1.03 to 1.84) 
1.54 (1.04 to 2.28) 
Time from 1st 
seizure 
(years) 
[Log] 
≤2 
(2 to 5) 
(6 to 17) 
(18 to 59) 
(60 to 239) 
>240 
1.00 
0.90 (0.86 to 0.95) 
0.83 (0.77 to 0.90) 
0.76 (0.68 to 0.86) 
0.76 (0.67 to 0.86) 
0.65 (0.54 to 0.79) 
1.00 
1.08 (1.03 to 1.12) 
1.14 (1.05 to 1.23) 
1.21 (1.08 to 1.36) 
1.22 (1.09 to 1.38) 
1.36 (1.13 to 1.64) 
Neurological 
insult 
Absent 
Present 
1.00 
0.83 (0.59 to 1.16) 
1.00 
1.07 (0.78 to 1.48) 
Total number 
of seizures 
[Scale: 100, 
power: 0] 
≤2 
(2 to 3) 
(4 to 11) 
(12 to 50) 
(51 to 299) 
>300 
1.00 
1.05 (1.04 to 1.07) 
1.20 (1.15 to 1.26) 
1.44 (1.32 to 1.57) 
1.80 (1.56 to 2.09) 
2.69 (2.11 to 3.44) 
1.00 
0.99 (0.97 to 1.00) 
0.95 (0.91 to 1.00) 
0.91 (0.83 to 1.00) 
0.86 (0.74 to 1.00) 
0.77 (0.60 to 1.00) 
EEG results 
Normal 
Missing 
Non-specific abnormality 
Epileptiform abnormality 
1.00 
0.78 (0.50 to 1.22) 
0.99 (0.72 to 1.37) 
1.13 (0.88 to 1.46) 
1.00 
1.34 (0.94 to 1.91) 
1.20 (0.90 to 1.60) 
1.15 (0.90 to 1.48) 
Seizure type 
Simple or complex focal only 
2° Generalised tonic-clonic 
Unclassified 
1.00 
1.07 (0.84 to 1.36) 
0.77 (0.10 to 6.08) 
1.00 
0.66 (0.52 to 0.82) 
Could not be estimated 
Focal 
Epilepsy Site 
of Onset 
Temporal 
Not Localised 
Frontal 
Other 
Unclassified 
1.00 
1.19 (0.92 to 1.52) 
0.93 (0.61 to 1.44) 
1.05 (0.66 to 1.67) 
1.38 (0.17 to 11.20) 
1.00 
1.18 (0.93 to 1.48) 
1.31 (0.85 to 2.01) 
0.76 (0.45 to 1.29) 
Could not be estimated 
Treatment 
Carbamazepine 
Gabapentin 
Lamotrigine 
Oxcarbazepine 
Topiramate 
1.00 
2.53 (1.85 to 3.47) 
1.08 (0.77 to 1.52) 
1.14 (0.73 to 1.77) 
1.45 (1.04 to 2.03) 
1.00 
0.58 (0.43 to 0.79) 
0.62 (0.45 to 0.84) 
0.84 (0.59 to 1.20) 
1.02 (0.78 to 1.33) 
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Table 7 shows multivariable results for a competing risks analysis for time to treatment 
failure for our two treatment failure categories; inadequate seizure control and adverse 
events.  Two models were fitted, one using all thirteen potential prognostic factors and one 
using only the variables included in the parsimonious multivariable model for overall 
treatment failure.  This latter model was fitted to determine if any of the results seen in the 
overall model can be explained by the effects of either or both of the competing risks.  
Results for the model using only the variables included in the parsimonious model for 
treatment failure can be seen in Table 8.  Results for the full multivariable model for the 
competing risks outcome can be seen in Table 7.   
In Table 7 two results could not be estimated.  The reason for the unusual results is that the 
two categories in question have exactly the same patients with treatment failure due to 
unacceptable adverse events.  A sensitivity analysis was undertaken to see the effect of this 
occurrence and it was found to have no implication on the model - the model was robust to 
removal of seizure type and focal epilepsy site of onset in turn and also to collapsing of the 
latter two categories of each of the offending variables in turn.  
4.3.2.1 Treatment Failure due to Inadequate Seizure Control 
For time to treatment failure due to inadequate seizure control the significant variables (5% 
level) according to the matched multivariable model (Table 8) were treatment history, age, 
number of seizures before randomisation, and treatment.  Compared to treatment naive 
patients, patients already taking a non-SANAD AED had a higher treatment failure rate 
(taking non-SANAD AED vs.  treatment naive: HR 1.56 95% CI (1.20 to 2.03)).  For age a 
linear effect was observed with older patients significantly less likely to have a treatment 
failure than younger patients (see discussion below also), while treatment failure rates 
increased significantly with increasing number of seizures before randomisation.   
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4.3.2.2 Treatment Failure due to Unacceptable Adverse Events 
For treatment failure due to adverse events the variables significantly (5% level) associated 
with outcome, according to the matched multivariable model (Table 8), were gender, 
treatment history, age, seizure type, and treatment.  Women were more likely to have 
treatment failure than men (male vs.  female: HR 0.81 95% CI (0.66 to 0.98)).   Patients 
restarting treatment following a period of remission had a higher treatment failure rate 
than treatment naive patients (seizures after remission vs.  treatment naive: HR 2.13 95% 
CI (1.22 to 3.73)).  For age a linear effect was observed with older patients significantly 
more likely to have a treatment failure than younger patients (see discussion below also).  
Patients with simple or complex partial seizures were significantly more likely to have a 
treatment failure than patients with secondary generalised tonic clonic seizures (secondary 
generalised tonic clonic vs.  simple or complex partial: HR 0.69 95% CI (0.55 to 0.86)).   
As shown in Figure 7, for time to treatment failure for any reason, according to the 
multivariable model, as age increases the likelihood of treatment failure decreases.  
However when the reason for treatment failure is considered an X-shaped plot is produced; 
the likelihood of treatment failure due to inadequate seizure control decreases with age 
while the likelihood of treatment failure due to unacceptable adverse events increases with 
age.  More explicitly, younger patients are at a higher risk of withdrawal due to inadequate 
seizure control whereas younger patients are at a lower risk of withdrawal due to 
unacceptable adverse events.  A similar X-shaped plot is produced for number of seizures 
before randomisation.  In the analysis of treatment failure for any reason the likelihood of 
treatment failure increased with number of seizures.  When the reason for treatment is 
considered, the likelihood of treatment failure due to inadequate seizure control increases 
with number of seizures while the likelihood of failure due to adverse events decreases 
(slightly) with number of seizures, therefore patients with a smaller number of seizures 
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before randomisation are at a higher risk of withdrawal due to unacceptable adverse 
events but lower risk of withdrawal due to inadequate seizure control. 
 
 
Solid lines are used for hazard ratio estimates while dotted lines represent confidence intervals. 
Figure 7: The SANAD Trial – arm A: Relative Hazard Plots for Age and Total Number of Seizures for the 
Outcome Time to Treatment Failure 
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Table 8: The SANAD Trial – arm A: Univariate and Multivariable Hazard Ratios and Confidence Intervals for 
Time to Treatment Failure - Competing Risks Analysis 
Hazard Ratio (95% CI) 
 Inadequate Seizure Control Unacceptable Adverse Events 
Prognostic 
Factor 
Comparison Univariate Multivariable Univariate Multivariable 
Gender 
Female 
Male 
1.00 
0.96 (0.78 to 1.18) 
1.00 
1.06 (0.86 to 1.31) 
1.00 
0.79 (0.65 to 0.97) 
1.00 
0.81 (0.66 to 0.98) 
Febrile 
seizure 
history 
Absent 
Present 
1.00 
0.94 (0.59 to 1.49) 
N/A 
1.00 
1.06 (0.68 to 1.65) 
N/A 
First 
degree 
relative 
Absent 
Present 
1.00 
0.99 (0.70 to 1.41) 
N/A 
1.00 
1.19 (0.87 to 1.62) 
N/A 
CT/MR 
scan result 
Normal 
Abnormal 
Not Done 
1.00 
1.18 (0.94 to 1.49) 
0.74 (0.53 to 1.03) 
N/A 
1.00 
0.98 (0.77 to 1.24) 
1.21 (0.93 to 1.58) 
N/A 
Treatment 
history 
Treatment 
naive 
Seizures after 
remission 
Taking non-
SANAD AED 
1.00 
 
0.61 (0.25 to 1.50) 
 
1.72 (1.34 to 2.19) 
 
1.00 
 
0.48 (0.19 to 1.23) 
 
1.56 (1.20 to 2.03) 
 
1.00 
 
1.89 (1.10 to 3.24) 
 
0.95 (0.72 to 1.26) 
 
1.00 
 
2.13 1.22 to 3.73) 
 
1.00 (0.75 to 1.33) 
 
Age 
(years) 
[Linear] 
≤10 
(10 to 24) 
(25 to 36) 
(37 to 49) 
(50 to 70) 
>71 
1.00 
0.85 (0.80 to 0.90) 
0.68 (0.60 to 0.78) 
0.56 (0.45 to 0.69) 
0.43 (0.32 to 0.58) 
0.32 (0.21 to 0.48) 
1.00 
0.85 (0.79 to 0.90) 
0.68 (0.58 to 0.78) 
0.55 (0.44 to 0.69) 
0.42 (0.30 to 0.58) 
0.31 (0.19 to 0.48) 
1.00 
1.07 (1.02 to 1.13) 
1.18 (1.04 to 1.34) 
1.29 (1.07 to 1.56) 
1.45 (1.10 to 1.91) 
1.65 (1.13 to 2.39) 
1.00 
1.06 (1.00 to 1.12) 
1.14 (1.01 to 1.30) 
1.23 (1.01 to 1.49) 
1.35 (1.02 to 1.79) 
1.50 (1.02 to 2.20) 
Time from 
1st seizure 
(months) 
[Log] 
≤2 
(2 to 5) 
(6 to 17) 
(18 to 59) 
(60 to 239) 
>240 
1.00 
1.00 (0.96 to 1.03) 
0.99 (0.93 to 1.06) 
0.99 (0.89 to 1.09) 
0.99 (0.89 to 1.10) 
0.98 (0.84 to 1.15) 
N/A 
1.00 
1.06 (1.02 to 1.09) 
1.10 (1.04 to 1.17) 
1.16 (1.05 to 1.27) 
1.16 (1.05 to 1.28) 
1.26 (1.09 to 1.46) 
N/A 
Neurologi
cal insult 
Absent 
Present 
1.00 
1.09 (0.80 to 1.47) 
N/A 
1.00 
1.03 (0.76 to 1.40) 
N/A 
Total 
number of 
seizures 
[Scale: 
100, 
power: 0] 
≤2 
(2 to 3) 
(4 to 11) 
(12 to 50) 
(51 to 299) 
>300 
1.00 
1.04 (1.03 to 1.05) 
1.14 (1.10 to 1.18) 
1.29 (1.21 to 1.38) 
1.52 (1.36 to 1.69) 
2.01 (1.67 to 2.42) 
1.00 
1.04 (1.03 to 1.05) 
1.14 (1.09 to 1.18) 
1.29 (1.19 to 1.39) 
1.51 (1.33 to 1.71) 
2.00 (1.62 to 2.47) 
1.00 
1.00 (0.99 to 1.01) 
1.01 (0.98 to 1.05) 
1.02 (0.95 to 1.10) 
1.04 (0.93 to 1.17) 
1.07 (0.88 to 1.30) 
1.00 
1.00 (0.99 to 1.01) 
0.99 (0.95 to 1.04) 
0.99 (0.91 to 1.07) 
0.98 (0.86 to 1.12) 
0.97 (0.77 to 1.21) 
EEG 
results 
Normal 
Not done 
Non-specific 
abnormality 
Epileptiform 
abnormality 
1.00 
0.81 (0.53 to 1.24) 
1.02 (0.75 to 1.38) 
 
1.34 (1.07 to 1.69) 
 
1.00 
0.79 (0.51 to 1.22) 
1.01 (0.74 to 1.38) 
 
1.21 (0.94 to 1.55) 
 
1.00 
1.33 (0.95 to 1.86) 
1.24 (0.94 to 1.64) 
 
1.34 (1.07 to 1.69) 
 
1.00 
1.34 (0.95 to 1.88) 
1.21 (0.91 to 1.61) 
 
1.11 (0.87 to 1.41) 
 
Epilepsy 
type 
Focal 
Unclassified 
1.00 
0.64 (0.43 to 0.96) 
N/A 
1.00 
0.90 (0.64 to 1.27) 
N/A 
Seizure 
type 
Simple or 
complex partial 
only 
2° Generalised 
tonic-clonic 
Unclassified 
 
1.00 
 
 
0.98 (0.78 to 1.22) 
 
0.65 (0.42 to 0.99) 
 
1.00 
 
 
1.01 (0.79 to 1.28) 
 
0.76 (0.08 to 7.29) 
 
1.00 
 
 
0.71 (0.58 to 0.87) 
 
0.71 (0.47 to 1.02) 
 
1.00 
 
 
0.69 (0.55 to 0.86) 
 
Could not be 
estimated 
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Hazard Ratio (95% CI) 
Inadequate Seizure Control Unacceptable Adverse Events 
Prognostic 
Factor 
Comparison Univariate Multivariable Univariate Multivariable 
Focal 
epilepsy 
site of 
onset 
Temporal 
Not localised 
Frontal 
Other 
Unclassified 
 
1.00 
1.00 (0.79 to 1.26) 
1.04 (0.68 to 1.58) 
1.08 (0.69 to 1.68) 
0.65 (0.42 to 0.99) 
 
1.00 
1.18 (0.92 to 1.51) 
1.04 (0.69 to 1.59) 
1.04 (0.66 to 1.66) 
1.28 (0.13 to 
12.72) 
 
1.00 
1.04 (0.83 to 1.30) 
1.13 (0.75 to 1.70) 
0.70 (0.43 to 1.15) 
0.91 (0.63 to 1.31) 
 
1.00 
1.17 (0.93 to 1.48) 
1.24 (0.81 to 1.90) 
0.76 (0.45 to 1.26) 
Could not be 
estimated 
Treatment 
Carbamazepine 
Gabapentin 
Lamotrigine 
Oxcarbazepine 
Topiramate 
1.00 
2.40 (1.77 to 3.25) 
1.10 (0.78 to 1.55) 
1.12 (0.73 to 1.71) 
1.39 (1.00 to 1.94) 
1.00 
2.45 (1.80 to 3.34) 
1.05 (0.75 to 1.48) 
1.12 (0.73 to 1.73) 
1.44 (1.03 to 2.00) 
1.00 
0.58 (0.43 to 0.78) 
0.61 (0.45 to 0.82) 
0.82 (0.57 to 1.16) 
1.01 (0.77 to 1.31) 
1.00 
0.59 (0.43 to 0.80) 
0.62 (0.46 to 0.85) 
0.84 (0.59 to 1.20) 
1.01 (0.77 to 1.32) 
 
Hazard ratio greater than 1 indicates that treatment failure is more likely in the alternative group than in the 
baseline group. 
4.3.3 Time to 12 Month Remission 
Results for both the univariate and the multivariable analyses for the outcome time to 12 
month remission are summarised in Table 9.  In the univariate analyses the variables 
significantly associated with time to 12 month remission at the 5% level were gender, 
treatment history, age, time from first seizure to randomisation, neurological insult, total 
number of seizures before randomisation, epilepsy type, seizure type, focal epilepsy site of 
onset, and treatment.  Of these, the parsimonious multivariable model did not include 
epilepsy type or seizure type but did include CT/MR scan results.   
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Table 9: The SANAD Trial – arm A: Univariate and Multivariable Hazard Ratios and 95% Confidence Intervals 
for Time to 12 Month Remission 
 Hazard Ratio (95% Confidence Interval) 
Prognostic Factor Comparison Univariate p-value Univariate Multivariable 
Gender 
Female 
Male 
0.00 
1.00 
1.21 (1.07 to 1.37) 
1.00 
1.19 (1.05 to 1.35) 
Febrile seizure history 
Absent 
Present 
0.89 
1.00 
1.02 (0.78 to 1.34) 
N/A 
First degree relative 
with epilepsy 
Absent 
Present 
0.85 
1.00 
0.98 (0.80 to 1.20) 
N/A 
CT/MR scan result 
Normal 
Abnormal 
Not Done 
0.08 
1.00 
0.89 (0.77 to 1.03) 
1.12 (0.94 to 1.33) 
1.00 
0.88 (0.76 to 1.03) 
1.12 (0.93 to 1.34) 
Treatment history 
Treatment naive 
Seizures after remission 
Taking non-SANAD AED 
0.00 
1.00 
1.09 (0.72 to 1.63) 
0.55 (0.46 to 0.67) 
1.00 
1.06 (0.70 to 1.61) 
0.64 (0.52 to 0.78) 
Age (years) 
[Scale: 100, 
powers: 1, 2] 
≤10 
(10 to 24) 
(25 to 36) 
(37 to 49) 
(50 to 70) 
>71 
0.00 
1.00 
0.84 (0.77 to 0.93) 
0.76 (0.64 to 0.91) 
0.79 (0.63 to 0.98) 
1.00 (0.81 to 1.24) 
1.56 (1.26 to 1.98) 
1.00 
0.88 (0.79 to 0.97) 
0.82 (0.68 to 0.99) 
0.85 (0.68 to 1.07) 
1.07 (0.86 to 1.34) 
1.60 (1.26 to 2.03) 
Time from 1st seizure 
(months) 
[Scale: 1000, 
power: 1] 
≤2 
(2 to 5) 
(6 to 17) 
(18 to 59) 
(60 to 239) 
>240 
0.00 
1.00 
1.00 (0.99 to 1.00) 
0.98 (0.98 to 0.99) 
0.95 (0.93 to 0.98) 
0.95 (0.92 to 0.97) 
0.69 (0.57 to 0.84) 
1.00 
1.00 (1.00 to 1.01) 
1.01 (1.00 to 1.02) 
1.03 (1.00 to 1.07) 
1.14 (1.01 to 1.29) 
1.39 (1.04 to 1.86) 
Neurological insult 
Absent 
Present 
0.00 
1.00 
0.72 (0.59 to 0.89) 
1.00 
0.75 (0.61 to 0.93) 
Total number of 
seizures 
[Log] 
≤2 
(2,3) 
(4,11) 
(12,50) 
(51,299) 
>300 
0.00 
1.00 
0.96 (0.95 to 0.97) 
0.87 (0.85 to 0.89) 
0.76 (0.72 to 0.80) 
0.64 (0.59 to 0.69) 
0.47 (0.41 to 0.54) 
1.00 
0.96 (0.95 to 0.97) 
0.87 (0.85 to 0.90) 
0.76 (0.72 to 0.81) 
0.65 (0.59 to 0.71) 
0.48 (0.41 to 0.56) 
EEG results 
Normal 
Not done 
Non-specific abnormality 
Specific abnormality 
0.73 
1.00 
0.96 (0.76 to 1.22) 
1.09 (0.92 to 1.31) 
1.00 (0.86 to 1.15) 
N/A 
Epilepsy type 
Focal 
Unclassified 
0.00 
1.00 
1.59 (1.31 to 1.93) 
N/A 
Seizure type 
Simple or complex partial only 
2° Generalised tonic-clonic 
Uncertain 
0.00 
1.00 
1.01 (0.88 to 1.16) 
1.63 (1.32 to 2.01) 
N/A 
Focal epilepsy site of 
onset 
Temporal 
Not localised 
Frontal 
Other 
Unclassified 
0.00 
1.00 
0.98 (0.85, 1.13) 
1.02 (0.79, 1.32) 
1.10 (0.84, 1.42) 
1.59 (1.29, 1.96) 
1.00 
0.87 (0.75, 1.02) 
1.12 (0.86, 1.45) 
1.02 (0.78, 1.34) 
1.15 (0.87, 1.44) 
Treatment 
Carbamazepine 
Gabapentin 
Lamotrigine 
Oxcarbazepine 
Topiramate 
0.02 
1.00 
0.75 (0.62 to 0.90) 
0.93 (0.78 to 1.11) 
0.99 (0.79 to 1.24) 
0.84 (0.70 to 1.01) 
1.00 
0.71 (0.59 to 0.86) 
0.90 (0.75 to 1.08) 
0.97 (0.77 to 1.22) 
0.81 (0.68 to 0.98) 
Hazard ratio greater than 1 indicates that 12 month remission is more likely in the alternative group than in the 
baseline group. 
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Solid lines represent the hazard ratio estimates while the dotted lines represent the confidence interval 
estimates. 
Figure 8: The SANAD Trial – arm A: Hazard ratio plots for age, time from first seizure to randomisation and 
total number of seizures for the outcome time to 12 month remission 
 
Focusing on the results of the multivariable model, for age, the relation is U-shaped with 
patients aged less than or equal to 10 years old or over 71 years having a significantly 
higher chance of remission (Figure 8).  The relationship between the other significant (5% 
level) variables in the multivariable model and time to 12 month remission are as follows; 
males had a higher 12 month remission rate than females (male vs.  female: HR 1.19 95% CI 
(1.05 to 1.35)); treatment naive patients had a higher 12 month remission rate than 
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patients currently taking a non-SANAD antiepileptic drug (taking non-SANAD AED vs.  
treatment naive: HR 0.64 (0.52 to 0.78)); 12-month remission rates decreased with an 
increasing number of seizures before randomisation, for example compared to patients 
with two seizures the estimate for patients with two to three seizures is 0.96 (0.95 to 0.97) 
and for patients with four to 11 seizures is 0.87 (0.85 to 0.90).  Regarding treatment, 12 
month remission rates were significantly higher for patients on carbamazepine than for 
those on gabapentin (gabapentin vs.  carbamazepine: 0.71 (0.59 to 0.86)) or topiramate 
(topiramate vs.  carbamazepine: HR 0.81 (0.68 to 0.98)).  Plots for the continuous variables 
within the multivariable model can be seen in Figure 8.   
In order to illustrate the range of 12 month remission rates predicted by the multivariable 
model, Figure 9 shows estimates of the proportion of patients achieving a remission one 
and three years after randomisation for patients treated with either carbamazepine or 
lamotrigine together with the associated 95% confidence intervals.  Patients were assumed 
to be treatment naive, have been randomised six months from their first seizure, not have 
neurological insult, have normal CT/MR result and have temporal lobe epilepsy.  In the 
subset of combinations considered, remission rates are highest in older patients.  Males are 
slightly more likely to achieve remission than women as are patients with fewer seizures.  
There is a very minor increase in probability of remission in patients on carbamazepine 
compared to those on lamotrigine. 
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Risk Factors 
Percentage of patients achieving 12 month remission, together 
with 95% confidence intervals at: 
Age Gender 
Seizures before 
randomisation 
Treatment 1 year 3 years 
10 Male 2 CBZ 47 (39 to 56) 92 (86 to 97) 
10 Female 2 CBZ 42 (34 to 50) 89 (81 to 94) 
10 Male 2 LTG 44 (36 to 52) 90 (83 to 95) 
10 Female 2 LTG 38 (31 to 47) 86 (78 to 92) 
10 Male 10 CBZ 36 (30 to 43) 83 (76 to 90) 
10 Female 10 CBZ 31 (25 to 38) 78 (70 to 85) 
10 Male 10 LTG 33 (27 to 40) 80 (72 to 87) 
10 Female 10 LTG 29 (23 to 35) 74 (66 to 82) 
40 Male 2 CBZ 43 (36 to 50) 89 (83 to 94) 
40 Female 2 CBZ 37 (31 to 45) 85 (78 to 91) 
40 Male 2 LTG 39 (32 to 47) 87 (79 to 92) 
40 Female 2 LTG 34 (28 to 41) 82 (74 to 88) 
40 Male 10 CBZ 32 (27 to 38) 79 (72 to 86) 
40 Female 10 CBZ 28 (23 to 33) 73 (66 to 80) 
40 Male 10 LTG 29 (24 to 35) 75 (67 to 83) 
40 Female 10 LTG 25 (21 to 31) 69 (61 to 77) 
75 Male 2 CBZ 63 (53 to 73) 98 (95 to 100) 
75 Female 2 CBZ 57 (48 to 67) 97 (92 to 99) 
75 Male 2 LTG 59 (49 to 70) 97 (93 to 99) 
75 Female 2 LTG 53 (44 to 63) 95 (90 to 98) 
75 Male 10 CBZ 50 (42 to 60) 94 (88 to 98) 
75 Female 10 CBZ 45 (36 to 53) 91 (84 to 95) 
75 Male 10 LTG 47 (38 to 56) 92 (85 to 96) 
75 Female 10 LTG 41 (33 to 50) 88 (80 to 94) 
 
 
Figure 9: The SANAD Trial – arm A: Combination of Risk Factors for Time to 12 Month Remission  
(N.B. ‘Seizures’ is ‘Total Number of Seizures before randomisation’ variable) 
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4.4 Discussion 
Predicting outcome in epilepsy is complex but necessary to inform patient counselling 
about prognosis and treatment choices.  Numerous clinical factors have been indentified in 
this chapter that influence the outcome measures time to treatment failure and time to 12 
month remission.  Multivariable models have also been produced that will inform clinicians 
and patients about likely outcomes. 
SANAD remains the largest randomised control trial in epilepsy and includes data on long 
term treatment outcomes which is vital if we are to inform the management of this chronic 
condition.  The dataset provides an unrivalled opportunity to investigate factors that 
influence treatment outcome for patients starting antiepileptic drug monotherapy.  SANAD 
recruited a heterogeneous group of patients which some have criticised [188, 189] but this 
can also be argued as a strength, as illustrated by this chapter, as the inclusion of a large 
heterogeneous population of patients enables a thorough investigation of factors that 
influence treatment outcome.   
Given that SANAD is a large dataset it is perhaps unsurprising that around nine prognostic 
covariates have been identified.  Obviously, of more importance than the statistical 
significance of these covariates is the ability of the models to predict outcome.  In this 
chapter we only provide a sense of this via the tables of probabilities of events at one and 
three years for various covariate combinations.  In Chapter 7, internal validation of these 
models is considered which provides a measure of how good they are at predicting the 
outcomes. 
Blinding a long term trial such as SANAD poses significant challenges, for example, patient 
groups such as women of child-bearing age potentially might be excluded.  The blinding 
would need a double dummy approach which could affect compliance and would come at 
significant expense such that it would be unaffordable to public funders such as the 
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National Institute for Health Research Health Technology Assessment programme.  SANAD 
was therefore an un-blinded trial which could have influenced outcome assessment, for 
example decisions as to whether a treatment had failed, although examination of dosing 
data indicates that reasonable doses were tried before a decision was made that treatment 
had failed.   
While randomised controlled trials are the best methodology for assessing treatment 
outcomes, they might recruit a selected population which might influence estimates of 
prognosis.  Ideally SANAD should have recruited a greater proportion of children and 
elderly patients; nonetheless the analysis has clearly identified the influence of age on 
outcome.   Additionally, the inclusion criteria for SANAD were broad.  There were few 
exclusion criteria and the vast majority of patients with a new diagnosis of epilepsy were 
eligible for inclusion.  Therefore, we believe that there are sufficient data provided for the 
clinicians to make a judgment.  Hence, in general terms the SANAD recruits should be fairly 
representative of a completely unselected population based cohort, that, ideally, a 
prognostic model would be based on. 
While some advocate separate trials for adults and children [190, 191], assuming that 
relative treatment responses differ according to age, our results emphasise the importance 
of trials that recruit a wide age range of patients, allowing a thorough investigation of the 
influence of age upon treatment outcome.  This is reinforced by the X-shaped relationship 
between age and reasons for treatment failure.  The notion that separate trials in children 
would be an inefficient approach to estimating treatment effects is supported by the EMAs 
decision to allow data from adults to be extrapolated to children down to the age of four 
for licensing purposes.   
Although randomised controlled trials might be an optimal design to detect treatment 
effects, they may not be ideal for building prognostic models, given that trials tend to 
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exclude subjects with comorbidities for safety reasons, and possibly select amongst those 
that are eligible a more motivated group.  However a population based study would be 
confounded in any assessment of relative treatment effects. 
For a prognostic model, it might well be that there are subgroups in which the model does 
not predict well for example children vs. adults.   We explored interactions for the models 
presented in this chapter.  No treatment-covariate interaction terms were found for time 
to 12 month remission and two were found for time to treatment failure - focal epilepsy 
site of onset and total number of seizures ever before randomisation.  Although these 
terms could easily be included in the multivariable model, interpretation of the results was 
very difficult due to the large number (6 levels of seizure category, 5 levels of treatment 
and 5 levels of lobe = 150) of possible combinations of interaction terms.  Both interactions 
were significant for inadequate seizure control only, and not for failure due to adverse 
effects.  Given that results for 12 month remission were also presented, which is a pure 
seizure outcome, we have not presented these data.  
While we have presented a number of predictive models that can further inform patient 
counselling and treatment decisions, ideally these models require validation in other 
similar datasets and the predictive power of the model also needs to be explored.  
Unfortunately there are no other datasets that are similar to SANAD.  The best match is a 
set of individual participant data collected by the Tudur Smith et al [192].  However this 
data is missing important covariates and the treatments patients were randomised to do 
not always coincide with SANAD drugs.  Therefore more work needs to be undertaken to 
determine how best to overcome these difficulties – see Chapters 8 and 9.    
While other prognostic models have been undertaken in epilepsy [119, 193, 194] no 
alternative epilepsy monotherapy trial has had sufficient power to thoroughly investigate 
prognostic factors.  Related datasets include the NGPSE study [195] and the MESS study 
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[133] as described in section 2.6.  NGPSE was a large prospective GP based observational 
study based on an unselected cohort of patients.  The only independent predictor of one 
year and two year remission was the number of seizures experienced by the patient in the 
six months after the first seizure.  It is important to note though that many patients in 
NGPSE were not prescribed antiepileptic drugs.  MESS was an unmasked, multicentre, 
randomised study of immediate and deferred antiepileptic drug treatment in 1447 patients 
with single seizures and early epilepsy.  Number of seizures of all types at presentation, 
presence of a neurological disorder, and an abnormal EEG were significant factors in 
indicating future seizures.   
Our results highlight the heterogeneity in terms of outcome in epilepsy and the complex 
interplay between the factors that influence it, given the numerous factors identified in our 
models.  Patients with differing risks of treatment failure, for unacceptable adverse events 
or inadequate seizures control, and differing risks of 12 month remission can however be 
identified at the point in time when antiepileptic drug treatment is initiated.  This is 
emphasised by the data presented in Figure 6 and Figure 9.  These data will inform patient 
counselling and inform decisions about monitoring and follow-up. 
While clinical predictors of outcome have been identified, the mechanism by which these 
factors influence outcome remain poorly understood, and it is likely that many are 
surrogates for underlying pathological processes.  Also, some variability in outcome 
remains unexplained, and we have not been able to identify factors that influence response 
to a specific drug.  There is much interest in personalised medicine and pharmacogenetics, 
although to date this endeavour has not identified genetic factors that predict outcome.  
Studies such as SANAD in which clinical outcome data and DNA are collected alongside one 
another should provide a powerful resource to investigate clinical and genetic predictors of 
outcome, and consortia pulling together such cohorts are evolving and should soon be 
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providing results.  We do of course need reliable evidence about outcome and predictors of 
outcome associated with newer drugs such as levetiracetam, zonisamide and lacosamide, 
and long term trials assessing these drugs are urgently required to inform clinical decision 
making and policy. 
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Chapter 5: Implications for Drivers 
with a First Seizure  
5.1 Introduction 
This Chapter begins with an overview of driving regulations both within the U.K. and 
further afield (section 5.1).  In section 5.2 the Multicentre centre for Early epilepsy and 
Single Seizures (MESS) is introduced and the methods used to calculate risk of seizure 
recurrence following a first ever seizure are calculated.  Results, together with recurrence 
risks for combinations of risk factors, are presented in section 5.3. 
The work in this chapter has been published in the British Medical Journal (BMJ) and I am 
first author.  The BMJ felt that the work was very important.  Consequently, they 
simultaneously published an editorial about the paper.  In addition, as a result of the 
analyses presented in this chapter and in the BMJ article, the DVLA have changed their 
guidelines concerning time off driving for patients with a first seizure.  The work is now 
being considered by the European Union in an attempt to harmonise driving regulations 
across the EU. 
Driving regulations in the European Union currently differ among member states [196] and 
there are extremes in regulations worldwide. In Bulgaria, Central African Republic, China, 
Estonia, Ghana, India, Korea, Pakistan, Portugal, Rwanda, Singapore, Taiwan, Turkey and 
Uzbekistan, a single seizure of any type, at any time in an individual’s life causes indefinite 
loss of driving privileges.  Conversely, in Argentina there are no specific laws prohibiting 
people with epilepsy from driving although patients generally rely on advice from their 
physicians [197, 198].  
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In 1995 and 1996 the International League Against Epilepsy and the International Bureau 
for Epilepsy organised workshops to discuss driving regulations around epilepsy and 
seizures, but the recommendations made were never reflected in an official European 
guideline or in European law.  Following further calls for harmonisation across the 
European Union [199-201] member states have been engaged in a process of identifying 
minimum standards for driving, and these are now in the process of being implemented in 
the United Kingdom and other European Union states.  
Where possible the United Kingdom based Driving and Vehicle Licensing Agency adopt a 
risk based approach to determine who can return to driving after an incapacitating event 
such as an epileptic seizure [202].  Epilepsy comes under the 1988 Road Traffic Act, but 
single seizures, which by definition do not constitute epilepsy, come under the domestic 
regulations (1999 Motor Vehicles (Driving Licences) Regulations).  People who have had a 
single unprovoked seizure are usually allowed to regain their ordinary, group 1, driving 
licence six months after the event provided their risk of a seizure recurrence in the next 
year is below 20%.  Drivers can regain their heavy goods vehicle, group 2, licence after five 
years provided their risk of a seizure recurrence is below 2% and they have been without 
the need for antiepileptic drug treatment for at least five years.  Although these minimum 
risk levels of 20% and 2% are somewhat arbitrary, they are supported by other member 
states [201] and have been adopted in the criteria determining minimum driving standards 
that are being harmonised across the European Union.  
Outside of the European Union there do not appear to be any countries that have such a 
risk based approach.  Within the United States each individual state has its own legislation 
for driving with epilepsy and single seizures.  When surveyed in 2001 [203] 28 states, out of 
a possible 50, including the District of Columbia, required people with epilepsy to be free of 
seizures for single fixed periods with a median restriction of six months (range, 3 to 12 
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months).  23 states adopted more flexible approaches to restricting driving such as varying 
seizure free restrictions based on individual clinical factors.  However, many states allow 
patients to drive after shorter seizure free periods than stated in law which may be because 
these laws are usually unpublished and not readily accessible.  In 13 states the time was 
decided by the treating doctor or a medical advisory board but in six of these states 
clinicians were not legally shielded for their assessments. 
When implementing the new European Union legislation, member states may adopt the 
minimum standard and should not allow a more lenient standard.  Member states can, 
however, adopt a stricter standard provided it can be justified, although it is likely that any 
state that sets a more stringent standard would face a challenge in court.  In October 2009, 
after a discussion at a meeting of the Secretary of State for Transport’s Joint Honorary 
Medical Advisor Panel on Vision and Neurology Disorders, at which the findings in this 
chapter were also discussed, the agency altered its guidance [202].  The new guidance 
stated that after a first unprovoked seizure, drivers may regain their ordinary, group 1, 
licence once they had been seizure free for six months, provided that their risk of a seizure 
recurrence in the next year was below the Driving and Vehicle Licensing Agency’s 20% cut-
off.  Note that the 20% risk threshold was unchanged. 
Very few published studies have estimated the risk of seizure recurrence and/or 
investigated factors that modify risk.  Publications that do exist [119, 204] have focused on 
recurrence immediately after a first seizure and none have presented risks of recurrence in 
the next 12 months at time points such as six or 12 months after an index seizure.  Reliable 
published data are therefore needed to inform Driving and Vehicle Licensing Agency 
guidance, European Union legislation, and legislation outside the European Union as well as 
decisions made by clinicians. 
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MESS [133] was a randomised controlled trial that compared the policies of immediate or 
deferred treatment in people presenting with a first unprovoked seizure or with early 
epilepsy.  The trial remains the largest reported study of patients with single seizures and 
early epilepsy, and although the primary purpose of the study was to compare treatment 
policies, it also provided an important opportunity to examine the risks of seizure 
recurrence and factors that modify those risks.  MESS was used to determine a predictive 
model for the risk of seizure recurrence after a single seizure [119].  The dataset is 
therefore ideal to obtain estimates of seizure recurrence within the next year at various 
time points following an index seizure.   
In this chapter, data from participants with only a single unprovoked seizure, referred to as 
the index seizure, at entry into the MESS study was analysed to estimate seizure recurrence 
risk in the 12 months after the index seizure.  Modelling was used to investigate how 
antiepileptic drug treatment and several clinical factors influence the risk of seizure 
recurrence. 
5.2 Methods 
Patients were eligible for inclusion in the MESS study [133] if they were at least one month 
old; had a history of at least one clinically definite, spontaneous, unprovoked epileptic 
seizure (excluding acute symptomatic seizures or febrile convulsions); and if both the 
clinician and the patient, or carer, were uncertain about whether or not to start 
antiepileptic drug treatment.  Exclusion criteria included previous treatment with 
antiepileptic drugs or the presence of a progressive neurological disease.  
People were recruited to the trial between 1 January 1993 and 31 December 2000 and 
were followed-up, if possible, from 31 December 2001 to 30 June 2002.  After the 
recruiting clinician had obtained informed consent and enrolled the participant, the 
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participant was allocated randomly to treatment policy by telephone or facsimile by way of 
the minimisation method, which was balanced across centre or region and number of 
seizures at randomisation.  For participants assigned to immediate treatment, the clinician 
selected the optimum antiepileptic drug treatment, dose and duration, based on their 
usual practice, and started treatment as early as possible.  Participants assigned to deferred 
treatment received no medication until the clinician and patient agreed that it was 
necessary, mainly after a seizure recurrence. 
Baseline clinical information and demographic data was obtained for all randomised 
participants and those eligible people who did not provide consent for randomisation.  EEG 
was requested for all randomised participants, and brain imaging (CT/MRI) was undertaken 
if clinically indicated.  Follow-up occurred at three, six, and 12 months and successive yearly 
intervals from randomisation, with additional visits as clinically indicated.  At each visit the 
occurrence and type of any seizures was recorded, together with antiepileptic drugs taken, 
if appropriate, and any adverse events.  Date and cause of death were also obtained as 
necessary. 
In the original MESS study primary seizure outcomes were time from randomisation to first 
seizure of any type, time from randomisation to first tonic-clonic seizure, time from 
randomisation to second and fifth seizure of any type, and time from randomisation to two 
year remission of seizures.  Additional primary outcomes were the proportion of patients 
seizure free for two years between one and three years after randomisation and three and 
five years after randomisation.  Secondary clinical outcomes consisted of adverse events in 
each group and quality of life, assessed at randomisation, two years and four years.  
To make the analyses reported here relevant to those of driving age, only participants aged 
16 years or over were included.  16 was chosen as the lower cut-off as, by age 17, after 12 
months of follow-up, these participants would be eligible to apply for a provisional licence.  
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Additionally, interest only lay in participants with a single seizure as the guideline for 
driving differs between these patients and those classified as having epilepsy, defined as at 
least two clinically unprovoked, spontaneous seizures. 
Patients were classified as remote symptomatic if on entry to MESS the clinician considered 
their seizure to be caused by a remote disease such as a head injury; meningitis or 
encephalitis, or both; intracranial surgery; or other disease.  Neurological deficit included 
hemiparesis (weakness on one side of the body) and learning difficulty, while an abnormal 
EEG was defined as epileptiform activity with focal, as shown in Figure 10, or generalised 
spikes, as shown in Figure 11, or spike and slow wave activity, as shown in Figure 12 [205, 
206]. 
 
Figure 10: EEG displaying an abnormal discharge called focal spike 
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Figure 11: EEG displaying an abnormal discharge called a generalised spike and wave 
 
Figure 12: EEG displaying a two-second burst of generalised polyspike-slow wave complex on eye closure in 
patient with eyelid myoclonia with absenses (idiopathic, myoclonic epileptic syndrome) 
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5.2.1 Statistical analysis 
Analyses were undertaken using R version 2.9.2 [182] and SAS version 9 [183]. 
Although MESS was a randomised trial, in this analysis time to event was measured from 
the date of the first seizure, occurring before study entry, referred to as the index seizure, 
and not the date of randomisation.  The outcome of interest was the probability of being 
seizure free for the next 12 months conditional on being seizure free from the index seizure 
to the time point in question.  This outcome is of interest as the Driving and Vehicle 
Licensing Agency require the probability of being seizure free for the next 12 months to be 
less than 20% before a person can regain their ordinary, group 1, driving license.  
The probability of someone who is seizure free at six months after the index seizure, 
remaining seizure free throughout months seven to 18 was calculated by dividing the 
probability of being seizure free for 18 months by the probability of being seizure free for 
six months.  This can be interpreted as the relative probability of being seizure free to 18 
months if six months seizure freedom has already been achieved.  Conditional probabilities 
for other time points were calculated similarly [207].   
Confidence intervals were estimated around the conditional seizure freedom probabilities.  
The variance of these rates was estimated as follows.  Given   time intervals 
                          , let    be the number of deaths during interval  ,   
  be the 
adjusted number at risk for interval  ,      be the probability of surviving past time  , and 
       be the conditional probability of surviving past   conditional on surviving past time 
 .  Then the variance of the conditional probability of surviving past    given survival past 
  , with      , is given by Equation 10 which is a variation of the usual Greenwood’s 
formula for unconditional survival [207, 208].   
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Equation 10 
Var                       
 
 
  
  
    
     
 
     
 
The 95% confidence intervals were constructed assuming that the conditional rates follow 
a normal distribution, and are as shown in Equation 11. 
Equation 11 
                  Var              
Variables associated with a higher risk of seizure recurrence in the next 12 months, both 
univariately and after adjusting for multiple variables, were determined using log-rank tests 
and Cox proportional hazards modelling methods as described in Chapter 3.  A best fitting, 
parsimonious, multivariable model was produced with variable reduction by Akaike’s 
Information Criterion [178], as also described in Chapter 3.  For this model missing values 
were excluded except in the case of EEG results and CT/MRI results, where a third category 
was created for missing results, or test not done, as there was too much missing data to 
ignore and the missingness was informative.  The proportional hazards assumption was 
investigated using Schoenfeld residual plots [173] and incorporation of time-dependent 
covariate effects [175] as described in Chapter 3. 
From the multivariable model the risk of recurrence in the next 12 months for 
combinations of risk factors was calculated [167] as it is important to determine which 
groups of patients are at highest risk of a recurrence and similarly, which patient groups are 
at least risk of a recurrence, not only for driving implications but also for treatment 
implications.  To determine annual recurrence risks for combinations of risk factors the 
baseline survivor function was estimated from the multivariate model assuming a 
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piecewise linear assumption.  The estimate was subsequently raised to a suitable power 
calculated from combinations of variable coefficient estimates [167].  For example if the 
estimated hazard function for the  th patient has the form  
                                    
where         equals unity for male patients and           equals unity for patients with 
a first degree relative with epilepsy, then the estimated survivor function for the  th 
individual is given by 
               
                            
 
where        is the baseline survivor function.  So, for a female with a first degree relative 
with epilepsy, the estimated survivor function for this individual is  
               
        
. 
From this, conditional probabilities can be calculated in the manner described above. 
An extension of this is to determine the length of time until the conditional seizure 
recurrence risk falls below the current Driving and Vehicle Licensing Agency threshold of 
20% for people with various combinations of risk factors.  As in the analysis involving 
combinations of risk factors, seizure recurrence risks can be calculated at each time point 
for any combination of variables within the multivariable model.  The seizure recurrence 
risk in the next 12 months for these combinations can also be calculated for each time 
point making it trivial to determine the time point where the seizure recurrence risk in the 
next 12 months falls below 20%. 
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5.3 Results 
 
Figure 13: The MESS Study: Flow of patients through the study 
Figure 13 shows the flow of patients through the MESS study.  Consent was not obtained 
for 404 of 1847 eligible patients.  The remaining 1443 patients were randomised; 722 to 
immediate antiepileptic drug treatment of whom 317 had a date of index seizure recorded 
and were consequently analysed, and 721 to deferred antiepileptic drug treatment, of 
whom 320 were analysed. Table 10 summarises the characteristics of the analysed 
patients.   
65% of the patients were male, the median age was 33, 16% had remote symptomatic 
seizures, 7% had neurological deficit, 5% had previous acute symptomatic seizures and 10% 
had a first degree relative with epilepsy.  32% of patients were classified with focal epilepsy 
and 66% with generalised epilepsy while 18% of patients had seizures only while asleep, 
49% had abnormal EEG results and 11% had an abnormal CT/MRI result. 
Assessed for eligibility (n=1847) 
Randomised to immediate antiepileptic drug 
treatment (n=722) 
Aged at least 16 years at randomisation 
(n=555) 
Only one seizure before randomisation 
(n=323) 
Had date of index seizure recorded; analysed 
(n=317; 44% of randomised patients) 
Randomised to deferred antiepileptic drug 
treatment (n=721) 
Aged at least 16 years at randomisation 
(n=544) 
Only one seizure before randomisation 
(n=324) 
Had date of index seizure recorded; analysed 
(n=320; 44% of randomised patients) 
Excluded (no consent; n=404) 
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Table 10: The MESS Study: Characteristics of patients; values are numbers (percentages) unless stated 
Characteristic 
Immediate Treatment 
(n=317) 
Delayed Treatment 
(n=320) 
Total 
(n=637) 
Age at randomisation in years, 
median (IQR) 
32.0 (21.5, 49.5) 33.8 (22.4, 50.6) 32.9 (21.9, 50.3) 
Gender 
    Male 
    Female 
 
199 (63) 
118 (37) 
 
213 (67) 
107 (33) 
 
412 (65) 
225 (35) 
Aetiology 
    Remote symptomatic 
    Not remote symptomatic 
 
55 (17) 
262 (83) 
 
49 (15) 
271 (85) 
 
104 (16) 
533 (84) 
Neurological deficit 
    Absent 
    Present 
    Missing 
 
288 (91) 
27 (8) 
2 (1) 
 
299 (94) 
19 (5) 
2 (1) 
 
587 (92) 
46 (7) 
4 (1) 
Previous acute symptomatic seizures 
    Febrile 
    Other 
    No 
 
15 (5) 
1 (0) 
301 (95) 
 
14 (4) 
7 (2) 
299 (94) 
 
29 (5) 
8 (1) 
600 (94) 
Epilepsy in first degree relative 
    Yes 
    No 
 
33 (10) 
284 (90) 
 
34 (11) 
286 (89) 
 
67 (10) 
570 (90) 
Seizures 
    Focal 
    Generalised/not definitely focal 
    Other 
 
102 (32) 
205 (65) 
10 (3) 
 
100 (31) 
217 (68) 
3 (1) 
 
202 (32) 
422 (66) 
13 (2) 
Seizures only while asleep 
    Yes 
    No 
    Missing 
 
65 (20) 
252 (80) 
- 
 
50 (16) 
269 (84) 
1 (0) 
 
115 (18) 
521 (82) 
1 (0) 
EEG results 
    Normal 
    Abnormal 
    Not done/Missing 
 
147(46) 
149 (47) 
21 (7) 
 
136 (43) 
160 (50) 
24 (7) 
 
283 (44) 
309 (49) 
45 (7) 
CT/MRI scan results 
    Normal 
    Abnormal 
    Not done/Missing 
 
219 (69) 
38 (12) 
60 (19) 
 
231 (72) 
34 (11) 
55 (17) 
 
450 (71) 
72 (11) 
115 (18) 
 
Seizures while asleep are very difficult to determine in people who have experienced few 
seizures.  The DVLA guidelines [202] make special provision for this – a person who has 
suffered a seizure whilst asleep must refrain from driving for at least one year from the 
date of seizure, as for patients with seizures while awake.  However, if the person has had a 
seizure whilst asleep more than three years previously, and has not had seizures whilst 
awake since the original seizure whilst asleep, they may be licensed even though seizures 
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during sleep may continue to occur.  Only if a seizure whilst awake occurs subsequently do 
the formal epilepsy regulations apply. 
Table 11 shows the risk of seizure recurrence in the next 12 months for patients 
randomised to immediate or delayed treatment at various time points following an index 
seizure.  For patients randomised to the immediate treatment group the unadjusted risk of 
seizure recurrence in the next 12 months at six months after the index seizure was 14% 
(95% confidence interval 10% to 18%), significantly below 20%.  For the delayed treatment 
group the estimate was 18% but the confidence interval (13% to 23%) did not exclude a 
20% risk of recurrence.  At 12 months, however, the risk was reduced to 10% (6% to 15%), 
significantly below 20%. 
Table 11: The MESS Study: Risk of seizure recurrence over 12 months at time points after index seizure:  
Risk (%, 95% confidence interval) 
 Immediate treatment Delayed treatment 
Time post index 
seizure (months) 
Number at 
Risk 
Risk of seizure in 
following 12 months 
Number at 
Risk 
Risk of seizure in 
following 12 months 
6 260 14 (10 to 18) 254 18 (13 to 23) 
12 230 7 (4 to 11) 219 10 (6 to 15) 
18 211 8 (5 to 12) 197 12 (8 to 17) 
24 199 7 (3 to 10) 182 10 (5 to 14) 
 
The univariate and multivariable results can be seen in Table 12.  In the univariate model, 
factors significantly associated with a higher risk of seizure recurrence in the next 12 
months were a remote symptomatic seizure (remote symptomatic vs. not remote 
symptomatic - HR: 1.45, 95% CI: (1.06 to 1.98)), neurological deficit (present vs. absent - 
HR: 1.80, 95% CI: (1.17 to 2.76)), seizure while asleep (yes vs. no - HR: 1.49, 95% CI: (1.11 to 
2.00)), abnormal EEG result (abnormal vs. normal - HR: 1.62, 95% CI: (1.25 to 2.09)), and 
absence of CT/MRI (not done/missing vs. normal - HR: 1.37, 95% CI: (1.00 to 1.86)).  
Treatment policy was not a significant factor (immediate vs. delayed – HR: 0.83, 95% CI: 
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(0.65 to 1.06)) probably owing to lack of power, as the effect estimate for immediate 
treatment is of a similar magnitude to that in the main analysis of the MESS trial. 
Table 12: The MESS Study: Effect estimates from univariate and multivariable analyses 
Variable Comparison 
Univariate 
p-value 
Univariate hazard 
ratio (95% CI) 
Multivariable hazard 
ratio (95% CI) 
Age at 
randomisation 
[16,25) 
0.71 
1.00 
N/A 
[25, 35) 0.86 (0.59 to 1.23) 
[35, 50) 1.00 (0.72 to 1.39) 
≥ 50 1.08 (0.79 to 1.48) 
Gender 
Male 
Female 
0.42 
1.00 
0.90 (0.69 to 1.16) 
N/A 
Aetiology 
Not remote symptomatic 
Remote symptomatic 
0.02 
1.00 
1.45 (1.06 to 1.98) 
1.00 
1.33 (0.95 to 1.87) 
Neurological 
deficit 
Absent 
Present 
0.01 
1.00 
1.80 (1.17 to 2.76) 
N/A 
Acute 
symptomatic 
seizures 
None 
0.96 
1.00 
N/A Febrile seizure(s) 0.98 (0.55 to 1.75) 
Other 1.17 (0.37 to 3.65) 
Epilepsy in first 
degree relative 
No 
Yes 
0.07 
1.00 
1.37 (0.97 to 1.94) 
1.00 
1.33 (0.94 to 1.90) 
Seizure type 
Generalised or not definitely focal 
0.23 
1.00 
N/A Partial 0.79 (0.61 to 1.04) 
Other 0.83 (0.34 to 2.01) 
Seizures only 
while asleep 
No 
Yes 
0.01 
1.00 
1.49 (1.11 to 2.00) 
1.00 
1.47 (1.09 to 1.97) 
EEG results 
Normal 
0.00 
1.00 1.00 
Abnormal 1.62 (1.25 to 2.09) 1.55 (1.20 to 2.01) 
Not done/Missing 1.48 (0.86 to 2.55)* 1.29 (0.74 to 2.27)* 
CT/MRI scan 
results 
Normal 
0.08 
1.00 1.00 
Abnormal 1.32 (0.91 to 1.91)* 1.07 (0.72 to 1.61) 
Not done/Missing 1.37 (1.00 to 1.86) 1.29 (0.94 to 1.78) 
Treatment policy 
Delayed 
Immediate 
0.13 
1.00 
0.83 (0.65 to 1.06) 
1.00 
0.82 (0.64 to 1.05) 
 
Table 13 shows the risk estimates for seizure recurrence in the next 12 months at several 
time points after the index seizure based on the univariate analysis for the variables with 
significant hazard ratios.  At six months the estimate for patients with a neurological deficit 
was above 20%, although the confidence interval (13% to 49%) did not exclude the 
possibility of the risk being below 20%.  By 12 months the estimate was 20% which is on 
the threshold set by the DVLA.  The risk of recurrence in the next year at six months for 
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patients with remote symptomatic epilepsy was 20% (10% to 30%) which reduced to 13% 
by 12 months although this estimate is still not significantly below 20% (4% to 22%). 
Table 13: The MESS Study: Risk of seizure recurrence over 12 months at time points after index seizure: 
univariate model 
Variables 
Risk of recurrence at time points (95% CI) 
6 months 12 months 18 months 
Cause of seizure:    
    Not remote  
        symptomatic 
15 (12 to 19) 8 (5 to 11) 11 (7 to 14) 
    Remote symptomatic 20 (10 to 30) 13 (4 to 22) 9 (1 to 17) 
Neurological deficit:    
    Absent 15 (12 to 18) 8 (6 to 11) 11 (7 to 14) 
    Present 31 (13 to 49) 20 (2 to 37) — 
Seizures only while 
asleep: 
   
    Yes 19 (11 to 28) 10 (3 to 17) 11 (3 to 19) 
    No 15 (12 to 19) 9 (6 to 12) 10 (6 to 13) 
EEG results:    
    Normal 13 (9 to 17) 6 (3 to 9) 8 (4 to 12) 
    Abnormal 19 (14 to 24) 12 (8 to 17) 13 (8 to 18) 
  Not done or missing* 15 (1 to 29) 10 (0 to 23) — 
*Missing entries arose as a result of insufficient follow-up data or insufficient participant numbers. 
As described in Chapter 3 and in section 5.2.1, the multivariable Cox model was developed 
with variable selection by AIC – the model with the smallest AIC was chosen as the best 
fitting model – selection starts with the full model and eliminates predictors one at a time, 
at each step considering whether the criterion will be improved, smaller AIC, by adding 
back in a variable removed at a previous step [178].  The parsimonious model (Table 12) 
included variables for aetiology (cause of the seizure), epilepsy in a first degree relative, 
seizure while asleep, EEG result, CT/MRI result, and treatment policy, which was forced 
into the model.  From the model, seizure while asleep (yes vs. no – HR: 1.47, 95% CI (1.09 
to 1.97)), and an abnormal EEG result (not done/missing vs. normal – HR: 1.37, 95% CI (1.00 
to 1.86)) were associated with a higher risk of seizure recurrence in the next 12 months, 
but again treatment policy was not a significant factor (immediate vs. delayed – HR: 0.83, 
95% CI (0.65 to 1.06)). 
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Figure 14: The MESS Study: Survival function over time for treatment policy 
 
Figure 15: The MESS Study: Schoenfeld residuals for treatment policy 
 
There was no evidence to suggest that the proportional hazards assumption, underlying 
the Cox model, was invalid – in the case of treatment policy, for example.  The graph of the 
survival function versus the survival time shows almost parallel curves (Figure 14) and the 
p-value for the test of the Schoenfeld residuals was 0.96 which was not significant so 
together with Figure 15, there is no reason to doubt the proportional hazards assumption. 
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The risk of recurrence at 12 months for patients with various combinations of risk factors 
(i.e. varying characteristics) was estimated from the parsimonious multivariable regression 
model.  As a large number of combinations was possible Table 14 shows selected results for 
remote and non-remote symptomatic seizure, EEG result, and CT/MRI results assuming 
that the index seizure was not during sleep and that participants did not have a first degree 
relative with epilepsy.  Appendix A shows the estimates for all possible combinations of 
factors. 
Table 14: The MESS Study: Risk of seizure recurrence in next 12 months estimated from multivariable model 
at specific seizure free periods.  Estimates presented assume seizures not confined to sleep and no first 
degree relative with epilepsy 
Cause of 
seizure 
Test results 
Months 
from index 
seizure 
Immediate treatment Delayed treatment 
EEG CT/MRI 
Risk of seizure 
in next 12 
months  
(%, 95% CI) 
Months 
from index 
seizure until 
annual risk 
falls <20% 
Risk of seizure 
in next 12 
months  
(%, 95% CI) 
Months 
from index 
seizure until 
annual risk 
falls <20% 
Not remote 
symptomatic 
Normal Normal 
6 13 (10 to 16)* 
1.2 
16 (12 to 19)* 
3.2 
12 7 (5 to 10)* 9 (6 to 12)* 
Not remote 
symptomatic 
Abnormal Normal 
6 20 (16 to 23) 
5.5 
23 (20 to 26) 
7.0 
12 11 (9 to 14)* 13 (11 to 16)* 
Not remote 
symptomatic 
Normal Abnormal 
6 14 (11 to 17)* 
2.1 
17 (14 to 20) 
3.6 
12 8 (5 to 11)* 10 (7 to 12)* 
Not remote 
symptomatic 
Abnormal Abnormal 
6 21 (18 to 24) 
6.1 
25 (22 to 28)† 
8.1 
12 12 (9 to 15)* 14 (12 to 17)* 
Remote 
symptomatic 
Normal Normal 
6 17 (14 to 20) 
3.6 
20 (17 to 23) 
6.0 
12 10 (7 to 12)* 12 (9 to 14)* 
Remote 
symptomatic 
Abnormal Normal 
6 25 (22 to 28)† 
8.7 
30 (27 to 32)† 
10.7 
12 15 (12 to 17)* 18 (15 to 20) 
Remote 
symptomatic 
Normal Abnormal 
6 18 (15 to 21) 
4.8 
22 (19 to 25) 
6.5 
12 10 (8 to 13)* 13 (10 to 15)* 
Remote 
symptomatic 
Abnormal Abnormal 
6 27 (24 to 30)† 
9.2 
32 (29 to 34)† 
11.3 
12 16 (13 to 18)* 19 (16 to 21) 
*Confidence interval lies completely below 20%. †Confidence interval lies completely above 20%. 
 
Although the unadjusted results suggested that patients who start treatment after a single 
seizure and are seizure free for six months, on average have a less than 20% risk of 
recurrence in the next 12 months, our multivariable results indicated that the risk in some 
subgroups was significantly greater than 20%.  This included patients with a remote 
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symptomatic seizure and an abnormal EEG result whether or not their CT/MRI result was 
normal.  For patients with a non-remote symptomatic seizure, abnormal EEG result and 
abnormal CT/MRI scan result the estimate was higher than 20% but the lower end of the 
confidence interval was less than 20% suggesting that some people with that combination 
of risk factors may have a less than 20% risk of seizure recurrence in the next 12 months.   
The estimate from the unadjusted results suggested that patients who had not started AED 
treatment after a single seizure and who were seizure free for six months had a less than 
20% risk of recurrence in the next 12 months.  However, the multivariable results indicated 
that some subgroups had a recurrence risk significantly greater than 20%.  This included 
patients with an abnormal EEG result and abnormal CT/MRI result whether or not their 
seizure was remote symptomatic.  This also included patients with a remote symptomatic 
seizure and an abnormal EEG result whether or not their CT/MRI result was normal.  
For some subgroups the estimate was higher than 20% but the confidence interval included 
or the lower bound of the confidence interval was less than 20%.  For example, patients 
with a remote symptomatic seizure, an abnormal EEG result and an abnormal CT/MRI 
result, and patients with a remote symptomatic seizure, a normal EEG result and abnormal 
CT/MRI  result.  This again highlights that although the group contains patients with a risk 
of seizure recurrence in the next 12 months in excess of 20%, some may have a risk that is 
below this threshold, set by the Driving and Vehicle Licensing Agency. 
5.4 Discussion 
MESS was a randomised trial comparing the policies of immediate or delayed treatment for 
patients presenting with a single seizure or early epilepsy.  This data can be used to 
estimate time from a first to second seizure, and for the purposes of informing driving 
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regulations, the risk of a further seizure following a specific period of seizure freedom can 
be calculated.  
The unadjusted estimates suggest that after a first seizure, the overall risk of a recurrence 
in the 12 months after a seizure free period of six months is below 20%.  The confidence 
intervals around these estimates suggest that this risk is significantly below 20% for 
patients who start antiepileptic drug treatment (risk 14%, 95% confidence interval (10% to 
18%)), but not for those who do not (risk 18%, 95% confidence interval (13% to 23%)).  
The univariate and multivariable analyses allow the identification of patients that are at 
differing risks of recurrence and hence those that might be at high or low risk of recurrence 
at specific time points after a first seizure.  In the multivariable analyses, patient subgroups 
were identified whose risk was significantly more than 20% irrespective of the treatment 
policy.  Hence guidance is needed from driving regulators as to how far to individualise risk 
and whether clinicians should focus on unadjusted results when making recommendations 
about driving, or on results from univariate or multivariable models. 
It could be argued that at the population level the risk, ignoring the confidence interval, of 
a seizure recurrence is below 20% after a six month seizure free period, thus all patients 
should be able to regain their driving licence, which would be in keeping with the new 
European Union standards, accepting that some in the population will have a risk above 
20%.  Alternatively a more conservative approach could be taken to individualise risk.  The 
multivariable model identified several subgroups that had a risk of recurrence that is 
significantly greater than 20% after a six month seizure free period, this includes those with 
a non-remote symptomatic seizure who do not start treatment and have both an abnormal 
EEG result and an abnormal CT/MRI result and those with a remote symptomatic seizure 
and an abnormal EEG result, irrespective of the result for CT/MRI and treatment policy.  
Additionally the risk estimate for several subgroups was greater than 20%, although the 
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lower confidence limit was below 20%.  Similarly, the estimate for some subgroups was 
below 20% but the upper limit of the confidence interval was above 20%.  These results 
might be used to justify a decision to prevent subgroups with a higher risk of seizure 
recurrence from returning to driving, which is reflected in the current guidance from the 
Driving and Vehicle Licensing Agency.  Any attempt to utilise these data to inform driving 
policy could have important implications on resources for health services, as investigations 
such as EEG may be required that are not otherwise clinically indicated, and patients could 
choose to take AED treatment, which is not otherwise clinically indicated. 
One risk of using a randomised controlled trial such as MESS is the recruitment of a 
selected population that is not necessarily representative of the general population.  This 
raises questions about the generalisability of results.  In MESS, the baseline characteristics 
of patients not randomised were similar to those randomised, which might argue against a 
major selection bias when patients made the decision to enter the trial or not.  However, 
patients were only given the opportunity to enter MESS if the clinician was uncertain about 
the need to start treatment, thus patients entered into MESS might not be representative 
of the general population of patients presenting with a first seizure.  This might have 
resulted in people at low risk of a seizure recurrence not entering the trial as they did not 
want to start treatment, and patients at a high risk of a seizure recurrence not entering the 
trial as they wanted to start treatment.  Given the possibility that patients at both low or 
high risk of a recurrence did not enter MESS it is difficult to predict whether this would 
have caused an underestimation or overestimation of risk for seizure recurrence in the 
unadjusted analyses.  In the multivariable analyses, this might have resulted in an 
overestimation of risk for subgroups at low risk of a recurrence and an underestimation of 
risk for patients at a high risk of a recurrence. 
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In MESS, most participants (75%) were randomised within three months of their first 
seizure.  Thus another potential selection bias is that some patients had a second seizure 
whilst waiting to see a specialist.  These patients were thus likely to start treatment at that 
point rather than join the trial therefore MESS might have recruited patients with a lower 
risk of a seizure recurrence than the general population.  It is unlikely that this has biased 
analyses, however, as patients with a recurrence within six months of their first seizure 
could not contribute to the risk estimates presented in this chapter.  This is because the 
estimates were conditional on being seizure free for six or 12 months after a first seizure.  
In MESS, participants were seen predominantly by neurologists who were experienced at 
identifying and classifying seizures.  However, a further challenge in outpatient based 
studies of seizures and epilepsy, such as MESS, is that seizures are reported to the clinician 
by the patient and it is possible that patients under-report the occurrence of seizures 
although there is no published evidence of this.  Validating patient reporting in an 
outpatient population with infrequent seizures is difficult and to date has not been done.  If 
under-reporting of seizures has occurred, this would result in an underestimate of the risks 
of recurrence. 
Although the possibility and effects of biases from selection and reporting of seizures 
cannot be ruled out, MESS remains the largest reported study of early epilepsy and single 
seizures.  The analyses presented in this chapter enabled an estimation of risk of seizure 
recurrence in the next 12 months after periods of seizure freedom and the identification of 
patients who might be at a high risk of recurrence. 
NGPSE [209] is the only other study where risks of recurrence have been estimated after 
seizure free periods.  As explained in sections 2.7 and 4.4, the trial was a population based 
study that recruited 564 patients with definite new onset seizures.  This included 446 with 
unprovoked seizures, 83 with acute symptomatic seizures, and 35 with alcohol induced 
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seizures.  Overall, 252 patients had a single seizure as their index seizure, whereas the 
remainder were ascertained after their second or a subsequent seizure.  While population 
based studies might be the ideal design to produce generalisable estimates of seizure 
recurrence risks, the results of the NGPSE highlight potential problems with ascertainment 
in epilepsy studies, particularly where the outcome of importance is the risk of recurrence 
after a first seizure.  In their paper assessing recurrence risks after a first seizure, the NGPSE 
group reported analyses for time from first to second seizure for all patients and for the 
subgroup of patients where the index seizure was the first seizure.  Risk estimates of 
recurrence were significantly lower for the group where the index seizure was the first 
seizure: 37% compared with 67% at 12 months [209].  Survival curves were also given for 
the risk of a recurrence for the whole study population for a seizure free period of six, 12, 
or 18 months after a first seizure.  After six months of being seizure free the risk of a 
recurrence over the next 12 months was about 35% for the whole study population, 
substantially higher than the overall estimates in our analyses of MESS: 14% with 
antiepileptic drug treatment and 18% without treatment.  
For the population in NGPSE where the first seizure was the index seizure, which is the 
comparable population in this analysis, the risk of a recurrence over the next 12 months 
after a seizure free period of six months was about 18%, similar to the estimate in this 
analysis of MESS.  This highlights the importance of ascertaining patients after their first 
seizure rather than after a second or subsequent seizure.  Multivariable analyses of the 
NGPSE identified symptomatic seizures, neurological deficit, and no AED treatment as risk 
factors for a recurrence of seizure after a first seizure, which were also identified in MESS.  
Data from the NGPSE have not been used to estimate the risks of recurrence in the next 12 
months for patients seizure free for various periods for individual risk groups, and with a 
fairly small sample size validation may not be reliable. 
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Further research and guidance is required to inform risk based policies, including 
regulations about returning to driving after a single seizure.  To inform recommendations 
about driving, clinicians and patients require guidance as to whether the focus should be 
on risk estimates alone or on risks and their associated confidence intervals.  If the focus is 
on the estimate only, the unadjusted estimates presented here suggest that treated and 
untreated patients are eligible to drive after being seizure free for six months.  If the focus 
is on the risk estimate and its associated confidence interval, a patient who starts 
treatment will be eligible to drive after being seizure free for six months.  For patients who 
do not start treatment the advice depends on the perspective taken.  A conservative 
approach would allow patients to regain their licence once the upper confidence interval 
has dropped below 20%.  However, this would prevent patients who do not start treatment 
from returning to driving after being seizure free for six months, and potentially coerce 
people into taking AED treatment that is not otherwise clinically indicated.  A more liberal 
approach would be to allow people to regain their licence provided that the lower 
confidence limit is below 20%.  This approach could result in those at a high risk of 
recurrence regaining their licence.  An intermediate approach might be to require the risk 
estimate to be below 20% and also to define the upper limit of the confidence interval that 
would be acceptable. 
The conditional probability survival estimates presented here require that long term follow-
up information be available on a large population of patients.  The estimates reported here 
are based on the MESS trial which remains the largest reported study of patients with 
single seizures and early epilepsy.  Even with this large dataset, there were some subgroups 
for which estimate could not be generated. 
Conditional survival estimates appear encouraging for patients in MESS; however different 
patterns may emerge for other patient groups as these patterns are dependent on the 
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underlying hazard rates.  If the hazard rate is decreasing over time, then the conditional 
survival will be better than at time 0, as demonstrated here.  However, if the hazard rate is 
increasing over time then the reverse would be apparent.  If there are no underlying 
changes in the hazard rate over time, then the conditional probabilities will be the same as 
the survival at time 0. 
This reanalysis of MESS provides data that can potentially inform decisions about returning 
to driving for people who have had a first unprovoked seizure.  MESS recruited a broad 
heterogeneous population, which has allowed the investigation of factors that influence 
seizure recurrence as presented in this chapter.  Results should therefore be relevant to the 
general population, but selection bias may be at play and some caution is required in 
interpreting results.  Ideally, external validation of the models presented here is required 
and work is ongoing to establishing a consortium to attempt to validate and refine the 
model presented here.  There are additional challenges to externally validating prognostic 
models, details of which can be found in Chapter 8.  
The MESS data allow an estimation of seizure recurrence risk conditional on having been 
seizure free for six or 12 months.  Further guidance is now required from driving authorities 
as to how these data should be interpreted.  In particular, guidance is needed as to 
whether a population approach should be taken, with a focus on unadjusted results or 
whether attempts should be made to individualise risk.  Guidance is also required as to 
whether the focus should be on risk estimates only or on the confidence interval as well.  If 
the confidence interval is to be included, guidance is needed as to whether the 
conservative, liberal, or intermediate approach should be taken. 
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Chapter 6: Implications for Drivers 
who Withdraw AED Treatment 
6.1 Introduction 
In this chapter a further analysis of data from the Antiepileptic Drug Withdrawal Study is 
presented.  The chapter begins with a background to the U.K. driving regulations for people 
who withdraw treatment following a period of remission from seizures (section 6.1).  The 
Medical Research Council Antiepileptic Drug Withdrawal Study is then introduced (section 
6.2.1).  A systematic review of AED withdrawal studies is also presented (section 6.2.2).  
The risk of seizure recurrence   is presented for people who have had their AED treatment 
withdrawn (section 6.3.2) and for people with a seizure recurrence during or following AED 
withdrawal who then restart treatment (section 6.3.3).   
The work presented in this chapter has been published in the Journal of Neurology, 
Neurosurgery and Psychiatry, and I am first author.  The DVLA are currently considering 
changing their guidelines for time off driving following treatment withdrawal after a period 
of remission as a result of this work. 
Around 60% to 70% of people with epilepsy will enter a remission from seizures on AED 
treatment [69] and many of these will become eligible to drive.  It is common for 
individuals who have had two or more years without seizures to consider AED withdrawal.  
However, a decision to withdraw AED treatment will increase the probability of a seizure 
occurring.  The seizure recurrence risks associated with the policies of continued treatment 
or withdrawal were examined in the Medical Research Council Antiepileptic Drug 
Withdrawal Study [132] which found a two year seizure recurrence risk of 22% with 
continued antiepileptic drug treatment and 41% with withdrawal of treatment.    
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The Driving and Vehicle Licensing Agency currently advises that patients undergoing 
antiepileptic drug withdrawal should not drive while the drug is being withdrawn and for a 
further six months after the last dose has been taken.  If an epileptic seizure does occur and 
treatment is reinstated, a further one year period of seizure freedom [202] is required, as 
per the Road Traffic Act [210].  Following calls for harmonisation across the European 
Union [199, 200, 202], member states have been engaged in a process of identifying 
minimum standards to drive which are now being considered by the United Kingdom and 
other European Union states.  The new European Union standard states that seizures 
occurring during physician advised change or withdrawal of medication requires three 
months without driving if the previously effective treatment is reinstated [199].  At present 
there is little published evidence to support either the United Kingdom or European Union 
standards.  There is therefore a need for reliable published data to inform 
recommendations made about people with epilepsy who have a seizure recurrence when 
withdrawing antiepileptic drug treatment with regards to driving. 
6.2 Methods 
Analyses were undertaken using R version 2.9.2 [182]. 
6.2.1 Antiepileptic Drug Withdrawal Study 
The Medical Research Council Antiepileptic Drug Withdrawal Study (MRC AEDWS) was a 
prospective multicentre randomised study of continued AED treatment versus slow 
withdrawal.  It randomised 1021 patients who had been free from seizures for at least two 
years.  Recruitment began in February 1984 and was completed in June 1988 with follow-
up continuing until June 1989, where possible.  Patients were eligible for entry in the 
Antiepileptic Drug Withdrawal Study provided they had a history of two or more definite 
unprovoked seizures, had been free of all seizures for at least two years, and were taking 
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antiepileptic drugs.  Those who had a progressive neurological disorder or other conditions 
likely to reduce follow-up below two years were excluded.   
Demographic and clinical data on all eligible patients were recorded at entry: presence of 
developmental delay, neurological handicap or neurological disorder; psychiatric history; 
results of most abnormal EEG based on review of historical reports when available; dates of 
first, second and most recent seizures and their classification from clinician’s review of 
historical data; details of AED therapy including starting date, drug and dose at remission of 
seizures and entry; diurnal pattern of seizures and family history of epilepsy; and previous 
unsuccessful attempts at AED withdrawal.   
Consenting patients were randomised to continued treatment or to slow withdrawal of 
AEDs by use of the method of minimisation.  Allocation to the two treatment policies was 
balanced by centre and by the seizure-free period before registration.  Patients randomised 
to slow withdrawal had therapy withdrawn according to guidelines suggested by the 
steering committee with decrements every four weeks.  Physicians were encouraged to 
make smaller decrements in patients receiving small doses of drugs with the aim being to 
extend withdrawal to a minimum of six months.  Patients taking more than one AED had 
the drugs withdrawn sequentially in an order determined by the clinician.  Follow-up was at 
three, six and 12 months and yearly thereafter from the date of randomisation.  At each 
follow-up appointment information was collected about AEDs, including dose and adverse 
events, and dates of any seizures together with a clinical description and whether or not 
AEDs were restarted.  Patients with seizures during follow-up could have their antiepileptic 
drug regimen modified by their clinician.  A Consort type diagram of the patient flow 
through the trial can be seen in Figure 16. 
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Figure 16: MRC AEDWS: Consort Diagram; Bold figures relate to patients used for these analyses 
In this chapter two outcomes were assessed: the risk of a seizure recurrence in the next 12 
months at a number of time points following AED withdrawal; the risk of a seizure 
recurrence in the next 12 months at a number of time points following AED withdrawal, a 
seizure recurrence and reinstatement of AED treatment.  For the purpose of this analysis, 
withdrawal is assumed to have taken exactly six months for each patient as the date of last 
dose was not recorded.  For the risk of recurrence following AED withdrawal, if a person 
Assessed for 
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(n=1797) 
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(n=1021) 
Allocated to slow 
withdrawal 
(n=510) 
Aged at least 16 
(n=406) 
Post-withdrawal 
Seizure free 
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(n=127) 
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Allocated to no 
withdrawal 
(n=503) 
Excluded (n=8) 
- History of only a single seizure (n=3) 
- AED withdrawal before randomisation 
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- Not seizure free before entry (n=1) 
- Withdrew consent (n=1) 
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Excluded (n=776) 
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had a seizure whilst withdrawing they were excluded from the analysis.  In the case of risk 
following seizure recurrence and reinstatement of AED treatment, patients were removed 
from the analysis if they: did not restart medication following a seizure; if they did not 
attempt to withdraw treatment despite being in the withdrawal arm of the study; if they 
were withdrawing treatment, had a seizure and then continued to withdraw; if they were 
withdrawing treatment, had a seizure and did not alter their dose; or if they restarted 
treatment despite not having a seizure. 
This analysis was restricted to patients randomised to slow withdrawal of AED treatment 
and aged at least 16 years.  The outcome of interest is the probability of being seizure free 
for the next 12 months given that a person is seizure free until the time point of interest 
post-withdrawal.  Conditional probabilities were calculated as per Chapter 4 and again 
confidence intervals for these estimates were calculated utilising a revised version of 
Greenwood’s formula [207, 208, 211].  Univariate analyses used log-rank tests and Cox 
proportional hazards modelling methods [31].   
6.2.2 Systematic Review 
The aim of the systematic review was to identify clinical trials that estimated the risk of 
seizure recurrence following antiepileptic drug withdrawal in patients of driving age who 
had been free from seizures for at least 24 months whilst on AED treatment.  Randomised 
controlled trials and prospective observational studies, in which at least 50 patients 
initiated AED withdrawal, were included.  Studies had to include patients with epilepsy 
treated with AED therapy, aged 16 years or over, who had been in remission for at least 
two years.  The search strategy used in MEDLINE can be found in Appendix B. 
Trials were assessed for inclusion by two investigators and one investigator extracted the 
data.  The primary outcome measure was time to seizure recurrence while a secondary 
analysis considered prognostic factors for seizure recurrence.  The risk of seizure 
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recurrence in the next 12 months following AED withdrawal was calculated, where 
possible, for each trial together with the risk following recurrence and reinstatement of 
AED treatment.  This was done using survival estimates obtained from the Kaplan-Meier 
curve. 
Risk of bias was assessed using standard Cochrane methodology in the case of randomised 
controlled trials.  In the case of observational studies, the Newcastle-Ottawa Scale (NOS) 
for assessing the quality of nonrandomised studies in meta-analyses was used [212].  
6.2.2.1 Cochrane Collaboration Tool 
Many tools have been proposed for assessing the quality of studies.  Most tools are scales, 
involving scoring various components of quality and combining them to give a summary 
score.  Alternatively a checklist can be used, in which specific questions are asked [213].  
The Cochrane Collaboration’s recommended tool for assessing risk of bias [214] is neither a 
scale nor a checklist.  Instead, it is a domain-based evaluation, in which critical assessments 
are made separately for different domains.  It was developed between 2005 and 2007 by a 
working group of methodologists, editors and review authors.  It is a two-part tool, 
addressing seven specific areas, namely sequence generation, allocation concealment, 
blinding of participants and personnel, blinding of outcome assessment, incomplete 
outcome data, selective outcome reporting and ‘other issues’. 
Each domain in the tool includes one or more specific entries in a ‘Risk of bias’ table.  For 
each entry, the first part of the tool describes what was reported to have happened in the 
study, while the second part of the tool assigns a judgement relating to the risk of bias for 
that entry; either low, high or unclear risk of bias. 
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6.2.2.2 Newcastle-Ottawa Scale 
Nonrandomised studies, including case-control and cohort studies, can be challenging to 
implement and conduct, however, assessment of the quality of such studies is essential for 
a proper understanding of nonrandomised studies.  The Newcastle-Ottawa Scale (NOS) 
[212] is an ongoing collaboration between the Universities of Newcastle, Australia and 
Ottawa, Canada.  It was developed to assess the quality of nonrandomised studies.  A 'star 
system' has been developed in which a study is judged on three broad perspectives: the 
selection of the study groups; the comparability of the groups; and the ascertainment of 
either the exposure or outcome of interest for case-control or cohort studies respectively.  
Stars are awarded for high quality choices. 
6.3 Results 
6.3.1 Antiepileptic Drug Withdrawal Study 
Table 15 summarises the patient demographics for the populations under analysis.  49% of 
all relevant patients, those randomised to slow withdrawal and aged 16 or over, were male, 
16% had delayed development, 8% had neurological deficit, 18% had a first degree relative 
with epilepsy, 9% had a history of febrile seizures and 78% had abnormal EEG results.  The 
median age at randomisation was 34 with mean duration of epilepsy at randomisation 9 
years, median duration of antiepileptic drug treatment at randomisation 8 years and 
median seizure free period at randomisation 3 years.   
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Table 15: MRC AEDWS: Characteristics of patients undergoing antiepileptic drug withdrawal 
Characteristic, n (%) 
Slow Withdrawal 
Group 16 years and 
older 
(n=406) 
Seizure Free 
Following AED 
Withdrawal 
(n=317) 
Seizure Recurrence 
Following 
Randomisation 
(n=197) 
Gender 
    Male 
    Female 
 
198 (49) 
208 (51) 
 
154 (49) 
163 (51) 
 
96 (49) 
101 (51) 
Development 
    Normal 
    Delayed 
 
343 (84) 
63 (16) 
 
265 (84) 
52 (16) 
 
166 (84) 
31 (16) 
Neurological Deficit 
    Absent 
    Present 
 
372 (92) 
34 (8) 
 
288 (91) 
29 (9) 
 
182 (92) 
15 (8) 
First Degree Relative with 
Epilepsy 
    No 
    Yes 
    Missing 
 
 
338 (83) 
66 (16) 
2 (1) 
 
 
270 (85) 
45 (14) 
2 (1) 
 
 
160 (82) 
36 (18) 
1 (0) 
History of Febrile Seizures 
    No 
    Yes 
    Missing 
 
377 (93) 
27 (6) 
2 (1) 
 
298 (94) 
17 (5) 
2 (1) 
 
179 (91) 
17 (9) 
1 (0) 
EEG Results 
    Normal 
    Abnormal 
    Missing 
 
71 (17) 
239 (59) 
96 (24) 
 
58 (18) 
178 (56) 
81 (26) 
 
34 (22) 
119 (78) 
- 
Age at Randomisation (years) 
    Median (IQR) 
 
34 (24 to 49) 
 
34 (24 to 50) 
 
34 (24 to 47) 
Age at First Seizure (years) 
    Median (IQR) 
 
18 (13 to 30) 
 
19 (13 to 30) 
 
16 (13 to 27) 
Duration of Epilepsy at 
Randomisation (years) 
    Median (IQR) 
 
 
9 (5 to 19) 
 
 
9 (5 to 19) 
 
 
9 (4 to 20) 
Duration of AED Treatment at 
Randomisation (years) 
    Median (IQR) 
 
 
6 (4 to 13) 
 
 
6 (3 to 13) 
 
 
8 (4 to 15) 
Period Seizure Free at 
Randomisation (years) 
    Median (IQR) 
 
 
4 (3 to 6) 
 
 
4 (3 to 6) 
 
 
3 (2 to 5) 
Seizure Types  
(n, % answering ‘yes’) 
    Simple Partial 
    Complex Partial 
    Simple Partial with 2° tonic- 
        clonic 
    Complex Partial with 2° tonic- 
        clonic 
    Tonic-Clonic 
    Myoclonic 
    Simple Absence 
    Complex Absence 
 
 
402 (99) 
377 (93) 
377 (93) 
 
316 (78) 
 
158 (39) 
389 (96) 
388 (96) 
394 (97) 
 
 
313 (99) 
293 (92) 
293 (92) 
 
254 (80) 
 
120 (38) 
309 (98) 
305 (96) 
309 (98) 
 
 
197 (100) 
182 (92) 
182 (92) 
 
155 (79) 
 
75 (38) 
183 (93) 
185 (94) 
189 (96) 
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6.3.2 Recurrence Risk Following Antiepileptic Drug Withdrawal 
Figure 17 shows time to first seizure from the date of complete treatment withdrawal for 
the 317 patients who remained seizure free during AED withdrawal.   
 
Figure 17: MRC AEDWS: Time to first seizure post-withdrawal 
Table 16 shows the probability of having a seizure in the next 12 months given that patients 
were seizure free at various time points post-withdrawal.  At three months following 
treatment withdrawal the estimated 12 month recurrence risk was 15% with 95% 
confidence interval (10% to 19%), significantly below the 20% risk bar set by the Driving 
and Vehicle Licensing Agency.  At six months the estimate was 9% with 95% confidence 
interval (5% to 13%). 
Table 16: MRC AEDWS: Probability of having a seizure in next 12 months at time points following 
antiepileptic drug withdrawal for patients who were seizure free during drug withdrawal 
Time post-
withdrawal 
(months) 
Number at 
Risk 
Number of Events 
from baseline 
Probability of seizure in next 12-months given seizure 
free at stated time post-withdrawal (% (95% CI)) 
0 317 0 30 (25 to 35) 
3 257 64 15 (10 to 19) 
6 235 84 9 (5 to 13) 
12 221 96 9 (5 to 14) 
18 188 105 8 (3 to 13) 
24 126 113 5(0 to 11) 
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Univariate regression analyses indicated that the following variables were significantly 
associated with seizure recurrence risk: duration of antiepileptic drug treatment at 
randomisation (≥20 years vs. 3 years - HR: 2.50, 95% CI: (1.05 to 5.98)) and myoclonic 
seizures (present vs. absent - HR: 2.47, 95% CI: (1.01 to 6.06)).  
6.3.3 Risk Following Recurrence and Recommencing Treatment 
 
Figure 18: MRC AEDWS: Time to first seizure from treatment restart 
Table 17: MRC AEDWS: Probability of having a seizure in next 12 months at time points after reinstating 
antiepileptic drug treatment for patients with a seizure recurrence following randomisation 
Time from 
treatment restart 
(months) 
Number at 
Risk 
Number of events 
from baseline 
Probability of seizure in next 12-months given 
seizure free at stated time post-withdrawal  
(% (95% CI)) 
0 127 0 45 (36 to 53) 
3 87 39 26 (17 to 35) 
6 79 47 18 (10 to 27) 
12 68 57 17 (8 to 27) 
18 62 61 12 (4 to 20) 
24 52 68 5 (0 to 11) 
 
Figure 18 shows time from restarting AED treatment to a further seizure recurrence for 
patients who withdrew treatment, had a further seizure and then reinstated treatment.  At 
three months after reinstating treatment the estimated seizure recurrence risk in the next 
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12 months was 26% with associated 95% confidence interval (17% to 35%), while the 
estimate at six months was 18% with 95% confidence interval (10% to 27%) as shown in 
Table 17. 
Univariate regression analyses indicated that the following were significantly associated 
with a seizure recurrence: history of psychiatric disease (present vs. absent - HR: 1.86, 95% 
Confidence CI: (1.07 to 3.23)), history of status epilepticus (present vs. absent - HR: 2.47, 
95% CI: (1.07 to 5.72)) and complex partial seizures with secondary tonic-clonic seizures 
(present vs. absent - HR: 2.14, 95% CI: (1.29 to 3.55)).  
6.3.4 Systematic Review 
In addition to the Antiepileptic Drug Withdrawal study [132], five studies were found that 
met all the inclusion criteria (Lossius [215], Aktekin [216], Specchio [121], Callaghan [217]  
and Overweg [218]).  Lossius, Antiepileptic Drug Withdrawal study and Callaghan were 
randomised controlled trials.  Lossius and Antiepileptic Drug Withdrawal study compared 
withdrawal to non-withdrawal while, in the case of Callaghan, the cohort had been 
recruited into a trial that compared treatment efficacy.  Patients were then followed up to 
the point of AED withdrawal and beyond.  Aktekin, Specchio and Overweg were 
prospective observational studies.  Characteristics of the included studies can be seen in 
Table 18. 
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Table 18: Studies Meeting the Inclusion Criteria - clinical trials that estimated the risk of seizure recurrence following antiepileptic drug withdrawal in patients of driving age who had 
been free from seizures for at least 24 months whilst on AED treatment 
Study Design 
Number of 
participants 
Setting Age range 
Duration AED 
treatment 
Duration of 
Remission 
Withdrawal policy 
Lossius 
[215] 
Randomised Controlled 
Trial 
168 
Hospital based 
neurological 
outpatient clinics 
18-67 Unknown 2+ years 
AED dose reduction by 
20% of initial dose in 
1
st
 6 weeks and 20% of 
the initial dose every 
2
nd
 week 
Aktekin [216] Observational 79 
Hospital based 
neurological 
outpatient clinics 
Mean ± Standard 
Deviation 
Seizure free: 
38.43±17.35 
Relapsed: 
39.39±13.68 
~ 7 years 4+ years 1/6
th
 every 2 months 
Specchio [121] Observational 330 
Hospital based 
neurological 
outpatient clinics 
< 15: (n=38) 
15-34: (158) 
35-54: (22) 
> 54: (7) 
1+ years 2+ years 
25% of the 
maintenance dose at 
entry was subtracted 
every 3 months or 
longer 
MRC AED Withdrawal 
Study Group [132] 
Randomised Controlled 
Trial 
1013 
Hospital based 
neurological 
outpatient clinics 
Median (IQR) 
27 (17, 42) 
Mean ~ 7 years 2+ years 
Decrements every 4 
weeks 
Callaghan [217] 
Longitudinal Follow-up 
of Randomised 
Controlled Trial 
92 Unknown Mean: 24 Unknown 2+ years 
Dosage decreased by 1 
unit in intervals of 2 
weeks 
Overweg [218] Observational 62 
2 Specialised 
Epilepsy Clinics 
18-60 Unknown 3+ years 
Dosage decreased by 1 
unit in intervals of 2 
weeks 
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Nine other studies (Ohta [219], Shinnar [220], Aldenkamp [221], Mastropaolo [90], 
Ehrhardt [222], Matricardi [91], Arts [94], Bouma [92] and Todt [93]) were found which 
might meet the inclusion criteria listed but further clarification from the authors together 
with individual patient data is required.  For example, some studies in children were long-
term studies and consequently patients may have been at least 16 years of age with at 
least two year remission.  All six included studies reported seizure relapse or recurrence, 
and prognostic factors for seizure recurrence were also reported.  For additional details see 
Table 19.   
There were potentially important differences among the cohorts that could have 
influenced the estimated risks of seizure recurrences.  Two studies recruited only adults 
while four had no age limits.  Specchio recruited patients of all ages, 7% of which were aged 
less than 15 and since data were not available for age subgroups calculations in this review 
were based on the whole study population.  The age of patients in the Callaghan study is 
unclear; the mean age is given as 24 but a standard error is not provided.  The patients 
reported in Callaghan were a subset of 181 patients previously reported in a separate 
publication by Callaghan [223].  Those 181 patients ranged in age from four to 75, however, 
no further information was provided therefore, once again, the whole study population 
was used for the analysis.  Four studies required patients to be in a remission of two or 
more years, one study three or more years and another study four or more years.   
Most of the studies had a low risk of bias, as shown in Table 20. 
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Table 19: Summary of results including predictors for seizure freedom for studies looking at AED withdrawal 
in patients of driving age in remission for at least 24 months on treatment 
Study Results 
Predictors for seizure 
freedom 
Lossius 
Seizure relapse within 12 months: 
7% (non withdrawers), 15% (withdrawers) 
 Prior use of CBZ 
 Neurological 
examination results 
Aktekin 
57% relapsed 
(although 42.8% did not relapse during the discontinuation 
programme) 
 
For patients discontinuing treatment, the probability of relapse 
was 21.4% during the tapering period, 28.6% at 1 month, 14.3% at 
3 months, 3.6% at 6 months, 7.1% at 12 months, 17.8% at 24 
months and 7.1% at 36 months 
 Age at onset  of epilepsy 
 Duration of active 
epilepsy 
Specchio 
In patients continuing treatment, the probability of remission was 
95% at 6 months, 91% at 12 months, 82% at 24 months, 80% at 36 
months and 68% at 60 months  
 
The corresponding values for patients discontinuing treatment 
were 88, 74, 57, 51 and 48% 
 Duration of active 
disease 
 Number of years of 
remission at study entry 
 Psychiatric examination 
results 
AED 
Withdrawal 
Study 
Group 
35% of the randomised patients had a seizure(s) during follow-up  
 
In the slow withdrawal group, 48% seizures occurred in patients 
during AED reduction and 52% after drug withdrawal 
 
In patients continuing treatment, the seizure recurrence per year 
was 14% up to 6 months, 11% up to 12 months, 13% to 18 months, 
11% to 24 months, 9% to 3 years  and 4% to 4 years  
 
The corresponding values for patients discontinuing treatment 
were 40, 37, 16, 14, 6 and 3% 
 Taking two or more AEDs 
at randomisation 
 History of either primary 
or secondarily 
generalised tonic-clonic 
seizure 
 Period free of seizures at 
randomisation 
Callaghan 
Relapse rate 33.7% 
Average duration of remission was 26 months (range 1-62) 
 Number of seizures a 
patient had before 
control was achieved 
 Number of drugs tried as 
single-drug therapy 
 Type of treatment 
withdrawal 
Overweg 
66% patients who completed the study relapsed.  
11% had relapsed by, or prior to, 50% reduction of AEDs, 45% up 
to the point of complete withdrawal of medication and 10 more in 
the following year.   
Three further late recurrences brought the total relapse rate to 
66%. 
 Age at withdrawal 
 Age at onset 
 Age at last seizure 
 Duration of Epilepsy 
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Table 20: Quality Assessment of studies looking at AED withdrawal in patients of driving age in remission for 
at least 24 months on treatment 
Study Item Author’s Judgement Description 
Lossius 
Sequence 
Generation? 
“Randomised in blocks of 10” Low Risk 
Allocation 
Sequence 
Concealment? 
“Receive blindly active medication or placebo in pre-
packed dispensers” 
Low Risk 
Blinding? Double Blind Low Risk 
Aktekin 
Representative of 
exposed cohort? 
Representative of the average epileptic in remission in 
the community 
Low Risk 
Assessment of 
outcome 
Self report (but of obvious outcome) Low Risk 
Adequacy of 
follow-up 
8 years follow-up and only four drop-outs Low Risk 
Specchio 
Representative of 
exposed cohort? 
“Patients discontinuing AEDs were younger, and had a 
poorer education, a shorter disease duration or a normal 
EEG at entry, less frequent seizure relapse after starting 
treatment, a shorter duration of active disease and more 
years of remission” 
High Risk 
Selection of the 
non exposed 
cohort 
Drawn from the same community as the exposed cohort Low Risk 
Assessment of 
outcome 
Self report (but of obvious outcome) Low Risk 
Adequacy of 
follow-up 
16 years follow-up and only 9 drop outs (5 from 
discontinuing group, 4 from continuing group) 
Low Risk 
AED 
Withdrawal 
Study Group 
Sequence 
Generation? 
“Randomisation by minimisation” Low Risk 
Allocation 
Sequence 
Concealment? 
Telephone Service Low Risk 
Blinding? No blinding High Risk 
Callaghan 
Sequence 
Generation? 
Randomisation was based on two Latin squares Low Risk 
Allocation 
Sequence 
Concealment? 
The drug was identified from the randomisation list by a 
person not otherwise involved in the study 
Low Risk 
Blinding? 
The drug was identified from the randomisation list by a 
person not otherwise involved in the study 
Low Risk 
Overweg 
Representative of 
exposed cohort? 
“Heavily weighted with subjects presenting special 
problems, including resistance to therapy.  227 patients 
were nevertheless found who had been seizure-free for 3 
years” 
Low Risk 
Assessment of 
outcome 
Self report (but of obvious outcome) Low Risk 
Adequacy of 
follow-up 
All drop-outs accounted for.  Follow-up continued 
beyond 2 years in some cases 
Low Risk 
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There were also important differences in the policy of AED withdrawal and lack of detail as 
to precisely when AED withdrawal was completed.  In the Lossius study, withdrawal 
commenced one month after recruitment into the study.  In the context of this analysis, 
the mean period of drug withdrawal was 18 weeks which is approximately 4.5 months.  
This is not a reported time point and very difficult to read from the Kaplan-Meier curve.  
Therefore, the mean period was rounded up to six months, a reported time point.  In the 
study reported by Specchio withdrawal is assumed to have taken exactly 12 months.  In 
Callaghan exact time to withdrawal is not known however the Kaplan-Meier curve shows 
the probability of remaining seizure free after the withdrawal of treatment.   
For estimation of the risk of a seizure recurrence in the next 12 months following AED 
withdrawal, Lossius, Specchio, Antiepileptic Drug Withdrawal Study Group and Callaghan 
provide Kaplan-Meier curves with numbers at risk.  Aktekin provides the number of 
patients who had relapsed at various time points and Overweg by the end of the study.  
Table 21 shows estimates for seizure recurrence in the next 12 months at zero, three, six, 
12 and 18 months after antiepileptic drug withdrawal for Lossius, Specchio, Antiepileptic 
Drug Withdrawal Study and Callaghan.  It was not possible to calculate confidence intervals 
for Lossius, Specchio and Callaghan as the number of events or number at risk at time 
points were not given.  Due to differences in study design and lack of sufficient data in 
published literature it was not possible to undertake a meta-analysis of results.  
Immediately following AED withdrawal the risk estimate of a seizure in the next 12 months 
was highest in Antiepileptic Drug Withdrawal Study 30% (95% confidence interval: 25% to 
35%), Callaghan gives a similar estimate at 28%, while the estimate for Lossius was 12% and 
for Specchio, 19%.  At three, six and 12 months following AED withdrawal the estimate 
from the Antiepileptic Drug Withdrawal study is intermediate with Lossius giving a lower 
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risk, Specchio a higher risk and Callaghan giving both lower and higher risks of recurrence in 
the next 12 months. 
For patients who had a seizure recurrence following AED withdrawal and reinstated 
treatment, none of the included papers provide data that enabled a calculation of the risk 
of a seizure recurrence.  
Table 21: Probability of having a seizure in the next 12 months at time points following antiepileptic drug 
withdrawal 
Time post-
withdrawal 
(months) 
Study Number at Risk 
Number of 
Events 
Percentage probability of 
seizure in next 12-months 
given seizure free at stated 
time post-withdrawal 
(95% CI) 
0 
Lossius 
Specchio 
MRC AEDW 
Callaghan 
65 
164 
317 
92 
Unknown 
38 
1 
Unknown 
12 
19 
30 (25 to 35) 
28 
3 
Lossius 
Specchio 
MRC AEDW 
Callaghan 
62 
Unknown 
257 
Unknown 
Unknown 
Unknown 
64 
Unknown 
7 
19 
15 (10 to 19) 
12 
6 
Lossius 
Specchio 
MRC AEDW 
Callaghan 
60 
Unknown 
235 
70 
Unknown 
Unknown 
84 
Unknown 
6 
16 
9 (5 to 13) 
12 
12 
Lossius 
Specchio 
MRC AEDW 
Callaghan 
53 
114 
221 
58 
Unknown 
50 
96 
Unknown 
4 
12 
9 (5 to 14) 
3 
18 
Lossius 
Specchio 
MRC AEDW 
Callaghan 
53 
Unknown 
188 
Unknown 
Unknown 
Unknown 
105 
Unknown 
6 
2 
8 (3 to 13) 
10 
 
6.4 Discussion 
The United Kingdom Driving and Vehicle Licensing Agency take a risk based approach to 
guidance with an individual usually being allowed to regain their ordinary driving license 
once their risk of a seizure in the next 12 months falls below 20% [202].  This re-analysis of 
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data from the Antiepileptic Drug Withdrawal study indicated that for patients who remain 
seizure free during AED withdrawal, the risk of a seizure recurrence in the next 12 months 
immediately following drug withdrawal was 30% (25% to 35%).  Once the patient has been 
seizure free for a further three months the risk is significantly less than 20%, 15% (10% to 
19%), and similarly at later time points.  For patients who have a seizure recurrence during 
or following AED withdrawal and reinstate treatment, their risk of a seizure recurrence in 
the next 12 months immediately after restarting treatment was 45% (36% to 53%) and 
following a further three months seizure freedom the risk was 26% (17% to 35%).  Once the 
patient has been seizure free for six months after restarting treatment the risk estimate 
was below 20% at 18% (10% to 27%) but not significantly so.   
While the Antiepileptic Drug Withdrawal study remains the largest study to assess 
outcomes following AED withdrawal, it does have a number of limitations when used to 
estimate absolute risk of seizure recurrences.  The study is over 20 years old, and 
treatment polices might now differ, particularly given the ever increasing number of AEDs 
available.  Thus there might be important differences in the population of patients offered 
AED withdrawal now compared to 20 years ago.  The ideal study design would be a 
population based cohort study, but the Antiepileptic Drug Withdrawal study was a 
randomized controlled trial designed to compare the policies of continued, or withdrawal 
of, AED treatment, and analyses reported here have used only data for those randomised 
to treatment withdrawal.  Patients entered the study if they were prepared to be 
randomised to either policy and thus selection bias might exist; patients recruited may not 
be representative of the general population as patients at high risk might not have been 
offered entry to the study while patients at low risk might have chosen drug withdrawal 
rather than to join the trial.  Any observational study would suffer from similar selection 
biases as AED withdrawal cannot be imposed upon an unselected population.  A further 
problem with the Antiepileptic Drug Withdrawal Study, and any other outpatient based 
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study of epilepsy, is that seizures are patient reported events and cannot be validated.  
There is thus a risk that patients might under report events, and if this occurred would 
result in an underestimation of the seizure recurrence risk.  
The systematic review identified five studies in addition to the Antiepileptic Drug 
Withdrawal study, three observational studies and two randomised controlled trials.  There 
were potentially important differences among these studies with respect to patient 
populations and withdrawal policy.  Only three of these studies provided data that allowed 
the calculation of seizure recurrence risks following AED withdrawal and at subsequent 
time points.  Lossius reported consistently lower estimates of a seizure recurrence than the 
Antiepileptic Drug Withdrawal Study even though duration of drug withdrawal was 
significantly longer.  Specchio reported consistently higher estimates while Callaghan’s 
results were mixed.  Immediately following AED withdrawal the risk of a seizure in the next 
12 months was estimated at 19% in Specchio, 12% in Lossius and 28% in Callaghan 
compared to an estimate of 30% (25%, 35%) from the Antiepileptic Drug Withdrawal Study.  
Following a further three months seizure freedom after AED withdrawal all four studies 
estimate the risk of a seizure in the next 12 months at below 20%.  Similarly risk estimates 
at subsequent time points are below 20%.      
Confidence intervals for the risk estimates in the published papers were unavailable.  
Parmar et al [224] describe a method to estimate the effective number alive at the start of 
a time interval, the effective number censored in a time interval, the effective number at 
risk in a time interval and the effective number of deaths in a time interval.  The standard 
adaptation of Greenwood’s formula for conditional probabilities, used to estimate the 
confidence intervals in this chapter, requires the number at risk and the number of events 
at each (survival) time point.  Therefore, to obtain confidence intervals for the estimates 
using data from Lossius, Specchio and Callaghan, it would be necessary to calculate the 
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estimates of number of events and number at risk at each possible survival time point 
between estimates (six and 18 months say).  Therefore, although it is possible to calculate 
confidence intervals from the published data, they have not been calculated here which 
means we are reliant on only point estimates.  Ideally, individual patient data would be 
obtained for the studies included in the systematic review and therefore a meta-analysis 
could be performed enabling more reliable estimates concerning risk of seizure recurrence 
to be obtained. 
Data from the Antiepileptic Drug Withdrawal study indicated that patients who withdrew 
AED treatment and then had a further six months of seizure freedom had a risk of a seizure 
recurrence in the next 12 months significantly below 20%.  The current United Kingdom 
guidance therefore avoids allowing patients to return to driving whilst their risk is above 
20%.  In fact the estimate at three months after treatment withdrawal was significantly 
below 20% at 15% (10% to 19%).  It might be therefore that current United Kingdom 
guidance is too conservative and patients might be eligible to return to driving earlier. 
For patients who have a seizure recurrence during or following AED withdrawal and 
reinstate treatment, data from the Antiepileptic Drug Withdrawal study indicated that the 
risk of a seizure recurrence in the next 12 months having been seizure free for six months 
after reinstating treatment was 18%.  However, due to the relatively small sample size, the 
95% confidence interval (10% to 27%) does not exclude a recurrence risk in excess of 20%.  
At three months after recommencing AED treatment, the risk of a seizure in the next 12 
months was estimated at 26% (17% to 35%) while at 12 months after reinstating treatment 
the risk was 17% (8% to 27%).  If the focus is purely upon the point estimates, these data 
suggest that the current United Kingdom legislation is too conservative.  Conversely, the 
new European Union minimum standard appears too liberal.  These data will need to be 
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taken into account by European Union member states as they make decisions about 
adopting the proposed minimum driving standards. 
As highlighted by the systematic review, few published prospective studies have assessed 
seizure recurrence risks following AED withdrawal and none have assessed seizure 
recurrence risks for patients who have a recurrence and reinstate treatment.  Further 
prospective studies are required to inform driving policy and patient counselling.  The 
epilepsies are a heterogeneous group of disorders and it is likely that some patients will be 
at a higher risk of seizure recurrence than others [119, 193, 225] and such studies will need 
to be large enough to allow an examination of predictors of risk.  However, further 
guidance is now required from driving authorities as to if and how to stratify risk when 
considering fitness to drive. 
  
 156 
 
  
 157 
 
Chapter 7: Internal Validation of 
Prognostic Models 
7.1 Introduction 
This chapter begins by explaining the purpose of a prognostic model and therefore 
identifies why validation is an important part of the modelling process.  The chapter then 
goes on to summarise methods for evaluating model performance (section 7.2) and for 
investigating internal validation via apparent (section 7.3.1), split-sample (section 7.3.2), 
cross (section 7.3.3) and bootstrap (section 7.3.4) validation.  Results from the internal 
validation of the prognostic models developed in Chapter 4 are then presented in section 
7.4. 
A predictive model’s purpose is to provide valid outcome predictions for new patients.  
When a prediction model is developed it is important to assess how good the model 
predictions are – this is known as model performance.  The distance between the predicted 
outcome and actual outcome is central to quantifying overall model performance from a 
statistical perspective.  These distances are related to the concept of goodness-of-fit of a 
model with better models having smaller distances between predicted and observed 
outcome. 
Essentially, the dataset used to develop a model is not of interest other than to learn for 
the future.  Validation is therefore an important aspect of the process of predictive 
modelling.  There are two types of validation – internal which assesses model validity for 
the setting where the development data originated from, and external which assesses 
validity in other samples which are fully independent from the development data and 
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originate from different but plausibly related settings.  Internal validity will be considered in 
this chapter whilst external validation will be considered in Chapters 8 and 9. 
7.2 Evaluating Model Performance 
A number of performance measures exist for prediction models many of which are related 
to each other.  From a statistical perspective a small distance between the observed 
outcome and the predicted outcome is desired.  Explained variation can then be used to 
indicate performance and assess the predictability of the outcome.  Measures that are in 
wide use in medical journals today include the concordance statistic (area under the ROC 
curve) for discrimination and various tests for calibration and goodness-of-fit.  
Discrimination and calibration are also considered as measures of external validation.  
Further details about the application of these measures can be found in Chapters 8 and 9. 
7.2.1 Measures of Explained Variation 
In linear regression the coefficient of determination,   , is widely used to indicate how well 
the covariates,  , in the form of a predictor   , ‘reduce the randomness’ in the outcome 
variable   in a particular dataset.     has many attractive properties [226]; it is the square 
of the Pearson correlation coefficient between the predictor    and  , it is maximised by 
the usual least-square or maximum likelihood estimators, it is asymptotically independent 
of the sample size and it is easy to understand and can be explained by graphical means.  
   is a population parameter so it depends not only on   parameters but also on the 
distribution of  .   
For other regression models a similar measure is desired, however, the concept of variance 
or residual variance is more elusive or not uniquely defined.  Generalisation of    to other 
regression models can be done in many ways depending on which properties one wishes to 
retain and which definition one wants to generalise. 
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Various authors have tried to develop a useful    measure for Cox’s model however an 
additional complication in this situation is censoring.  Some authors aim at measuring how 
well the covariates explain the variation in a particular dataset given its censoring structure 
while some aim at measuring how well the covariates actually predict survival in the wider, 
underlying population from which the data were sampled. 
Schemper and Stare [227] suggest that for measures of explained variation for the Cox 
model: the expected value of a measure should not be substantially affected by censoring 
provided that an underlying uncensored population can be assumed [228]; a measure 
should not be affected by monotonic transformation of the time scale as the estimation of 
the coefficients in the Cox model is also invariant to such transformation; a measure should 
have an intuitively clear interpretation [229]; if a dataset could alternatively be analysed by 
a linear model the resulting values of explained variation should be similar for both 
approaches; and a measure should also be robust when applied to mis-specified models.  
There are further criteria [229] which should be met, such as independence from the units 
of measurements of model variables, and a range of possible values between 0 and 1.   
Several measures of explained variation have been suggested for the Cox model.  These are 
outlined in sections 7.2.1.1 to 7.2.1.9 together with a description of their adherence to the 
criteria. 
7.2.1.1 Spearman, Kendall and Somer 
When attempting to measure the correlation between two sets of data, various correlation 
coefficients may be used.  In particular, two non-parametric correlation coefficients are 
Spearman’s rank correlation coefficient,   , and Kendall’s rank correlation coefficient,   
[230].  Of these, Spearman’s is more widely used [231].  In significance testing both 
measures usually produce very similar results [232].  Although Kendall’s   is more 
demanding from a calculation point of view, its distribution approaches normality more 
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rapidly than Spearman’s   .  Additionally, although the two coefficients produce similar 
results, Spearman’s    tends to be larger than Kendall’s   in absolute value [232].  Somers’ 
  is an ordinal measure of association introduced by Somers [233].  It can be defined in 
terms of Kendall’s  .  Both Somers’   and Kendall’s   are conservative estimates of the 
degree of relationship between the dependent variable and the independent variable 
[234].  Somers’   is different from Kendall’s   in that it only makes a correction for tied 
pairs on the independent variable [235]. 
Korn and Simon [236] suggest an approach to calculate Somers’ D which in general requires 
numerical integration and leads to results dependent on the choice of   , a common 
censoring time for all survival times, which cannot exceed the maximum observed survival 
time.  Brown et al. [237] suggested two generalisations of Kendall’s   for censored data 
which are both biased towards zero as their ‘imputation’ for an undefined score from the 
comparison of two survival times does not take into account the correlation of the 
covariates.   
The definition of   -measures based on the squared correlation of the predictor and of 
survival for the general linear model is appealing for its simplicity.  It is obvious that  , 
denoting any of the standard correlation coefficients, has to be replaced by a measure of 
monotonic association as the relationship between predictor and outcome is non-linear but 
usually monotonic.  Furthermore, to be consistent with the Cox model, the measure should 
only use the order of survival times.  Therefore, Spearman’s   , Kendall’s  , Somers’   or 
related measures are appropriate in this situation. 
A hybrid of   and    is     (partial ranking); this coefficient is the Pearson correlation,  , of 
the predictor    and the ranks of survival time  .    It is more consistent with the semi-
parametric character of the Cox model, and its superiority over    can be demonstrated for 
a model with a strong binary and a weak continuous covariate [238].  
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7.2.1.2 Schemper (& Henderson) 
In 1990 Schemper described a  measure,    [239], based on a measure of the proportion of 
explained variation, a generalisation of the sum of squares definition of   , with 
differences being calculated on the axis of survival proportion rather than survival times.  
Schemper also proposed [239] a measure    which is identical to    except for the squaring 
of the averaged residuals which are omitted.     is preferred over    because of the 
consistency with related methodology.  Additionally, in the case of   , the Kaplan-Meier 
estimator produces means of the individual survival process under the assumption of non-
informative censoring and these means minimise the average squared ‘residuals’.  
Both measures are, however, dependent on the amount of censoring and therefore violate 
the first criterion for an assumed uncensored population.  Schemper’s approaches permit a 
very intuitive interpretation:  the measures quantify the degree to which prediction of the 
values of an individual survival process can be improved when replacing the unconditional 
with the conditional expectation (survival functions) of the process. 
None of the measures described in sections 7.2.1.1 and neither    and   , which relate to 
the    definition based on the squared correlation of the predictor and of survival, provide 
an unbiased estimate of the correlation in an uncensored population from a censored 
population [227].  However, in 1997 Schemper accomplished this using multiple imputation 
[240].  In this technique, censored survival times are terminated with random residual 
lifetimes to become uncensored survival times.  The algorithm enforces consistency with 
the estimates from the Cox model and with observed conditional distributions of survival 
times.  Several such augmented datasets are generated, a measure of association between 
survival and predictor being calculated for each and the squared average association taken 
as the explained variation. 
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With the multiple imputation algorithm, proposed by Schemper [240], the computed 
values of all rank correlation measures considered in section 7.2.1.1,   
 ,    
 ,    and   , are 
unaffected by censoring and are also invariant under transformation of survival time.  Only 
   
  is sensitive to transformation of the explanatory variables, thus being more consistent 
with the assumptions underlying the Cox model than the others.  Also, the criterion of good 
intuitive interpretability and simplicity is fulfilled. 
In 2000, Schemper and Henderson [238] suggested a new measure of the proportion of 
variation of possibly censored survival times explained by a given proportional hazards 
model.  The proposed measure, termed  , shares several favourable properties with the 
earlier    but also improves the handling of censoring.  The statistic contrasts distance 
measures between individual survival processes and fitted survival curves with and without 
covariate information.  Schemper and Henderson recommend graphical comparisons of 
survival curves for prognostic index groups to improve the understanding of obtained 
values.  The main advantages of the new measures are correction for the weakness in the 
handling of censoring [241] and direct estimation of well-defined population quantities. 
7.2.1.3 Korn & Simon 
Korn and Simon [236] suggest using the proportion of explained variation measure in the 
context of survival data.  Apart from the squared difference, they consider other possible 
forms of the distance of the response    from a central location parameter, unconditional 
or conditional on a given model and covariate vector    for the  
   observation.  The 
problem with survival data is these distances usually cannot be calculated because of the 
censoring in  .  To overcome this problem Korn and Simon [236] do not use the actual 
survival times, but times derived from the predicted survival functions.  Thus the actual 
survival times are used only in fitting the model, while in calculating the distance for an 
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individual an expected value of the distance of   from its predictor is calculated where   is 
distributed according to the estimated survival function for individual  . 
This measure is dependent on the amount of censoring so violates the criterion for an 
assumed uncensored population.  Furthermore, this approach also violates another 
criterion as the required differences in the time scale make their measure dependent on 
transformations of time; measures for two Cox models with identical regression 
coefficients can therefore differ.  This measure quantifies the degree to which prediction of 
the time of death, within a range of interest, can be made more precise when replacing 
unconditional by conditional survival functions.   
7.2.1.4 Graf & Schumacher 
Graf and Schumacher [241] investigated relationships of Korn and Simon’s [236] explained 
variation measure based on integrated binary squared loss and of Schemper’s [239]   .  
They also dealt with the interesting aspect of describing explained variation in the course of 
time rather than averaging over time.  The resulting measures are similar to those of 
Schemper et al. [227, 238-240]. 
7.2.1.5 Nagelkerke 
Nagelkerke [226] suggested the use of likelihood based measures,    
     
  
  
     
where    is the likelihood for the model without predictors (otherwise known as the 
intercept model) and    is the likelihood for the full model, for the Cox model which will 
work for time dependent     .  There are three possible definitions of  ;   is the total 
sample size including censored observations which had been proposed already in 1988 by 
Kent and O’Quigley [242],   is the number of uncensored observations i.e. (for continuous 
time) the number of failure times, or   is 2log (cardinality of the outcome space). 
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Additional requirements should be imposed to make a choice; the definition of   should be 
meaningful in the context of conditional logistic regression, for which there are no 
censored observations, and joining or splitting of datasets from the same population 
should not (much) affect the value of   .  This leaves only the number of uncensored 
observations, failure times, as a valid choice.  For tied data Nagelkerke suggests taking the 
number of failures and not the failure times.   
This likelihood based measure is a reasonable measure of how well the covariates reduce 
the randomness in a particular dataset with particular censoring properties.  It is easy to 
calculate and to interpret, also for time dependent     , but it depends on the censoring 
pattern.  The dependency is usually not very much if the proportional hazards assumption 
is correct and the censoring is random – the distribution of      changes with time and 
censoring removes more late failure times than early failure times, but the effect is usually 
small [226].   
7.2.1.6 Haegerty & Zheng 
Haegerty and Zheng (2005) link predictive accuracy to sensitivity and specificity of a marker 
M (e.g.   ) at any time point where sensitivity is              and specificity is 
            .  This leads to time dependent ROC curves.  The suggested measure is 
the weighted average of the areas under the curve of such curves. 
7.2.1.7 O’Quigley 
O’Quigley et al [243] derived a ‘variance’ measure on the basis of squared Schoenfeld 
residuals [173].  It is based on predicted covariates at failure times rather than predicted 
survival time.  The measure is elegant and stays close to properties of the proportional 
hazards model.  However, it is focused on a specific dataset, does not have an intuitive 
interpretation and has little meaning outside the proportional hazards setting. 
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7.2.1.8 Kent & O’Quigley 
Kent and O’Quigley [242] apply the information gain approach of Kent [244] to their 
measure.  They use the fact that estimates of the coefficient in the Cox model are invariant 
under monotonic transformation of the time scale to choose a Weibull model for the 
baseline hazard.  In their paper, Kent and O’Quigley also present a simple approximation 
for squared multiple correlation coefficients   
 ,    
 , and a related simple measure    
 .  
The usage of expected log-likelihoods makes   
  independent of censoring.  The measures 
  
 ,    
  and    
  fulfil the first  and second of Schemper and Stare’s [227] criteria. 
7.2.1.9 Maddala 
Maddala’s   
  is appealing as it is easily calculated and is equal to the usual    in linear 
regression under normally distributed errors [245].  It is not affected by monotonic 
transformation of the time scale, but it violates the first criteria, its expectation being 
affected by censoring.  Under no censoring, Kent and O’Quigley’s   
  is not necessarily 
close to Maddala’s   
 , because the likelihoods are calculated based on the densities of the 
extreme value distribution and not using partial likelihoods [239].   
7.2.1.10 Conclusion 
The proportion of variation in a response variable that is explained by a fitted model is 
often used in statistical modelling to summarise the fit of the model.  A number of 
measures of explained variation have been proposed for use in modelling survival data, 
which are analogues of the    statistic that is widely used in linear regression analysis. 
There are clearly other possibilities to those listed in section 7.2.1 for measures of 
explained variation.  According to Nagelkerke [226], nobody has looked at the reduction by 
using covariates in the predicted time span that an individual will die with       
probability.  This has direct relevance for doctors and patients and also has meaning 
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outside the context of specific models.  This proposal however lacks all the invariance 
properties of the proportional hazards model. 
Schemper and Stare [227], in a review of new measures for explained variation, conclude 
that no particular statistic can be recommended for general use.  Moreover, the most 
satisfactory measures are more difficult to compute.  For this reason, measures of 
explained variation are not routinely used in modelling survival data [167]. 
7.2.2 Discrimination 
Harrell’s   
  [246] has been shown to be inadequate as a measure of proportion of 
explained variation [239].  The explained proportion of log-likelihood does not permit an 
analogous interpretation of explained variation for the dependent variables, its values 
being implausibly low when compared with all other measures.   
Harrell also suggested the  -index [247] which is based on pairwise comparisons of 
individuals in a sample for which the shorter life-time is uncensored.  Each pair is either 
‘concordant’ (one individual has higher values on both covariate and survival time), 
‘discordant’ (the individual with a lower value on one covariate has a higher value on the 
other) or ‘uncertain’ (explanatory variable    is tied).  This  -index, the ‘explained 
proportion of concordances’ can be transformed to Somers’  .  The  -index is frequently 
used, typically ranges between 0.5 and 1, and cannot be regarded as a measure of 
explained variation although it can be used as a measure of discrimination. 
Discrimination refers to a model’s ability to correctly distinguish the two classes of 
outcome [248].  A model with good discrimination ability produces higher predicted 
probabilities for subjects who had events than subjects who did not have events.  The area 
under the ROC curve is one of the most used measures for model discrimination [249] and 
relates to Harrell’s   statistic described in further detail in Chapter 8.  In the literature a 
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value of more than 0.70 for the area under the ROC curve is considered satisfactory for 
discrimination [250]. 
7.2.3 Calibration 
Model calibration describes how well the estimates of survival from the model correspond 
to the survival from the observed data [251, 252] and can be described as a measure of the 
extent of bias in a model [184].  A model is well calibrated when predicted and observed 
values agree for any reasonable grouping of the observation, ordered by increasing 
predicted values.  A common form of the calibration statistics is based on the Pearson χ2 
statistic that compares the observed and expected outcomes within each group defined by 
the rank ordering of the predicted probabilities [253].   
In a survival context the calibration of a model is usually studied at fixed time points.  For 
these time points grouped patients can be considered with sufficient numbers per group to 
allow for calculation of survival rates with the Kaplan-Meier method [254].  This observed 
survival is compared with the mean predicted survival from the prognostic model.   
7.3 Internal Validation of Prediction Models 
Internal validation assesses model validity for the setting where the development data 
originated from [8].  It is important to obtain an honest estimate of performance for 
patients that are similar to those in the development sample.  Several techniques are 
available to assess internal validity such as apparent validation, split-sample validation, 
cross-validation and bootstrap validation.   
7.3.1 Apparent Validation 
With apparent validation, model performance is assessed directly in the sample from 
where it was derived, but this leads to a biased estimate of performance as model 
parameters were optimised for the sample [8].  However all of the available data is used to 
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develop the model and all of the data is used to test the model hence the procedure gives 
optimistic but stable estimates of performance. 
7.3.2 Split-sample validation 
With split-sample validation, the sample is randomly divided into two groups.  In one group 
the model is created and in the other the model performance is evaluated.  Typical splits 
are fifty-fifty or two thirds to one third. 
If samples are split fully at random, imbalances may occur with respect to the outcome and 
the distribution of predictors.  For predictors with skewed distributions the consequences 
may be even worse.  Stratifying the random sampling by outcome and relevant predictors 
may alleviate this problem. 
There are many drawbacks to split-sample methods [254-256] - only part of the data is 
used for model development which leads to less stable model results compared with 
development with all development data i.e. there are problems related to variance.  There 
are also problems related to bias - an assessment of the performance is obtained when 
part of the data is used.  The performance of a model based on the full sample is actually 
required. 
Split-sample validation is a classical but inefficient approach to model validation [8].  
Simulation studies have shown that large sample sizes are required to make split-sample 
validation reasonable [257] but with large samples, the apparent validity is already a good 
indicator of model performance.  Steyerberg [8] therefore concludes that split-sample 
validation is a method that works when it is not needed.  
7.3.3 Cross-validation 
Cross-validation is an extension of split-sample validation aiming for more stability [8].  A 
prediction model is again tested on a random part that was left out from the sample and 
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the model is developed in the remaining part of the sample.  However in cross-validation 
this process is repeated for consecutive fractions of patients.  For example, the dataset may 
be split into deciles with model development in nine of the ten and testing in one of the 
ten, which is repeated ten times.  In this way all patients have served once to test the 
model.  The performance is commonly estimated as the average of all assessments [254]. 
Cross-validation can use a larger part of the sample for model development than split-
sample validation which is an advantage.  However, the cross-validation procedure may 
need to be repeated several times to obtain stable results.  The most extreme cross-
validation is to leave out each patient once, which is equivalent to the jack-knife procedure 
[258] but with large numbers of patients, this procedure is not very efficient. 
Cross-validation may not properly reflect all sources of model uncertainty, such as that 
caused by automated variable selection methods.  The underestimation of variability is 
easily recognised for jack-knife cross-validation, where the development sample is identical 
to the full sample except for one patient [258], hence the same predictors will generally be 
selected in each jack-knife sample as in the full sample.  Such model uncertainty can better 
be reflected with bootstrap validation. 
7.3.4 Bootstrap Validation 
Bootstrapping reflects the process of sampling from the underlying population.  Bootstrap 
samples, which are of the same size as the original sample, are drawn with replacement 
from the original sample, reflecting the drawing of samples from an underlying population 
[258].  In the context of model validation, 100-200 bootstraps may often be sufficient to 
obtain stable estimates.   
For bootstrap validation a prediction model is developed in each bootstrap sample.  This 
model is evaluated both in the bootstrap sample and in the original sample.  The difference 
 170 
 
in performance indicates the optimism which is subtracted from the apparent performance 
of the original model in the original sample [254, 257-259]. 
There are many advantages of bootstrap validation; the optimism-corrected performance 
estimate is stable since samples of size   are used to develop the model as well as to test 
the model.  This is similar to apparent validation and an advantage over split-sample and 
cross-validation methods.  Compared with apparent validation, some uncertainty is added 
by having to estimate the optimism.  When sufficient bootstraps are taken, this additional 
uncertainty is however negligible. 
Additionally, bootstrap validation can appropriately reflect all sources of model 
uncertainty, especially variable selection [260].  Disadvantages of bootstrap validation, and 
other resampling methods such as cross-validation, include that only automated modelling 
strategies can be used, such as fitting a full model without selection, or following an 
automated stepwise selection approach. 
7.4 Internal Validation of the SANAD Models 
Analyses were undertaken using R version 2.9.2 [182]. 
It is of importance to determine whether the models presented in Chapter 4 are good at 
predicting outcome.  The SANAD dataset is a large dataset and therefore it is unsurprising 
that nine prognostic factors were identified.  Of greater importance than the statistical 
significance of these covariates is the ability of the models to predict outcome.  
Consequently, internal validation was performed with bootstrap resampling to assess this.   
To assess explained variation, the Nagelkerke    measure of model fit was estimated.  As 
described in 7.2.1.5, Nagelkerke’s measure is easy to calculate and interpret.  It is also 
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readily available in statistical software packages and the most frequently reported    
measure [261].  For these reasons it was our preferred measure.   
The bootstrap resampling approach was applied to assess the extent of model over-
optimism (overfitting) in the final model using 200 bootstrap resamples.  The bootstrap 
validation method was preferred as the optimism-corrected performance estimate is 
stable.  This is an advantage over split-sample and cross-validation methods.  Additionally, 
bootstrap validation can reflect all sources of model uncertainty and does not lead to 
biased estimates of performance, unlike apparent validation, if sufficient bootstraps are 
taken (section 7.3.4).  The bootstrap resampled estimate of    was produced to give an 
improved estimate of model accuracy.   
Model discrimination was considered via Harrell’s  -statistic, again bootstrapped over 200 
resamples.  Finally, calibration plots were produced using the same 200 bootstrap 
resamples.  Graphical results can be easier to interpret than p-values, therefore we 
preferred calibration plots over the use of Pearson’s    statistic [238]. 
7.4.1 Time to Treatment Failure 
The Nagelkerke    measure of model fit was 0.133.  This suggested that the covariates 
reduce the randomness in the SANAD dataset by 13%.  This is a low value however, as 
explained above, the    measure is not ideal for Cox models.  The bootstrap resampled 
estimate of    was 0.139 suggesting that model under-optimism was only 1%. 
The concordance statistic was 0.596 for the model and for the bootstrapped model it was 
0.600.  These values differ by only 0.004 which suggested that there is little under-
optimism.  The  -statistic of 0.6 showed that the model accurately discriminated patients 
60% of the time.  Given the desire was to predict patients with poorer outcome our  -
statistic represents reasonable internal validation. 
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Calibration plots at one, two and three years can be seen in Figure 19, Figure 20 and Figure 
21 respectively.  If the model was perfectly calibrated at each time point the predicted 
(blue lines) and observed (black lines) values would sit perfectly on each other.  In the case 
of the SANAD model for time to treatment failure, the predicted and observed lines are not 
perfectly matched although they are close, especially at two and three years.  Therefore, 
there is no reason to doubt the internal validity of the time to treatment failure model for 
the SANAD data. 
 
Figure 19: The SANAD Trial – arm A: Calibration plot for time to treatment failure (Table 6, Chapter 4) at 1 
year 
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Figure 20: The SANAD Trial – arm A: Calibration plot for time to treatment failure (Table 6, Chapter 4) at 2 
years 
 
Figure 21: The SANAD Trial – arm A: Calibration plot for time to treatment failure (Table 6, Chapter 4) at 3 
years 
7.4.2 Time to 12 Month Remission 
The Nagelkerke    measure of model fit was 0.118 suggesting that the covariates reduced 
the randomness in the SANAD dataset by 12%.  The bootstrap resampled estimate of    
was 0.144 suggesting that model under-optimism was only 3%. 
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The concordance statistic was 0.665 for the model and for the bootstrapped model it was 
0.666.  These values differ by only 0.001 which suggested that there was little under-
optimism.  The  -statistic of 0.7 showed that the model accurately discriminated patients 
70% of the time which therefore suggested acceptable internal validation [139, 262].   
Calibration plots at one, two and three years can be seen in Figure 22, Figure 23 and Figure 
24 respectively.  In the case of the SANAD model for time to 12 month remission, the 
predicted and observed lines are very close at two and three years suggesting good model 
validity.  At one year the lines are not very close suggesting that the model does not fit the 
data particularly well at one year.  This may be because approximately 30% of patients 
achieved remission immediately at 365 days.  Therefore more sophisticated techniques 
may be needed to take account of this in the modelling process.  Mixture modelling is used 
in Chapter 10 to see if this patient subgroup, together with those who achieve remission 
but at a later time point, and those who do not achieve remission, can be modelled more 
appropriately.   
 
Figure 22: The SANAD Trial – arm A: Calibration plot for time to 12 month remission (Table 9, Chapter 4) at 1 
year 
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Figure 23: The SANAD Trial – arm A: Calibration plot for time to 12 month remission (Table 9, Chapter 4) at 2 
years 
 
Figure 24: The SANAD Trial – arm A: Calibration plot for time to 12 month remission (Table 9, Chapter 4) at 3 
years 
7.5 Conclusion 
Prognostic models have many uses such as guiding health-care policy, determining study 
eligibility of patients for new treatments, defining inclusion criteria for clinical trials to 
control for variation in prognosis, and selecting appropriate tests and therapies in 
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individual patient management including supporting decisions on withholding or 
withdrawing therapy.  The evaluation of prognostic models has become an increasingly 
important topic with a rise in the number of such models in the public domain.  There has 
therefore been a requirement to evaluate and validate prediction models.  There are three 
main ways that a model can be evaluated and two ways that a model can be validated.   
In section 7.2.1 a number of measures of explained variation were proposed for evaluating 
survival data, which are variations of the    statistic that is widely used in linear regression 
analysis.  Schemper and Stare [227], in a review of new measures for explained variation, 
concluded that no particular statistic could be recommended for general use.  Moreover, 
the most satisfactory measures are more difficult to compute [167].   
Overall statistical performance measures incorporate both calibration and discrimination 
aspects.  Discrimination was described in section 7.2.2.  It relates to how well a prediction 
model can discriminate those with the outcome from those without the outcome.  
Calibration, described in section 7.2.3, relates to the agreement between observed 
outcomes and predictions.  Studying discriminative ability and calibration is often more 
meaningful than an overall measure such as    when the quality of model predictions for 
individuals needs to be appreciated [8].  
A model is developed within a representative sample of patients from an underlying 
population.  This underlying population has specific characteristics.  At least the internal 
validity, or reproducibility, of the predictive model should be determined for the underlying 
population.  This can be done by testing the model in the development sample by either 
apparent, split-sample, cross or bootstrap validation as outlined in section 7.3.  
Bootstrapping appears most attractive provided that all modelling steps can be replayed 
which may sometimes be difficult. 
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Having applied bootstrap resampling to the SANAD models for time to treatment failure 
and time to 12 month remission (sections 7.4.1 and 7.4.2), it was found that both models 
showed signs of fairly good internal validation.  There are concerns over the validity of the 
12 month remission model at one year.  However, in Chapter 10 mixture modelling 
techniques will be employed to attempt to better account for the patient subgroups – 
immediate remission at 365 days, delayed remission and no remission.   
Further work is now needed to validate the models in external data.  A simulation study 
assessing methods for external validation is presented in Chapter 8 while an application of 
the results of the simulation study to real data can be found in Chapter 9. 
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Chapter 8: Externally Validating 
Prognostic Models – Simulation 
Study 
8.1 Introduction 
In Chapters 4, 5 and 6, I developed prognostic models for various patient groups and 
various outcomes.  Before a predictive or prognostic model can be introduced into general 
practice, it should be externally validated to ensure that it performs satisfactorily in 
datasets that are fully independent of the development data.  In theory the dataset used to 
externally validate the model will be plausibly related to the development data meaning 
that both datasets will effectively be samples taken from the same ‘super-population’ [8].  
Therefore this chapter will now examine external validation methods, while Chapter 9 will 
apply the results of this chapter to real data. 
This chapter begins with an overview of types of external validation (section 8.2), a 
literature review (section 8.2.1) and a summary of the most commonly employed methods 
of external validation (sections 8.2.2 to 8.2.6).  Methods for handling missing data within 
covariates are then presented in section 8.3 together with possible adaptations of these 
methods to the situation of handling a covariate missing from the validation dataset.  A 
simulation study which compares the performance of methods of external validation and 
also compares the performance of methods of handling a covariate missing from the 
validation dataset is then presented in section 8.4. 
As yet, very few authors externally validate their predictive model(s).  This may be due to a 
lack of evidence as to the best method to apply or perhaps because it is difficult to identify 
comparative studies that provide information on the same set of potential confounders 
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[263] and consequently the development and validation datasets are unlikely to provide 
information on the same set of potential confounders.  There is no literature available on 
how to deal with this situation apart from the suggestion of filling in any gaps with a 
constant value [8].   
Initial work has been presented for missing covariates in an individual patient data meta-
analysis [263] via way of a bivariate random-effects meta-analysis.  For this method 
information is used from all available cohorts while adjusting for all the potential 
confounders; fully adjusted and partially adjusted estimated effects are used in cohorts 
with full confounder information together with an estimate of their within-cohort 
correlation.  This method cannot be used as a method of external validation with a 
validation dataset missing a covariate because the method [263] assumes that full and 
partial covariate models are correlated and that this correlation is similar across trials – 
with one development dataset and one validation dataset this is a big assumption to make. 
Prognostic models have many uses such as guiding health-care policy, determining study 
eligibility of patients for trials of new treatments, defining inclusion criteria for clinical trials 
to control for variation in prognosis, and selecting appropriate tests and therapies in 
individual patient management including supporting decisions on withholding or 
withdrawing therapy.  The evaluation of prognostic models has become an increasingly 
important topic recently with an increase in the number of such models in the public 
domain.   Therefore prognostic models must be externally validated and consequently 
simple but reliable methods for external validation, especially in the common situation of 
covariates missing from the validation dataset, must be determined. 
In what follows, the data used to derive the model will be referred to as the development 
dataset.  The external, independent, data used to validate the model will be referred to as 
the validation dataset. 
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8.2 External Validation 
The purpose of a prognostic model is to provide valid outcome predictions for patients.  
Before a prognostic model is used in clinical practice it is important to have an indication 
that the model would work well on a second similar cohort to that used to develop the 
model.  External validity, also known as generalisability or transportability, is essential to 
support general applicability of a prediction model to populations that are ‘plausibly 
related’.  The definition of plausibly related populations requires subject knowledge as it is 
not self-evident.  Steyerberg [8] defines such populations as those that can be thought of as 
parts of a ‘super-population’ and therefore populations that have matching covariates.   
There are different types of plausibly related populations leading to several variations of 
external validation: temporal, geographic and fully independent [8].  With temporal 
validation, a predictive model is validated in more recently treated patients.  This may be 
achieved straightforwardly by splitting the development data into a part containing early 
treated patients, used to develop the model, and another part containing the most recently 
treated patients, used to assess the performance.  An alternative is a prospective 
application of the model in a specifically collected cohort. 
With geographic validation, a predictive model is validated according to site.  It can be 
labelled leave-one-centre-out cross-validation.  In geographic validation, the splits are not 
at random unlike in standard cross-validation.  A drawback of geographic validation is that 
validation samples may get quite small, leading to unreliable results.  
With fully independent validation, a predictive model is validated by independent 
investigators.  Other investigators may use slightly different definitions of predictors, 
outcome and study patients that are differently selected compared with the development 
setting.  Fully independent validation studies often provide more unfavourable results than 
temporal or geographical external validation [8].  If model performance is found adequate 
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by fully independent investigators the validation is more convincing than when found by 
the investigators who developed the model. 
There are several main considerations when validating a model such as study design, 
measuring the intrinsic prognostic information, comparing predictions with observations, 
quantifying the performance of a model and pre-specifying adequate performance [264].  A 
system, however, can never be fully validated – you can never be certain that it will apply 
to the next suitable patient or subject [264, 265].   
There are a  few inter-related reasons why prognostic models may not perform well such as 
deficiencies of standard modelling methods, deficiencies in the design of prognostic studies 
and non-transportability of models [264].  In terms of inadequate model development, the 
sample size may be relatively small, or patients may be selected from a single centre.  Also, 
statistical analysis may often be suboptimal e.g. with stepwise selection in relatively small 
samples with many potential predictors, and no shrinkage of regression coefficients to 
compensate overfitting [8].  Other explanations include true differences between 
development and validation settings, especially in coding of predictors and outcome.  
Moreover, variables required for a model may not be available at validation.  
External validation is often referred to in the discussion section of a paper however it is 
unusual for external validation results to be presented.  This may be because there is a 
variety of methods but no direct comparison of them and therefore it is difficult to know 
which methods to apply.  Additionally, it may be because a suitable dataset for validation is 
missing a significant covariate.  Again there are no published guidelines on how to handle 
this situation.  This chapter addresses both of these issues.   
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8.2.1 Literature Review 
There are several well-known examples of predictive models or indices used in medicine.  
Two such models are the Framingham risk prediction model for atherosclerotic 
cardiovascular disease [266] and the Nottingham Breast Cancer Index [267].  The 
performances of the models or indexes have been evaluated differently but authors of 
both have a common aim to ensure that the models perform sufficiently well and perform 
suitably in relation to prior knowledge.  Neither model has been externally validated in the 
true sense but both have been validated sufficiently to be accepted into general clinical 
practice. 
The Framingham model [266] was assessed via discrimination and calibration.  In addition, 
the sensitivity of the top quantile resulting from the model was considered and finally,  the 
performance of the model was compared with that of another popular Framingham risk 
score [268] in terms of survival probabilities.  The Nottingham Breast Cancer Index [267] 
was assessed by comparing the performance of the index with that of the most significant 
factor alone in terms of survival probability.  Additionally the index was compared with an 
earlier criterion for poor prognosis, again in terms of survival probabilities.  In addition they 
considered a group of patients in the lowest quantile in terms of expected and observed 
survival and finally they examined the performance of the new index as a predictor of five 
year survival. 
A literature review was undertaken to summarise characteristics of other previous studies 
that have externally validated a prognostic model.  Any studies, excluding laboratory based 
ones, in which a prognostic model was externally valid were included.  Information was 
collected on the size of the development dataset, the size of the validation dataset, the 
type of outcome measure, the number of covariates included in the development model, 
external validation methods and methods for handling covariates missing from the 
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validation dataset.  A summary of the prognostic models was also obtained together with a 
description of the similarity in the data between the development and validation datasets. 
The following strategy was used in MEDLINE which was searched from 2002 to 9th June 
2011 – the last ten years was chosen to reflect the large volume of prognostic models 
published in recent years. 
1. (Prognostic adj (model* or factor*)).ti. 
2. (Predictive adj (model* or factor*)).ti. 
3. 1 or 2 
4. validat*.tw. 
5. 3 and 4 
6. limit 5 to yr="2002 - 2011" 
 
One hundred and nine studies were found that met the inclusion criteria.  Of these, 29 
externally validated at least one previously published prognostic model, 38 validated a 
previously unpublished Cox proportional hazards model and 35 validated other 
unpublished models while seven did not mention the type of model being validated.  The 
unpublished models that were not developed via the Cox model were developed using a 
variety of methods including Monte Carlo Markov Chains, regression (parametric, logistic, 
linear, fuzzy logic, bivariate), recursive partitioning, proportional odds, Bayesian networks, 
Generalised Estimating Equations, Artificial Neural Network and Real Time-Quantitative 
Polymerase Chain Reaction.  Table 22 summaries the size of the development and 
validation datasets, the number of covariates and the methods of external validation per 
validated model type: published, unpublished Cox, unpublished other and not specified. 
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Overall the median size of the development dataset was larger than that of the validation 
dataset.  On an individual level there were many occasions where the validation dataset 
was larger than the development dataset irrespective of the type of model being validated.  
In most cases only a few covariates were included in the model, irrespective of the type of 
model being validated although, of course, there are many exceptions to this.  Most 
authors only employed one method of external validation while some listed up to seven.  
There was also large variation in the description of the methods.   
  
 
1
8
6 
Table 22: Summary of Literature Review identifying studies which externally validated a prognostic model.  Entries are numbers of studies (percentage) 
 
Published 
(n=29) 
Unpublished Cox 
(n=38) 
Unpublished other 
(n=35) 
Not specified 
(n=7) 
Total 
(n=109) 
Summary Statistics  
Size of Development Dataset, 
Median (IQR) 
395 (150, 1298) 337 (124, 851) 478.5 (213, 2763) 124 (62, 174) 395 (151.5 to 1348) 
Size of Validation Dataset, 
Median (IQR) 
280 (117, 1230) 158.5 (110, 449) 280 (116, 1351) 189 (103.5, 306) 280 (115.5 to 1318) 
Number of covariates in the model, 
Median (IQR); Maximum 
4 (5, 7); 11 4 (3, 6); 12 5 (4, 7); 20 5 (3, 5); 6 5 (4 to 7); 20 
Number of external validation methods used, 
Median (IQR) 
1 (1, 2) 1 (1, 2) 2 (1, 2.5) 1 (1, 1.5) 1 (1, 2) 
Methods  
Discrimination 
    c-statistic 
    Other* 
 
15 
2 
 
16 
4 
 
20 
3 
 
3 
0 
 
54 
9 
Repeat analysis and compare results 6 12 6 2 26 
Calibration 
    Hosmer-Lemeshow 
    Plots 
    Other* 
 
4 
3 
1 
 
1 
2 
1 
 
5 
2 
3 
 
0 
1 
0 
 
10 
8 
5 
Graphical comparison via    1 5 2 0 8 
Comparison of analysis product 
       
    Proportion of separation 
    t-test 
    Other* 
 
1 
0 
1 
5 
 
2 
1 
0 
10 
 
3 
2 
3 
7 
 
2 
0 
1 
1 
 
8 
3 
5 
23 
Comparison of accuracy 
   Brier 
   Sensitivity/Specificity 
   Positive predictive value 
   Negative predictive value 
   Other* 
 
1 
1 
2 
1 
3 
 
0 
1 
1 
1 
3 
 
1 
5 
4 
4 
1 
 
1 
0 
0 
0 
1 
 
3 
7 
7 
6 
8 
Other methods (Cochrane-Armitage, trend test, two-way 
ANOVA, Sheffé procedure, shrinkage etc.) 
3 4 4 0 11 
 
 
187 
 
In general, discrimination (n=63), calibration (n=23) and comparison of analysis product 
(n=39) such as prognostic separation, were the most frequently implemented methods of 
external validation.    Other frequently employed methods of external validation were 
comparison of accuracy (n=31) and repetition of the analysis with comparison of the results 
(n=26).  Accuracy of models is frequently compared via sensitivity, specificity, positive 
predicted value and negative predictive value.  Sensitivity and specificity are statistical 
measures of the performance of a classification function.  Sensitivity measures the 
proportion of actual positives which are correctly identified as such while specificity 
measures the proportion of negatives which are correctly identified [269].  The whole point 
of a prognostic model is to use it to make a prognosis, so it is important to know the 
probability that the model will give the correct prognosis.  The sensitivity and specificity do 
not give us this information.  Instead the data can be approached from the direction of the 
results, using predictive values - the positive predictive value is the proportion of subjects 
with positive results who are correctly identified while the negative predictive value is 
defined as the proportion of subjects with negative results who are correctly identified 
[270].  The latter tend to be used for diagnostic tests although it can be adapted to other 
situations. 
Many of the methods identified in the literature review are dependent on the type of 
model being validated.  For example, positive and negative predictive values are most 
appropriate for models concerning diagnosis while the  -statistic can be used to measure 
the predictive power of any model [271] and the area under the ROC curve can be used to 
test the ability of a model to correctly classify those with and without the disease or event 
as appropriate [272]. 
Only one study considered how to handle a covariate missing from the validation dataset.  
In Mekhail’s study [273] variables with a lot of missing data were not considered when the 
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model was re-developed using the validation dataset therefore the variables were forced 
to be missing from the validation dataset.  Risk groups were developed using the 
development data and also using the validation data and were then compared.  Any other 
study that mentioned missing data did so in the context of missing data within a covariate 
only.  In most cases however, the validation datasets were collected specifically for 
validating a prognostic model, hence missing covariates were not an issue. 
There is little evidence in the literature as to how to externally validate prognostic models 
and even less on which methods should be used in preference.  In the literature review 
four broad methods of external validation were found: repeat analysis with comparison of 
results, comparison of observed and predicted values, calibration and discrimination.  
Although we found 109 studies which had made some attempt to externally validate a 
prognostic model many hundreds or even thousands of models for clinical prediction 
(prognosis or diagnosis) are published in the medical literature every year [274].  Therefore 
it seems that external validation is still infrequently implemented and often poorly 
reported. 
Some methods of external validation are now described. 
8.2.2 Predictive Performance 
Proving that a model has good predictive qualities is not trivial.  Several statistical measures 
have been proposed for this purpose and deciding which is the most suitable can often be 
challenging and will depend, not only on the type of outcome the model is predicting, but 
also on the clinical area within which it is being utilised as predictive values calculated in 
one clinical setting are not necessarily applicable in another.  Popular choices of outcomes 
are continuous and binary however they are not exclusive as time-to-event outcomes are 
also useful.  Censored observations are inherent to time-to-event datasets and survival 
analysis methods such as the Cox proportional hazards model are required to deal with 
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them.  This censoring also necessitates special consideration when testing the performance 
of survival models. 
Jorgensen [275] summarises such tests for binary and continuous outcomes but does not 
provide a summary for survival outcomes.   In the case of binary outcomes goodness of fit 
via the Brier score, calibration, and sensitivity and specificity are considered.  ROC curves 
are reviewed which determine a threshold probability above which a drug will not be 
prescribed, for example.  To determine a model’s diagnostic accuracy, positive and 
negative predictive values are suggested while contingency tables are recommended to 
calculate the measure of discriminatory ability.  These methods constitute a toolkit for 
assessing how well a model fits a dataset, as well as how it performs in reflecting the true 
situation both at the population and at an individual level.  However, none of these 
methods give consideration to the clinical consequences of applying the model in practice 
and as a result the conclusions can sometimes be misleading.   
A regression model may be externally validated by checking the predictive accuracy of the 
model in the validation data and the goodness of fit of the model [275].  Some proposals 
for quantifying the predictive performance of survival models have concentrated on 
discrimination, while others have considered accuracy of predictions either at the group 
level, or for individual patients.  
8.2.3 Discrimination 
Discrimination is the ability of the model to allocate to patients who experience the 
outcome of interest a higher predicted probability of experiencing the event than that 
allocated to those who did not experience the event.  It is often assessed via the area under 
the ROC curve.  For continuous data the area under the ROC curve can be interpreted as 
the probability that the results of a randomly selected patient experiencing the event will 
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be greater than the result of a randomly selected patient without the event, i.e. the 
probability that the two results are ranked in the correct order [249]. 
To apply ROC curve methodology to survival data it is necessary to choose a particular time 
point    at which the survival status can be ascertained.  Popular choices for    include a 
fixed number of years, the median follow up time or the median survival time.  Graf [276] 
pointed out that when the prediction is made at     the status of    is not yet 
determined, but will evolve in the period from 0 to    according to some stochastic 
mechanism.  For many patients the status at    will never be known because they are 
censored before   .  Another criticism of this approach is that area under the ROC curve 
measures the discrimination of the model at an arbitrary time point rather than over all the 
relevant time period. 
These issues are addressed by an adaptation of ROC methodology to survival data 
proposed by Harrell [184].  This method does not depend on choosing a fixed time for 
evaluation of the model and takes into account censoring of individuals.  Harrell’s  -index is 
defined as the proportion of all usable subject pairs in which the predictions and outcomes 
are concordant.  In predicting the time to an event,   is calculated using all possible pairs of 
subjects, at least one of whom has suffered the event.  If the predicted survival time is 
larger for the subject who actually survived longer, the predictions for that pair are 
concordant with the outcomes.  If one subject suffered the event and the other is known to 
have survived at least to the survival time of the first, the second subject is assumed to 
survive the first.  When predicted survival times are identical for a pair then 0.5 rather than 
1 is added to the count of concordant pairs in the numerator of  , but one is added to the 
denominator which counts usable pairs.  The formula for the concordance statistic is 
     
 
 
    where   is the number of orderings as expected,   is number of tied 
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predictions and   is number of comparisons.  A value of       corresponds to the 
agreement expected by chance and     corresponds to perfect concordance. 
Harrell’s   is a reparameterisation of Somers’  , similar to the area under the ROC curve.  
Rather than measuring the ability of a continuous variable to predict disease say, Harrell’s    
measures the ability of a continuous variable to predict survival.  Somers’   is an 
asymmetric measure of association between two variables and is defined in terms of 
Kendall’s    [230] whose population value is traditionally defined as  
                               
where         and         are bivariate random variables sampled independently from 
the same population and      denotes expectation. 
This definition can be generalised to left- or right-censored, stratified, clustered, or 
weighted data in the following way.  Suppose that 4-variate observations               are 
sampled from an arbitrary population using an arbitrary sampling scheme.  The    are 
censorship indicators for the corresponding    and the    are censorship indicators for the 
corresponding   .  These censorship indicators are negative for left censorship, positive for 
right censorship and zero for non-censorship [277].   
Define a censored sign difference for two values,   and   with respective censorship 
indicators   and   as  
                
                 
                   
           
  . 
Given two observations               and              , call the product of 
                   and                    the concordance-discordance difference for the 
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two observations and say that the two observations are concordant if the product is 1, 
discordant if the product is -1 and neither concordant nor discordant if the product is 0. 
Kendall’s    can now be redefined as                                             i.e. 
the mean concordance-discordance difference.  The population value of Somers’ D [233] is 
defined as 
    
   
    . 
Therefore     is the difference between two probabilities - the probability that the larger 
of the two   values is associated with the larger of the two   values and the probability 
that the larger   value is associated with the smaller   value.      is the difference 
between the two corresponding conditional probabilities, given that the two   values are 
known to be unequal.  Somers’  is related to Harrell’s   index by       [184, 247]. 
To determine if there is a significant difference between two prediction models within the 
same dataset Newson [277] proposes calculating confidence intervals for the difference 
between Somers’   (equivalently Harrell’s  ) parameters of the predictors with respect to 
the outcome.  Confidence intervals for Kendall’s    and Somers’   are more informative 
than  -values alone for three reasons.  Firstly, confidence intervals show that a high  -
value does not prove a null hypothesis.  Secondly, for continuous data, Kendall’s    can 
often be used to define robust confidence limits for Pearson’s correlation [277] by 
Greiner’s relation [278].  Thirdly, confidence limits can be defined for differences between 
two Kendall’s   ’s or Somers’ ’s and these are informative because a larger Kendall’s    or 
Somers’   cannot be secondary to a smaller one.  The sampling variances of the point 
estimates can be estimated using a jack-knife method via Newson’s Stata package 
somersd [279].  
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It is not, however, appropriate to calculate a confidence interval for a difference in 
concordance statistic between the development and validation dataset.  This is because the 
prognostic model would be fitted using the development dataset and then its predictive 
power would be measured.  In general, confidence interval formula do not cover this 
situation because the fitting process typically chooses parameter values to maximise the 
apparent predictive power of the model in the development dataset.  This will usually imply 
that the predictive power observed in the development dataset will be overoptimistic 
[271]. 
8.2.4 Calibration 
The deviance of a model,  , defined as minus twice the log-likelihood can be thought of as 
a measure of the lack of fit of the data to the model.  The performance of a survival model 
on external data may be measured by comparing the fit using the parameters estimated 
from the development dataset (‘fixed’ parameters) with the fit using the parameters 
estimated from the validation dataset [280]. 
Denote the deviance using the fixed parameters as    and the deviance using re-estimated 
parameters as   .  If the two deviances are similar then the model generalises well.  The 
difference in deviances,      , has an approximate  
  distribution with degrees of 
freedom equal to the number of parameters,  , in the model since this is the difference in 
the number of degrees of freedom between the model fitted with re-estimation and the 
model fitted without re-estimation of parameters [281].  
This methodology was discussed by Spiegelhalter [281] et al when they used deviance 
statistics to choose the best model in the context of a Bayesian framework.  The result that 
the deviance difference is distributed as    with degrees of freedom equal to the number 
of re-estimated parameters depends on the independence of the parameters.  It is likely 
that the assumption is violated in this application of external validation.  However, a test 
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based on the assumption of independence will tend to be liberal since the effective number 
of parameters must be less than or equal to the actual number of parameters and the sum 
of the degrees of freedom with the corresponding    reference value still provides a useful 
benchmark for comparing models [280].  
8.2.5 Prognostic Separation 
The aim of prognostic classification schemes is to define subgroups of patients with well 
separated survival distributions [282].  For survival data, the statistical methodology for 
assessing such schemes consists mainly of a range of ad hoc approaches [276].  Measures 
of separation may be used in situations where the proposed measures of inaccuracy cannot 
be calculated as a classification scheme is not supplemented by predictions of any kind 
such as survival time, survival status or survival probability.  There are several measures of 
separation including, SEP [276] and PSEP [264], however no proposal seems to be 
universally accepted [283]. 
In survival analysis, a ‘natural’ approach often used in the medical literature to measure the 
prognostic ability of a model is to generate a prognostic classification scheme comprising 
two or more risk groups and to plot the Kaplan-Meier survival curves for each group.  This 
leads to the idea of separation of survival curves as a measure of prognostic information, 
and led Graf and colleagues to propose a measure that they called SEP [276].  SEP is 
defined as 
        
  
 
     
 
   
  
where    denotes the number of patients in risk stratum  ,     is the estimated log-hazard 
ratio or log-relative risk of patients in risk stratum   with respect to a baseline reference, 
  is the total number of patients and   is the number of groups of patients.  The baseline 
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reference can be estimated in a Cox model where the dummy covariates for risk strata are 
centred to have mean zero and therefore the SEP measure is based on the assumption of 
proportional hazards between risk strata [276]. 
The measure, SEP, incorporates weights of relative size of the subgroups because a 
clinically useful categorisation needs to define groups which are not only well separated, 
but which additionally incorporate a substantial part of the patients.  The SEP may be used 
for a comparison of different schemes but the measure itself is not very informative and 
gives no estimate of the degree of separation of the different subgroups.  In the case of 
three or more categories, it does not take into account the ordering of the categories and 
therefore it may be misleading [282].   
A simple index of separation, PSEP, can be defined as follows.  Suppose the outcome of 
concern is death within a predefined period following measurement of prognostic factors.  
Suppose also that a prognostic classification scheme of some kind has been defined in 
some way.  All that is required is that any patient may be classified into one of two or more 
prognostic groups, and that the groups with best and worst predicted prognosis have been 
identified.  When there are more than two groups it is essential to ensure that the extreme 
groups, from which PSEP is calculated, are large enough and have sufficient events to allow 
adequate estimates of        and      .  If not, amalgamation of groups may be required 
[264].  Let 
                                                                                      
                                                                                      
Then the predicted prognostic information can be measured by the separation,      
            .  For example [284], if there were three risk groups, low, medium and high, 
and the respective six month death rates were 0.571, 0.787 and 0.947 then             
and            so           .  To compare the PSEP for the original data with the 
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PSEP for the validation data, it is necessary to use the same data points and consider PSEP 
agreements at each time point.  This method does not however, take into account fewer 
numbers at risk and increased uncertainty later in the curve.    
Royston and Sauerbrei’s method of separation [283] is based on the estimation of the 
underlying spread of the log hazard ratios compared with baseline.  The estimate is most 
accurate when the underlying log hazard ratios are approximately normally distributed 
between individuals, although the method is applicable more generally. 
Suppose the data on   individuals are denoted by                        , where for the 
 th individual    is the observed time,    is 1 if the event of interest is experienced at    or 0 
otherwise (right censoring), and    is the covariate vector of prognostic factors.  The Cox 
model may be written as  
Equation 12 
                       
where     
    is the prognostic index for the  th individual [283]. 
Consider the distribution of the prognostic index values.  Defining order statistics 
            it is possible to write               where    is the  th expected 
standard Normal order statistic (rankit) in a sample of size  .  Ordering the data on the    
and substituting for      in Equation 12 gives 
                                  . 
So far no specific distribution has been assumed for the   .  Now suppose that the    are 
Normally distributed         where   is the standard deviation of the prognostic index 
values.  By definition, the regression of the      on the    is linear with               
and         [283]. 
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To a first approximation, ignore the random perturbation    and set     .  Then  
Equation 13 
                               . 
Under the Normality assumption, the special Cox model (Equation 13) is approximately 
linear in the   .  On fitting it to the data, the constant   becomes part of the baseline 
hazard function and the regression coefficient,   , will estimate  .  Royston and Sauerbrei’s 
proposed measure  is defined as 
      
where            . 
Let     
    .  The slope from Cox regression (Equation 13) on the    is   
 , giving   
directly.  The scaled rankits         may be calculated using Blom’s approximation to 
rankits [285] 
    
      
      
  
 
 
  
 
 
  
where       is the inverse standard Normal distribution function.  If some of the       are 
tied the relevant    are averaged within the groups defined by the tied values. 
To calculate a confidence interval for the difference in separation between two models it is 
possible to take bootstrap resamples and compute the difference in separation between 
the development model and validation model [258] in each sample.  For a large number of 
bootstrap resamples, the ratio of the mean difference in separation to its standard 
deviation may be assumed standard Normal under the hypothesis that there is zero 
difference between the separations.  A confidence interval can therefore be calculated in 
the usual way [283]. 
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8.2.6 Royston-Parmar’s Alternative to the Cox Model 
The Cox proportional hazards model was designed to estimate the effects of covariates on 
the hazard function, but not to estimate or predict survival probabilities.  By definition, it 
does not satisfy full validation requirements.  Instead Royston and Parmar [277, 286] 
recommend use of adequately flexible parametric survival models, both for estimation and 
validation. 
The Cox proportional model is a near-universal tool in the analysis of prognostic models in 
clinical medicine [287].  However, it was not formulated with the concept of full external 
validation in mind.  The main issue is that a parametric estimate of the baseline survival 
function is not available.  Prediction in new data of survival probabilities from a Cox model 
is therefore problematic.  Further, covariate effects must conform to the proportional 
hazards assumption, which is quite limiting, particularly in data with medium- or long-term 
follow-up. 
Royston and Parmar describe families of flexible parametric survival models resembling 
generalised linear models with various link functions.  The models rely on transformation of 
the survival function by a link function     . 
Equation 14 
                      
where              is the baseline survival function and   is a vector of parameters to 
be estimated for covariate vectors      
Exponentiating Equation 14, proportional cumulative hazards models are obtained as 
                    
where       is the cumulative hazard function and  
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Equation 15 
             
is the baseline cumulative hazard function.  This is also a proportional hazard model.   
Royston and Parmar approximated         by a restricted cubic spline function of log time 
with two ‘boundary’ knots and  interior knots 
Equation 16 
                                         
where                               is a vector of spline basis functions [288].  
Ignoring the constant term   , a spline with   knots has     degrees of freedom.  The 
proportional hazards model obtained by substituting Equation 16 for       in Equation 15 
is fully specified parametrically and may be written as 
Equation 17 
                      . 
If the prognostic index is written as      then Equation 17 may be rewritten as  
Equation 18 
           
             . 
Since the term         in Equation 18 has not changed, the shape of the baseline 
cumulative hazard function is unaltered, but its location changes through   
      when 
     
  or     .  Estimation of    is relevant in validation studies where recalibration is 
of interest [289].  Regression on the prognostic index in the development data yields 
     .  In the validation data, a value of     much less than 1 may indicate a model with 
poor performance.   If       the model is probably useless [290]. 
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In a validation study, interest lies in whether values of   ,  , or   from the development 
dataset still hold in the validation dataset.  Sometimes a simple recalibration,    , of   
improves model fit in the validation dataset.  In the validation dataset the prognostic index 
  is calculated using values of the parameter vector,   , estimated on the development 
dataset and applied to the covariate values of the validation dataset.  The components of   
are not re-estimated on the validation dataset.  Similarly, the baseline survival function is 
calculated in the validation dataset using the parameter vector        estimated on the 
primary dataset, together with the time values in the validation dataset and the set of 
spline knots used in the development dataset. 
It is possible that the predicted survival probabilities derived from   ,   and    are 
sufficiently accurate in the validation dataset to remove the need to adjust any of the 
model parameters.  This is the ideal situation regarding validation (case 1).  There are six 
additional cases which comprise a structured ordered set of models allowing one to assess, 
and if necessary improve, the fit of the original model in the validation dataset.  The 
adjustments provide a route to updating a given model in a simple way, thus avoiding 
complete reconstruction.  Of course, in some situations reconstruction may be 
unavoidable.  In any case, an updated model should be re-validated in further independent 
data [290]. 
The need for updating, if detected, indicates different types of lack of fit of the original 
model: 
1. Re-estimate   .  Altering    moves the entire baseline distribution function up or 
down.  The shift is sometimes referred to as ‘recalibration in the large’ [254].  A 
situation in which    changes is where the susceptibility of the patients to an event 
differs systematically between the primary and secondary datasets. 
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2. Re-estimate   (but not   ).  This is a more radical revision.  Changing   alters the 
shape of the baseline distribution but not its general level. 
3. Re-estimate    and  .  Similar to 2 except that the general level is also changed. 
4. Regarding   as a continuous covariate with a linear effect in the secondary dataset, 
estimate its slope,   .  This idea, which was proposed for the logistic model by 
Miller [291], proposes that the effect of   is linear but may be mis-calibrated (i.e. 
    ).  Since     is often less than one,    is sometimes described as a shrinkage 
factor. 
These simple adjustments to the original model may produce major or minor changes in 
the goodness of fit (deviance).  Such information may guide the interpretation of the 
results, and where appropriate, the choice of a ‘final’ updated model for the validation 
dataset. 
Cox’s model does not include a transportable estimate of the baseline survival function, 
making prediction of the latter from the development to the validation dataset infeasible.  
An alternative approach to validating a Cox model is to regard a Royston-Parmar 
proportional hazard model as a Cox model with a parametric baseline distribution function.  
The steps of the analysis are therefore: 
1. Fit the Cox model to the development data and estimate the prognostic index   
2. In Royston-Parmar proportional hazard models for the development data with   
offset, search for a parsimonious spline function for the baseline cumulative hazard 
function 
3. Apply the above methods to the validation dataset 
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Since Cox and Royston-Parmar proportional hazard models yield almost identical 
parameter estimates, one could dispense with fitting the Cox model and regard validating a 
Royston-Parmar model as equivalent to validating a Cox model with the same covariates. 
According to Royston and Parmar [290] validation is not about refitting the predictors in a 
postulated model on the validation dataset and comparing the estimated  ’s as some have 
done.  It is about predicting relevant quantities, such as survival distributions, from a model 
fully specified on the development dataset to a validation dataset and examining its 
accuracy.  Only parametric models support this approach for time-to-event data and 
therefore Royston and Parmar suggest that since the Cox model does not estimate the 
baseline distribution, it cannot be fully validated [290]. 
8.2.7 Conclusion 
As shown by the literature review in section 8.2.1 a variety of methods are currently 
employed by researchers who externally validate their prognostic model(s).  The most 
frequently reported measures encompass repeating the analysis and comparing the results, 
discrimination, calibration and comparing the products of the analysis, all of which have 
been described in sections 8.2.2 to 8.2.6. 
The literature review did not, however, identify studies that have compared different 
methods of external validation.  Therefore there is a gap in the literature with regards to 
guidelines for the best method of external validation or indeed which the better methods 
of external validation are.  The simulation study presented in section 8.4 will compare the 
performance of methods for external validation in an attempt to address this lack of 
evidence.  
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8.3 Missing Data 
It is often difficult to identify studies, independent from the data used to develop a 
prognostic model, which provide information on the same set of potential confounders.  
Consequently the development and validation datasets are unlikely to provide information 
on the same set of covariates.  This is certainly the case for the models developed using 
SANAD in Chapter 4 and using MESS in Chapter 5.   
There are many available strategies for handling missing data within covariates [292, 293] 
within individual studies.  These include the simple deletion approaches of complete case 
analysis and available case analysis [294] and all case approaches of analysing the missing 
data as a separate category [295], single imputation [293] and multiple imputation [296, 
297].  More complex approaches based on the use of the maximum likelihood can also be 
effective and practical methods for handling missing covariate data [298].  These 
approaches are suitable for handling small amounts of missing data within a covariate 
either by removing cases or by making informed decisions based on non-missing entries of 
the covariate.  There are also methods for handling missing data in individual patient data 
meta-analyses [299].  There are, however, no guidelines on how to handle the situation of 
a covariate with every entry missing, equivalent to a missing covariate, apart from the 
suggestion of filling in any gaps with a constant value [8].   
Section 8.3.1 considers the mechanisms of missing data before the methods of handling 
missing data within a covariate are summarised in section 8.3.2.  Adaptations of these 
methods to handling covariates with every entry missing in the context of external 
validation are then presented in section 8.3.3. 
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8.3.1 Mechanisms 
In 1976 Rubin [300] rigorously defined different assumptions that might plausibly be made 
about missing data mechanisms.  He defined four assumptions: missing completely at 
random, missing at random, ignorable missingness and non-ignorable missingness. 
8.3.1.1 Missing Completely at Random 
Suppose there are missing data on a particular variable  .  The data on   are said to be 
missing completely at random (MCAR) if the probability of missing data on   is unrelated to 
the value of   itself or to the values of any other variables in the dataset.  When this 
assumption is satisfied for all variables, the set of individuals with complete data can be 
regarded as a simple random subsample from the original set of observations.  Although 
MCAR is a rather strong assumption, there are times when it is reasonable, especially when 
data are missing as part of the research design [298].   
8.3.1.2 Missing at Random 
A considerably weaker assumption is that the data are missing at random (MAR).  Data on 
  are said to be missing at random if the probability of missing data on   is unrelated to 
the value of  , after controlling for other variables in the analysis.  This means that the 
conditional probability of missing data on  , given both   and  , is equal to the probability 
of missing data on   given   alone. 
It is impossible to test whether the MAR condition is satisfied - because the values of the 
missing data are unknown it is not viable to compare the values of those with and without 
missing data to see if they are systematically different on that variable. 
8.3.1.3 Ignorable 
The missing data mechanism is said to be ignorable if the data are MAR and the parameters 
that govern the missing data process are unrelated to the parameters to be estimated.  
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Ignorability means that there is no need to model the missing data mechanism as part of 
the estimation process.  However, special techniques are needed to utilise the data in an 
efficient manner [298]. 
8.3.1.4 Non-Ignorable 
If the data are not MAR the missing data mechanism is said to be non-ignorable.  In that 
case, usually the missing data mechanism must be modelled to get good estimates of the 
parameters of interest.  Unfortunately, for effective estimation with non-ignorable missing 
data, very good prior knowledge about the nature of the missing data process usually is 
needed, because the data contain no information about what models would be appropriate 
and the results typically will be very sensitive to the choice of model. 
8.3.2 Missing Data within Covariates 
Currently there are many strategies for handling missing data within a covariate - complete 
case analysis, available case analysis, all case approach of analysing the missing data as a 
separate category, single imputation, multiple imputation and more complex approaches 
based on the use of the maximum likelihood.  A summary of each of these methods is 
presented in sections 8.3.2.1 to 8.3.2.6. 
8.3.2.1 Complete Case Analysis 
Complete case analysis restricts attention to cases where all variables are present; any 
observations with missing values for any of the covariates are deleted.  Complete case 
analysis assumes missingness in the covariates is not associated with the outcome [301].  It 
is also known as listwise deletion or casewise deletion [302]. 
Complete case analysis provides a statistical analysis that is fully adjusted for all potential 
confounders.  Advantages of this approach are simplicity, since standard statistical analyses 
can be applied without modifications, and comparability of univariate statistics since these 
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are all calculated on a common sample base of cases.  Additionally, complete case analysis 
is the method that is most robust to violations of MAR among independent variables in a 
regression analysis – specifically, if the probability of missing data on any of the 
independent variables does not depend on the values of the dependent variable then 
regression estimates using complete case analysis will be unbiased if all the usual 
assumptions of the regression model are satisfied [298].  Disadvantages stem from the 
potential loss of information, and resulting precision, in discarding incomplete cases.  The 
loss in sample size can be considerable, especially if the number of missing variables is large 
[293].  If the data are not MCAR but only MAR complete case analysis can yield biased 
estimates. 
8.3.2.1.1 Propensity Score Correction 
An extension to the idea of complete case analysis is to weight the remaining complete 
cases after the incomplete cases have been removed so that their distribution more closely 
resembles that of the full sample or population with respect to auxiliary variables.  Pugh et 
al [303] propose a propensity score correction which uses derived sampling weights to deal 
more appropriately with missing covariate data than blind use of only the complete cases. 
The method weights observations based on their likelihood of being incomplete.  The 
underlying idea is to reweight cases from under-represented groups; let      if individual 
  has no missing covariates, 0 otherwise.  Logistic regression can be used to estimate each 
subject’s probability of complete data,   , or ‘propensity score’ and in the Cox model 
 
    
can be used.  A subject with complete data and a low propensity score is treated as the 
representative for a large cohort of similar subjects for whom data collection failed and is 
thus given a correspondingly large weight.    It need not improve on complete case analysis 
and may do worse - the relative performance of the two approaches depends on the 
mechanism leading to the missing data [175]. 
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If the probability of a particular covariate entry being missing depends on the possibly 
unobserved value of the covariate, but not on other covariates or data, then the complete 
case approach is consistent but the propensity score method need not be [175].  If the 
probability of missingness depends on the values of completely observed variables, but not 
on the value of the missing covariate itself then Pugh’s method is consistent, but complete 
case analysis need not be so [175].  If missingness depends on both of these factors both 
methods may be inconsistent.  The completeness propensity score approach is valid when 
the probability of being missing depends only on the values of observed data, response, or 
prediction, and not on the values of missing covariates [304].  
8.3.2.2 Available Case Analysis 
For univariate analyses a natural alternative is to include all cases with complete data for 
the variables in the fitted model, an option termed available case analysis, also known as 
pairwise deletion.  The idea of available case analysis is to compute each required summary 
statistic using all the cases that are available.  Once the summary measures have been 
computed they can be used to calculate the parameters of interest such as regression 
coefficients.  Although missing data may cause different observations to be used in 
calculating different statistics, the missing data do not cause observations to be omitted 
from the entire analysis as in complete case analysis.  For example, in a sample consisting 
of 10 observations, the correlation between variables   and   may be computed only by 
using observations one to five because   is missing for observations six to 10, whereas the 
correlation between variables   and   may be calculated only by using observations six to 
10 because   is missing for observations one to five.   
The main problem with pairwise deletion is that the estimated standard errors and test 
statistics produced by conventional software are biased [298]. 
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8.3.2.3 Additional Category or Missing Indicator Method 
In some situations missing data may be a valid response and consequently a larger 
proportion of responses may be missing than expected.  For example, the variable for the 
results of a clinical test could have normal or abnormal as responses for patients who had 
the test.  Some patients however may not have had the test because it was deemed not to 
be relevant.  Therefore a third category can be introduced for ‘not done’ or ‘missing’.  This 
ensures all cases can be analysed and takes account of the validly missing data. 
A variation on this method is to create a dummy variable   that is equal to 1 if data are 
missing on variable   and equal to 0 otherwise.  A new variable    can be created such 
that 
    
                         
                     
  
where   can be any constant.  The dependent variable   can be regressed on   ,  , and 
any other variables in the intended model.  This technique, known as dummy variable 
adjustment or the missing-indicator method, can be extended easily to the case of more 
than one independent variable with missing data.  The apparent virtue of the dummy 
variable adjustment method is that it uses all the information that is available about the 
missing data [298].  Unfortunately this method generally produces biased estimates of the 
coefficients, as proven by Jones [305]. 
8.3.2.4 Imputation 
Except in special circumstances that usually involve only very simple models, the primary 
alternative to deleting incomplete observations is imputation of the missing values.  The 
basic idea is to substitute some reasonable guess, imputation, for each missing value and 
then proceed to do the analysis as if there were no missing data.  Imputation is a general 
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and flexible method for handling missing data problems, however, it is not without issues 
[293, 306]. 
Decisions need to be made regarding which information to use in computing imputed 
values for missing data.  They can be filled in by sampling non-missing values of the 
variable, or by using a constant such as the median or mean non-missing value.  Imputation 
algorithms can be based only on external information not otherwise used in the model or 
they can be derived by only analysing inter-relationships between the predictor variables.  
Imputations can also use relationships among the predictor and outcome variables and 
they can take into account the reason for non-response if known [139]. 
8.3.2.4.1 Single Imputation 
In single imputation only one estimate, such as a mean, is imputed and then the resulting 
data is analysed as if there were no missing data.  Single imputation is simple, reduces bias 
due to non-response compared to complete and available case analyses, and improves 
precision but it underestimates the standard error and can lead to incorrect p-values.  
Several variations of single imputation exist: unconditional mean imputation, conditional 
mean imputation and hot deck imputation.   
8.3.2.4.1.1 Unconditional Mean Imputation 
A particularly simple form of imputation is to estimate missing values     by   
   
, the mean 
of the recorded values of   .  In mean substitution missing values are replaced by the 
average of the observed values for that item.  The average is preserved but other aspects 
of its distribution are altered with potentially serious consequences [292].   
Unconditional mean imputation is simple to implement for any type of variable and in 
addition, once missing values are imputed and incorporated into the dataset, multiple 
users can use the data with consistent results.  However, one value cannot reflect sampling 
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variability and marginal distributions and associations are distorted because there is no 
residual variance after the imputation [293]. 
8.3.2.4.1.2 Conditional Mean Imputation 
A more promising form of imputation is to substitute means that are conditioned on the 
variables recorded in an incomplete case.  This method, proposed by Buck [307], first 
estimates the mean and covariance from the multivariate normal distribution, from the 
sample mean and covariance matrix based on the complete cases.  These estimates are 
then used to calculate the linear regressions of the missing variables on the present 
variables, case by case.  Substituting the observed values of the present variables for a case 
in the regressions yields predictions for the missing values in that case.  
In the simple case a multiple regression could be estimated with several independent 
variables.  One of these variables,  , may have missing data for some of the cases.  For 
those cases with complete data, it is possible to regress   on all other independent 
variables.  Using the estimated equation, predicted values for the cases with missing data 
on   can be generated which are substituted for the missing data and the analysis 
proceeds as if there were no missing data [298].   
Buck’s method [307] projects the incomplete cases to the regression line, a process that 
makes the assumption that the regression is linear.  This assumption is particularly tenuous 
if the imputation involves extrapolation beyond the range of the complete data.  However, 
the filled-in data from Buck’s method [307] yields reasonable estimates of means, 
particularly if the normality assumptions are plausible.  The sample covariance matrix from 
the filled-in data underestimates the sizes of variances and covariances, although the 
extent of underestimation is less than that obtained when unconditional means are 
substituted. 
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Although the regression based imputations in Buck’s method [307] appear to require that 
the variables         are interval scaled, the method can be applied to categorical 
variables by replacing each of them by a set of dummy variables, numbering one less than 
the number of categories.  If a categorical variable is completely observed, then the dummy 
variables always appear as independent variables in the regressions for Buck’s method and 
no problems arise.  If it is sometimes missing, then the set of dummy variables also appear 
as dependent variables in linear regressions.  The imputations from the regressions are 
linear estimates of the probability of falling into the categories represented by each of the 
dummy variables.  Problems can arise from the fact that linear regression is used to predict 
these probabilities; for example, the predicted values can lie outside the range (0,1).  Thus 
Buck’s method has limitations when some of the missing variables are categorical [293].  
8.3.2.4.1.3 Hot Deck Imputation 
Another example of a simple imputation technique is the hot deck method in which a single 
value is imputed for each missing observation.  This technique selects a value at random, 
usually with replacement from a donor pool of complete cases, and the missing value is 
then replaced by the selected value [308].  This strategy introduces variation into the 
analysis consistent with the range of possible values seen in the complete data [309].  The 
matching process can be carried out using so-called filter variables.  The records match if 
they have the same values on the filter variables [310]. 
The main advantage of this non-parametric technique is that it does not require strong 
distributional assumptions or careful modelling to develop selection criteria for imputing a 
value – in fact it preserves the distribution of item values and permits the use of the sample 
weight for all items.  Additionally, the results obtained from different analyses are 
consistent with one another [310].  However the disadvantages of the method are that 
there are no clear criteria to guide the selection of the donor set of complete cases, and, 
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although the variability of items is not distorted, it still distorts correlations and other 
methods of association [309].  In addition, the predictor variable must all be categorical, or 
treated as such, which imposes serious limitations on the number of possible predictor 
variables [310]. 
8.3.2.4.2 Multiple Imputation 
The key idea of the multiple imputation procedure is to replace each missing value with a 
set of   plausible values.  Each value is a Bayesian draw from the conditional distribution 
of the missing observation given the observed data [311].  The imputations produce   
‘completed’ datasets, each of which is analysed using the method that would have been 
appropriate had the data been complete.  The model for the latter analysis is called the 
substantive model, while that used to produce the imputations is called the imputation 
model.  A strength of the multiple imputation procedure is that, to a certain extent, the 
two models can be considered separately.   
Multiple imputation is most straightforward to use under MAR, and most software 
implementations make this assumption.  However, it is quite possible to apply it in missing 
not at random settings, and this is particularly convenient when certain classes of pattern-
mixture models are used to construct the imputation model.  Multiple imputation involves 
three distinct phases [296]: 
1. The missing values are filled in  times to generate  complete datasets 
2. The  complete datasets are analysed by using standard procedures 
3. The results from the  analyses are combined into a single inference 
Suppose that interest lies in making inferences about the     parameter vector   from 
the substantive model and that it is possible to make appropriate Bayesian posterior draws 
from the imputation model.  Replacing the missing data by their corresponding imputation 
samples,   completed datasets are constructed.  Denote by     and    respectively the 
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estimate of   and its covariance matrix from the  th completed dataset          .  
The multiple imputation estimate of  is the simple average of the estimates,  
    
 
 
        . 
The advantages of multiple imputation are that a single set of imputed datasets can be 
used for a variety of analyses and it accounts for missing data uncertainty.  However, it is 
cumbersome to use because of the need to analyse multiple datasets and combine the 
results to make one overall inference. 
8.3.2.5 Maximum Likelihood Algorithms 
Theory-based maximum likelihood approaches for dealing with missing data have been 
known in the technical literature for some time [306, 312, 313].  As the methods require 
the less restrictive MAR assumption, unbiased parameter estimates should result under 
both MCAR and MAR [314].  In addition maximum likelihood methods should yield more 
efficient estimates than listwise and pairwise deletion under MCAR.  In theory, likelihood 
methods are more attractive than ad hoc techniques of case deletion and single imputation 
[292].  However, they still rest on a few crucial assumptions - the sample is large enough for 
maximum likelihood estimates to be approximately unbiased and normally distributed, and 
the likelihood function comes from an assumed parametric model for the complete data.  
Depending on the application, likelihood methods may or may not be robust to departures 
from model assumptions. 
Intuitively the missing data is ‘filled in’ with a best guess at what it might be under the 
current estimate of the unknown parameters, then the parameters are re-estimated from 
the observed and filled-in data.  In a formal sense there is no difference between the 
maximum likelihood estimation for incomplete data and maximum likelihood estimation 
for complete data: the likelihood for the parameters based on the incomplete data is 
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derived and the maximum likelihood estimates are found by solving the likelihood equation 
[293]. 
8.3.2.6 The Expectation-Maximisation Algorithm 
The expectation-maximisation (EM) algorithm is a convenient and widely applicable 
computational technique that can be used when the observed data likelihood is awkward 
and/or difficult to compute.  It is a general-purpose iterative algorithm for calculating 
maximum likelihood estimates in parametric models for incomplete data.  The condition 
for the EM algorithm to be valid, in its basic form, is ignorability, and hence MAR.  Within 
each iteration of the EM algorithm there are two steps called the expectation step, or E 
step, and the maximisation step, or M step.  
The fundamental idea behind the EM algorithm is to associate with the given incomplete 
data problem a complete data problem for which maximum likelihood estimation is 
computationally easier.  Starting from suitable initial parameter values, the E and M steps 
are repeated until convergence.  Given a set of parameter estimates, such as the mean 
vector and covariance matrix for a multivariate normal setting, the E step calculates the 
conditional expectation estimates.  This step often reduces to calculating simple sufficient 
statistics.  Given the complete data log-likelihood, the M step then finds the parameter 
estimates to maximise the complete data log-likelihood from the E step. 
The fact that the EM algorithm is guaranteed to converge to a, possibly local, maximum is a 
great advantage.  However a disadvantage is that this convergence is slow and that 
precision estimates are not automatically provided. 
8.3.3 Methods for Handling Missing Covariates 
Within an individual study missing covariates have not been considered as there is no data 
to base the imputation (or similar) on.  However, in the case of external validation, extra 
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data is available that may inform ‘replacement’ of the covariate.  It may be possible to 
adapt some of the existing methods for handling missing data within covariates to the 
situation of every entry missing.  The situation of a missing covariate may  reasonably 
satisfy the MCAR assumption if missingness is not related to anything within the study 
design –  there may be examples where this is not the case for example if the reason for 
the missing data was related to severity of disease, say if a CT scan was not indicated.  In 
these cases further consideration would be needed to decide which methods of imputation 
were valid. 
Of the standard methods for handling missing data within a covariate outlined in section 
8.3.2, available case analysis, additional category for missing responses, mean imputation 
and maximum likelihood methods are not adaptable to covariates with every entry missing.  
In the case of available case analysis this is because all cases would be removed while in the 
case of an additional category for missing responses it would not be possible to fit a Cox 
model as the variable with the additional category would have only one category.   Mean 
imputation is not possible as there is no data to estimate the mean from and if the mean 
from the relevant variable within the development data was imputed, all cases would have 
the same response and therefore the Cox model could not be fit.  Finally, for maximum 
likelihood methods, the joint distribution of the observed and missing covariates is 
required but this is unobtainable in the situation of a missing covariate. 
Five adaptations of existing methods for handling missing data within a covariate to the 
situation of handling a covariate missing from the validation dataset are (1) remodelling 
with variable matching; (2) random selection with replacement; (3) single imputation via 
estimated proportions; (4) hot deck imputation; (5) random selection with replacement 
multiple times.  These methods will be outlined in sections 8.3.3.1 to 8.3.3.5. 
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8.3.3.1 Remodelling with Variable Matching 
The extension of complete case analysis to external validation involves fitting the model on 
a reduced covariate set.  To externally validate a prognostic model using a validation 
dataset missing at least one covariate, the model is refit with the development dataset 
restricted to include only covariates that are available in the validation dataset.  This is 
similar to Mekhail’s [273] approach for handling missing covariates by remodelling the data 
on the reduced dataset as described in the literature review of section 8.2.1. 
There are limitations to this approach in terms of how many variables are missing - if the 
validation dataset has no variables in common with the development data then, obviously, 
this approach is unsuitable.  This is, however, also true for the other imputation methods. 
8.3.3.2 Random Selection with Replacement 
In random selection with replacement, each entry of the missing variable is imputed by 
randomly selecting an entry from the equivalent variable in the development dataset.  
Random selection with replacement is used to ensure that the imputed variable in the 
validation dataset is not just a re-ordered copy of the variable from the development 
dataset. 
8.3.3.3 Single Imputation via Estimated Proportions 
In single imputation via estimated proportions each entry of the missing variable is imputed 
with a random number.  The imputed random number is based on the summary statistic(s) 
of the equivalent variable in the development dataset.  For example, if the missing variable 
in the validation dataset is a binary variable, then the proportion of positive responses in 
the equivalent variable within the development dataset is estimated.  The missing variable 
is then imputed with zeros and ones generated according to these proportions.  In the case 
of continuous variables, the mean and standard deviation are estimated from the 
development dataset and these estimates are used to obtain values that can be imputed 
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into the validation dataset.  Finally, for categorical variables the percentage of each 
response is used to inform the imputation.  Essentially we are assuming that the missing 
values are random draws from a normal distribution with mean and standard deviation 
estimated from the development dataset. 
8.3.3.4 Hot Deck Imputation 
In the case of a missing covariate there is no way to match a missing with a non-missing 
respondent.  The only plausible alternative is to impute the missing covariate values with 
values recorded for similar respondents in the development data.  In our simulation study 
(section 8.4), similar respondents have matched binary, categorical and continuous 
variables.  Continuous variables are matched to the nearest respondent based on the 
smallest mean square error between the continuous variable in the development dataset 
and the equivalent continuous variable in the validation dataset.  
8.3.3.5 Multiple Imputation  
The conditional distribution of the missing observation is not known in the case of a 
variable with every entry missing.  However a variation is to randomly select, with 
replacement, values of the missing covariate from the development set to produce   
datasets.  In the first step the validation data is used to fit the Cox model except for the 
missing covariate which is substituted with data from the relevant covariate within the 
development data, using random selection with replacement.  This is repeated   times.  
The outcomes are calculated as usual and finally, results from all the analyses are combined 
to produce a mean outcome across the repetitions.  Rubin [296] claimed that only three to 
10 imputations may be needed.  He showed that the efficiency of an estimate based on  
imputations is approximately  
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where   is the rate of missing information for the quantity being estimated.  The 
efficiencies achieved for various values of m and rates of missing information are shown in 
Table 23. 
Table 23: Efficiencies achieved for various numbers of imputations and rates of missing information 
   
  0.1 0.3 0.5 0.7 0.9 
3 97 91 86 81 77 
5 98 94 91 88 85 
10 99 97 95 93 92 
20 100 99 98 97 96 
 
8.3.3.6 Conclusion 
In the literature review (section 8.2.1) we found only one study where there was an issue 
with a covariate missing from the validation dataset.  This was because nearly every study 
had collected a validation dataset specifically with the intention of externally validating 
either a previously published prognostic model, or validating a prognostic model they had 
developed. 
As observed by Royston, of the many hundreds of prognostic models published each year, 
only very few are externally validated [274].  Perhaps a reason for this is a lack of funding to 
obtain a validation dataset with covariates that match those in the prognostic model.  
Plausibly related datasets are already available within the field of epilepsy however, and I 
imagine the same applies to many other medical fields.  Unfortunately, many of them are 
missing covariates found to be significant in a prognostic model.  Therefore methods for 
handling missing covariates in the context of external validation need to be found.  In the 
simulation study of section 8.4 the performance of methods for handling a covariate 
missing from the validation dataset are compared to potentially address this issue. 
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8.4 Simulation Study 
The simulations were conducted using the R statistical programming language versions 
2.9.2 and 2.14.1 [182]. 
As described in Bonnett [315] and in Chapter 4, the SANAD dataset has recently been used 
to determine if any clinical factors influence outcome and to develop prognostic models.  
These prognostic models should be validated in plausibly related validation datasets.  
Unfortunately no other datasets that are similar to SANAD exist.  The best match is a set of 
individual participant data that has been collected [192].  However these data do not 
include all the covariates that were found to be significant in the multivariable model.  
Therefore, it is of particular relevance to see how data, based on SANAD, can be validated 
using independent data with missing covariates.    
As shown in the literature review, in section 8.2.1, various methods of external validation 
exist however there is no evidence to suggest which method is most appropriate.  
Additionally, methods for handling covariates missing from the validation data do not 
currently exist.  To determine which methods of external validation are appropriate and to 
investigate strategies for handling covariates missing from the validation dataset, a 
simulation study was undertaken. 
8.4.1 Methods Under Consideration 
The most common methods of external validation listed in the literature were repetition of 
the complete analysis (53%), discrimination (41%), calibration (39%) and comparison of a 
product of the analysis (35%).  Repetition of the analysis involves re-running the model 
selection process in the validation dataset.  Given a dataset it is possible to fit thousands of 
models and therefore different researchers might discover or learn different things from 
the same dataset [316].  Additionally, it is possible to gear model building and model 
selection efforts towards criteria that favour good performance [316].  Therefore repeating 
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the analysis may lead to biased results as researchers could engineer the model selection 
process to produce a multivariable model that closely matches that developed using the 
development model.  For this reason, and together with the time-consuming nature of 
repeating the analysis, repetition of the analysis will not be considered as a method of 
external validation in the simulation study. 
Instead, the other popular methods of external validation will be considered – comparison 
of discrimination, comparison of calibration and a comparison of products of the analysis.  
We will consider discrimination via comparison of concordance (Harrell’s   or equivalently 
Somers’  ) statistics, calibration via comparison of deviance statistics and comparison of a 
product of the analysis via a measure of prognostic separation.   
As shown in the literature review in section 8.2.1, very few prognostic models are 
externally validated.  In clinical medicine, the focus of this thesis, the Cox proportional 
hazards model is a near-universal tool in the analysis of prognostic models [287].  Therefore 
for our purpose it is most appropriate to focus on external validation of Cox models 
although it would be interesting to extend the simulation study to Royston-Parmar’s 
alternative in the future.  
The five methods of handling covariates missing from the validation dataset under 
consideration in the simulation study are (1) remodelling with variable matching; (2) 
random selection with replacement; (3) single imputation via estimated proportions; (4) 
hot deck imputation; and (5) random selection with replacement multiple times, all of 
which were described in section 8.3.3. 
8.4.2 Simulation Procedures – Data Generation 
Data used to derive the data-generation process for the simulations consisted of 1644 
patients recruited to the SANAD study [180], although development datasets of size 1500 
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were simulated for simplicity.  Time to first seizure after randomisation was the chosen 
outcome variable as this was the simplest time to event outcome of the SANAD study. 
Sections 8.4.2.1 through to 8.4.2.3 describe how the data were simulated. 
8.4.2.1 Survival Data 
It is common to model survival times through the hazard function.  As the Cox proportional 
hazards model is formulated through the hazard function, the simulation of appropriate 
survival times is not straightforward [317] - the effect of the covariates have to be 
translated from the hazard to the survival times because the usual software packages for 
Cox models require the individual survival time data, not the hazard function.  The 
translation of the regression coefficients from hazard to survival time is simple if the 
baseline hazard function is constant i.e. the survival times are exponentially distributed 
[317]. 
Among the commonly used survival time distributions, only the exponential, Weibull and 
Gompertz distributions share the assumption of proportional hazards with the Cox model 
as described in section 1.4.2.  The survival function of the Cox model is given by        
               
     where             
 
 
d  is the cumulative baseline hazard 
function [30].  Thus the distribution function of the Cox model is          
               
    .   
Let   be a random variable and let the distribution function,  , of   be constant.  Then 
       follows a uniform distribution on the interval from 0 to 1 [318].  Then let   be 
the survival time of the Cox model,                  
   .   
It therefore follows that                    
            and, as both          
and            according to the properties of a standard uniform distribution, 
                 
           .   
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If         for all  , then    can be inverted and the survival time,  , of the Cox model 
can be expressed as Equation 19 by taking the logarithm of both sides of the equation, 
dividing through by –          and inverting     . 
Equation 19 
    
                     
where   is a random variable with         .  By applying Equation 19, uniformly 
distributed random numbers can be transformed into survival times following a specific Cox 
model.  An appropriate cumulative baseline hazard function, such as the exponential, 
Weibull or Gompertz, then just needs to be inserted into the formula.   
Table 24 summarises the survival time and hazard function equations for these three 
distributions where  is a variable following a uniform distribution on the interval from 0 to 
1.  By inserting the inverse of the cumulative hazard function for the exponential 
distribution,   
          , into Equation 19 we transformed uniformly distributed 
random numbers into survival times following a Cox-exponential model [317].  The Cox-
exponential distribution was used for simplicity in our simulation study. 
Table 24: Survival time and hazard function equations for the Cox-exponential, Cox-Weibull and Cox-
Gompertz distributions 
 Model 
Characteristic Cox-exponential Cox-Weibull Cox-Gompertz 
Survival time    
       
         
     
       
         
 
   
   
 
 
      
        
         
  
Hazard function                                                              
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8.4.2.2 Censoring Indicator 
A censoring indicator is a binary variable which follows a binomial distribution.  In this case 
  is the probability of being censored as a result of either loss to follow-up or study 
completion without an event.  Any survival times equal to or in excess of the maximum 
follow-up time were censored.   
A patient randomised to SANAD could potentially have been followed-up for a maximum of 
seven years.  In the case of time to first seizure the longest follow-up occurred 
approximately 6.5 years into the trial.  Therefore, the maximum possible simulated survival 
time was 6.5 years.  Any survival times equal to or in excess of this time were censored.  
For all other patients, censoring was in the same proportions as in SANAD. 
For each case, if the uncensored survival time for a case was less than or equal to the 
censored time, then the event was considered to be observed and the survival time 
equalled the uncensored survival time.  Otherwise the event was considered censored and 
the survival time equalled the censored time. 
8.4.2.3 Covariate Data 
We assumed that there were three predictor variables.  We selected the following variables 
from the SANAD dataset: gender, age and epilepsy type.  For simplicity, covariate data was 
generated using an underlying multivariate normal distribution [319] with means and 
covariance matrix as per the SANAD data (Table 25).  Age was normally distributed so no 
transformation was required to make the assumption of normality more appropriate.  
However, in the clinical setting, continuous variables are often considered to follow the log 
normal distribution [320].  Therefore, the generated covariate data for the continuous 
variable was transformed onto the log scale prior to analysis.  The continuous covariate 
(simulated age) was truncated using the upper and lower observed limits of 86 and five 
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respectively to produce realistic values and reasonable estimates for the mean and 
standard deviations [321]. 
Binary and categorical variables were generated as latent normal variables – they were 
generated as continuous variables and then a cut-point of 0.5 was used to obtain the binary 
covariate and cut-points of 0.33 and 0.66 were used for the three-level categorical 
covariate [321].  Two dummy variables were then created accordingly. 
Table 25: Data structure for the SANAD dataset and associated means, standard deviations (SDs) and 
variance-covariance matrix 
 Variance-Covariance Matrix 
Covariate 
Variable 
Type 
Groupings/ 
Measurement 
Mean (SD) Gender 
Epilepsy 
Type 
Age 
Gender Binary 
0 = female 
1 = male 
0.55 (0.50) 0.25 0.01 -0.15 
Epilepsy 
Type 
Categorical 
0 = partial 
1 = generalised 
2 = unclassified 
1.21 (0.60) 0.01 0.35 -0.26 
Age Continuous Years 38.30 (18.34) -0.15 -0.26 336.36 
 
8.4.3 Simulation Procedures - Scenarios to be Investigated 
There are a large number of variations that could be tested, irrespective of the aim - 
number and combination of covariates present and missing; types of covariates present 
and missing; size of the development and validation datasets; how closely the ‘super-
population’ assumption is adhered to; length of follow-up etc.   We varied the following 
factors in our simulations: the size of the validation dataset and the missing variable.  
During the literature review (section 8.2.1), data was collected on the sample size of both 
the validation and development datasets.  The size of the validation dataset could be 
considered as a percentage of the size of the development dataset.  Of those articles that 
externally validated a Cox model, the 25th percentile of these values was 57% while the 75th 
percentile was 115%.  Therefore, the two sample sizes we considered were 855 and 1725.  
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With regards to the missing variable, none or one of the binary, continuous and categorical 
variables were forced to be missing in turn. 
The scenarios examined are shown in Table 26 with scenarios 1 and 5 testing the methods 
of external validation and 2, 3, 4, 6, 7 and 8 testing the methods of imputation.  The missing 
data methods have been compared by comparing each method of external validation 
(concordance, deviance and prognostic separation) from the validation dataset with 
missing data to the corresponding method of external validation from the validation 
dataset without missing data. 
Table 26: Simulation Strategies used to consider methods of external validation and methods to handle a 
covariate missing from the validation dataset 
 implies the variable is present in the dataset;  implies that the variable is missing from the dataset 
Scenario Dataset to be generated Number of subjects 
Variable present? 
Binary Continuous Categorical 
- Development 1500   
1 Validation 855   
2 Validation with missing data 855   
3 Validation with missing data 855   
4 Validation with missing data 855   
5 Validation 1725   
6 Validation with missing data 1725   
7 Validation with missing data 1725   
8 Validation with missing data 1725   
 
8.4.4 Simulation Procedures – Statistical Methods 
Once a development dataset and a fully independent validation dataset had been randomly 
generated a Cox model, adjusted for the three simulated covariates, was fitted to each.  
The prognostic measure of separation for each model was obtained together with the 
deviance, concordance statistic, regression coefficients and respective standard errors.  
This process was then repeated 1400 times for each possible combination of size of 
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validation dataset (855 and 1725) and missing data (none, missing binary, missing 
categorical, missing continuous).  The number of simulations was based on the accuracy of 
the regression coefficients and was calculated using the following formula: 
   
         
 
 
 
 
where   was the specified level of accuracy of the estimate that we were willing to accept, 
         was the         quantile of the standard normal distribution and  
  was the 
variance from the parameter of interest [322].  In our case, a 5% accuracy of the true 
coefficient was required and               therefore 1400 simulations were run.   
Within each scenario we computed: the proportion of the 1400 differences in prognostic 
separation between the development and validation datasets within 5% tolerability limits 
of zero, the proportion of the 1400 p-values for the difference in deviance between the 
development and validation datasets within 5% of zero (indicating that the models are not 
externally valid) and the proportion of the 1400 differences in concordance between the 
development and validation datasets within 5% of zero.  
To summarise the estimates once all simulations had been performed, the average 
regression coefficient over the simulations was calculated as a true estimate of interest 
where   was the number of simulations and     was the regression coefficient for 
simulation  . 
    
   
 
 
   
 
As the simulation study had been designed to mimic the results that could have been 
obtained from a single study, an assessment of the uncertainty in the regression coefficient 
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between simulations, denoted       , was the empirical standard error calculated as the 
standard deviation of the regression coefficients from all simulations. 
                   
 
 
   
 
 
Standardised bias was calculated as per Equation 20.  A standardised bias of greater than 
40% in either direction has been shown [323] to have noticeable adverse impact on the 
efficiency, coverage and error rate.  Therefore, a result of greater than 40% in either 
direction was taken as a poor result. 
Equation 20 
 
    
      
      
Mean square error (MSE) was calculated as per Equation 21.  It provided a useful measure 
of the overall accuracy because it incorporated both measures of bias and variability and 
was calculated for each method.  A mean square error of 0 suggests the estimator    
predicts observations of the parameter   with perfect accuracy [319]. 
Equation 21 
      
 
         
 
 
The coverage of a confidence interval is the proportion of confidence intervals that contain 
the true specified parameter value [319].  The coverage should be approximately equal to 
the nominal coverage rate, usually taken as 95%.  Coverage above 95% suggests that the 
estimates are too conservative as more simulations will not find a significant result when 
there is a true effect leading to a loss of statistical power with too many type II errors.  In 
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contrast, coverage below 95% is unacceptable as it indicates inappropriate over-confidence 
in the estimates since more simulations will incorrectly detect a significant result which 
leads to higher than expected type I errors. 
The coverage should not fall outside of approximately two standard errors of the nominal 
coverage probability,   where 
               . 
So, if 95% confidence intervals are calculated using 1400 independent simulations then 
               and hence between 1314 and 1346 of the confidence intervals should 
include the true regression coefficient value. 
8.4.5 Results 
Each method should conclude that the model developed using the development dataset 
was externally validated by the validation dataset due to the way the data were simulated.  
Any method which did not reach this conclusion was deemed to be a poor method of 
external validation.  However, a dataset could be chosen that differs from the development 
dataset just by chance hence bootstrap resampling has been used.   
To enable comparison across methods sensitivity and specificity could be calculated.  
However, this would require further simulation settings so that we could capture situations 
where the ‘truth’ is that the model is not externally valid.  This is obviously virtually 
impossible to define and so this simulation study is liable to criticism as we have only 
assessed performance for cases where the data are related.  In pre-emption of this, 
external validation hinges on satisfying the condition that datasets have come from a 
super-population.  There will, of course, be different degrees of how well this is satisfied in 
practice and so an extension to this simulation study would consider varying degrees of 
adherence to the super-population condition.   
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In the case of the concordance and prognostic separation methods the model would be 
externally valid if the difference between the development and validation datasets was 
zero hence the proportion of simulations within 5% tolerability limits of zero have been 
calculated.  In the case of the deviance method, a p-value for the comparison of deviance 
between the development and validation dataset would be less than 0.05 if the model is 
not externally valid, although some comparisons would be significant just by chance. 
8.4.5.1 Concordance 
For ease of interpretation results are presented graphically although numerical results are 
available in Appendix C.  Only the results for the 5% tolerability limits are presented here - 
the 10% results can also be found in Appendix C.  Figure 25 shows the mean concordance 
values over 1400 simulations.   The concordance statistic shows almost perfect agreement 
between the validation and development datasets for the case of no missing data and for 
each method of imputation (mean development  -statistic variable matching: 0.55; mean 
validation  -statistic variable matching: 0.55; mean development  -statistic otherwise: 
0.56; mean validation  -statistic otherwise: 0.56).  The poorest, although still good, 
agreement is in the case of variable matching where 97.1% of differences in concordance 
values between the development and the validation dataset are within 5% of zero 
difference suggesting that the model is externally valid 97% of the time. 
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Figure 25: Mean Concordance Values from simulation study examining methods of external validation and 
methods of handling a covariate missing from the validation dataset 
 
8.4.5.2 Deviance 
Figure 26 shows the proportion of p-values less than 5% for the comparison of deviances 
between the development and validation datasets over 1400 simulations – a p-value less 
than 5% implies that the model is not externally valid.  The deviance statistic seems to 
suggest that although there is agreement between the development and validation models, 
it is weak agreement which should not be the case given the method of data simulation.  
Results for validation datasets which are larger than the development ones are slightly 
better than for those where the validation dataset is smaller than the development dataset 
irrespective of the method of imputation.  In the case of multiple imputation (random 
selection with replacement multiple times) only 13.4% of models had a significant p-value 
(at the 5% level) and were therefore not externally valid.  This method of imputation has 
performed much better than the other four methods – in the case of variable matching at 
least 43% of models had a significant p-value.  For random selection with replacement, 
single imputation via estimation and hot deck imputation at least 62% of models had a 
significant p-value and therefore were not externally valid. 
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Figure 26: Mean p-values for Comparison of Deviance from simulation study examining methods of external 
validation and methods of handling a covariate missing from the validation dataset 
 
The simulations without missing data gave poorer results than the simulations with missing 
data.  A reason for this is that by using imputation methods, or removing a covariate in the 
case of variable matching, the validation dataset is a closer match to the development 
dataset by the nature of the imputation than two randomly generated datasets – when the 
validation dataset was forced to be identical to the development dataset the method lead 
to 100% agreement as expected.  An additional reason may be the possible violation of the 
assumption required for the distribution of the deviance difference - the result that the 
deviance difference is distributed as    with degrees of freedom equal to the number of 
re-estimated parameters depends on the independence of the parameters, details of which 
are explained in section 8.2.4.   
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8.4.5.3 Prognostic Separation 
The mean difference in prognostic separation between the development and validation 
datasets over 1400 simulations can be seen in Figure 27. Generally the prognostic 
separation measure showed poor agreement between the validation and development 
datasets.  Validation datasets which were larger than the development datasets tended to 
show slightly better agreement.  In the case of multiple imputation the prognostic 
separation measure showed near perfect agreement between the validation and 
development datasets especially with validation datasets which were larger than the 
development datasets (over 97.1% of mean differences within 5% of 0 for the small 
validation sets and over 99.5% of difference within 5% of 0 for large validation sets). 
Figure 27: Mean Separation Values from simulation study examining methods of external validation and 
methods of handling a covariate missing from the validation dataset 
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8.4.5.4 Measures of Accuracy 
Average coefficient values,   , were similar for the development and validation dataset as 
shown by Figure 28.  Standard error values were also similar (not presented – see Appendix 
C).  In Figure 28 values presented are the mean coefficient values over all coefficients per 
scenario per method.   
Figure 29 shows the mean bias results, taken over all coefficients.  In most cases 
standardised bias was very small and certainly within the recommended 40% limits 
suggesting that bias was not an issue.  Only in the situation of variable matching does bias 
become an issue, especially when a categorical variable is the variable missing from the 
validation dataset.  In this case some individual biases exceed 40%.  However, the mean 
results are within the 40% boundary. 
Figure 28: Mean Coefficient Values from simulation study examining methods of external validation and 
methods of handling a covariate missing from the validation dataset 
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Figure 29: Mean Bias Results from simulation study examining methods of external validation and methods 
of handling a covariate missing from the validation dataset 
 
Values presented in Figure 30 are the mean MSE values over all coefficients per scenario 
per method while those in Figure 31 are the mean coverage values over all coefficients per 
scenario per method.  The MSE values are also very close, or equal, to zero which suggests 
almost perfect accuracy in the results irrespective of the presence of missing data and the 
strategies employed to impute missing data (Figure 30). 
No method led to 95% coverage (Figure 31).  The mean coverage values ranged from 80% 
to 100% with validation datasets that were smaller than the development validation 
datasets having larger coverage values generally.  In the case of multiple imputation the 
coverage values were 100% irrespective of the size of the validation datasets. 
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Figure 30: Mean MSE Values from simulation study examining methods of external validation and methods of 
handling a covariate missing from the validation dataset 
 
Figure 31: Mean Coverage Values from simulation study examining methods of external validation and 
methods of handling a covariate missing from the validation dataset 
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8.5 Conclusion 
We conducted a series of bootstrap simulations to examine the performance of methods of 
external validation and methods for handling covariates missing from the validation 
dataset.  Concordance has been applied to many previous models (as shown by the 
literature review in section 8.2.1) while deviance and the measure of prognostic separation 
have been applied sparingly as shown by [251, 280].  A comparison of these methods has 
not previously been made, nor an assessment of their ease of application to prognostic 
models.  Standard methods of handling missing data within covariates have been regularly 
applied but this simulation study is the first to vary these methods to handle covariates 
that are completely missing in the context of external validation of prognostic models. 
In the current study, we found that the use of concordance showed most often that the 
model was externally valid when the development and validation datasets were simulated 
in the same way.  The measure of prognostic separation showed that the models were 
externally valid for over 90% of the simulations in the case of random selection with 
replacement multiple times (multiple imputation).  This is likely to be as a result of the 
mechanics of multiple imputation – the imputation process was applied 20 times and the 
results averaged.   Given that the measure of prognostic separation should have shown 
almost all models to be externally valid, especially in the case of no missing data, it cannot 
be recommended for general practice.   
The deviance measure showed that the models were externally valid for over 80% of the 
simulations in the case of multiple imputation only.  In the case of no missing data, over 
60% of models had p-values for the comparison of deviance less than 5% and therefore at 
least 60% of models were not externally valid according to this measure.  This should not 
be the case given the way the data were simulated and therefore comparison of deviance 
also cannot be recommended for general practice.   
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In the case of deviance it is also important to note that a significant p-value suggests that a 
model is not externally valid.  However a non-significant p-value does not necessarily 
indicate that the model is externally valid.  This is obviously not an ideal conclusion to draw 
from a measure of external validation – we want to conclude that a model is externally 
valid rather than there not being enough evidence to conclude it is not externally valid.  
Therefore this is another reason that this method cannot be recommended for general 
practice. 
Variable matching was a poor method of imputation leading to results which were highly 
biased in this simulation study.  Methods random selection with replacement, single 
imputation via estimation, hot deck imputation and random selection with replacement 
multiple times were all appropriate methods of imputation in this simulation study as they 
generally led to unbiased, accurate results.  The more data missing from the validation 
dataset the better the model performed in terms of external validation because the 
validation dataset was effectively converging to the development dataset.  Therefore 
caution is required when interpreting these results and further investigation is needed to 
examine the effect of more than one missing covariate. 
It is important to note that the methods of external validation examined here are 
measuring different things – discrimination and calibration in the case of Harrell’s  -statistic 
and deviance respectively.  Ideally, it would be possible to use any of the methods to 
examine the external validity of a prognostic model and therefore use multiple methods to 
confirm the conclusion.  However, our results suggested that it may be only concordance 
which was a reliable method of external validation.  It is also worth noting that different 
degrees of external validation are likely rather than a clear-cut yes or no answer.  The 
degree of external validity may be influenced by what the model will be used for as the 
consequences of using an ‘incorrect’ model in practice may have different impacts.  For 
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example a model used to predict a mild adverse event such as a rash or head ache may not 
need to be as accurate as a model predicting risk of seizure recurrence and hence a lower 
degree of external validity may be acceptable for the adverse event model than the seizure 
risk model.    
Further limitations of the work in this chapter include the simplicity of the simulated model 
which is unrealistic in having only three covariates – as shown in the literature review 
(section 8.2.1) the median number of covariates was five although a maximum of 20 has 
been observed.  Additionally, all the imputation methods rely on having access to the 
development dataset which is often not possible.  The simulation study presented here also 
makes a large assumption that the development and validation datasets are similar which 
is often not the case as the purpose of external validation is to evaluate the model for a 
slight different, though not dissimilar, case-mix.  The simulation study as it currently stands, 
however, highlights the problems of external validation of prognostic models – even in the 
situation of an over-simplistic development prognostic model with a very similar validation 
model, two out of the three chosen methods of external validation failed to show 
validation when it was known to be present.  This highlights the need for considerable 
further research in this area. 
In 2004 May [280] measured the quality of predictions from prognostic models for survival 
time data using three different methods: Harrell’s concordance statistic, Brier statistic and 
a novel method using deviance differences.  The results showed that the deviance statistic 
was able to discriminate between quite similar models and could be used to choose a 
prognostic model that generalised well to new data.  May found Harrell’s  -statistic worked 
well in evaluating discrimination but was insensitive to differences in calibration and 
insensitive to differences between prognostic models [280]. 
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The Brier score compares predicted probabilities with Bernouilli outcomes at a particular 
time, which is problematic in the context of censored survival data since different models 
may predict better at different lengths of follow up.  May found that it failed to 
discriminate between the predictive performance of candidate prognostic models [280].   
May’s newly proposed approach based on deviance differences was able to discriminate 
between candidate prognostic models, however, further methodological work was 
recommended to support the use of deviance differences in model validation.  In our 
simulation study we found that deviance differences were not usually appropriate in 
external validation of prognostic models. 
While there is no doubt that models should be validated [264] and some authors do 
externally validate their model, as highlighted in the literature review, there are no specific 
guidelines on the best method of external validation.  Also, although the recommended 
practice is to validate a model in a dataset that is plausibly related to the development 
dataset [8] there is very little literature on how to handle a covariate missing from the 
validation dataset.  The work presented here suggests that concordance may be a simple 
method to externally validate prognostic models.   
With regards to methods for handling covariates missing from the validation dataset in our 
simulation study, random selection with replacement, single imputation via estimation, hot 
deck imputation and random selection with replacement multiple times were found to be 
suitable imputation options.  Computation time was extensive for hot deck imputation and 
multiple imputation.  However, for validation of a single model via hot deck imputation, 
rather than validation of 1400 models as per the simulation study, computational time was 
up to five minutes, while it was up to one minute for multiple imputation.  Results were 
available instantly for the other methods of imputation.  Therefore, although hot deck and 
multiple imputation take marginally longer to run, there is little practical difference 
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between them.  Therefore hot deck imputation or random selection with replacement 
multiple times may be the most appropriate methods, as shown by slightly improved 
results in this simulation study. 
A personal decision regarding whether an increased type 1 or type 2 error is more 
acceptable then needs to be made.  If an increased type 1 error is more acceptable then 
hot deck imputation may be the best method, otherwise random selection with 
replacement multiple times may be better. 
Further work is now required to test these findings in other settings.  Application of these 
methods of external validation and methods for handling missing covariates to real 
datasets can be seen in Chapter 9. 
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Chapter 9: Externally Validating 
Prognostic Models – Case Study 
9.1 Introduction 
In Chapter 5 a model was developed to determine for how long after a first unprovoked 
seizure a driver must be seizure-free before the risk of recurrence in the next 12 months 
falls below 20% enabling them to regain their driving license [193].  In this chapter the 
methods of external validation considered in Chapter 8 will be applied to real data to 
examine the externally validity of the prognostic model from Chapter 5.  A summary of the 
developed model can be found in section 9.1 together with the three external validation 
datasets.  Validation of the model is considered in sections 9.2 to 9.4.  In section 9.5 
simulated results are compared to real data which is forced to be missing to further 
investigate the methods of handling a missing covariate.  
The model developed in Chapter 5 contained variables for aetiology, first degree relative 
with epilepsy, seizures only while asleep, EEG result, CT/MRI result and treatment policy 
which was forced into the model.  We wished to externally validate this model using 
plausibly related datasets –NGPSE [131], a dataset collected in local epilepsy clinics in 
Western Australia (WA) [324] and the FIRST (FIRST) dataset from Italy [204].  NGPSE used 
the United Kingdom primary care system to obtain comprehensive data on a large and 
unselected cohort of patients with a possible diagnosis of epilepsy.  It was initiated in 1984 
and is one of the largest prospective cohort studies of epilepsy undertaken anywhere in the 
world.   The WA dataset was collected in a hospital based study with the majority of 
patients referred from the emergency room following a first-ever tonic-clonic seizure.  The 
dataset is in excess of 2000 patients who were recruited between 2000 and 2009.  The 
FIRST dataset comprises patients from a randomized clinical trial on the efficacy of 
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antiepileptic drugs in reducing the risk of relapse after a first unprovoked tonic-clonic 
seizure. 
NGPSE and WA do not have missing covariates and therefore provide a useful case study 
for the methods of external validation described in Chapter 8.  FIRST is missing a covariate 
and therefore can be used to investigate the methods of imputation also discussed in 
Chapter 8.  In addition to the three methods of external validation and five methods of 
imputation, and although not strictly a method of external validation, it is of interest to 
compare the conditional seizure risks across the validation and MESS datasets.    
A summary of the demographics of patients in MESS, NGPSE, FIRST and WA, of driving age 
with only one seizure at randomisation (or recruitment as appropriate) can be seen in Table 
27.  A combined Kaplan-Meier curve for time from first to second seizure for these datasets 
can be seen in Figure 32. 
Analyses were undertaken using R version 2.9.2 [182]. 
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Figure 32: Kaplan-Meier curve for MESS, NGPSE, WA and FIRST including numbers at risk 
(Patients of driving age with only one seizure at randomisation/recruitment)
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Table 27: Demographics of patients in MESS, NGPSE, FIRST and WA (of driving age with only one seizure at randomisation/recruitment) 
Entries in bold relate to variables included in the multivariable model 
 MESS NGPSE WA FIRST 
Characteristic 
Immediate 
Treatment  
(n=317) 
Delayed 
Treatment 
(n=320) 
Total 
(n=637) 
On 
Treatment at 
Recruitment 
(n=79) 
Not On 
Treatment at 
Recruitment 
(n=196) 
Total 
(n=275) 
On 
Treatment 
at 
Recruitment 
(n=235) 
Not On 
Treatment at 
Recruitment 
(n=621) 
Total 
(n=856) 
On 
Treatment 
at 
Recruitment 
(n=156) 
Not On 
Treatment at 
Recruitment 
(n=149) 
Total 
(n=305) 
Age at 
randomisation 
in years, 
median (IQR) 
32.0  
(21.5, 49.5) 
33.8  
(22.4, 50.6) 
32.9  
(21.9, 50.3) 
53.7  
(39.7, 74.6) 
44.1  
(27.0, 66.6) 
50.3  
(31.8, 68.7) 
48.0  
(34.0, 64.5) 
36.0  
(24.0, 52.0) 
39.0  
(26.0, 56.0) 
29.0  
(20.0, 45.0) 
28.0  
(20.0, 48.0) 
28.0  
(20.0, 46.0) 
Gender 
    Male 
    Female 
 
199 (63) 
118 (37) 
 
213 (67) 
107 (33) 
 
412 (65) 
225 (35) 
 
39 (49) 
40 (51) 
 
97 (49) 
99 (51) 
 
136 (49) 
139 (51) 
 
154 (66) 
81 (34) 
 
390 (63) 
231 (37) 
 
544 (64) 
312 (36) 
 
91 (58) 
65 (42) 
 
82 (55) 
67 (45) 
 
173 (57) 
132 (43) 
Aetiology 
    Remote 
symptomatic 
    Not remote 
symptomatic 
55 (17) 
 
262 (83) 
49 (15) 
 
271 (85) 
104 (16) 
 
533 (84) 
57 (72) 
 
22 (28) 
100 (51) 
 
96 (49) 
157 (57) 
 
118 (43) 
136 (58) 
 
99 (42) 
138 (22) 
 
483 (78) 
274 (32) 
 
585 (68) 
11 (7) 
 
145 (93) 
11 (7) 
 
138 (93) 
22 (7) 
 
283 (93) 
Neurological 
deficit 
    Absent 
    Present 
    Missing 
 
 
288 (91) 
27 (8) 
2 (1) 
 
 
299 (94) 
19 (5) 
2 (1) 
 
 
587 (92) 
46 (7) 
4 (1) 
NA NA NA 
 
183 (78) 
52 (22) 
 
574 (92) 
47 (8) 
 
757 (88) 
99 (12) 
 
 
135 (87) 
21 (13) 
0 (0) 
 
 
131 (12) 
18 (88) 
0 (0) 
 
 
266 (87) 
39 (13) 
0 (0) 
Previous acute 
symptomatic 
seizures 
    Febrile 
    Other 
    No 
 
 
 
15 (5) 
1 (0) 
301 (95) 
 
 
 
14 (4) 
7 (2) 
299 (94) 
 
 
 
29 (5) 
8 (1) 
600 (94) 
 
NA 
 
NA 
 
NA 
 
 
 
2 (1) 
231 (98) 
2 (1) 
 
 
 
20 (3) 
595 (96) 
6 (1) 
 
 
22 (3) 
826 (96) 
7 (1) 
 
 
 
38 (24) 
0 (0) 
118 (76) 
 
 
 
31 (21) 
0 (0) 
118 (79) 
 
 
 
69 (23) 
0 (0) 
236 (77) 
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 MESS NGPSE WA FIRST 
Characteristic 
Immediate 
Treatment  
(n=317) 
Delayed 
Treatment 
(n=320) 
Total 
(n=637) 
On 
Treatment at 
Recruitment 
(n=79) 
Not On 
Treatment at 
Recruitment 
(n=196) 
Total 
(n=275) 
On 
Treatment at 
Recruitment 
(n=235) 
Not On 
Treatment at 
Recruitment 
(n=621) 
Total 
(n=856) 
On 
Treatment at 
Recruitment 
(n=156) 
Not On 
Treatment at 
Recruitment 
(n=149) 
Total 
(n=305) 
Epilepsy in first 
degree relative 
    Yes 
    No 
    Missing 
 
 
33 (10) 
284 (90) 
 
 
 
34 (11) 
286 (89) 
 
 
 
67 (10) 
570 (90) 
 
 
 
4 (5) 
75 (95) 
 
 
 
17 (9) 
179 (91) 
 
 
 
21 (8) 
254 (92) 
 
 
 
20 (9) 
207 (88) 
8 (3) 
 
 
73 (12) 
532 (85) 
16 (3) 
 
 
93 (11) 
739 (86) 
24 (3) 
 
 
24 (15) 
132 (85) 
 
 
 
12 (8) 
137 (92) 
 
 
 
36 (12) 
269 (88) 
 
Seizures 
    Partial 
    Generalised/ not 
definitely partial 
    Other 
 
102 (32) 
205 (65) 
 
 
10 (3) 
 
100 (31) 
217 (68) 
 
 
3 (1) 
 
202 (32) 
422 (66) 
 
 
13 (2) 
NA NA NA NA NA NA NA NA NA 
Seizures only 
while asleep 
    Yes 
    No 
    Missing 
 
 
65 (20) 
252 (80) 
- 
 
 
50 (16) 
269 (84) 
1 (0) 
 
 
115 (18) 
521 (82) 
1 (0) 
 
 
19 (24) 
60 (76) 
0 (0) 
 
 
21 (11) 
175 (89) 
0 (0) 
 
 
40 (15) 
235 (85) 
0 (0) 
 
 
57 (24) 
177 (75) 
1 (1) 
 
 
473 (76) 
147 (24) 
1 (0) 
 
 
650 (76) 
204 (24) 
2 (0) 
NA NA NA 
EEG results 
    Normal 
    Abnormal 
    Not 
done/Missing 
 
147(46) 
149 (47) 
21 (7) 
 
 
136 (43) 
160 (50) 
24 (7) 
 
 
283 (44) 
309 (49) 
45 (7) 
 
 
9 (10) 
26 (33) 
44 (57) 
 
 
41 (21) 
45 (23) 
110 (56) 
 
 
50 (18) 
71 (26) 
154 (56) 
 
 
63 (27) 
157 (67) 
15 (6) 
 
 
363 (59) 
250 (40) 
8 (1) 
 
 
426 (50) 
407 (48) 
23 (2) 
 
 
73 (47) 
83 (53) 
 
 
 
71 (52) 
78 (48) 
 
 
 
144 (47) 
161 (53) 
 
 
CT/MRI results 
    Normal 
    Abnormal 
    Not 
done/Missing 
 
219 (69) 
38 (12) 
60 (19) 
 
231 (72) 
34 (11) 
55 (17) 
450 (71) 
72 (11) 
115 (18) 
19 (24) 
15 (19) 
45 (57) 
38 (20) 
24 (12) 
134 (68) 
57 (21) 
39 (14) 
179 (65) 
89 (38) 
134 (57) 
12 (5) 
457 (74) 
108 (17) 
56 (9) 
546 (64) 
242 (28) 
68 (8) 
124 (79) 
32 (21) 
0 (0) 
122 (82) 
27 (18) 
0 (0) 
246 (81) 
59 (19) 
0 (0) 
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In theory, data used to externally validate a prognostic model should be plausibly related to 
the development dataset, such that the datasets can be considered to come from the same 
super-population.  There are however, no guidelines suggesting how to check whether the 
development and validation datasets are from a super-population.   
In the case of our validation datasets some are more plausibly related to MESS than others.   
Patients in NGPSE tended to be older than those in MESS and there were more females in 
NGPSE, although the variables for age and gender were not included in the multivariable 
model being validated here.  Considerably more patients in NGPSE had a remote 
symptomatic aetiology than those in MESS and many more patients in NGPSE had missing 
results for EEG and CT/MRI.  Characteristics for patients in the WA dataset were mostly 
similar to those in MESS except for previous acute symptomatic seizures which were more 
frequently reported in WA.  Additionally, many more patients had seizures only while 
asleep in WA than in MESS. 
The FIRST dataset had a similar distribution of characteristics to those of MESS.  More 
patients had previous febrile seizures in FIRST although this variable was not included in 
the multivariable model for MESS.  In FIRST, data on seizures while asleep was not 
collected.  Additionally in FIRST, EEG and CT/MRI result were divided into two categories 
(normal/not done and abnormal) unlike in MESS where patients could have three result 
categories: normal, abnormal and not done.  Follow-up in FIRST was considerably shorter 
than in MESS as shown in Figure 32. 
Table 28 summarises the unadjusted 12 month seizure recurrence risks at time points 
following a first seizure for each dataset.  The risks, according to NGPSE, were similar to the 
overall estimates in our analysis of MESS.  All estimates from 12 months onwards were 
significantly below 20% in both MESS and NGPSE.  Estimates at six months varied however - 
according to the NGPSE results, patients who were treated immediately should wait 12 
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months until their recurrence risk in the next 12 months was significantly below 20% unlike 
the MESS results which suggested only six months.  Patients in NGPSE who were treated 
immediately had a higher risk of a seizure in the following 12 months generally than those 
who were not treated.  This is probably due to the ability of clinicians to detect patients at 
high risk of seizure recurrence and to recommend relevant treatment.  Confidence intervals 
for NGPSE were wider than for MESS as a result of the smaller sample size for NGPSE.   
The 12 month seizure recurrence risks at time points post index seizure for the WA dataset 
were similar to those for the MESS data.  Instead of concluding that patients who were 
treated should be allowed to drive after six months and those who were not treated after 
12 months, results from WA suggested patients should wait 12 months irrespective of the 
treatment policy - the conditional risks were not significantly below 20% until 12 months.   
The results for FIRST were very similar to those using the MESS data.  As for the MESS data 
the point estimates at six month were less than the 20% risk level set by the DVLA but the 
result was only significantly below 20% for patients randomised to immediate treatment. 
Despite the differences in characteristics and follow-up it is plausible that these datasets 
came from the same super-population.  FIRST is the closest match to MESS in terms of the 
proportions of patients with certain characteristics, however the follow-up is much shorter 
and a significant covariate is missing.  In the case of NGPSE and WA, information on the 
same covariates is available but the proportions of patients with some characteristics are 
not always similar to the MESS data.  These datasets are, however, the closest matches 
available and hence we will continue with the external validation of MESS with NGPSE, WA 
and FIRST.  MESS is validated with NGPSE in section 9.2, with WA in 9.3 and FIRST in 9.4.  
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Table 28: 12 month seizure recurrence risks at time points post index seizure: 
Risk of seizure in next 12 months (%, 95% Confidence Interval) 
 
MESS NGPSE WA FIRST 
Immediate treatment Delayed treatment 
Immediate 
Treatment (Treated) 
Delayed Treatment 
(Not treated) 
Immediate 
Treatment (Treated) 
Delayed Treatment 
(Not treated) 
Immediate 
Treatment (Treated) 
Delayed Treatment 
(Not treated) 
Time post 
index 
seizure 
(months) 
No. at 
Risk 
Risk of 
seizure 
No. at 
Risk 
Risk of 
seizure 
No. at 
Risk 
Risk of 
seizure 
No. at 
Risk 
Risk of 
seizure 
No. at 
Risk 
Risk of 
seizure 
No. at 
Risk 
Risk of 
seizure 
No. at 
Risk 
Risk of 
seizure 
No. at 
Risk 
Risk of 
seizure 
6 260 
14  
(10 to 18) 
254 
18  
(13 to 23) 
56 
19  
(8 to 29) 
136 
16  
(10 to 23) 
128 
23  
(16 to 30) 
382 
18  
(14 to 22) 
139 
11  
(5 to 16) 
106 
19  
(11 to 27) 
12 230 
7  
(4 to 11) 
219 
10  
(6 to 15) 
44 
5  
(0 to 12) 
113 
8  
(3 to 13) 
106 
10  
(4 to 16) 
335 
11  
(8 to 15) 
128 
9  
(4 to 14) 
86 
11  
(4 to 17) 
18 211 
8  
(5 to 12) 
197 
12  
(8 to 17) 
41 
8  
(0 to 16) 
102 
3  
(0 to 7) 
91 - 286 
8  
(4 to  11) 
114 
7  
(2 to 12) 
74 
12  
(3 to 20) 
24 199 
7  
(3 to 10) 
182 
10  
(5 to 14) 
39 
6  
(0 to 13) 
102 
3  
(0 to 7) 
82 - - - 106 
8  
(2 to 14) 
65 
11 
(2 to 20) 
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9.2 Validation using NGPSE 
Of the 792 patients recruited to the NGPSE study, 217 were aged less than 16 years at 
ascertainment.  For 300 patients this was not their first episode so they were removed 
from the analysis.  This left 275 suitable patients in comparison to 637 available for analysis 
in the MESS study.   
9.2.1 Results 
The external validation results of MESS via NGPSE can be seen in Table 29.  The p-value for 
the comparison of deviance was significant (0.01).  Therefore the prognostic model 
developed using the MESS data does not appear to generalise well to the NGPSE data 
according to the deviance statistic.  However, in the simulation study, comparison of 
deviance was found to be a poor method of external validation.  The poor validation could 
therefore be a reflection on the method of validation rather than a lack of agreement 
between the datasets.  Additionally, this may be because of the small sample size of 
NGPSE. 
Table 29: Summary of Results of external validation of MESS model via NGPSE dataset 
 MESS NGPSE 
Deviance 
Statistic 30.91 10.26 
Degrees of Freedom 8 
p-value 0.01 
Concordance 
Statistic 0.591 (0.556, 0.627) 0.601 (0.547, 0.654) 
Difference in Concordance 0.01 
Prognostic Separation 
Statistic 0.636 0.634 
Difference ( 95% CI) 0.00 (-0.02, 0.03) 
 
As explained in section 8.2.3 it is not appropriate to calculate a confidence interval for a 
difference in concordance statistic between the development and validation datasets.  
However it is possible to obtain estimates of confidence intervals for individual 
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concordance statistics [277].  If two statistics have non-overlapping confidence intervals 
they are necessarily significantly different.  However, if they have overlapping intervals it is 
not necessarily true that they are not significantly different [325].  In the absence of a 
better method, we considered the similarity of the concordance statistic across the 
development and validation dataset via examination of the individual confidence intervals 
[326].  In the case of MESS and NGPSE, as shown in Table 29, the confidence intervals and 
estimates were very similar.  Therefore it seems reasonable to conclude that the MESS 
model generalises well to NGPSE according to the concordance measure.   
A confidence interval for the difference in prognostic separation between the development 
and validation datasets was calculated via bootstrap resampling.  In the case of MESS and 
NGPSE the confidence interval for a difference in separation was (-0.02, 0.03) which 
included 0.  Therefore, the MESS model generalises well to the NGPSE dataset according to 
prognostic separation (Table 29).   
Table 30 shows the conditional risk estimates for MESS and NGPSE according to the 
prognostic model for time to second seizure following a first ever seizure.  This model was 
developed using patients from the MESS study who were of driving age (over 16 at 
randomisation) and had had only one seizure at recruitment.  Full details of the calculations 
can be found in Bonnett et al. 2010 [193] and in Chapter 5.  The estimates presented 
assume that seizures were not confined to sleep and that there were no first degree 
relatives with epilepsy.  The estimates for NGPSE were generally in agreement with the 
estimates for MESS although they were marginally higher for patients in NGPSE who were 
treated at ascertainment than they were for the comparable patients in MESS.   
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Table 30: Seizure recurrence risk in the next 12 months estimated from multivariable model at specific time points of seizure freedom. Estimates presented assume seizures not confined 
to sleep and no first degree relative with epilepsy – MESS & NGPSE 
 
 
MESS NGPSE 
Variable Immediate Treatment Delayed Treatment Treated Not Treated 
Aetiology EEG 
CT/MRI 
scan 
results 
Months 
from 
index 
seizure 
Risk of 
seizure 
within next 
12 months 
(%, 95% CI) 
Months from 
index seizure 
until annual 
risk falls 
below 20% 
Risk of 
seizure 
within next 
12 months 
(%, 95% CI) 
Months from 
index seizure 
until annual 
risk falls 
below 20% 
Risk of seizure 
within next 12 
months 
(%, 95% CI) 
Months from 
index seizure 
until annual 
risk falls 
below 20% 
Risk of 
seizure 
within next 
12 months 
(%, 95% CI) 
Months from 
index seizure 
until annual 
risk falls below 
20% 
Not remote 
symptomatic 
Normal Normal 
6 
12 
13 (10 to 16) 
7 (5 to 10) 
1.2 
16 (12 to 19) 
9 (6 to 12) 
3.2 
17 (11 to 22) 
7 (3 to 11) 
4.8 
16 (11 to 22) 
7 (3 to 11) 
4.8 
Not remote 
symptomatic 
Abnormal Normal 
6 
12 
20 (16 to 23) 
11 (9 to 14) 
5.5 
23 (20 to 26) 
13 (11 to 16) 
7.0 
21 (15 to 26) 
9 (5 to 13) 
6.2 
20 (15 to 25) 
9 (5 to 13) 
6.1 
Not remote 
symptomatic 
Normal Abnormal 
6 
12 
14 (11 to 17) 
8 (5 to 11) 
2.1 
17 (14 to 20) 
10 (7 to 12) 
3.6 
19 (13 to 24) 
8 (4 to 12) 
5.7 
18 (13 to 24) 
8 (4 to 12) 
5.5 
Not remote 
symptomatic 
Abnormal Abnormal 
6 
12 
21 (18 to 24) 
12 (9 to 15) 
6.1 
25 (22 to 28) 
14 (12 to 17) 
8.1 
23 (18 to 28) 
10 (6 to 14) 
7.5 
23 (17 to 28) 
10 (6 to 14) 
7.4 
Remote 
symptomatic 
Normal Normal 
6 
12 
17 (14 to 20) 
10 (7 to 12) 
3.6 
20 (17 to 23) 
12 (9 to 14) 
6.0 
19 (14 to 25) 
8 (4 to 12) 
5.7 
19 (13 to 24) 
8 (4 to 12) 
5.7 
Remote 
symptomatic 
Abnormal Normal 
6 
12 
25 (22 to 28) 
15 (12 to 17) 
8.7 
30 (27 to 32) 
18 (15 to 20) 
10.7 
24 (18 to 29) 
10 (6 to 14) 
7.5 
23 (18 to 28) 
10 (6 to 14) 
7.5 
Remote 
symptomatic 
Normal Abnormal 
6 
12 
18 (15 to 21) 
10 (8 to 13) 
4.8 
22 (19 to 25) 
13 (10 to 15) 
6.5 
21 (16 to 27) 
9 (5 to 13) 
6.3 
21 (16 to 26) 
9 (5 to 13) 
6.2 
Remote 
symptomatic 
Abnormal Abnormal 
6 
12 
27 (24 to 30) 
16 (13 to 18) 
9.2 
32 (29 to 34) 
19 (16 to 21) 
11.3 
26 (21 to 31) 
12 (8 to 16) 
9.4 
26 (21 to 31) 
11 (7 to 15) 
9.3 
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9.2.1.1 Sensitivity Analysis 
External validity involves checking that a model is valid in populations that are plausibly 
related to the development dataset.  In this section a sensitivity analysis is presented which 
investigated the impact of length of follow-up of the development and validation datasets 
on external validation. 
As shown in Figure 32, there are very few patients at risk after about eight years in MESS.  
It is therefore of interest to investigate if truncating NGPSE at eight years to match the 
MESS data makes a difference to the external validity.  If patients with follow-up in excess 
of eight years in NGPSE are influencing seizure risk estimates this may have an impact on 
the results of external validation.  This is because the agreement between the MESS and 
NGPSE models without influential patients may be reduced. 
The external validation results in this truncated setting can be seen in Table 31.  The 
confidence intervals for the concordance statistics were very similar between the MESS and 
truncated NGPSE datasets.  Together with the small difference in concordance it seems 
that the MESS model generalises well to the NGPSE dataset, truncated at eight years.  The 
confidence interval for a difference in prognostic separation between the development and 
validation datasets was (-0.02, 0.03) which includes 0.  Therefore it seems that the MESS 
model does generalise well to the NGPSE data.  These conclusions are the same as those 
obtained for the external validation of MESS with the complete NGPSE dataset. 
The p-value of 0.02 was significant for the comparison of deviance between the 
development (MESS) and validation (NGPSE) datasets.  Therefore the prognostic model 
developed using the MESS data does not appear to generalise well to the truncated NGPSE 
data.  This conclusion is as per the comparison of MESS and the complete NGPSE dataset. 
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Table 31: Summary of Results of external validation of MESS model via a truncated NGPSE dataset 
 MESS NGPSE 
Deviance 
Statistic 30.91 13.08 
Degrees of Freedom 8 
p-value 0.02 
Concordance 
Statistic 0.591 (0.556, 0.627) 0.599 (0.544, 0.655) 
Difference in Concordance 0.01 
Prognostic Separation 
Statistic 0.636 0.632 
Difference (& 95% CI) 0.00 (-0.03, 0.02) 
 
 
Table 32: Seizure recurrence risk in the next 12 months estimated from multivariable model at specific time 
points of seizure freedom. Estimates presented assume seizures not confined to sleep and no first degree 
relative with epilepsy – truncated NGPSE 
Variable  Immediate Treatment Delayed Treatment 
Aetiology EEG CT/MRI 
Months 
from 
index 
seizure 
Risk of 
seizure 
within next 
12 months 
(%, 95% CI) 
Months 
from index 
seizure 
until 
annual risk 
falls below 
20% 
Risk of 
seizure 
within next 
12 months 
(%, 95% CI) 
Months from 
index seizure 
until annual 
risk falls 
below 20% 
Not remote 
symptomatic 
Normal Normal 
6 
12 
26 (19, 33) 
12 (6, 18) 
9.4 
22 (15, 30) 
10 (4, 16) 
6.9 
Not remote 
symptomatic 
Abnormal Normal 
6 
12 
27 (20, 34) 
12 (6, 18) 
9.5 
23 (16, 30) 
11 (4, 17) 
7.5 
Not remote 
symptomatic 
Normal Abnormal 
6 
12 
31 (24, 37) 
14 (9, 20) 
10.7 
27 (20, 34) 
12 (6, 18) 
9.5 
Not remote 
symptomatic 
Abnormal Abnormal 
6 
12 
32 (25, 38) 
15 (9, 21) 
10.7 
28 (21, 35) 
13 (7, 19) 
9.5 
Remote 
symptomatic 
Normal Normal 
6 
12 
27 (20, 34) 
12 (6, 18) 
9.5 
23 (16, 31) 
11 (5, 17) 
7.5 
Remote 
symptomatic 
Abnormal Normal 
6 
12 
28 (21, 35) 
13 (7, 19) 
9.5 
24 (17, 31) 
11 (5, 17) 
8.0 
Remote 
symptomatic 
Normal Abnormal 
6 
12 
32 (25, 38) 
15 (9, 21) 
10.7 
28 (21, 35) 
13 (7, 19) 
9.5 
Remote 
symptomatic 
Abnormal Abnormal 
6 
12 
33 (27, 39) 
16 (10, 21) 
10.7 
29 (22, 36) 
13 (7, 19) 
9.5 
 
Truncating NGPSE at eight years did not have an impact on the results of the external 
validation.  However the conditional seizure risks shown in Table 32 were higher than the 
original NGPSE analyses and were also higher than the MESS results (Table 30).  For this 
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reason it seems better not to truncate the dataset.  However, further sensitivity analyses, 
and potentially simulation studies, are needed to determine if this result is valid over many 
situations.  They are also needed to develop guidelines for checking that the development 
and validation datasets are from the same super-population. 
9.2.2 Conclusion 
According to the comparison of deviance method, the MESS model does not generalise 
well to NGPSE.  However the concordance and prognostic separation measures suggest 
that, in fact, the MESS model does generalise well to NGPSE.  In addition the conditional 
seizure risks were similar across MESS and NGPSE.  
 Truncating the NGPSE dataset to more closely match the length of follow-up in MESS had 
no impact on the external validity of the MESS model.  It did, however, lead to increased 
risk estimates in NGPSE which were less similar to MESS.  Therefore truncating the NGPSE 
dataset had a negative impact on the results. 
9.3 Validation using WA 
In the WA dataset there were 856 suitable patients with one seizure at recruitment and 
aged over 16 years.   
9.3.1 Results 
The results of comparison of deviance, concordance and prognostic separation can be seen 
in Table 33.  The p-value of 0.07 for the comparison of deviance was not significant at the 
5% level.  Therefore there was no evidence (at the 5% level) to suggest that the MESS 
model was not externally valid although at the 10% level of significance there is such 
evidence.  
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The confidence intervals for the concordance statistics for the MESS and NGPSE datasets 
were very similar.  Therefore, together with the small difference in concordance, it seems 
that the MESS model generalises well to the WA dataset.  The confidence interval for a 
difference in separation between the development and validation datasets did not include 
0.  Therefore it seems that the MESS model does not generalise very well to the WA 
dataset according to prognostic separation. 
Table 33: Summary of Results of external validation of MESS model via WA dataset 
 MESS WA 
Deviance 
Statistic 30.91 45.40 
Degrees of Freedom 8 
p-value 0.07 
Concordance 
Statistic 0.591 (0.556, 0.627) 0.590 (0.563, 0.618) 
Difference in Concordance 0.00 
Prognostic Separation 
Statistic 0.636 0.556 
Difference (& 95% CI) 0.08 (0.06, 0.10) 
 
Table 34 shows the seizure recurrence risks in the next 12 months at specific time points of 
seizure freedom as estimated from the multivariable model fitted to the WA dataset.  The 
estimates presented assumed that seizures were not confined to sleep and that there were 
no first degree relatives with epilepsy.  These estimates are generally in agreement with 
those in MESS (Table 30) for patients with normal and abnormal EEG and CT/MRI results, 
but lower for patients with abnormal EEG but normal CT/MRI results.  Additionally, the risk 
estimates were generally higher in the WA dataset for patients with abnormal CT/MRI 
results and normal EEG results than in MESS.    
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Table 34: Seizure recurrence risk in the next 12 months estimated from multivariable model at specific time 
points of seizure freedom. Estimates presented assume seizures not confined to sleep and no first degree 
relative with epilepsy 
Variable  Immediate Treatment Delayed Treatment 
Aetiology EEG CT/MRI 
Months 
from 
index 
seizure 
Risk of 
seizure 
within next 
12 months 
(%, 95% CI) 
Months 
from index 
seizure until 
annual risk 
falls below 
20% 
Risk of seizure 
within next 12 
months 
(%, 95% CI) 
Months from index 
seizure until annual 
risk falls below 20% 
Not remote 
symptomatic 
Normal Normal 
6 
12 
19 (16 to 23) 
11 (8 to 14) 
5.8 
22 (19 to 25) 
11 (8 to 14) 
7.0 
Not remote 
symptomatic 
Abnormal Normal 
6 
12 
6 (2 to 10) 
12 (9 to 15) 
3.6 
10 (7 to 14) 
12 (9 to 15) 
4.0 
Not remote 
symptomatic 
Normal Abnormal 
6 
12 
29 (26 to 32) 
12 (10 to 15) 
7.3 
32 (29 to 35) 
13 (10 to 16) 
7.3 
Not remote 
symptomatic 
Abnormal Abnormal 
6 
12 
20 (17 to 23) 
13 (10 to 16) 
6.0 
23 (20 to 27) 
14 (11 to 16) 
7.3 
Remote 
symptomatic 
Normal Normal 
6 
12 
18 (15 to 22) 
14 (11 to 17) 
5.6 
22 (19 to 25) 
14 (11 to 17) 
6.5 
Remote 
symptomatic 
Abnormal Normal 
6 
12 
0 (0 to 2) 
15 (12 to 18) 
3.5 
4 (0 to 8) 
15 (12 to 18) 
3.8 
Remote 
symptomatic 
Normal Abnormal 
6 
12 
31 (28 to 34) 
16 (13 to 18) 
8.5 
35 (32 to 37) 
16 (13 to 19) 
8.7 
Remote 
symptomatic 
Abnormal Abnormal 
6 
12 
17 (14 to 21) 
16 (14 to 19) 
5.5 
22 (19 to 25) 
17 (14 to 20) 
6.5 
 
9.3.2 Conclusion 
According to comparison of prognostic separation the MESS model does not generalise well 
to the WA dataset.  The comparison of deviance results suggest that the model also does 
not generalise well at the 10% level of significance but it is alright at the 5% level.  The 
comparison of concordance suggests that the MESS model does generalise well to WA.  The 
conditional risk estimates for WA were similar to those for MESS but there were some 
subgroups that had very different risk estimates. 
In the simulation study of Chapter 8 neither comparison of deviance nor prognostic 
separation performed as expected and were consequently not recommended as methods 
of external validation.  Based on this, it appears that the MESS model does generalise well 
to WA as the concordance statistics were very similar across the MESS and WA datasets. 
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9.4 Validation using FIRST 
Of the 420 patients randomised to the FIRST study, 305 were older than 16 at recruitment.  
Within FIRST there are issues with the EEG and CT/MRI variables which were only recorded 
as abnormal or normal with the normal response also being used for patients who did not 
have such a scan in FIRST.  Additionally, no data was collected on seizures only while 
asleep.  As the seizures while asleep variable is missing from FIRST, the five methods of 
imputation described in Chapter 8 were employed: (1) remodelling with variable matching; 
(2) random selection with replacement; (3) single imputation via estimated proportions; (4) 
hot deck imputation; and (5) random selection with replacement multiple times. 
9.4.1 Sensitivity Analysis 
In MESS, patients could have result categories normal, abnormal or not done for EEG and 
CT/MRI result.  In FIRST however, results were only available in the form of normal/not 
done and abnormal.  In the interests of completeness a sensitivity analysis was performed 
for a single method of imputation, variable matching, to determine if this difference in 
classification had a significant impact on the external validation results.   
When the sleep variable was removed from MESS, to match FIRST, and when EEG and CT 
were left unchanged in MESS, it was not possible to obtain a comparison of deviance with 
FIRST.  This was because the number of degrees of freedom was different across the 
models - in MESS there were seven but in FIRST there were only five.  When EEG and CT 
were collapsed to two categories each in MESS to match FIRST, the p-value for the 
comparison of deviance between MESS and FIRST was 0.86 which was not significant (Table 
35).  Therefore there is no evidence to suggest that the prognostic model developed using 
the MESS data (with EEG and CT/MRI collapsed to two categories each) does not generalise 
well to the FIRST data (with variable matching).  
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The confidence intervals for concordance were quite similar for MESS and FIRST 
irrespective of the categorisation of the EEG and CT/MRI variables in MESS.  Together with 
the relatively small differences in concordance, the MESS model seems to generalise fairly 
well to the FIRST data with variable matching. 
Table 35: Summary of Results of external validation of MESS model with EEG and CT variables with 3 
categories and the FIRST dataset using variable matching 
 
FIRST  
(variable matching) 
MESS 
 (EEG/CT as 3 
categories) 
MESS  
(EEG/CT as 2 
categories) 
Deviance 
Statistic 23.03 N/A 21.11 
Degrees of Freedom - N/A 5 
p-value - N/A 0.86 
Concordance 
Statistic 0.646(0.593, 0.699) 0.581 (0.545, 0.618) 0.576 (0.541, 0.612) 
Difference in 
Concordance 
 0.07 0.07 
Prognostic Separation 
Statistic 0.830 0.578 0.517 
Difference (& 95% CI)  -0.27 (-0.28, -0.22) -0.31 (-0.34, -0.29) 
 
The confidence intervals for the difference in prognostic separation between the 
development and validation datasets did not include 0, irrespective of the number of 
categories used to model EEG and CT/MRI in MESS.  Therefore the MESS model does not 
generalise to the FIRST dataset according to this measure. 
The external validation results were comparable across the sensitivity analysis.  The only 
difference was that it was not possible to draw a conclusion for external validation via 
comparison of deviance when EEG and CT/MRI were grouped in three categories in MESS 
but in two in FIRST.  Given that the results for the concordance and separation measures 
were very similar across the sensitivity analysis, the external validation of MESS via FIRST 
proceeded with the EEG and CT/MRI variables collapsed to only two categories each for 
MESS.  This ensured that all three methods of external validation could be tested. 
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Another option would be to remove the differently categorised variable from the 
development dataset, especially if it has a small influence on the model, re-develop the 
reduced model and then validation it.  Methodologically neither are ideal solutions.  It is 
preferable to leave the developed model untouched during the external validation phase of 
analysis.  Therefore, if other validation datasets were available it would be best to exclude 
FIRST from the external validation stage, especially as, in addition to the differing 
categorisations of EEG and CT/MRI, a variable is missing. 
9.4.1.1 Conditional Seizure Risks 
Table 36 shows the seizure recurrence risks in the next 12 months, estimated from the 
amended multivariable model for MESS, at specific time points of seizure freedom – EEG 
and CT/MRI were collapsed to two categories each and the variable for seizures while 
asleep has been removed from MESS as per the variable matching method of handling a 
missing covariate.  Estimates presented assume no first degree relative with epilepsy.  
Without the variable for seizures while asleep some confidence intervals for MESS do not 
overlap which makes them difficult to interpret.  
The recurrence risks for patients without a remote symptomatic aetiology were higher in 
the model for MESS without the sleep variable (Table 36) than in the model with the 
variable (Table 30).  The risks for patients with a remote symptomatic aetiology were lower 
in the case of the model without the sleep variable than for the model with the variable.  
This suggests an interaction may exist between seizures while asleep and aetiology.  The 
log-likelihood for the model with aetiology and sleep was 10.7 on two degrees of freedom.  
For the model inclusive of an interaction term the log-likelihood was 11.3 on three degrees 
of freedom.  The difference in log-likelihood was not statistically significant as the p-value 
for the difference was 0.53.  Therefore there was insufficient evidence of an interaction 
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between aetiology and sleep.  The differences observed between the results in Table 36 
and Table 30 are therefore likely to be because of the highly influential sleep variable. 
The conditional risks for FIRST were quite different to those for MESS (without the sleep 
variable and with EEG and CT/MRI categories each collapsed) as can be seen in Table 36.  In 
most cases they were much lower than the MESS results.  However, for patients with 
remote symptomatic aetiology who were in the delayed treatment category, the estimates 
were generally much higher than for the same patients in MESS. 
 
  
 
2
6
1 
Table 36: Seizure recurrence risk in the next 12 months estimated from multivariable model at specific time points of seizure freedom. Estimates presented assume no first degree 
relative with epilepsy. MESS (EEG/CT 2 categories) & FIRST (variable matching) 
 MESS FIRST 
Variable  Immediate Treatment Delayed Treatment Immediate Treatment Delayed Treatment 
Aetiology EEG 
CT/MRI 
scan 
results 
Months 
from 
index 
seizure 
Risk of seizure 
within next 12 
months 
(%, 95% CI) 
Months from 
index seizure 
until annual 
risk falls below 
20% 
Risk of 
seizure 
within next 
12 months 
(%, 95% CI) 
Months from 
index seizure 
until annual 
risk falls below 
20% 
Risk of 
seizure 
within next 
12 months 
(%, 95% CI) 
Months from 
index seizure 
until annual 
risk falls below 
20% 
Risk of 
seizure 
within next 
12 months 
(%, 95% CI) 
Months from 
index seizure 
until annual 
risk falls below 
20% 
Not remote 
symptomatic 
Normal Normal 
6 
12 
18 (15, 21) 
10 (8, 13) 
4.8 
22 (19, 25) 
12 (10, 15) 
6.5 
6 (2,11) 
4 (0, 9) 
<1 
14 (9, 18) 
10 (5, 14) 
0.6 
Not remote 
symptomatic 
Abnormal Normal 
6 
12 
26 (24,29) 
15 (13, 18) 
9.2 
31 (28, 34) 
18 (16, 20) 
10.8 
10 (5, 14) 
7 (2, 11) 
<1 
20 (16,24) 
14 (10, 18) 
5.3 
Not remote 
symptomatic 
Normal Abnormal 
6 
12 
19 (16, 22) 
11 (8, 13) 
5.3 
22 (19, 25) 
13 (10, 15) 
6.8 
8 (3, 13) 
5 (1, 10) 
<1 
16 (12, 21) 
11 (7, 15) 
2.2 
Not remote 
symptomatic 
Abnormal Abnormal 
6 
12 
27 (24, 30) 
16 (13, 18) 
9.2 
32 (29, 34) 
19 (16, 21) 
11.3 
11 (7, 16) 
8 (4, 12) 
<1 
23 (19, 27) 
16 (13, 20) 
7.4 
Remote 
symptomatic 
Normal Normal 
6 
12 
13 (10, 17) 
7 (5, 10) 
1.2 
16 (13, 19) 
9 (6, 12) 
3.2 
10 (6, 15) 
7 (3, 11) 
<1 
21 (17, 25) 
15 (11, 19) 
6.7 
Remote 
symptomatic 
Abnormal Normal 
6 
12 
19 (16, 22) 
11 (8, 14) 
5.5 
23 (20, 26) 
13 (10, 16) 
6.9 
15 (11, 19) 
10 (6, 14) 
0.7 
30 (26, 34) 
21 (18, 25) 
12.4 
Remote 
symptomatic 
Normal Abnormal 
6 
12 
14 (10, 17) 
8 (5, 10) 
1.7 
16 (13, 19) 
9 (6, 12) 
3.4 
12 (7, 17) 
8 (4, 12) 
<1 
25 (21, 29) 
17 (14, 21) 
10.2 
Remote 
symptomatic 
Abnormal Abnormal 
6 
12 
20 (17, 23) 
11 (9, 14) 
5.7 
24 (21, 26) 
13 (11, 16) 
7.6 
18 (13, 22) 
12 (8, 16) 
2.7 
35 (31, 38) 
25 (22, 28) 
16.0 
 262 
 
 
9.4.2 Methods for Handling a Missing Covariate 
The results of external validation via variable matching were presented in section 9.4.1.  
Following on from the sensitivity analysis of section 9.4.1, the EEG and CT/MRI variables 
were modeled as two categories each in MESS for the external validation via FIRST. 
Comparison of deviance led to non-significant p-values for all methods of imputation (Table 
37).  Therefore there is no evidence to suggest that the prognostic model developed using 
the MESS data does not generalise well to the FIRST dataset irrespective of the method 
used to handle the missing covariate.  This conclusion was confirmed by the confidence 
intervals for the concordance statistics which were fairly similar across all imputation 
methods.  Together with the relatively small differences in concordance between MESS and 
the imputed FIRST datasets, it seems that the MESS model generalises fairly well to FIRST. 
 The confidence intervals for the difference in separation between the development and 
validation datasets did not include 0, the value of no difference.  Therefore it seems that 
the MESS model does not generalise well to the FIRST dataset according to prognostic 
separation, again irrespective of the method of imputation used. 
Tables of the conditional seizure risks for FIRST via these four methods of imputation can 
be seen in Appendix D - they were almost identical to those presented for FIRST in Table 
36. 
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Table 37: Summary of Results of external validation using MESS with EEG and CT variables having 2 categories each and the FIRST dataset 
 MESS 
FIRST 
(random selection) 
FIRST 
(single imputation) 
FIRST 
(hot deck) 
FIRST 
(multiple imputation) 
Deviance 
Statistic 27.09 24.70 23.04 25.43 24.40 
Degrees of Freedom - 6 6 6 6 
p-value - 0.88 0.67 0.95 0.85 
Concordance 
Statistic (95% CI) 
0.587  
(0.552, 0.622) 
0.648  
(0.596, 0.700) 
0.651  
(0.597, 0.705) 
0.655  
(0.601, 0.709) 
0.648  
(0.595, 0.701) 
Difference in Concordance - 0.06 0.06 0.07 0.06 
Prognostic Separation 
Statistic 0.587 0.853 0.845 0.931 0.932 
Difference (& 95% CI) - 
-0.27  
(-0.29, -0.24) 
-0.26  
(-0.29, -0.23) 
-0.35  
(-0.37, -0.32) 
-0.35  
(-0.32, -0.27) 
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9.4.3 Conclusion 
The conditional seizure risks for FIRST are considerably lower than they are for MESS.  
Irrespective of the method of imputation chosen, comparison of deviance suggests that the 
MESS model generalises well to the FIRST dataset.  This was also confirmed by the 
comparison of concordance.   
The comparison of prognostic separation suggests that the MESS model does not 
generalise well to the FIRST data however.  In the simulation study of Chapter 8, prognostic 
separation was found to be an inadequate method of external validation.  Therefore the 
poor validation seen here may be as a result of the method of external validation rather 
than the validity of the model. 
9.5 Missing Data – Comparing Simulated and Real Results 
In the FIRST dataset there was a variable missing.  Therefore, in section 9.4, the five 
methods of handling missing covariates tested in the simulation study of Chapter 8 were 
applied.  All five performed fairly equally, whereas the simulation study results suggested 
that variable matching was a poor method of imputation whilst the others were 
acceptable. 
The NGPSE and WA datasets are complete and therefore provide an opportunity to 
compare the ‘true’ results with results from the five methods of imputation using real data 
rather than simulated data.  There are only two types of covariate in the MESS model - 
binary and categorical.  One of each of these was forced to be missing in turn from the 
NGPSE and WA datasets.  The five methods of imputation were then applied and the 
deviance, concordance and separation statistics were calculated.  This enabled us to 
compare the results of the imputed data with the truth, and further investigate methods 
for handling covariates missing from the validation dataset. 
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9.5.1 Results 
The binary variable chosen to be missing from the MESS model was aetiology and the 
categorical variable was EEG result.  External validation results for each scenario can be 
seen in Table 38, Table 39, Table 40 and Table 41. 
9.5.1.1 Missing Binary Covariate 
In the case of a missing binary covariate, the deviance, concordance and prognostic 
separation measures all showed good agreement between the complete NGPSE dataset 
and each of the imputed versions.  The dataset that had the binary variable replaced via 
multiple imputation showed closest agreement with the complete dataset according to the 
deviance and concordance measures.  The prognostic separation measure showed closest 
agreement with the complete dataset when the missing binary variable was imputed by 
random selection with replacement. 
For a binary variable forced to be missing from the WA dataset, the deviance and 
concordance measures showed good agreement between the complete dataset and each 
of the imputed versions.  In both these cases the closest agreement between the complete 
and imputed datasets occurred when the binary variable was replaced via multiple 
imputation.  The measure of prognostic separation showed quite poor agreement between 
the complete and imputed datasets irrespective of the method of imputation – all 
confidence intervals for a difference between the complete and imputed datasets did not 
include the value of no difference, 0.  However, the differences in prognostic separation 
were fairly small (≤0.05 in all cases) with the difference between the complete dataset and 
the one imputed via hot deck imputation being the smallest. 
9.5.1.2 Missing Categorical Variable 
When a categorical covariate was forced to be missing from the validation dataset, the 
concordance statistic showed good agreement between the complete dataset and the 
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imputed versions across all five methods of imputation for both the NGPSE and WA 
datasets.  In the case of NGPSE the closest agreement was found when multiple imputation 
was implemented.  For WA the closest agreement was as a result of hot deck imputation.   
For NGPSE, the deviance measures were comparable across the complete and imputed 
datasets with random selection with replacement leading to the closest agreement.  For 
the WA dataset, the deviance measure showed varying levels of agreement – all methods 
of imputation except hot deck imputation led to significant p-values.  There was 
consequently sufficient evidence at the 10% level to conclude no agreement between the 
complete and imputed datasets.  Therefore the deviance measure may not be an 
appropriate method of assessing external validation.  It could also be that the methods of 
handling the missing covariate are not appropriate in this case.  This may be due to the 
large size of the WA dataset, the level of correlation between the variables, or some other 
reason.  
With regards to prognostic separation, the only non-significant difference was for the 
NGPSE dataset imputed via random selection with replacement.  None of the differences in 
prognostic separation between the complete WA dataset and each imputed version were 
non-significant.  The prognostic separation measure therefore suggested there was no 
agreement between the complete and imputed datasets for the WA dataset.  Again, this 
suggests that the prognostic separation measure may be inappropriate, but also it may be 
the case that the methods of imputation are inappropriate in this case. 
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Table 38: Methods of Imputation tested on a missing binary variable in NGPSE 
Missing Binary - NGPSE Complete Variable Matching Random Selection Single Imputation Hot Deck Multiple Imputation 
Deviance 
Statistic 10.26 N/A 9.64 10.13 9.7 10.24 
Degrees of Freedom - N/A 8 8 8 8 
p-value - N/A 1.00 1.00 1.00 1.00 
Concordance 
Statistic 
0.601 
(0.547, 0.654) 
0.597 
(0.543, 0.651) 
0.596 
(0.541, 0.651) 
0.596 
(0.541, 0.651) 
0.595 
(0.540, 0.650) 
0.598 
(0.544, 0.652) 
Difference in Concordance - 0.004 0.005 0.005 0.006 0.003 
Prognostic Separation 
Statistic 0.634 0.622 0.639 0.647 0.624 0.645 
Difference (& 95% CI) - 
0.01 
(-0.02, 0.05) 
0.00 
(-0.04, 0.03) 
-0.01 
(-0.05, 0.02) 
0.01 
(-0.02, 0.04) 
-0.01 
(-0.05, 0.02) 
 
Table 39: Methods of Imputation tested on a missing binary variable in WA 
Missing Binary - WA Complete Variable Matching Random Selection Single Imputation Hot Deck Multiple Imputation 
Deviance 
Statistic 45.4 N/A 39.65 38.93 38.94 39.66 
Degrees of Freedom - N/A 8 8 8 8 
p-value - N/A 0.68 0.59 0.60 0.68 
Concordance 
Statistic 
0.590 
(0.563, 0.618) 
0.579 
(0.551, 0.607) 
0.581 
(0.554, 0.609) 
0.579 
(0.551, 0.607) 
0.580 
(0.552, 0.607) 
0.598 
(0.544, 0.652) 
Difference in Concordance - 0.011 0.009 0.011 0.010 -0.008 
Prognostic Separation 
Statistic 0.554 0.505 0.513 0.507 0.522 0.511 
Difference (& 95% CI) - 
0.05 
(0.03, 0.06) 
0.04 
(0.03, 0.06) 
0.05 
(0.03, 0.06) 
0.03 
(0.02, 0.05) 
0.04 
(0.03, 0.06) 
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Table 40: Methods of Imputation tested on a missing categorical variable in NGPSE 
Missing Categorical - NGPSE Complete Variable Matching Random Selection Single Imputation Hot Deck Multiple Imputation 
Deviance 
Statistic 10.26 N/A 11.02 7.29 6.75 8.27 
Degrees of Freedom - N/A 8 8 8 8 
p-value - N/A 1.00 0.94 0.90 0.98 
Concordance 
Statistic 
0.601 
(0.547, 0.654) 
0.578 
(0.525, 0.632) 
0.592 
(0.537, 0.648) 
0.578 
(0.526, 0.631) 
0.579 
(0.524, 0.634) 
0.585 
(0.531, 0.639) 
Difference in Concordance - 0.023 0.009 0.023 0.022 0.005 
Prognostic Separation 
Statistic 0.634 0.506 0.657 0.576 0.548 0.588 
Difference (& 95% CI) - 
0.13 
(0.10, 0.16) 
-0.02 
(-0.06, 0.01) 
0.06 
(0.03, 0.09) 
0.09 
(0.06, 0.12) 
0.05 
(0.01, 0.08) 
 
Table 41: Methods of Imputation tested on a missing categorical variable in WA 
Missing Categorical - WA Complete Variable Matching Random Selection Single Imputation Hot Deck Multiple Imputation 
Deviance 
Statistic 45.4 N/A 30.29 29.99 35.84 31.27 
Degrees of Freedom - N/A 8 8 8 8 
p-value - N/A 0.06 0.05 0.30 0.08 
Concordance 
Statistic 
0.590 
(0.563, 0.618) 
0.578 
(0.550, 0.605) 
0.579 
(0.550, 0.607) 
0.578 
(0.550, 0.605) 
0.582 
(0.554, 0.610) 
0.578 
(0.550, 0.606) 
Difference in Concordance - 0.012 0.011 0.012 0.008 0.012 
Prognostic Separation 
Statistic 0.554 0.446 0.457 0.450 0.495 0.463 
Difference (& 95% CI) - 
0.11 
(0.09, 0.12) 
0.10 
(0.08, 0.11) 
0.10 
(0.09, 0.12) 
0.06 
(0.04, 0.07) 
0.09 
(0.07, 0.11) 
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9.5.2 Conclusion 
We have once again demonstrated that the concordance measure most frequently shows 
agreement when it is known to be present.  Consequently it seems that concordance is the 
best method of external validation.  In terms of handling covariates missing from a 
validation dataset, all five methods of imputation are fairly comparable, with multiple 
imputation being the most consistent method across a missing binary or categorical 
variable. 
Given that there are slight differences in the results for missing binary and missing 
categorical variables, it may not be sensible to infer these results to a missing continuous 
variable.  Ideally, another prognostic model, which contains a binary, categorical and 
continuous variable, should be obtained together with a suitable validation dataset.  The 
analysis in section 9.5.1 can then be repeated and the performance of the methods of 
external validation and methods for handling covariates missing from the validation dataset 
can then be compared across all types of missing data.  Guidelines for handling one missing 
variable of each type may then be produced with possible extensions to more than one 
missing covariate. 
9.6 Summary 
We have attempted to validate a prognostic model for time to second seizure following a 
first ever seizure, in the context of patients who drive, with the NGPSE, FIRST and WA 
datasets.  Following on from the simulation study of Chapter 8, three methods of external 
validation were tested together with five methods of imputation where necessary. 
In the simulation study, concordance was found to correctly identify agreement between 
the validation and development datasets when they were simulated in the same way.  In 
this case study we found, based on the concordance statistic, that the model developed 
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using MESS generalised well to the NGPSE and WA datasets.  The MESS model did not 
generalise as well to the FIRST dataset (Table 42). 
Table 42: Summary of concordance for external validation of MESS model via NGPSE, WA and FIRST datasets 
 Concordance Difference 
MESS 0.591 (0.556, 0.627) NA 
NGPSE 0.601 (0.547, 0.654) 0.01 
 WA 0.590 (0.563, 0.618) 0.00 
MESS: No Sleep Variable 0.576 (0.541, 0.612) NA 
FIRST: Variable Matching 0.646 (0.593, 0.699) 0.07 
MESS: Sleep Variable 0.587 (0.552, 0.622) NA 
FIRST: Random Selection 0.648 (0.596, 0.700) 0.06 
FIRST: Single Imputation 0.651 (0.597, 0.705) 0.06 
FIRST: Hot Deck 0.655 (0.601, 0.709) 0.07 
FIRST: Multiple Imputation 0.648 (0.595, 0.701) 0.06 
 
In the case of NGPSE and WA where no variables were missing, the prognostic measure of 
separation (Table 43) showed that the MESS model did generalise but not very well.  The 
comparison of deviance (Table 44) suggested that the model is not externally valid.  
Table 43: Summary of prognostic separation for external validation of MESS model via NGPSE, WA and FIRST 
datasets 
 Separation Difference Confidence Interval  
MESS 0.636 NA NA 
NGPSE 0.634 0.04 (-0.02, 0.03) 
WA 0.553 0.05 (0.06, 0.10) 
MESS: No Sleep Variable 0.482 NA NA 
FIRST: Variable Matching 0.782 0.30 (-0.34, -0.29) 
MESS: Sleep Variable 0.587 NA NA 
FIRST: Random Selection 0.853 0.27 (-0.29, -0.24) 
FIRST: Single Imputation 0.845 0.26 (-0.29, -0.23) 
FIRST: Hot Deck 0.931 0.35 (-0.37, -0.32) 
FIRST: Multiple Imputation 0.932 0.35 (-0.32, -0.27) 
 
In the case of FIRST where a variable was missing, comparison of deviance suggested no 
evidence to conclude that the MESS model was not externally valid.  Comparison of 
separation suggested that the MESS model did not generalise well.  It is likely that this is as 
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a result of the method of external validation rather than the model and data in question 
although it could be as a result of underlying differences in the population as outlined in 
section 9.1. 
Table 44: Summary of deviance for external validation of MESS model via NGPSE, WA and FIRST datasets 
 Deviance P-value 
MESS 30.91 NA 
NGPSE 10.26 0.01 
WA 45.40 0.07 
MESS: No Sleep Variable 21.11 NA 
FIRST: Variable Matching 23.03 0.86 
MESS: Sleep Variable 27.09 NA 
FIRST: Random Selection 24.70 0.88 
FIRST: Single Imputation 23.04 0.67 
FIRST: Hot Deck 25.43 0.95 
FIRST: Multiple Imputation 24.40 0.85 
 
In the simulation study of Chapter 8 variable matching was found to be a poor method of 
imputation.  Methods random selection with replacement, single imputation via 
estimation, hot deck imputation and random selection with replacement multiple times 
were found to be appropriate.  In our external validation of MESS all five methods led to 
poor comparison of separation although the concordance statistic showed good 
agreement, and p-values for the comparison of deviance were highly non-significant.  
When the methods of imputation were tested on real data, all five methods were found to 
be comparable, with multiple imputation being the most consistent method across a 
missing binary or categorical variable. 
In the case of comparison of deviance, a significant p-value suggests that the deviances are 
not comparable across the development and validation datasets – in other words the 
development model is not externally valid.  A non-significant p-value, on the other hand, 
only implies that there is insufficient evidence of a difference in deviances.  From this, it is 
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not possible to infer that the models are externally valid [231] – this confusing 
interpretation of the results provide an additional justification for not using comparison of 
deviance as a method of external validation (Chapter 8). 
The MESS model appears to be externally valid, to different degrees, using different 
datasets; the model generalises fairly well to the NGPSE and WA datasets and not quite so 
well to the FIRST dataset.  This may be due to underlying population differences - FIRST is 
the closest match to MESS in terms of the proportions of patients with certain 
characteristics, however the follow-up is much shorter and a significant covariate is 
missing.  In addition, EEG result and CT/MRI result were categorised differently in FIRST 
than in MESS and there may be other differences in unmeasured covariates. 
Data used to externally validate a prognostic model should come from the same super-
population as the development data.  There are however, no guidelines suggesting how to 
check whether the development and validation datasets are from a super-population.  
From our analyses it appears that length of follow-up is not too important, as the results of 
the external validation were unaffected when we truncated NGPSE to match the length of 
follow-up in MESS.  However, the conditional risk estimates became considerably higher 
than those for the complete NGPSE dataset, and consequently became considerably higher 
than those for MESS which suggested that truncating was not a sensible option.   
If a prognostic model is only externally valid in a population that is too similar, say almost 
identical, to that used to derive the model then it may not be generaliseable more widely.  
The three external validation datasets investigated here were plausibly related datasets to 
MESS but were not a perfect match.  Given that the model appears to be externally valid in 
populations that are slightly different in some respects to the MESS dataset it may be 
possible to conclude that the model is more useful as a clinical tool. 
 273 
 
Inevitably, studies brought together for external validation will differ.  This is also the case 
in systematic reviews and meta-analyses.  According to Cochrane guidelines [214], meta-
analyses should only be considered when a group of studies is sufficiently homogeneous in 
terms of participants, interventions and outcomes to provide a meaningful summary.  This 
can be equated to  performing external validation when an independent dataset needs to 
be sufficiently similar to the development dataset to provide a reasonable estimate of 
validity [8].   
The decision of sufficient homogeneity is often based on clinical input in the case of meta-
analyses and I recommend a similar process for external validation – if the independent 
dataset(s) is sufficiently homogenous in terms of participants, interventions and outcomes 
then it may be suitable for external validation.  Obviously, this will vary according to 
medical area and therefore clinical input would be required. 
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Chapter 10: Prognostic Models for 
Remission – Mixture Modelling 
10.1 Introduction 
In this chapter more complex modelling methods than those used in Chapter 4 will be 
investigated to assess if a model can be developed which more appropriately accounts for 
the different patient groups.  The chapter begins with a summary of the theory of mixture 
modelling (section 10.2), especially in the context of survival data (section 10.2.2).  Then 
two alternative methods for modelling time to 12 month remission are presented.   In 
section 10.3.1, the patients are split into two groups - those who achieve immediate 12 
month remission and those who achieve delayed 12 month remission.  Patients with 
refractory epilepsy are included in the delayed 12 month remission group as censored 
observations.  Prognostic models for each group are derived.  In section 10.3.2, mixture 
modelling techniques are implemented to derive a single prognostic model for all three 
patient groups. 
In Chapter 7, the prognostic model for time to 12 month remission, derived using a Cox 
model, showed poor internal validation at one year.  This may be because prognostic 
factors for the patient group achieving remission immediately at 365 days differ from those 
for the patient group achieving remission after one year.   
Considering arm A of the SANAD dataset (described thoroughly in Chapter 4), time to 12 
month remission is thought to comprise three distinct sections, as can be seen in Figure 33.  
The first section is at one year where a spike represents people who achieve remission 
immediately at 12 months.  The second section represents who achieve 12 month 
remission but not immediately, referred to as the delayed remission group.  Finally, the 
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survival curve flattens out although most Kaplan-Meier curves flatten towards the end of 
follow-up due to fewer subjects being at risk.  However, in the case of epilepsy, clinical 
knowledge suggests that not all patients achieve remission.  Therefore, in Figure 33, the 
flattening out is likely to represent patients who do not achieve remission, called the 
refractory epilepsy group (or the ‘cure’ group in frailty modelling terminology).   
 
Figure 33: The SANAD Trial – arm A: Kaplan-Meier curve for time to 12 month remission 
10.2 Mixture Modelling 
Finite mixture models were first proposed over a century ago in the classic paper of 
Pearson [327].  He fitted a mixture of two univariate Normal components to data on crab 
measurements provided by his colleague Weldon [328, 329] via moments-based fitting.  
Pearson’s approach [327] involved large amounts of algebra.  In the early part of the 
twentieth century various attempts were made to simplify the method [330].  Over the 
following 30 years, work continued on the use of the method of moments for this mixture 
problem - Charlier and Wicksell [331] extended the method to the case of more than two 
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univariate normal components.  In addition, Stromgren [332] considered the use of 
cumulants.  More recently, Cohen [333] showed how an iterative procedure, involving the 
solving of a cubic equation for a negative root, could be used as an alternative to solve 
Pearson’s [327] nonic.  Tan and Chang [334] and Fryer and Robinson [335], and others, 
showed however that maximum likelihood estimation was, in fact, superior to the methods 
of moments for this problem.  Recent work by Lindsay and Basak [336], amongst others, 
shows renewed interest in the method of estimation for normal mixtures. 
Following the introduction of high-speed computers, interest focused on maximum 
likelihood estimation of the parameters in a mixture distribution.  Rao [337] first used this 
method for a mixture model applying Fisher’s method of scoring for a mixture of two 
univariate distributions with equal variances.  It has, however, been noted [338] that 
Newcomb [339] predates Pearson’s early attempt at mixture models with the method of 
moments.  He suggested an iterative reweighting scheme, which can be interpreted as an 
application of the EM algorithm of Dempster [306], to compute the maximum likelihood 
estimate of the common mean of a mixture in known proportions of a finite number of 
univariate normal populations with known variances. 
After Rao’s paper [337] maximum likelihood estimation was not pursued further until 
Hasselblad [340, 341] who addressed the problem, initially for a mixture of   univariate 
normal distributions with equal variances, and then for mixtures of distributions from the 
exponential family.  Convergence properties of the maximum likelihood solution for the 
mixture problem were established theoretically after Dempster et al. [306] had formalised 
this iterative scheme in a general context.  In addition, their paper proved to be a spring-
board for further research into the applications of finite mixture models which is continuing 
to this day. 
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10.2.1 General Finite Mixture Models 
Finite mixture densities are a family of probability density functions of the form  
                    
 
     
where    is a  -dimensional random variable,                   and 
      
    
      
   with the    being the mixing proportions, or mixing weights, and the 
             the component densities of the mixture, with density    parameterised by 
  .  The mixing proportions are non-negative and are such that    
 
     .  The number 
of components forming the mixture is   [342].   In most applications of mixture densities, 
the    are assumed to take the same specified form, such as a univariate Gaussian.  In some 
applications it is better to allow different forms as   varies.  A particular case of this, 
referred to as a nonstandard mixture, is for     where one of the component densities is 
concentrated on a single value. 
Finite mixture densities are frequently used in either the situation where the population, 
whose distribution is to be modelled, is known to consist of well-defined subpopulations 
but the individual class memberships are unavailable or too expensive to obtain, or in the 
situation where subpopulations are only suspected and finite mixture models are used to 
explore the data for any potentially informative groupings.  A simple example of the first 
scenario would be if clinical measurements were available for patients, but disease 
classifications were not.  In the second case, finite mixture densities act as a relatively 
sound model for cluster analysis [342]. 
10.2.1.1 Estimating the Parameters in Finite Mixture Densities 
One of the main challenges when applying finite mixture densities is the estimation of the 
parameters of the mixture, which may or may not include the number of components,  .  
Given a sample of observations,           , from the mixture density, the log-likelihood 
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function,  , is defined as               
 
    [342].  The likelihood equation 
     
  
  , 
where           , can be solved to give estimates of the parameters in the model.  In 
addition, it has been shown [340, 341, 343-346] that the likelihood equations can be 
rearranged such that the likelihood estimate of    satisfies the equations 
Equation 22 
    
 
 
         
 
   
 
and 
Equation 23 
          
 
   
 
               
   
   
where          is the estimated posterior probability of an observation,  , arising from 
component density,  .   
In the situation of a mixture where the  th component density is multivariate normal with 
mean,   , and covariate matrix,   , Equation 22 and Equation 23 become [342] 
Equation 24 
    
 
 
         
 
   , 
Equation 25 
   
 
    
   
 
           , 
and 
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Equation 26 
   
 
    
               
 
        
 
   . 
The estimation of the unknown parameters,  , on the basis of the observations    is only 
meaningful if  is identifiable [347].  In general, a parametric family of densities         is 
identifiable if  
Equation 27 
              
  , 
if and only if     .  Identifiability for mixture distributions is defined in a slightly 
different way.  Suppose that         has two component densities, say           and  
          that belong to the same parametric family.  Then Equation 27 will still hold 
when the component labels   and   are interchanged in  .  That is, although this class of 
mixtures may be identifiable,   is not [347].  This lack of identifiability is not of concern in 
the normal course of events in the fitting of mixture models by maximum likelihood, say, 
via the EM algorithm.  However, it does cause problems in a Bayesian framework where 
posterior simulation is used to make inferences from the mixture model [347]. 
Hasselblad [340, 341], Wolfe [343-345] and Day [346] all suggested an iterative scheme for 
solving the likelihood equations.  This involved finding initial estimates of the posterior 
probabilities from given initial values of the parameters of the mixture, and then evaluating 
the right-hand sides of Equation 24, Equation 25 and Equation 26 to give revised estimates 
of the parameter values.  From these, new estimates of the posterior probabilities were 
derived and the procedure was repeated until a suitable convergence criterion was 
satisfied.  This procedure is a particular example of the EM algorithm [342], described by 
Dempster, Laird and Rubin [306] in the context of likelihood estimation for incomplete data 
problems. 
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One of the problems of the EM algorithm, noted by McLachlan and Basford [348], is its 
generally slow convergence rate.  Others have highlighted the fact that the algorithm need 
not converge at the global maximum.  Alternative algorithms, such as the Quasi-Newton 
algorithm, have also been shown to have convergence problems.  A more general problem 
of likelihood estimation for mixture models is that examples can be found where the 
likelihood is unbounded, so that the maximum likelihood estimate does not exist [342]. 
10.2.1.2 Detecting Finite Mixture Densities 
Finite mixture densities are most applicable in situations where separate groups of 
observations, with different distributions, seem to exist as a result of the nature of the 
application.  In many real-life situations however, the evidence for modelling data with a 
mixture distribution will need to be obtained empirically.  It is in these situations that the 
number of components in the mixture,  , is important having determined if a mixture 
density is an appropriate model for the data.  The procedures that have been suggested for 
answering such questions involve a combination of graphical techniques and quasi-
significance tests [342]. 
In the case of univariate data the simplest way to determine whether a mixture distribution 
is a suitable model for a sample of observations is to draw a sample histogram; clear 
multimodality is assumed to provide strong evidence that a mixture distribution is 
appropriate [342].  However, only in particular circumstances will the mixing of at least two 
unimodal densities lead to a mixed density with more than a single mode [349].  Therefore, 
it is important to look for alternatives to the histogram for evidence of a mixture.   One 
possibility, particularly for mixtures with normal components, is to use a Q-Q plot of the 
data, or a variation of such a plot proposed by Fowlkes [350], which he claims is particularly 
sensitive to the presence of mixtures. 
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Fowlkes’ suggested procedure is to plot            against   
       
 
     where 
                 represent the ordered sample values, which have mean   and 
standard deviation  ,              and   is the standard normal distribution function.  
When the observations arise from a single normal density, Fowlkes’ proposed plot results 
in an approximately horizontal line at    .  Mixture densities lead to plots having a 
characteristic cyclical pattern about zero, which differs from the pattern given by other 
non-normal distributions [350]. 
To detect multivariate normal mixtures an option is a chi-squared probability plot of the 
Mahalanobis distance of each observation from the sample mean vector [342].  If the data 
are from a single multivariate normal density these distances have an approximately chi-
squared distribution with   degrees of freedom, where   is the number of variables.  
Therefore a chi-squared probability plot of the ordered distances will result in an 
approximately straight line through the origin.  Mixtures of multivariate normals will, 
however, tend to give plots that are ‘S’ shaped. 
10.2.1.3 Determining the Number of Components in a Mixture 
Despite the widespread use of finite mixture models, the decision of how many 
components are required to adequately represent the data is, according to many authors 
[351-354] an important problem, but without a satisfactory statistical solution.   
A natural candidate for testing the hypothesis      against             , where   is 
the number of components in a mixture density, is the likelihood ratio statistic,  .  
However, this does not lead to a suitable significance test, because, for mixture densities, 
regularity conditions do not hold for       to have its usual asymptotic null distribution 
which is a chi-squared distribution with degrees of freedom equal to the difference in the 
number of parameters under the competing hypotheses [342].  This is because the null 
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distribution is on the edge of the parameter space.  Despite there being no completely 
satisfactory method of using the likelihood ratio statistic as a formal significance test for 
number of components, McLachlan and Basford [348] suggest that Wolfe’s modified 
likelihood ratio test [355] can be used as an informal guide to the appropriate number of 
components.  Wolfe, on the basis of a limited simulation study, suggested that the null 
distribution of the likelihood ratio statistic, for testing     against   components, is chi-
squared with      degrees of freedom, where   is the number of extra parameters in the 
    component mixture. 
In the context of survival data, Hunsberger et al [356] propose a maximum-likelihood 
approach to estimate the number of mixture components.  For Hunsberger’s [356] 
approach to estimating the number of mixture components let    be the true failure time 
for individual  , let    be an individual’s potential censoring time and    be the 
corresponding censoring indicator.  Observations then consist of               with 
     if       (uncensored) and      if       (censored). 
Alternative Bayesian approaches are also possible such as reversible-jump Monte Carlo 
methods [357] and a Markov-chain Monte Carlo method that treats the parameters of the 
model as a marked Poisson process [358].  These require bootstrapping to obtain an 
assessment of the p-value. 
Carrying out a hypothesis test based on bootstrapping can be computationally demanding.  
Therefore the estimation of the order of a mixture model has been considered mainly by 
using a penalised form of the log-likelihood function – as the likelihood increases with the 
addition of a component to a mixture model, information criteria such as AIC [163] and BIC 
[166] attempt to balance the increase in fit obtained against the larger number of 
parameters estimated for models with more components. 
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In addition, to ensure that over-parameterisation is accounted for, it is important to ensure 
that the segments are sufficiently separated.  An entropy statistic can be used to evaluate 
the degree of separation and hence assess the ability of a mixture model to provide well-
separated components. 
10.2.1.4 Including Covariates in a Finite Mixture Model 
Introduce a finite mixture model with   groups where the probability of being in a 
particular group           can be allowed to depend on subject-specific covariates 
where     denotes covariates           measured on subject  .  Polychotomous logistic 
regression parameterisation is used as per Equation 28 with           
 
   , 
                  
 
 and                   
 .  The vector    contains parameters 
that characterise the effect of covariates    on the probability of being in the  
th group. 
Equation 28 
              
               
 
    
                    
 
     
 
    
 
10.2.2 Finite Mixture Models for Survival 
Finite mixtures have frequently been used in a variety of fields to model heterogeneous 
data.  The potential of finite mixture models has been extended to survival analysis as they 
can be used to analyse failure-time data in a variety of situations including in the case of 
competing risks.  In the case of survival analysis, the observations are the times to failure 
and since failure can be due to a variety of causes, each with its own particular survival 
time distribution, the overall survival time distribution will be a mixture.  Historical 
attempts to fit negative exponential or Weibull distributions etc. have been described by 
Mendenhall and Hader [359] and by Kao [360] while, more recently, applications of mixture 
distributions to survival times have been described by McGiffin et al [361] and Lui, Darrow 
and Rutherford [362].  
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In general, to specify a survivor function by a mixture model, it is assumed that the 
probability density function,     , of the survival time,  , has the finite mixture form [363]  
Equation 29 
             
 
   
 
where               denote   component densities occurring in proportions         
where                 .  The survival function      corresponding to Equation 29 
has the functional form 
             
 
      
where  
              
 
 
          . 
For the mixture model specification, Equation 29, of the survivor function,     , the 
corresponding hazard function      is  
      
        
  
 
             
 
   
    
  
where       is the hazard function corresponding to the  
th component survivor function 
      in the model.       can be written as  
Equation 30 
             
 
   
 
where  
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          . 
Thus, the imposition of a mixture model on the survivor function implies a mixture model 
for the hazard function of the form in Equation 30 [363]. 
Suppose that       has the proportional hazards form 
              
          
where   is the vector of covariates and        is the baseline hazard function that does not 
depend on           .  Then 
Equation 31 
        
                       
  
   
 
           
  
 
where  
                     
 
 
  
and  
        
      
for        .  It can be seen from Equation 31 that although         has a proportional 
hazards form,         does not in general [363]. 
In the context of cure mixture models with survival data Greenhouse and Silliman [364] use 
a parametric cure model to analyse a dataset where the patients who are not cured are 
modelled according to a Weibull distribution.  The approach of Hunsberger [356] is similar 
to that of Greenhouse and Silliman but it potentially allows for more than two mixture 
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components.  Both use a Weibull distribution to model the survival in the non-cured 
groups. 
In Hunsberger [356] the survivor function for the  th patient is  
Equation 32 
                                                             
where             is a Weibull survival distribution indexed by parameters   ,    also 
              
  and               
 .  Alternatively, a cure component can replace 
a Weibull distribution in this formulation.  For example a cure component can replace the 
Weibull distribution for group 1 by replacing             with         in Equation 32.  
Models are identifiable up to a permutation of the group labels.  Therefore, the groups are 
ordered in terms of the median survival in each group. 
Hunsberger [356] uses maximum likelihood to estimate the model parameters.  As an 
example, the likelihood,         , for the model with three groups, two Weibull and a 
cure component is  
Equation 33 
                                           
  
 
   
                                      
       
where             and             are different Weibull distributions and             and 
            are the respective cumulative distribution functions.  The maximum likelihood 
estimates are found by maximising               with respect to the set of unknown 
parameters.  The parameter estimates are obtained using a quasi Newton-Raphson 
algorithm, which is available in the software package ‘gauss’ [365].  Hypothesis testing for 
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assessing the effect of covariates on the probability of being in a particular group is 
conducted with likelihood ratio tests. 
10.2.2.1 Long-Term Survivor Model (Proportion Cured Model) 
In some situations where the aim is to estimate the survival distribution for a particular 
type of failure, a certain fraction of the population, say   , may never experience this type 
of failure.  It is characterised by the overall survival curve being levelled at a non-zero 
probability.  In some applications, the surviving fractions are said to be cured [347] and the 
estimation of    is of interest.  Although it can be difficult to distinguish between a cure 
group and survival functions with long tails [366], Yu et al [367] showed that the cure 
fraction could be estimated well if follow-up was longer than the median survival. 
Assume that an individual has probability         of failing from the cause of interest 
and probability    of never experiencing failure from this cause.  Further, assume that the 
individual cannot fail from any other cause during the course of the study.  Let   be a 
random variable denoting the time to failure, where     denotes the event that the 
individual will not fail from the cause of interest.  The probability of this latter event is    
[347].  The unconditional survival function of   can then be expressed as  
Equation 34 
                 
where        denotes the conditional survival function for failure from the cause of 
interest.  The mixture model described in Equation 34, with the first component having 
mass one at    , can be regarded as a nonstandard mixture model [347] and is used in a 
variety of applications in survival analysis.  This model is sometimes referred to as the long-
term survival mixture model as individuals who will never fail can be viewed as being long-
term survivors.  This approach enables the proportion,   , of patients suffering no relapse 
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of the disease to be estimated without needing to specify a survivor function for those 
patients who die without evidence of a relapse of the disease under study.  This mixture 
approach, which was adopted by Farewell [368] and by McLachlan et al [369], among 
others, provides an alternative to the use of the Kaplan-Meier estimate. 
In more recent work involving this class of mixture models, Kuk and Chen [370] proposed a 
semi-parametric generalisation of the parametric model of Farewell.  Their model also 
assumes a proportional hazards model for the component hazard function      , 
              
         , 
but the baseline hazard function can be any arbitrary unspecified function not necessarily 
in the Weibull or Gompertz families.  Estimates of the regression parameters are obtained 
by maximising a Monte Carlo approximation of a marginal likelihood and the EM algorithm 
is used to estimate the baseline survivor function. 
Usually, for the long-term survival mixture model to be applicable, the observed data are of 
the form        
 
 for the  th entity where      implies that the  
th individual was 
observed to fail from the cause of interest at time    during the following up period, and 
     implies that the failure time was censored at time    [347].  In this context, Equation 
34 can be fitted by maximum likelihood after the specification of a parametric model 
         for      .   
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An individual who fails from the cause of interest at time              contributes a 
likelihood factor             where          is the density of   corresponding to         .  
An individual who has been followed to time    without failure contributes a likelihood 
factor                which is the probability that an individual never experiences 
failure.  The log likelihood,        , for        
    is then given by 
                                                               
 
   
 
10.2.2.2 Fitting by Maximum Likelihood 
In order to fit the mixture model, defined by Equation 29, to the observed failure-time data 
maximum likelihood can be used such that the form of each component density is specified 
up to a manageable number of unknown parameters.  These parameters are then inferred 
by considering the likelihood function that can be formed under these specified parametric 
forms [363].   
Let                                      denote the parametric forms of the density, 
survivor and hazard functions respectively with respect to the  th component in the mixture 
representation, Equation 29.  Here,    is a vector containing the unknown parameters in 
the parametric representation of these quantities for the  th component of the mixture.  
The vector of all unknown parameters is denoted by  .  When parametric forms are 
adopted for the mixing proportions        ,   is given by                   where 
     
      
   .   
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In some situations, the mixing proportions    are modelled as logistic functions of the 
covariate vector  .  In this case, the vector   of all unknown parameters is given by 
          .  With  defined in either way, the log-likelihood function for  is given by 
                       
 
   
        
 
   
              
where          and          denote the mixture density and survivor functions with 
components modelled parametrically [363].  The maximum likelihood estimator    of   is 
then obtained as an appropriate root of the likelihood equation 
Equation 35 
                 . 
10.2.2.3 Application of the EM Algorithm 
Rather than solving the likelihood equation, Equation 35, directly, solutions can be found 
by applying Dempster et al.’s EM algorithm [306].  This algorithm can be applied in the 
same manner in the context of survival analysis as for mixture models in general, with 
modifications to allow for the presence of censored data [363].  On the      th iteration 
of the EM algorithm,       is given by the value of  that globally maximises 
                           ,  
which is the conditional expectation of the complete-data log-likelihood,         , given 
the observed data   and the current fit      for  .  The calculation of this equation 
corresponds to the E-step while its maximisation with respect to   corresponds to the M 
step of the EM algorithm [363], as described in section 8.3.2.6. 
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10.3 Modelling Time to 12 Month Remission  
The SANAD time to 12 month remission data was investigated in two ways.  In section 
10.3.1 a non-mixture modelling approach was used while in section 10.3.2 a three 
component mixture model was derived. 
10.3.1 Non-Mixture Modelling 
The outcome immediate 12 month remission was assessed by logistic regression.  For each 
prognostic factor for this outcome, the log-odds ratio and 95% confidence interval was 
calculated.  Model fits were tested by chi-square methods.  Of the 1620 patients suitable 
for analysis in arm A, 32 had no follow-up data and 74 (5%) had a follow-up of less than 365 
days, 12 months.  47 of these patients had a seizure during follow-up and were therefore 
included in the denominator  
The outcome time to 12 month remission conditional on not achieving it immediately at 
365 days was assessed by life table analysis according to Kaplan-Meier.  The prognostic 
values of factors for these outcomes were tested by log-rank methods.  For each factor the 
hazard ratio and associated 95% confidence interval were calculated.  Best-fitting, 
parsimonious, Cox multivariable models were produced with backwards elimination by AIC 
– selection starts with the full model and eliminates predictors one at a time, at each step 
considering whether the criterion will be improved, smaller AIC, by adding back in a 
variable removed at a previous step [178].  Of the 1514 patients with a follow-up of at least 
365 days, 471 had a remission time of exactly 365 days and were consequently removed 
from the dataset.  Therefore 1043 patients were analysed to determine prognostic factors. 
10.3.1.1 Immediate 12 Month Remission 
The outcome immediate 12 month remission is equivalent to a time to 12 month remission 
of 365 days.  Univariate and multivariable odds ratios can be seen in Table 45. 
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In the univariate model the following factors were significantly associated with immediate 
12 month remission: gender, treatment history, neurological insult, epilepsy type, seizure 
type, focal epilepsy site of onset, age, time from first seizure to randomisation, total 
number of seizures ever before randomisation and treatment.  The resulting parsimonious 
multivariable model included variables for gender, treatment history, age, time from first 
seizure to randomisation, neurological insult, total number of seizures ever before 
randomisation and treatment, which was forced into the model.  
Immediate 12 month remission was more likely in men than women (male vs. female: HR 
1.06 95% CI (1.01 to 1.11)) and less likely in patients who were taking non-SANAD AEDs at 
randomisation compared to those who were treatment naive (non-SANAD AEDs vs. naive: 
HR 0.90 95% CI (0.85 to 0.96)).  Immediate 12 month remission was also less likely in 
patients with a neurological insult (present vs. absent: HR 0.92 95% CI (0.86 to 0.99)) and in 
patients taking gabapentin rather than carbamazepine (gabapentin vs. carbamazepine: HR 
0.89 95% CI (0.83 to 0.95)).  Immediate 12 month remission was increasingly likely with 
increasing age while it was less likely with an increase in the number of seizures ever 
before randomisation. 
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Table 45: The SANAD Trial – arm A: Univariate and Multivariable Odds Ratios for Immediate 12 Month 
Remission 
 Odds Ratio (95% Confidence Interval) 
Prognostic Factor Comparison 
P-value 
(univariate) 
Univariate 
(n=1513) 
Multivariable 
(n=1513) 
Gender 
Female 
Male 
0.00 
1.00 
1.42 (1.14 to 1.77) 
1.00 
1.06 (1.01 to 1.11) 
Febrile seizure history 
Absent 
Present 
0.13 
1.00 
0.69 (0.39 to 1.17) 
NA 
First degree relative with 
epilepsy 
Absent 
Present 
0.13 
1.00 
0.78 (0.54 to 1.13) 
NA 
CT/MRI scan result 
Normal 
Abnormal 
Not Done 
0.20 
1.00 
1.03 (0.79 to 1.33) 
1.18 (0.87 to 1.61) 
NA 
Treatment history 
Treatment naive 
Seizures after remission 
Taking non-SANAD AEDs 
0.00 
1.00 
1.30 (0.63 to 2.62) 
0.43 (0.29 to 0.60) 
1.00 
1.09 (0.94 to 1.27) 
0.90 (0.85 to 0.96) 
Age (years) 
[Linear] 
≤10 
(10 to 24) 
(25 to 36) 
(37 to 49) 
(50 to 70) 
>71 
0.00 
1.00 
1.15 (1.08 to 1.22) 
1.39 (1.21 to 1.61) 
1.66 (1.34 to 2.07) 
2.10 (1.53 to 2.88) 
2.73 (1.78 to 4.18) 
1.00 
1.03 (1.01 to 1.04) 
1.06 (1.03 to 1.09) 
1.10 (1.05 to 1.15) 
1.15 (1.08 to 1.22) 
1.20 (1.10 to 1.31) 
Time from 1st seizure 
(months) 
[Log] 
≤2 
(2 to 5) 
(6 to 17) 
(18 to 59) 
(60 to 239) 
>240 
0.00 
1.00 
0.99 (0.99 to 1.00) 
0.98 (0.96 to 0.99) 
0.93 (0.89 to 0.97) 
0.92 (0.87 to 0.97) 
0.57 (0.40 to 0.81) 
1.00 
1.00 (1.00 to 1.00) 
1.00 (1.00 to 1.01) 
1.01 (1.00 to 1.02) 
1.01 (1.00 to 1.02) 
1.09 (1.01 to 1.18) 
Neurological insult 
Absent 
Present 
0.00 
1.00 
0.56 (0.38 to 0.82) 
1.00 
0.92 (0.86 to 0.99) 
Total number of seizures 
[Scale: divided by 100,  
power 0: log] 
≤2 
(2 to 3) 
(4 to 11) 
(12 to 50) 
(51 to 299) 
>300 
0.00 
1.00 
0.92 (0.91 to 0.93) 
0.76 (0.72 to 0.79) 
0.57 (0.52 to 0.63) 
0.40 (0.34 to 0.47) 
0.22 (0.17 to 0.29) 
1.00 
0.99 (0.98 to 0.99) 
0.95 (0.94 to 0.96) 
0.90 (0.89 to 0.92) 
0.85 (0.82 to 0.87) 
0.76 (0.72 to 0.79) 
EEG results 
Normal 
Missing 
Non-specific abnormality 
Epileptiform abnormality 
0.17 
1.00 
1.05 (0.70 to 1.55) 
1.10 (0.80 to 1.50) 
0.87 (0.67 to 1.13) 
NA 
Seizure type 
Simple or complex focal only 
2° Generalised tonic-clonic 
Uncertain 
0.00 
1.00 
1.31 (1.03 to 1.69) 
2.60 (1.78 to 3.79) 
NA 
Epilepsy type 
Focal 
Unclassified 
0.00 
1.00 
2.16 (1.53 to 3.04) 
NA 
Focal epilepsy site of onset 
Temporal 
Not localised 
Frontal 
Other 
Unclassified 
0.00 
1.00 
1.04 (0.81 to 1.35) 
0.94 (0.58 to 1.50) 
0.86 (0.51 to 1.40) 
2.17 (1.49 to 3.16) 
NA 
Treatment 
Carbamazepine 
Gabapentin 
Lamotrigine 
Oxcarbazepine 
Topiramate 
0.01 
1.00 
0.56 (0.40 to 0.78) 
0.76 (0.55 to 1.04) 
0.94 (0.64 to 1.39) 
0.83 (0.60 to 1.15) 
1.00 
0.89 (0.83 to 0.95) 
0.94 (0.88 to 1.00) 
0.99 (0.91 to 1.07) 
0.96 (0.90 to 1.03) 
 
 295 
 
10.3.1.2 Time to Delayed 12 Month Remission 
The outcome time to delayed 12 month remission is equivalent to time to 12 month 
remission conditional on not having achieved it at 365 days.  Univariate and multivariable 
hazard ratios can be seen in Table 46. 
In the univariate model CT/MRI results, treatment history, seizure type, time from first 
seizure to randomisation and total number of seizures ever before randomisation were 
significantly associated with delayed 12 month remission.  The resulting parsimonious 
multivariable model included variables for gender, CT/MRI result, treatment history, 
seizure type, total number of seizures ever before randomisation and treatment which was 
forced into the model.  
Delayed 12 month remission was less likely in patients with an abnormal CT/MRI result 
compared to a normal result (abnormal vs. normal: HR 0.81 95% CI (0.66 to 0.99)) and in 
patients who were taking non-SANAD AEDs at randomisation compared to those who were 
treatment naive (non-SANAD AEDs vs. naive: HR 0.67 95% CI (0.53 to 0.86)).  Delayed 12 
month remission was decreasingly likely with an increase in the number of seizures ever 
before randomisation. 
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Table 46: The SANAD Trial – arm A: Univariate and Multivariable Hazard Ratios for Time to Delayed 12 Month 
Remission 
 Hazard Ratio (95% Confidence Interval) 
Prognostic Factor Comparison 
P-value 
(univariate) 
Univariate 
(n=1043) 
Multivariable 
(n=1043) 
Gender 
Female 
Male 
0.24 
1.00 
1.11 (0.94 to 1.31) 
1.00 
1.13 (0.96 to 1.35) 
Febrile seizure history 
Absent 
Present 
0.20 
1.00 
1.25 (0.90 to 1.74) 
NA 
First degree relative with 
epilepsy 
Absent 
Present 
0.39 
1.00 
1.12 (0.87 to 1.46) 
NA 
CT/MRI scan result 
Normal 
Abnormal 
Not Done 
0.03 
1.00 
0.79 (0.65 to 0.97) 
1.09 (0.85 to 1.39) 
1.00 
0.81 (0.66 to 0.99) 
1.09 (0.85 to 1.40) 
Treatment history 
Treatment naive 
Seizures after remission 
Taking non-SANAD AEDs 
0.00 
1.00 
0.95 (0.52 to 1.73) 
0.60 (0.47 to 0.76) 
1.00 
0.98 (0.53 to 1.79) 
0.67 (0.53 to 0.86) 
Age (years) 
[Linear] 
≤10 
(10 to 24) 
(25 to 36) 
(37 to 49) 
(50 to 70) 
>71 
0.12 
1.00 
0.96 (0.48 to 1.93) 
0.94 (0.30 to 2.92) 
0.93 (0.23 to 3.67) 
0.92 (0.18 to 4.62) 
0.91 (0.15 to 5.48) 
NA 
Time from 1st seizure 
(months) 
[Log] 
≤2 
(2 to 5) 
(6 to 17) 
(18 to 59) 
(60 to 239) 
>240 
0.00 
1.00 
0.95 (0.93 to 0.98) 
0.92 (0.87 to 0.97) 
0.88 (0.81 to 0.95) 
0.88 (0.81 to 0.95) 
0.82 (0.72 to 0.93) 
NA 
Neurological insult 
Absent 
Present 
0.09 
1.00 
0.81 (0.62 to 1.04) 
NA 
Total number of seizures 
[Scale: 100, power: 0] 
≤2 
(2 to 3) 
(4 to 11) 
(12 to 50) 
(51 to 299) 
>300 
0.00 
1.00 
0.98 (0.97 to 0.99) 
0.93 (0.90 to 0.96) 
0.86 (0.81 to 0.92) 
0.79 (0.71 to 0.87) 
0.67 (0.56 to 0.80) 
1.00 
0.98 (0.97 to 0.99) 
0.94 (0.91 to 0.97) 
0.88 (0.82 to 0.94) 
0.81 (0.73 to 0.90) 
0.70 (0.58 to 0.84) 
EEG results 
Normal 
Missing 
Non-specific abnormality 
Epileptiform abnormality 
0.59 
1.00 
0.89 (0.63 to 1.25) 
1.10 (0.86 to 1.41) 
1.08 (0.89 to 1.31) 
NA 
Seizure type 
Simple or complex focal only 
2° Generalised tonic-clonic 
Uncertain 
0.03 
1.00 
0.86 (0.72 to 1.03) 
1.26 (0.92 to 1.73) 
1.00 
0.83 (0.69 to 1.00) 
1.05 (0.75 to 1.46) 
Epilepsy type 
Focal 
Unclassified 
0.07 
1.00 
1.34 (0.99 to 1.81) 
NA 
Focal epilepsy site of onset 
Temporal 
Not localised 
Frontal 
Other 
Unclassified 
0.14 
1.00 
0.93 (0.77 to 1.12) 
1.07 (0.76 to 1.49) 
1.27 (0.91 to 1.76) 
1.32 (0.96 to 1.83) 
NA 
Treatment 
Carbamazepine 
Gabapentin 
Lamotrigine 
Oxcarbazepine 
Topiramate 
0.29 
1.00 
0.87 (0.68 to 1.12) 
1.06 (0.83 to 1.35) 
1.02 (0.73 to 1.42) 
0.83 (0.64 to 1.08) 
1.00 
0.84 (0.66 to 1.08) 
1.04 (0.82 to 1.33) 
1.00 (0.72 to 1.38) 
0.84 (0.65 to 1.09) 
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10.3.1.3 Discussion 
A prognostic model for overall time to 12 month remission was derived in Chapter 4.  It 
included variables for gender, CT/MRI scan result, treatment history, age, time from first 
seizure to randomisation, neurological insult, total number of seizures before 
randomisation, focal epilepsy site on onset and treatment.  All these variables were found 
to be significant prognostic factors for either the model for immediate 12 month remission 
(section 10.3.1.1), or time to delayed 12 month remission (section 10.3.1.2), or both.   
Gender, treatment history, total number of seizures, site of onset and treatment were 
included in both the model for immediate 12 month remission, and the model for delayed 
remission.  In the immediate remission model, age, time from first seizure and neurological 
insult were significant factors while in the delayed model CT/MRI result and seizure type 
were significant. 
As there were some differences in the prognostic factors for immediate 12 month 
remission and those for delayed remission it is possible that the model developed in 
Chapter 4 with these patient groups combined is not the most appropriate model.  This 
may explain why the internal validation of the model developed in Chapter 4 was poor at 
one year – patients with immediate 12 month remission have different significant clinical 
factors to those with delayed 12 month remission and therefore need to be modelled 
independently. 
It is difficult to provide clinical reasoning for the difference in the results when comparing 
variables identified for immediate and delayed 12 month remission.  If anything, this work 
highlights the need for further work into the biology of epilepsy.  This research may then 
explain why age is important for predicting immediate remission but not delayed remission 
while time from first seizure and total number of seizures are similar across both outcomes.  
One reason may be that the immediate and delayed analyses comprise different number of 
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patients.  Therefore, the delayed analyses have less power to detect the effects of 
prognostic factors. 
10.3.2 Mixture Modelling 
As the SANAD time to 12 month remission data comprised three distinct patient groups, a 
three component mixture model for the outcome was investigated.  There were several 
stages to the derivation process – existence of a cure fraction, distribution of the survival 
data, covariate selection and likelihood formulation.  These are described in sections 
10.3.2.1 to 10.3.2.4. 
10.3.2.1 Stage 1: Is there a cure fraction? 
In the case of the refractory group, assume that an individual has probability           
of achieving 12 month remission and probability    of never achieving 12 month remission.  
Additionally, assume that the individual cannot fail from any other cause during the course 
of the study.   
In the case of SANAD, follow-up may be insufficient to determine a cure fraction.  A crude 
way to determine if there is a cure fraction is to ignore patients who achieved 12 month 
remission immediately.  Then, a normal cure rate model can be fitted to the delayed and 
potentially refractory patient group using standard cure rate methodology via the ‘gfcure’ 
programme within R [371].   
Table 47: The SANAD Trial – arm A: Cure Fractions 
 Cure Fraction 
Exponential 0.08% 
Weibull 29.8% 
Log-logistic 30.4% 
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The distribution of the delayed remission group is unknown.  Therefore, the test for a cure 
fraction was performed using exponential, Weibull and log-logistic baseline distributions.  
The cure fractions for each distribution can be seen in the Table 47. 
The ‘gfcure’ package uses an extended generalised gamma distribution which, with 
appropriate reparameterisation, includes most commonly used distributions as special 
cases.  The boundary conditions of the likelihood ratio test are not violated with this 
distribution and the standard asymptotic theory of the likelihood ratio test can be applied 
[372]. 
Table 48: The SANAD Trial – arm A: Log-likelihoods for potential model fits to the data 
 
Log-likelihood  
Survival Model Cure Rate Model Cure Fraction Present? 
Exponential -4656.467 -1055.915 Yes 
Weibull -4544.611 -896.314 Yes 
Log-logistic -4494.850 -853.357 Yes 
 
Therefore, to test whether these cure fractions were significant, a form of the log-
likelihood was used for the inclusion of the cure rate.  A model was fitted with all relevant 
covariates included, as per the multivariable analysis of time to 12 month remission for the 
SANAD data (Chapter 4), and a cure fraction.  This was then compared to a standard model 
fitted to the survival data only, with all the same covariates.  The results, shown in Table 
48, suggest that there is a cure fraction, irrespective of the distribution.  The log-logistic 
model appeared to be the better fit based on these results. 
10.3.2.2 Stage 2: Distribution of Delayed Remission Group 
To determine the distribution of the patients who achieve 12 month remission but not 
immediately at 12 months, the so-called delayed remission group, the exponential, Weibull 
and log-logistic distributions were considered.  To begin with, the survivor functions were 
estimated and then graphs were plotted to assess whether the data appeared to follow an 
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underlying exponential, Weibull or log-logistic distribution.  Next, a straight line was fitted 
to these graphs to estimate the model parameters.  Maximum likelihood estimation of the 
parameters was then carried out and the results compared to the estimates from the 
straight line.  The fitted distribution was then compared to the actual data. 
The exponential distribution has density function               , hazard function 
       and survivor function               where   is a positive constant.  It 
therefore follows that              .  To test if the exponential distribution fits the 
data, –            can be plotted against  .  If the lifetime distribution underlying the data is 
exponential, then the plot will, approximately, be a straight line through the origin, 
gradient  . 
The Weibull distribution has density function                      , hazard function  
            and survivor function                where     are positive constants.  
It therefore follows that                           .      –             can be plotted 
against      and if the lifetime distribution is Weibull, then the plot will approximately be a 
straight line, gradient  , intercept      [373].   
The log-logistic distribution has the density function      
         
          
, hazard function  
     
         
       
 and survivor function      
 
       
 where     are positive constants.  It 
therefore follows that     
 
     
               .  If the lifetime distribution is log-
logistic, the plot of     
 
     
    against      should approximately give a straight line 
with intercept       and gradient   [373].  
The three plots can be seen in Figure 34.  None of the plots are a perfect straight line. 
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Figure 34: The SANAD Trial – arm A: Plots to test fit of various models to the data 
 
Having fitted a straight line to each plot, the intercepts and gradients are as shown in Table 
49.  The parameters were additionally estimated by the maximum likelihood method and 
can also be seen in Table 49.  
In the case of the straight line estimates,       intercept  and           .  In the case 
of the maximum likelihood estimates, the output from R for the estimated survivor 
function is in parametric form with the relationship between this and the estimates for a 
straight line model being               
 
 
          , and          .  Therefore, 
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                  and           [373].  The parameters can now be compared, as 
per Table 49.   
For an exponential fit, the gradient is required to be one.  This is not the case according to 
our parameter estimates suggesting that the exponential is not a suitable model. 
Table 49: The SANAD Trial – arm A: Parameter estimates for various model fits to the data 
Distribution 
Straight Line Estimates Maximum Likelihood Estimates 
Intercept Gradient λ γ Intercept Scale λ γ 
Exponential 0.1547 0.0007 1.1673 0.0007 7.4539 1.000 0.0006 1.0000 
Weibull -5.447 0.775 0.0043 0.775 7.2910 0.608 0.0007 1.6447 
Log-logistic -6.540 1.006 0.0014 1.006 6.9604 0.431 0.0009 2.3202 
 
The fit was then evaluated by plotting the estimated survivor function along with the 
model estimates as shown in Figure 35.  The unusual cure fraction of 0.08% together with 
the exponential fit plot in Figure 35 shows, convincingly, that a constant hazard was not a 
sensible assumption.  This distribution is therefore not appropriate for the delayed 
remission group.  The log-logistic model fits the data better than the Weibull.  Therefore, 
the log-logistic distribution appears to be the best choice of model for the delayed 
refractory group. 
 
Figure 35: The SANAD Trial – arm A: Model Fit plots; Black line represents the data 
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Mixture modelling was therefore undertaken to model patients who achieved 12 month 
remission immediately (logistic regression), those who achieved 12 month remission but 
not immediately at 12 months (parametric survival model with log-logistic distribution) and 
those who did not achieve 12 month remission (refractory patient group i.e. cure fraction).   
The effects of covariates were considered to investigate whether predictions could be 
made about which remission group a patient fell into based on their baseline 
characteristics. 
10.3.2.3 Step 3: Covariates 
10.3.2.3.1 Immediate Remission 
With 12 possible covariates there are 212=4096 possible combinations of variables to try in 
the model.  Although there are pre-set routines available in standard software packages to 
try all these combinations with logistic regression and survival analysis, they are not 
available for cure rate models.  Therefore Collett [167] recommends a general strategy for 
model selection. 
In step one, each possible variable is fit, one at a time, and the resulting         for each 
model is compared with that for the null model.  This determines which variables are 
significant independently.   In step two, the variables that appear to be important in step 1 
are then fitted together.  The change in the value of         is computed when each 
variable on its own is omitted from the set.  Only those that lead to a significant increase in 
the value of         are retained in the model.  Once a variable has been dropped, the 
effect of omitting each of the remaining variables in turn is then examined. 
In the third step variables that were not important on their own, and so were not under 
consideration in step 1 may become important in the presence of others.  These variables 
are therefore added to the model from step 2, one at a time, and any that reduce         
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significantly are retained in the model.  In the last step, a final check is made to ensure that 
no term in the model can be omitted without significantly increasing the value of        , 
and that no term not included significantly reduces       . 
Before Collett’s strategy was employed, the functional form for the continuous variables in 
SANAD was determined.  In line with Chapter 4, our preferred transformations were linear, 
log or FP.  However, FP transformations are not available with cure rate models currently 
and consequently were not considered here.   
Table 50: The SANAD Trial – arm A: Coefficients and Standard Errors for Immediate Remission 
Variable Coefficient Standard Error Comparison Odds Ratio (95% CI) 
Intercept 0.39 0.05 - N/A 
Time from First Seizure 0.04 0.01 
≤2 
(2 to 5) 
(6 to 17) 
(18 to 59) 
(60 to 239) 
>240 
1.00 
1.02 (1.01 to 1.03) 
1.04 (1.03 to 1.06) 
1.06 (1.04 to 1.09) 
1.09 (1.05 to 1.12) 
1.16 (1.09 to 1.23) 
Total Number of Seizures -0.10 0.01 
≤2 
(2 to 3) 
(4 to 11) 
(12 to 50) 
(51 to 299) 
>300 
1.00 
0.95 (0.95 to 0.96) 
0.91 (0.90 to 0.93) 
0.86 (0.84 to 0.88) 
0.80 (0.77 to 0.83) 
0.71 (0.68 to 0.75) 
Treatment: GBP -0.12 0.03 GBP vs. CBZ 0.89 (0.84 to 0.95) 
Treatment: LTG -0.06 0.03 LTG vs. CBZ 0.94 (0.88 to 1.00) 
Treatment: OXC -0.01 0.04 OXC vs. CBZ 0.99 (0.91 to 1.07) 
Treatment: TPM -0.03 0.03 TPM vs. CBZ 0.97 (0.91 to 1.03) 
 
Following Collett’s general strategy for model selection, the final model included variables 
for time from first seizure to randomisation, total number of seizures ever before 
randomisation and treatment, which was forced into the model, with coefficient values, 
standard errors and associated odds ratios and confidence intervals as in Table 50.  The 
chance of immediate remission increases with an increase in the time from first seizure to 
randomisation but decreases with an increase in total number of seizures before 
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randomisation.  Immediate remission is less likely in patients treated with gabapentin than 
in those treated with carbamazepine. 
10.3.2.3.2 Delayed Remission 
Collett’s strategy was used to determine the parsimonious multivariable model for delayed 
epilepsy.  As before, every patient was treated, therefore treatment was forced into the 
model.  The final model included variables for treatment history, time from first seizure to 
randomisation, total number of seizures ever before randomisation and treatment.  The 
coefficients, standard errors, odds ratios and confidence intervals can be seen in Table 51. 
The log-logistic model is both an accelerated failure time model and a proportional odds 
model [374].  Hence the regression coefficients can be interpreted as the log odds ratio (for 
surviving) with one unit increase in the variable. 
Table 51: The SANAD Trial – arm A: Coefficients and Standard Errors for Delayed Remission 
Variable Coefficient 
Standard 
Error 
Comparison 
Odds Ratio  
(95% CI) 
Log(Scale) -0.89 0.03 - N/A 
Intercept 6.66 0.08 - N/A 
Treatment History: Recent 
Seizures 
0.05 0.18 
Recent Seizures vs. 
Treatment Naive 
1.06 (0.74 to 1.51) 
Treatment History: 
Taking non-SANAD AEDs 
0.25 0.07 
Taking non-SANAD AEDs 
 vs. Treatment Naive 
1.28 (1.11 to 1.48) 
Time from First Seizure 0.00 0.00 
≤2 
(2 to 7) 
(8 to 18) 
(19 to 60) 
(61 to 277) 
>277 
1.00 
1.00 (1.00 to 1.00) 
1.00 (1.00 to 1.00) 
0.99 (0.97 to 1.02) 
0.97 (0.87 to 1.07) 
0.92 (0.73 to 1.17) 
Total Number of Seizures 0.07 0.02 
≤2 
(2 to 3) 
(4 to 11) 
(12 to 50) 
(51 to 299) 
>300 
1.00 
1.03 (1.02 to 1.05) 
1.07 (1.03 to 1.10) 
1.11 (1.06 to 1.17) 
1.17 (1.09 to 1.26) 
1.27 (1.13 to 1.43) 
Treatment: GBP 0.09 0.07 GBP vs. CBZ 1.09 (0.94 to 1.26) 
Treatment: LTG -0.03 0.07 LTG vs. CBZ 0.97 (0.84 to 1.12) 
Treatment: OXC 0.00 0.09 OXC vs. CBZ 1.00 (0.83 to 1.21) 
Treatment: TPM 0.11 0.08 TPM vs. CBZ 1.12 (0.96 to 1.30) 
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Delayed remission was more likely in patients with recent seizures following previous 
remission on monotherapy than in treatment naive patients.  The chance of delayed 
remission increased with an increase in total number of seizures before randomisation. 
10.3.2.3.3 Refractory Epilepsy 
The final model for the refractory epilepsy group just included treatment – no covariates 
were found to be significant for this group.  Standard errors were not estimable from the 
cure part of the model but the coefficients and associated odds ratios can be seen in Table 
52.  It is unknown why the standard errors are not estimable – Dr Peng, the author of 
‘gfcure’ was unable to suggest why this anomaly occurred. 
Table 52: The SANAD Trial – arm A: Coefficient values for Refractory Epilepsy 
Variable Coefficient Comparison Odds Ratio 
Intercept 2.54 - NA 
Treatment: GBP 0.18 GBP vs. CBZ 1.20 
Treatment: LTG 0.47 LTG vs. CBZ 1.60 
Treatment: OXC 0.26 OXC vs. CBZ 1.29 
Treatment: TPM 0.40 TPM vs. CBZ 1.49 
 
10.3.2.4 Step 4: Setting Up the Likelihood 
There are several mixture models published in the literature such as [375] and [376].  For 
epilepsy, there are examples of seizure count analyses via mixture modelling [377, 378] but 
no models for remission from seizures.  Now the component densities and covariates have 
been determined for each patient group (immediate remission, delayed remission and 
refractory) we wish to combine them to produce one overall model.  To do this we need to 
specify the survivor function by a mixture model. 
All times were transformed so that the adjusted time to 12 month remission for a patient 
with immediate 12 month remission was 0, i.e.     . 
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 Let individual,  , have time to 12 month remission    where    = time to 12 month 
remission – 365 days.   
 Let     be an indicator variable which is equal to 1 if time to 12 month remission is 
0 and 0 otherwise, equivalent to an indicator variable for immediate 12 month 
remission.   
 Let     be an indicator variable which is equal to 1 if    is observed (and greater 
than 0) and 0 if    is censored (and greater than 0).  This is equivalent to an 
indicator variable for delayed 12 month remission.   
 Let    be an (imaginary) indicator variable for the refractory group – it is imaginary 
as it is not possible to determine if a patient is refractory.  We can only determine if 
they achieved 12 month remission.   
 Let    be the probability that     equals 1, i.e. the probability of achieving 12 
month remission immediately. 
 Let    equal the probability that      which is equivalent to the probability that 
   is equal to one, i.e. the probability of having refractory epilepsy.   
The function,                   can be considered in three sections which correlate with 
the three shapes of the curve – the peak related to immediate 12 month remission, the 
curve related to achieving 12 month remission but not immediately at 12 months 
(‘delayed’), and the flattened line related to patients who do not achieve 12 month 
remission (‘refractory’).  In Equation 36,        is the hazard function for time period    and 
       is the survival function.  The middle two parts of the function relate to the observed 
time to delayed 12 month remission (2nd line) and censored time to delayed 12 month 
remission (3rd line). 
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Equation 36 
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The log-likelihood is therefore 
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From this log-likelihood parameter estimates may be obtained.  This requires use of an EM 
algorithm such as Newton-Raphson [379].  Implementation of these algorithms would need 
to be done in a software package such as Matlab [380] and is a complex stage of the 
analysis.  Alternatively, software packages such as Latent GOLD [381] could be used to fit 
the mixture model but these require a new programming language to be learnt.  
Additionally, the relevant covariates need to be included into the model which is again, 
very complex, involving either a one-step full information maximum-likelihood approach, 
standard three-step approach or two adjusted three-step approaches [382].  Literature on 
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these methods is currently in press and was therefore unavailable for use as part of this 
thesis. 
10.3.2.5 Step 5: Is the assumption valid? 
In all the analyses above we have assumed that there were no withdrawals before 365 
days.  If some patients were censored with time to 12 month remission less than 365 days 
then further investigation is necessary.   
There were 77 patients who withdrew before 365 days.  The minimum time to withdrawal 
was 17 days while the maximum was 364 days with median 258 days (IQR 154 to 329).  Of 
these 77 patients, 12 withdrew their consent, 22 died and 43 provided no reason for 
withdrawal. 
To handle the potential invalidity of the assumption a sensitivity analysis could be 
performed considering the coefficient estimates at six months, nine months, 12 months 
and 15 months.  If the coefficients were broadly similar then there would be some stability 
in the model so the invalidity would be less concerning.  However, if the assumption was 
not valid then the negative binomial, Poisson or similar model would need to be invoked 
but this would require more research as the methodology needed is not currently available.  
10.3.2.6 Discussion 
Analyses in section 10.3.2.1 suggested the presence of a cure fraction (refractory patient 
group) for the time to 12 month remission outcome of the SANAD dataset.  The log-logistic 
distribution was found to be the most appropriate distribution for the delayed remission 
group.   
Significant covariates for immediate 12 month remission were time from first seizure to 
randomisation, total number of seizures before randomisation and treatment, which was 
forced into the model.  For delayed 12 month remission, the significant covariates were 
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treatment history, time from first seizure to randomisation, total number seizures before 
randomisation and treatment, which was again forced into the model.  No covariates were 
found to be significant for refractory epilepsy so only treatment was included in the model. 
The cured population (refractory group) may be more like the delayed 12 month remission 
population so that the variables included in the model may be more like those identified in 
Table 46 for overall time to delayed 12 month remission.  This is because patients who 
achieve immediate 12 month remission are unlikely to be similar to those who never 
achieve remission.  However, those who achieve remission but at a later time point than 12 
months may take 5 years to achieve remission, or longer, and hence are more likely to be 
similar to the refractory group who have not achieved remission whilst under observation.  
The impact of this on these results is unknown but could be explored in sensitivity analyses. 
Fewer covariates were found to be significant via the mixture modelling approach (section 
10.3.2) than both the non-mixture modelling approach (section 10.3.1) and the modelling 
all data together approach (Chapter 4).   Given that the models in section 10.3.1 were 
derived via stepwise selection with AIC, and those in this section (10.3.2) were derived 
using Collett’s strategy, it is unsurprising that the same significant covariates were not 
identified.  Additionally, a different modelling approach has been used which may also 
account for the different covariate list.  If the same strategies were employed to determine 
both the mixture and non-mixture models, the covariates may be the same.  This is 
because the immediate remission group is the same in both approaches.  Additionally, no 
significant covariates were identified for the refractory group via the mixture modelling 
approach.  Therefore, despite the refractory patients being unidentifiable during the non-
mixture modelling approach, this is unlikely to impact on the covariates. 
Although a direct comparison of results across the mixture modelling and non-mixture 
modelling approaches is not appropriate, broad comparisons can be made.  For patients 
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who achieve remission immediately at 12 months results are quite similar – time from first 
seizure to randomisation is moderately significant via the mixture modelling approach and 
slightly significant for the non-mixture modelling approach.  The relationship between 
chance of immediate remission and total number of seizures before randomisation is the 
same across both approaches – as number of seizures increases, chance of immediate 
remission decreases.  Immediate remission is less likely in patients on gabapentin than in 
those on carbamazepine, irrespective of the modelling method.  Therefore, these 
prognostic factors appear to be robust to the choice of modelling method. 
For time to delayed 12 month remission, remission was more likely in patients who were 
previously treated with non-SANAD AEDs but had a change in drug indicated than in 
treatment naive patients via the mixture modelling approach.  In the non-mixture 
modelling results this conclusion was reversed – remission was less likely in patients who 
were previously treated with non-SANAD AEDs but had a change in drug indicated than in 
treatment naive patients.  The effect of total number of seizures before randomisation was 
inconsistent across the mixture and non-mixture modelling methods.  In the non-mixture 
modelling case, as number of seizures increased the chance of remission decreased while 
in the mixture modelling case the chance of remission increased. 
The mixture modelling work is based on parametric modelling techniques while the non-
mixture modelling work is based on semi-parametric modelling techniques.  If parametric 
methods were used to model the immediate and delayed remission groups in the non-
mixture approach the results may be more similar to those from the mixture modelling 
approach. 
10.3.3 Future Work 
Many issues remain in this area of my research.  To begin with we need to determine why 
there is a difference between the maximum likelihood and straight line estimates (Table 
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49).  It is most likely that the difference is caused by the influential curve up until log(time) 
three.  To investigate whether this conjecture is correct, the fitted values could be plotted 
against actual times, taking account of the censoring.  If the values do not match then this 
suggests our assumption is correct.  Another option is to simulate data with both sets of   
and   and then plot the two related lines and compare them with the actual fit. 
Assuming that a mixture model for time to 12 month remission, adjusted for covariates, 
can be developed it will be necessary to validate it both internally and externally.  No 
literature on how to validate mixture models exists.  It may be possible to ensure that the 
covariates chosen for the immediate 12 month remission group are robust by performing a 
sensitivity analysis, checking the covariates by Cox’s method at nine months and at 15 
months.  If the same covariates were found to be included in the multivariable model the 
choice of covariates may be robust.  If not, further work may be required into covariate 
selection.  For the delayed 12 month remission and the refractory groups, it may again be 
possible to perform a kind of internal validation via a sensitivity analysis.  In this case the 
included covariates could be modelled together with any known clinically significant 
variables simultaneously, via Cox’s method, for the delayed and refractory parts of the 
model. 
10.4 Conclusion 
Substantial progress has been made in the fitting of mixture models, especially by the 
method of maximum likelihood, since mixture models were first proposed in the 19th 
Century.  Despite the arrival of high-speed computers, people have been generally 
unwilling to fit mixture models to data of more than one dimension [347].  This may be 
because of a lack of understanding of issues that arise with their fitting such as the 
presence of multiple maxima in the mixture likelihood function and the unboundedness of 
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the likelihood function in the case of normal components with unequal covariance matrices 
[347].  As the difficulties of these computational issues come to be properly understood 
and addressed there is hope for an increase in the use of mixture models in practice. 
The first 50 years of using finite mixture densities, following Pearson’s pioneering work in 
1894, was focussed on the development of techniques designed to simplify the large 
amount of arithmetic involved in applying the method of moments in estimating 
parameters.  During the last 20 years the wide availability of powerful computers has 
lessened these problems and maximum likelihood estimation can now be applied routinely 
to find parameter estimates for mixtures of normal and of other densities [342].  Mixtures 
continue, however, to provide a rich source of material for statisticians and recent work 
includes the development of models for data consisting of both continuous and categorical 
variables [383, 384], the linking of mixture models with hidden Markov chain models and 
with artificial neural networks [385, 386], the use of influence-based diagnostics for normal 
mixtures [387, 388] and further consideration of the number of components problem 
[389]. 
In section 10.3.1 prognostic models for immediate 12 month remission and delayed 12 
month remission were developed.  Variables found to be significant for these models were 
similar to those included in the overall model for time to 12 month remission in Chapter 4.  
Given that the immediate and delayed models in section 10.3.1 were found to have fairly 
distinct significant variables it is unsurprising that the model in Chapter 4 did not validate 
well internally, especially at one year – modelling techniques need to take account of the 
different patient groups. 
Section 10.3.2 extended the work of section 10.3.1 by considering a mixture model for the 
time to 12 month remission outcome which considered the three patient groups 
independently, but together in one model.  There were very few covariates found to be 
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significant for this model however a different variable selection technique was employed 
than used in Chapter 4 and section 10.3.1.  Initial work suggests that mixture modelling 
may provide a reliable way of modelling the three distinct ‘types’ of remission – immediate, 
delayed and refractory, however, to date this is ongoing work due to the complexity of the 
modelling.  The next stage is to derive the likelihood inclusive of the chosen covariates.  
From this estimates of risk may be obtained. 
The tools required to derive a mixture model are complex and the literature on how to use 
mixture models is not always available.  However, as we have shown in this thesis, if 
distinct groups are known to be present in the data they should be modelled 
independently.  We have investigated two methods of doing this, one with mixture 
modelling methods and one without.  The advantage of the non-mixture method is that it is 
computationally fairly simple, however in the case of epilepsy, the refractory patient group 
cannot easily be identified – a cure model could be fitted to the model that did not achieve 
immediate remission, however this is a form of mixture modelling.  Therefore, mixture 
modelling techniques are required if prognostic models for time to 12 month remission 
from seizures is to be appropriately modelled. 
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Chapter 11: Conclusions and 
Further Work 
11.1 Introduction 
Predicting outcome in epilepsy is complex but necessary to inform patient counselling 
about prognosis and treatment choices.  This thesis has examined prognostic factors for 
patients with a first seizure, with newly diagnosed epilepsy, and with established epilepsy 
or frequent unremitting seizures despite optimum treatment.  It has been shown that very 
few prognostic models exist for epilepsy and within this thesis prognostic factors have been 
modelled for these patient groups for outcomes including seizure recurrence, seizure 
remission and treatment failure. 
Prognostic models for time to treatment failure and time to 12 months of remission, 
developed using The SANAD Trial (Chapter 4), have been published in Lancet Neurology, 
which is owned by The Lancet.  I am first author on this paper.  The work within the 
publication has been actively discussed at several epilepsy meetings and conferences. 
Patients with epilepsy are subject to driving restrictions if their risk of a seizure in the next 
12 months is in excess of 20%.  We have produced prognostic models from which we can 
estimate the length of time until the risk of a seizure is under this risk threshold for patients 
with a first ever seizure, and also for patients who withdraw treatment after a period of 
remission. 
The prognostic model for patients with a first seizure (Chapter 5) has been published in the 
British Medical Journal (BMJ) and I am first author.  In addition, the editors of the BMJ felt 
that the paper was sufficiently important to warrant an editorial, especially as it led the 
DVLA to change their guidelines for time off driving for patients with a first seizure. 
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The prognostic models for risk of recurrence after treatment withdrawal following a period 
of remission (Chapter 6) have been published in the Journal of Neurology, Neurosurgery 
and Psychiatry, which is owned by the BMJ.  Again, I am first author of the paper and the 
DVLA are currently considering changing their guidelines following this publication. 
Validation is an integral part of the modelling process and therefore internal validation 
methods have been applied to selected models in this thesis.  A search of the literature 
revealed that very few prognostic models are externally validated, possibly due to a lack of 
guidance on suitable methods, or possibly due to the lack of appropriate datasets on which 
to perform external validation.  A simulation study was therefore undertaken to assess 
methods of externally validating a prognostic model and also to assess methods for 
handling covariates missing from the validation dataset.  The investigated methods were 
also demonstrated in a motivating example.   
The prognostic model for time to 12 month remission for patients with newly diagnosed 
epilepsy was found to be internally valid via calibration plots at two and three years, but 
not at one year.  It is possible that this is because of the distinct patient groups present for 
the outcome – some patients achieved remission immediately at 365 days, some achieved 
remission at a later time point, and some did not achieve remission.  Mixture modelling 
techniques were thought to be appropriate for this scenario; they were therefore 
employed to attempt to develop a combined prognostic model which included all patient 
groups simultaneously, adjusted for covariates. 
11.2 Recommendations for Practice 
In this thesis strategies for model development and presentation, and strategies for model 
validation have been considered.  In addition, prognostic models for epilepsy have been 
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developed which were shown to be fairly well validated both internally and externally.  
They, consequently, may be recommended for practice.   
11.2.1 Model Development 
Many methods need to be considered when developing a prognostic model.  For example, 
variables should be centred to reduce multicollinearity and also to increase the relevance 
of the estimated regression coefficient [152].  Similarly, when model building, variable 
selection techniques such as AIC [163] must be carefully decided upon to balance the need 
for simplicity with a minimal loss of information.   When only one of several different types 
of event can occur, the probability of these events must be modelled via competing risk 
techniques such as cumulative incidence analysis [177] with covariate testing via Gray’s 
method [174]. 
When developing prognostic models, continuous covariates should not usually be 
dichotomised [390] and instead modelled via spline [254] or FP [144] transformations.  
Splines can be poorly behaved in the tails [141] and are very complex to write down [145].  
However, FPs offer increased flexibility over polynomial transformations while still 
preserving the simplicity of the final model [184].  FPs were first proposed by Royston and 
Sauerbrei in 1994 [144] and are consequently relatively new.  Therefore there may be 
elements to these methods which are not understood properly yet, especially with regard 
to treatment-covariate interactions.  Consequently, although we recommend that 
continuous covariates be modelled via FP transformations, some caution is still required 
when using them. 
11.2.2 Model Presentation 
Prognostic models are developed to inform patient counselling and treatment choices.  
Therefore they must be easy to interpret by clinicians and patients alike.  It is thus 
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inadvisable to present statistical models for clinical interpretation.  Instead, we recommend 
presenting forest-style plots for combinations of risk factors as shown in this thesis.  These 
can be used to illustrate the proportion of patients with the event of interest at various 
time points, for any combination of risk factors together with confidence intervals. 
11.2.3 Model Validation 
For a prognostic model to be implemented in general practice it needs to be validated.  
Internal validation assesses model validity for the setting where the development data 
originated from, and external validation assesses validity in other samples which are fully 
independent from the development data and originate from different but plausibly related 
settings [8].   
Methods of internal validation are readily available and include an assessment of model 
performance such as    [226] together with discrimination [248] and calibration [251, 252] 
methods.  They must be applied to each prognostic model developed. 
Literature on methods of external validation is lacking, as shown by our review.  However, 
in our simulation study we discovered that Harrell’s  -statistic [184], a measure of 
concordance, is a reliable method of highlighting agreement between the development and 
validation datasets when it exists.  The simulation study has also shown that a covariate 
missing from the validation dataset may be imputed via several adaptations of methods for 
handling missing data within a covariate.  The best performing methods were hot deck 
imputation and multiple imputation.  Therefore external validation should be implemented 
for each prognostic model developed, assuming there is a plausibly related dataset 
available.  If a suitable dataset is not available, attempts should be made to recruit a 
relevant cohort. 
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11.3 Recommendations for Research 
This thesis has highlighted areas where further research is recommended particularly with 
regards to model development and validation. 
11.3.1 Model Development 
Investigation of possible treatment-covariate interactions for the time to treatment failure 
model using the SANAD dataset suggested two such interactions - focal epilepsy site of 
onset with treatment, and total number of seizures ever before randomisation with 
treatment.  Although these terms could easily have been included in the multivariable 
model, interpretation of the results was difficult due to the 150 possible combinations of 
interaction terms.  Current literature for interpreting regression coefficients for multiple 
inter-linked interaction terms is lacking.  Further research into how to interpret hazard 
ratios and confidence intervals for large numbers of interaction terms is required. 
Mixture modelling techniques, enabling all patient groups to be combined in a single 
prognostic model, are becoming increasingly popular.   Our initial work suggests that 
mixture modelling may provide a way of modelling patients with immediate remission, 
delayed remission and refractory epilepsy together in one prognostic model.  However, due 
to the complexity of the modelling, further research is required particularly with regards to 
deriving the likelihood and obtaining risk estimates.  Additionally, further research is 
required into the estimation of standard errors for the group of refractory patients 
(Chapter 10) using the ‘gfcure’ package.  It is currently unknown why the errors are 
unestimable. 
Assuming a suitable mixture model for time to 12 month remission can be developed, it will 
be necessary to validate it both internally and externally.  Literature on how to validate a 
mixture model is currently lacking – a brief search revealed no articles that mentioned 
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validation of a mixture model.  Further research into internal and external validation 
methods of mixture models is required.  
11.3.2 Model Validation 
In our simulation study, which assessed methods of external validation and methods for 
handling covariates missing from the validation dataset, eight scenarios were considered in 
which the size of the validation dataset and the type of missing data were varied.  Clearly 
there are many other possible scenarios including varying the number and combination of 
covariates present and missing, the types of covariates present and missing, the size of the 
development and validation datasets, how closely the super-population assumption is 
adhered to, and the length of follow-up etc.    During the case study extension to the 
simulation study, length of follow-up of the NGPSE dataset was truncated to match the 
length of follow-up of the MESS study.  In this single case, truncating NGPSE did not affect 
the level of external validation.  This suggests that length of follow-up may not have an 
impact on the external validity of a model.  However, the conditional seizure risks were 
found to be much higher in the truncated dataset.  Further research is required to build 
upon the initial findings presented in this thesis and to investigate alternative scenarios. 
In the simulation study discrimination was investigated via Harrell’s  -statistic, calibration 
via deviance, and separation via Royston’s measure of prognostic separation.  However, 
alternative methods exist to investigate these areas such as calibration plots [391, 392], 
ROC curves [272] and the Hosmer-Lemeshow statistic [262].   These alternative methods 
need to be investigated to see if they show agreement between the validation and 
development datasets when it is known to be present.  If so, then a battery of tools for 
external validation could be produced.  However, interpretation of the methods of external 
validation is not always easy – the methods can give conflicting results and there are 
different degrees of agreement between the development and validation datasets rather 
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than clear cut “agreement” or “no agreement” conclusions.  This makes it difficult to draw 
firm conclusions. 
In theory, the dataset used to externally validate a prognostic model will be plausibly 
related to the development data.  Therefore both datasets will effectively be samples taken 
from the same super-population.  There are, however, no guidelines for choosing plausibly 
related datasets.  We proposed that plausibly related datasets should conform to the 
Cochrane guidelines for combining studies in a meta-analysis [214].  Namely, that a group 
of studies is sufficiently homogeneous in terms of participants, interventions and outcomes 
to provide a meaningful summary.  However, further simulation studies are required to 
determine if such guidelines are relevant and if extra conditions or amended conditions are 
required.    
11.4 Future Work 
Multivariable prognostic models for time to treatment failure and time to 12 month 
remission have been developed using the SANAD data [315].  In this thesis the models 
showed fairly good internal validity.  External validation has not been undertaken due to 
the lack of a plausibly related dataset.  The best match is a set of individual participant data 
collected by Tudur Smith et al [192].  This data is missing important covariates though and 
the treatments patients were randomised to do not always coincide with SANAD drugs.   
It is important that the SANAD models developed in this thesis are externally validated so 
that the models may be implemented in general practice.  One option would be to recruit a 
cohort of patients, with the same inclusion criteria as SANAD, and treated with 
carbamazepine, gabapentin, topirimate, oxcarbazepine and lamotrigine, as per SANAD.  
Baseline demographics, gender, treatment history, age, time from first seizure to 
randomisation, neurological insult, total number of seizures, EEG result, CT/MRI scan 
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result, seizure type, focal epilepsy site of onset and treatment, should then be obtained so 
that external validation methods can be employed.  This however, is a very costly and time-
consuming process.   
Another option would be to use the individual patient dataset [192] to validate the SANAD 
models.  Before this could happen however, methods for handling multiple missing 
covariates need to be found.  Additionally, methods for handling non matching treatments 
need to be found which may involve clinical methods such as matching drugs by indication 
or chemical structure, or statistical methods such as mixed treatment comparisons [192].  
Therefore, further research is required to develop methods for handling multiple missing 
covariates and also handling treatments that do not coincide with those used in the 
development dataset. 
The methods of external validation investigated in the simulation study were demonstrated 
in a case study which validated a model developed using MESS via NGPSE, WA and FIRST.  
The MESS model was shown to generalise well to the NGPSE and WA datasets and fairly 
well to the FIRST dataset.  Given that the model generalised fairly well to three alternative 
datasets it may be possible to use the combined information from the four studies to 
produce more precise conditional risk estimates in a similar fashion to a meta-analysis 
[214].   Given the heterogeneity between the datasets, a random-effects model is most 
likely to be appropriate if the meta-analysis style analysis is implemented  [214].   
This aim could be achieved by analysing all the data together in a Cox model stratified by 
dataset [167, 393].  Following on from modelling the combined data, more accurate, and 
potentially more representative, estimates of months from index seizure until annual 
seizure risk falls below 20% may be obtainable.  These estimates could be used to better 
inform driving regulations both within the United Kingdom and European Union about 
length of time before the risk of a seizure in the next 12 months falls below the 20% 
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threshold level for specific patient subgroups.  Further work is also needed to inform 
regulators as to whether a 20% threshold is optimum [202]. 
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Appendix A – Further Results from Chapter 5 
Table 53: The MESS Study: Risk of seizure recurrence at 12 months for patients with various combinations of risk factors -estimated from the multivariable regression model 
Variable  Immediate Treatment Delayed Treatment 
Aetiology 
First Degree 
Relative with 
Epilepsy 
Seizures Only 
While Asleep 
EEG Results 
CT/MRI Scan 
Results 
Months from 
index seizure 
Risk of seizure in next 
12 months (%, 95% CI) 
Months from 
index seizure 
until annual 
risk falls <20% 
Risk of seizure in next 
12 months (%, 95% CI) 
Months from 
index seizure 
until annual 
risk falls <20% 
Not remote 
symptomatic 
No No Normal Normal 
6 13 (10 to 16)* 
1.2 
16 (12 to 19)* 
3.2 
12 7 (5 to 10)* 9 (6 to 12)* 
Not remote 
symptomatic No No Normal Abnormal 
6 14 (11 to 17)* 
2.1 
17 (14 to 20) 
3.6 
12 8 (5 to 11)* 10 (7 to 12)* 
Not remote 
symptomatic No No Normal Not Done 
6 17 (13 to 20)  
3.5 
20 (17 to 23) 
5.7 
12 9 (7 to 12)* 11 (9 to 14)* 
Not remote 
symptomatic No No Abnormal Normal 
6 20 (16 to 23) 
5.5 
23 (20 to 26) 
7.0 
12 11 (9 to 14)* 13 (11 to 16)* 
Not remote 
symptomatic No No Abnormal Abnormal 
6 21 (18 to 24) 
6.1 
25 (22 to 28)† 
8.1 
12 12 (9 to 15)* 14 (12 to 17)* 
Not remote 
symptomatic No No Abnormal Not Done 
6 24 (22 to 27)† 
7.8 
29 (26 to 32)† 
10.0 
12 14 (12 to 17 * 17 (15 to 20) 
Not remote 
symptomatic No No Not Done Normal 
6 17 (13 to 20) 
3.5 
20 (17 to 23) 
5.7 
12 9 (7 to 12)* 11 (9 to 14)* 
Not remote 
symptomatic No No Not Done Abnormal 
6 18 (15 to 21) 
4.0 
21 (18 to 24) 
6.2 
12 10 (7 to 13)* 12 (10 to 15)* 
Not remote 
symptomatic No No Not Done Not Done 
6 21 (18 to 24) 
6.1 
25 (22 to 28)† 
8.1 
12 12 (9 to 15)* 14 (12 to 17)* 
Not remote 
symptomatic No Yes Normal Normal 
6 19 (15 to 22) 
4.8 
22 (19 to 25) 
6.8 
12 11 (8 to 13)* 13 (10 to 15)* 
Not remote 
symptomatic No Yes Normal Abnormal 
6 20 (19 to 23) 
5.7 
24 (21 to 27)† 
7.6 
12 11 (9 to 14)* 14 (11 to 16)* 
Not remote 
symptomatic No Yes Normal Not Done 
6 23 (20 to 26) 
7.0 
28 (25 to 30)† 
9.8 
12 14 (11 to 16)* 16 (14 to 19)* 
Not remote 
symptomatic No Yes Abnormal Normal 
6 27 (25 to 30)† 
9.2 
32 (30 to 35)† 
11.8 
12 16 (14 to 19)* 19 (17 to 22) 
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Not remote 
symptomatic No Yes Abnormal Abnormal 
6 29 (26 to 32)† 
10.0 
34 (32 to 37)† 
16.3 
12 17 (15 to 20) 21 (18 to 23) 
Not remote 
symptomatic No Yes Abnormal Not Done 
6 34 (31 to 36)† 
12.5 
39 (37 to 42)† 
24.4 
12 20 (18 to 23) 24 (22 to 26)† 
Not remote 
symptomatic No Yes Not Done Normal 
6 23 (20 to 26) 
7.0 
28 (25 to 30)† 
9.8 
12 14 (11 to 16)* 16 (14 to 19)* 
Not remote 
symptomatic No Yes Not Done Abnormal 
6 25 (22 to 28)† 
8.2 
29 (27 to 32)† 
10.5 
12 15 (12 to 17)* 17 (15 to 20) 
Not remote 
symptomatic No Yes Not Done Not Done 
6 29 (26 to 32)† 
10.0 
34 (32 to 37)† 
16.3 
12 17 (15 to 20) 20 (18 to 23) 
Not remote 
symptomatic Yes No Normal Normal 
6 17 (14 to 20) 
3.6 
20 (17 to 23) 
6.0 
12 10 (7 to 12)* 12 (9 to 14)* 
Not remote 
symptomatic Yes No Normal Abnormal 
6 18 (15 to 21) 
4.8 
22 (19 to 25) 
6.5 
12 10 (8 to 13)* 13 (10 to 15)* 
Not remote 
symptomatic Yes No Normal Not Done 
6 21 (18 to 24) 
6.3 
25 (23 to 28)† 
8.7 
12 12 (10 to 15)* 15 (12 to 17)* 
Not remote 
symptomatic Yes No Abnormal Normal 
6 25 (22 to 28)† 
8.7 
30 (27 to 32)† 
10.7 
12 15 (12 to 17)* 18 (15 to 20) 
Not remote 
symptomatic Yes No Abnormal Abnormal 
6 27 (24 to 30)† 
9.2 
32 (29 to 34)† 
11.3 
12 16 (13 to 18)* 19 (16 to 21) 
Not remote 
symptomatic Yes No Abnormal Not Done 
6 31 (29 to 34)† 
11.3 
37 (34 to 39)† 
23.6 
12 19 (16 to 21) 22 (20 to 24) 
Not remote 
symptomatic Yes No Not Done Normal 
6 21 (18 to 24) 
6.3 
25 (23 to 28)† 
8.7 
12 12 (10 to 15)* 15 (12 to 17)* 
Not remote 
symptomatic Yes No Not Done Abnormal 
6 23 (20 to 26) 
7.0 
27 (24 to 30)† 
9.2 
12 13 (11 to 16)* 16 (13 to 18)* 
Not remote 
symptomatic Yes No Not Done Not Done 
6 27 (24 to 30)† 
9.2 
32 (29 to 34)† 
11.3 
12 16 (13 to 18)* 19 (16 to 21) 
Not remote 
symptomatic Yes Yes Normal Normal 
6 24 (21 to 27)† 
7.7 
28 (26 to 31)† 
10.0 
12 14 (11 to 17)* 17 (14 to 19)* 
Not remote 
symptomatic Yes Yes Normal Abnormal 
6 26 (23 to 28)† 
8.8 
30 (28 to 33)† 
10.8 
12 15 (12 to 17)* 18 (15 to 20) 
Not remote 
symptomatic Yes Yes Normal Not Done 
6 30 (27 to 33)† 
10.7 
35 (33 to 38)† 
23.4 
12 18 (15 to 20) 21 (19 to 23) 
Not remote 
symptomatic Yes Yes Abnormal Normal 
6 35 (32 to 37)† 
16.3 
40 (38 to 43)† 
24.6 
12 21 (18 to 23) 25 (22 to 27)† 
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Not remote 
symptomatic Yes Yes Abnormal Abnormal 
6 37 (34 to 39)† 
23.6 
43 (41 to 45)† 
25.1 
12 22 (20 to 25) 26 (24 to 29)† 
Not remote 
symptomatic Yes Yes Abnormal Not Done 
6 42 (40 to 45)† 
25.1 
49 (47 to 51)† 
27.0 
12 26 (24 to 28)† 31 (29 to 33)† 
Not remote 
symptomatic Yes Yes Not Done Normal 
6 30 (27 to 32)† 
10.7 
35 (33 to 37)† 
23.4 
12 18 (15 to 20) 21 (19 to 23) 
Not remote 
symptomatic Yes Yes Not Done Abnormal 
6 32 (29 to 34)† 
11.3 
37 (35 to 40)† 
24.1 
12 19 (16 to 21) 22 (20 to 25) 
Not remote 
symptomatic Yes Yes Not Done Not Done 
6 37 (34 to 39)† 
23.6 
43 (41 to 45)† 
25.1 
12 22 (20 to 25) 26 (24 to 29)† 
Remote symptomatic No No Normal Normal 
6 17 (14 to 20) 
3.6 
20 (17 to 23) 
6.0 
12 10 (7 to 12)* 12 (9 to 14)* 
Remote symptomatic 
No No Normal Abnormal 
6 18 (15 to 21) 
4.8 
22 (19 to 25) 
6.5 
12 10 (8 to 13)* 13 (10 to 15)* 
Remote symptomatic 
No No Normal Not Done 
6 21 (18 to 24) 
6.3 
25 (23 to 28)† 
8.7 
12 12 (10 to 15)* 15 (12 to 17)* 
Remote symptomatic 
No No Abnormal Normal 
6 25 (22 to 28)† 
8.7 
30 (27 to 32)† 
10.7 
12 15 (12 to 17)* 18 (15 to 20) 
Remote symptomatic 
No No Abnormal Abnormal 
6 27 (24 to 40)† 
9.2 
32 (29 to 34)† 
11.3 
12 16 (13 to 18)* 19 (16 to 21) 
Remote symptomatic 
No No Abnormal Not Done 
6 31 (29 to 34)† 
11.3 
37 (34 to 39)† 
23.6 
12 19 (16 to 21) 22 (20 to 24) 
Remote symptomatic 
No No Not Done Normal 
6 21 (18 to 24) 
6.3 
25 (23 to 28)† 
8.7 
12 12 (10 to 15)* 15 (12 to 17)* 
Remote symptomatic 
No No Not Done Abnormal 
6 23 (20 to 26) 
7.0 
27 (24 to 30)† 
9.2 
12 13 (11 to 16)* 16 (13 to 18)* 
Remote symptomatic 
No No Not Done Not Done 
6 27 (24 to 30)† 
9.2 
32 (29 to 34)† 
11.3 
12 16 (13 to 18)* 19 (16 to 21) 
Remote symptomatic 
No Yes Normal Normal 
6 24 (21 to 27)† 
7.7 
28 (26 to 31)† 
10.0 
12 14 (11 to 17)* 17 (14 to 19)* 
Remote symptomatic 
No Yes Normal Abnormal 
6 26 (23 to 28)† 
8.8 
30 (28 to 33)† 
10.8 
12 15 (12 to 17)* 18 (15 to 20) 
Remote symptomatic 
No Yes Normal Not Done 
6 30 (27 to 33)† 
10.7 
35 (33 to 38)† 
23.4 
12 18 (15 to 20) 21 (19 to 23) 
Remote symptomatic 
No Yes Abnormal Normal 
6 35 (32 to 37)† 
16.3 
40 (38 to 43)† 
24.6 
12 21 (18 to 23) 25 (22 to 27)† 
  
  
 
3
4
8
 
Remote symptomatic 
No Yes Abnormal Abnormal 
6 37 (34 to 39)† 
23.6 
43 (41 to 45)† 
25.1 
12 22 (20 to 25) 26 (24 to 29)† 
Remote symptomatic 
No Yes Abnormal Not Done 
6 42 (40 to 45)† 
25.1 
49 (47 to 51)† 
27.0 
12 26 (24 to 28)† 31 (29 to 33)† 
Remote symptomatic 
No Yes Not Done Normal 
6 30 (27 to 32)† 
11.7 
35 (33 to 37)† 
23.4 
12 18 (15 to 20) 21 (19 to 23) 
Remote symptomatic 
No Yes Not Done Abnormal 
6 32 (29 to 34)† 
11.3 
37 (35 to 40)† 
24.1 
12 19 (16 to 21) 22 (20 to 25) 
Remote symptomatic 
No Yes Not Done Not Done 
6 37 (34 to 39)† 
23.6 
43 (41 to 45)† 
25.1 
12 22 (20 to 25) 26 (24 to 29)† 
Remote symptomatic 
Yes No Normal Normal 
6 22 (19 to 25) 
6.7 
26 (23 to 29)† 
8.8 
12 13 (10 to 15)* 15 (13 to 18)* 
Remote symptomatic 
Yes No Normal Abnormal 
6 24 (21 to 26)† 
7.6 
28 (25 to 31)† 
9.8 
12 14 (11 to 16)* 16 (14 to 19)* 
Remote symptomatic 
Yes No Normal Not Done 
6 27 (25 to 30)† 
9.8 
32 (30 to 35)† 
12.0 
12 16 (14 to 19) * 19 (17 to 22) 
Remote symptomatic 
Yes No Abnormal Normal 
6 32 (29 to 35)† 
11.8 
37 (35 to 40)† 
24.1 
12 19 (17 to 21) 23 (20 to 25) 
Remote symptomatic 
Yes No Abnormal Abnormal 
6 34 (32 to 37)† 
16.3 
40 (37 to 42)† 
24.6 
12 20 (18 to 23) 24 (22 to 27)† 
Remote symptomatic 
Yes No Abnormal Not Done 
6 39 (37 to 42)† 
24.4 
46 (43 to 48)† 
25.6 
12 24 (22 to 26)† 28 (26 to 30)† 
Remote symptomatic 
Yes No Not Done Normal 
6 27 (25 to 30)† 
9.8 
32 (30 to 35)† 
12.0 
12 16 (14 to 19)* 19 (17 to 22) 
Remote symptomatic 
Yes No Not Done Abnormal 
6 29 (27 to 32)† 
10.0 
34 (32 to 37)† 
16.3 
12 17 (15 to 20) 21 (18 to 23) 
Remote symptomatic 
Yes No Not Done Not Done 
6 34 (31 to 37)† 
16.3 
40 (37 to 42)† 
24.4 
12 20 (18 to 23) 24 (22 to 26)† 
Remote symptomatic 
Yes Yes Normal Normal 
6 31 (28 to 33)† 
10.8 
36 (33 to 38)† 
23.5 
12 18 (16 to 21) 22 (19 to 24) 
Remote symptomatic 
Yes Yes Normal Abnormal 
6 33 (30 to 35)† 
12.0 
38 (36 to 40)† 
24.2 
12 19 (17 to 22) 23 (21 to 25)† 
Remote symptomatic 
Yes Yes Normal Not Done 
6 38 (35 to 40)† 
24.2 
44 (42 to 46)† 
25.5 
12 23 (21 to 25)† 27 (25 to 29)† 
Remote symptomatic 
Yes Yes Abnormal Normal 
6 43 (41 to 45)† 
25.5 
50 (48 to 52)† 
27.0 
12 27 (25 to 29)† 32 (30 to 34)† 
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Remote symptomatic 
Yes Yes Abnormal Abnormal 
6 46 (44 to 48)† 
25.6 
52 (51 to 54)† 
28.8 
12 29 (26 to 31)† 34 (32 to 35)† 
Remote symptomatic 
Yes Yes Abnormal Not Done 
6 52 (50 to 54)† 
27.0 
59 (57 to 61)† 
55.6 
12 33 (31 to 35)† 39 (37 to 41)† 
Remote symptomatic 
Yes Yes Not Done Normal 
6 38 (35 to 40)† 
24.2 
44 (42 to 46)† 
25.5 
12 23 (21 to 25)† 27 (25 to 29)† 
Remote symptomatic 
Yes Yes Not Done Abnormal 
6 40 (38 to 42)† 
24.6 
46 (44 to 48)† 
25.7 
12 24 (22 to 27)† 29 (27 to 31)† 
Remote symptomatic 
Yes Yes Not Done Not Done 
6 46 (44 to 48)† 
25.6 
52 (51 to 54)† 
28.8 
12 28 (26 to 31)† 33 (31 to 35)† 
 
*Confidence interval lies completely below 20%. †Confidence interval lies completely above 20%. 
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Appendix B – Search Strategy used 
in Chapter 6 
MEDLINE (Ovid) search strategy: 
1. randomized controlled trial.pt. 
2. controlled clinical trial.pt. 
3. (randomized or randomised).ab. 
4. placebo.ab. 
5. clinical trials as topic.sh. 
6. randomly.ab. 
7. trial.ti. 
8. epidemiologic studies/ or case-control studies/ or cohort studies/ or longitudinal studies/ 
or follow-up studies/ or prospective studies/ 
9. (case control or case-control).tw. 
10. (cohort adj (study or studies)).tw. 
11. cohort analy$.tw. 
12. (("follow up" or "follow-up") adj (study or studies)).tw. 
13. (observational adj (study or studies)).tw. 
14. (longitudinal adj (study or studies)).tw. 
15. or/1-14 
16. (epilep$ or convulsion$ or seizure$).ti,ab. 
17. exp Epilepsy/ 
18. exp Seizures/ 
19. convulsive disorder.tw. 
20. or/16-19 
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21. 15 and 20 
22. exp animals/ not humans.sh. 
23. 21 not 22 
24. withdraw$.ti,ab. 
25. alcohol withdrawal.tw. 
26. alcohol dependence.tw. 
27. 25 or 26 
28. 24 not 27 
29. 23 and 28 
30. limit 29 to english language 
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Appendix C – Further Results from Chapter 8 
Numerical results for the simulation study.  Values used as part of the multivariable normal distribution can be seen in section C.1 while numbers of failed 
simulations can be seen in section C.2.  Results of the three measures of external validation can be seen in sections C.3 to C.5.  Coefficient values are 
shown in section C.6 and measures of bias, mean square error and coverage can be seen in section C.7. 
C.1 Multivariate Normal Distribution 
Values obtained from SANAD data. 
C.1.1 Means 
Binary Continuous Categorical 
0.55 38.30 1.21 
C.1.2 Covariance Matrix 
 Binary Continuous Categorical 
Binary 0.25 -0.15 0.01 
Continuous -0.15 336.36 -0.26 
Categorical 0.01 -0.26 0.35 
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C.2 Number of failed simulations 
Scenario 
Imputation Method 
(1) – Variable Matching (2) – Random Selection with Replacement (3) – Imputation via Estimation (4) – Hot Deck (5) – Multiple Imputation 
1a & 1b 0 
1a & 1c 0 0 0 0 0 
2a & 2b 0 0 0 0 0 
3a & 3b 0 0 0 0 0 
4a & 4b 0 
4a & 4c 0 0 0 0 0 
5a & 5b 0 0 0 0 0 
6a & 6b 0 0 0 0 0 
C.3 Concordance Statistic 
C.3.1 No missing data 
Scenario Development Concordance Validation Concordance Mean difference % p-values ≤ 0.05 % p-values ≤ 0.10 
1a & 1b 0.56 0.56 0.00 99.8 100 
4a & 4b 0.56 0.56 0.00 99.9 100 
C.3.2 Variable Matching 
Scenario Development Deviance Validation Deviance Mean difference % p-values ≤ 0.05 % p-values ≤ 0.10 
1a & 1c 0.54 0.54 0.01 97.1 100 
2a & 2b 0.55 0.55 0.00 99.9 100 
3a & 3b 0.55 0.55 0.00 99.9 100 
4a & 4c 0.54 0.54 0.00 99.2 100 
5a & 5b 0.55 0.55 0.00 100 100 
6a & 6b 0.55 0.55 0.00 100 100 
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C.3.3 Random Selection with Replacement 
Scenario Development Deviance Validation Deviance Mean difference % p-values ≤ 0.05 % p-values ≤ 0.10 
1a & 1c 0.56 0.56 0.00 99.8 100 
2a & 2b 0.56 0.56 0.00 99.8 100 
3a & 3b 0.56 0.56 0.00 99.6 100 
4a & 4c 0.56 0.56 0.00 100 100 
5a & 5b 0.56 0.56 0.00 99.9 100 
6a & 6b 0.56 0.56 0.00 100 100 
C.3.4 Single Imputation via Estimation 
Scenario Development Deviance Validation Deviance Mean difference % p-values ≤ 0.05 % p-values ≤ 0.10 
1a & 1c 0.56 0.56 0.00 99.8 100 
2a & 2b 0.56 0.56 0.00 99.6 100 
3a & 3b 0.56 0.56 0.00 99.4 100 
4a & 4c 0.56 0.56 0.00 99.9 100 
5a & 5b 0.56 0.56 0.00 99.9 100 
6a & 6b 0.56 0.56 0.00 100 100 
C.3.5 Hot Deck Imputation 
Scenario Development Deviance Validation Deviance Mean difference % p-values ≤ 0.05 % p-values ≤ 0.10 
1a & 1c 0.56 0.56 0.00 99.6 100 
2a & 2b 0.56 0.56 0.00 99.7 100 
3a & 3b 0.56 0.56 0.00 99.6 100 
4a & 4c 0.56 0.56 0.00 99.8 100 
5a & 5b 0.56 0.56 0.00 100 100 
6a & 6b 0.56 0.56 0.00 100 100 
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C.3.6 Random Selection with Replacement Multiple Times 
Scenario Development Deviance Validation Deviance Mean difference % p-values ≤ 0.05 % p-values ≤ 0.10 
1a & 1c 0.56 0.56 0.00 100 100 
2a & 2b 0.56 0.56 0.00 100 100 
3a & 3b 0.56 0.56 0.00 100 100 
4a & 4c 0.56 0.56 0.00 100 100 
5a & 5b 0.56 0.56 0.00 100 100 
6a & 6b 0.56 0.56 0.00 100 100 
C.4 Deviance Statistic 
Mean differences are mean differences in deviance statistics between the development and validation statistics over 1400 simulations.  The p-value is the 
mean p-value for the chi-squared test of difference in deviances between the development and validation data.  
C.4.1 No missing data 
Scenario Development Deviance Validation Deviance Mean difference 
p-value for 
difference 
% p-values ≤ 0.05 % p-values ≤ 0.10 
1a & 1b 45.63 28.12 -17.51 0.11 73.9 78.6 
4a & 4b 46.50 52.14 5.64 0.17 61.1 68.8 
C.4.2 Variable Matching 
Scenario Development Deviance Validation Deviance Mean difference 
p-value for 
difference 
% p-values ≤ 0.05 % p-values ≤ 0.10 
1a & 1c 15.19 4.72 -10.46 0.20 52.1 61.6 
2a & 2b 37.74 22.59 -15.16 0.14 68.4 73.6 
3a & 3b 37.56 22.51 -15.06 0.12 70.6 75.5 
4a & 4c 15.30 7.30 -8.00 0.24 43.2 51.2 
5a & 5b 37.42 42.96 5.54 0.18 58.6 65.4 
6a & 6b 38.07 42.61 4.54 0.17 60.3 68.0 
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C.4.3 Random Selection with Replacement 
Scenario Development Deviance Validation Deviance Mean difference 
p-value for 
difference 
% p-values ≤ 0.05 % p-values ≤ 0.10 
1a & 1c 45.74 27.93 -17.81 0.11 74.1 79.0 
2a & 2b 45.71 27.51 -18.20 0.11 74.7 79.1 
3a & 3b 45.67 27.99 -17.68 0.12 73.4 78.5 
4a & 4c 45.62 52.63 7.02 0.16 64.4 70.1 
5a & 5b 45.45 51.88 6.44 0.16 64.8 70.6 
6a & 6b 46.10 52.83 6.74 0.14 66.5 72.4 
C.4.4 Single Imputation via Estimation 
Scenario Development Deviance Validation Deviance Mean difference 
p-value for 
difference 
% p-values ≤ 0.05 % p-values ≤ 0.10 
1a & 1c 45.74 27.74 -18.00 0.11 74.3 79.2 
2a & 2b 45.71 27.70 -18.01 0.11 73.7 78.4 
3a & 3b 45.67 28.15 -17.52 0.11 73.9 78.9 
4a & 4c 45.62 52.69 7.07 0.16 62.4 68.4 
5a & 5b 45.45 51.58 6.13 0.15 64.4 71.3 
6a & 6b 46.10 52.75 6.65 0.15 65.9 72.1 
C.4.5 Hot Deck Imputation 
Scenario Development Deviance Validation Deviance Mean difference 
p-value for 
difference 
% p-values ≤ 0.05 % p-values ≤ 0.10 
1a & 1c 45.74 28.23 -17.52 0.12 73.2 77.9 
2a & 2b 45.71 27.63 -18.08 0.11 72.9 78.1 
3a & 3b 45.64 27.98 -17.69 0.11 75.1 79.1 
4a & 4c 45.62 52.18 6.57 0.16 65.0 69.8 
5a & 5b 45.45 51.69 6.24 0.15 63.1 69.8 
6a & 6b 46.10 52.95 6.85 0.15 64.9 70.5 
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C.4.6 Random Selection with Replacement Multiple Times 
Scenario Development Deviance Validation Deviance Mean difference 
p-value for 
difference 
% p-values ≤ 0.05 % p-values ≤ 0.10 
1a & 1c 45.71 27.93 -17.78 0.11 13.4 45.9 
2a & 2b 45.63 27.54 -18.08 0.11 13.6 47.1 
3a & 3b 45.60 28.15 -17.45 0.11 12.1 44.9 
4a & 4c 45.59 52.24 6.64 0.16 2.3 18.9 
5a & 5b 45.63 51.75 6.12 0.16 3.0 17.7 
6a & 6b 45.71 52.82 7.11 0.15 2.8 18.4 
C.5 Prognostic Separation 
  values are the mean prognostic separation values over 1400 simulations.     represents the change in prognostic separation values. 
C.5.1 No missing data 
Scenario              
%     
(-0.05, 0.05) 
%    
(-0.10, 0.10) 
1a & 1b 0.36 0.37 0.01 41.6 72.6 
4a & 4b 0.36 0.36 0.00 49.5 80.4 
 
C.5.2 Variable Matching 
Scenario              
%     
(-0.05, 0.05) 
%    
(-0.10, 0.10) 
1a & 1c 0.21 0.24 0.03 30.4 57.4 
2a & 2b 0.39 0.39 0.00 34.4 63.5 
3a & 3b 0.31 0.31 0.00 43.6 72.9 
4a & 4c 0.21 0.21 0.00 38.8 68.8 
5a & 5b 0.39 0.39 0.00 41.7 72.6 
6a & 6b 0.31 0.31 0.00 48.7 81.3 
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C.5.3 Random Selection with Replacement 
              
%     
(-0.05, 0.05) 
%    
(-0.10, 0.10) 
1a & 1c 0.36 0.37 0.01 41.7 73.3 
2a & 2b 0.36 0.37 0.01 40.6 73.2 
3a & 3b 0.36 0.37 0.01 41.5 72.4 
4a & 4c 0.36 0.36 0.00 48.5 80.8 
5a & 5b 0.36 0.36 0.00 50.1 82.8 
6a & 6b 0.36 0.36 0.00 47.9 80.6 
C.5.4 Single Imputation via Estimation 
              
%     
(-0.05, 0.05) 
%    
(-0.10, 0.10) 
1a & 1c 0.36 0.37 0.01 42.9 73.7 
2a & 2b 0.36 0.37 0.01 40.0 72.4 
3a & 3b 0.36 0.37 0.01 42.6 73.1 
4a & 4c 0.36 0.36 0.00 49.7 80.5 
5a & 5b 0.36 0.36 0.00 50.6 81.7 
6a & 6b 0.36 0.36 0.00 47.7 81.3 
C.5.5 Hot Deck Imputation 
              
%     
(-0.05, 0.05) 
%    
(-0.10, 0.10) 
1a & 1c 0.36 0.37 0.01 40.2 72.1 
2a & 2b 0.36 0.37 0.01 41.1 72.3 
3a & 3b 0.36 0.37 0.01 43.2 72.1 
4a & 4c 0.36 0.36 0.00 48.9 80.7 
5a & 5b 0.36 0.36 0.00 49.6 82.0 
6a & 6b 0.36 0.36 0.00 48.0 81.8 
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C.5.6 Random Selection with Replacement Multiple Times 
Scenario              
%     
(-0.05, 0.05) 
%    
(-0.10, 0.10) 
1a & 1c 0.36 0.37 0.01 98.1 100 
2a & 2b 0.36 0.37 0.01 98.2 100 
3a & 3b 0.36 0.37 0.01 97.1 100 
4a & 4c 0.36 0.36 0.00 99.8 100 
5a & 5b 0.36 0.36 0.00 99.5 100 
6a & 6b 0.36 0.36 0.00 99.8 100 
C.6 Coefficient Values 
The values presented are the mean values over 1400 simulations 
C.6.1 No missing data 
Scenario 
Development Validation 
Binary Continuous 
Categorical 
(Dummy 1) 
Categorical 
(Dummy 2) 
Binary Continuous 
Categorical 
(Dummy 1) 
Categorical 
(Dummy 2) 
                                                                                
1a & 1b -0.19 0.07 -0.18 0.07 -0.52 0.13 -0.50 0.15 -0.19 0.09 -0.18 0.09 -0.53 0.17 -0.51 0.21 
4a & 4b -0.20 0.07 -0.19 0.07 -0.52 0.13 -0.51 0.16 -0.19 0.07 -0.18 0.06 -0.52 0.12 -0.50 0.14 
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C.6.2 Variable Matching 
Scenario 
Development Validation 
Binary Continuous 
Categorical 
(Dummy 1) 
Categorical 
(Dummy 2) 
Binary Continuous 
Categorical 
(Dummy 1) 
Categorical 
(Dummy 2) 
                                                                                
1a & 1c -0.18 0.07 -0.18 0.07 NA -0.20 0.16 -0.15 0.15 NA 
2a & 2b -0.19 0.07 NA -0.52 0.13 -0.50 0.15 -0.19 0.09 NA -0.52 0.17 -0.51 0.21 
3a & 3b NA -0.18 0.07 -0.52 0.13 -0.49 0.15 NA -0.18 0.09 -0.52 0.17 -0.49 0.21 
4a & 4c -0.18 0.07 -0.18 0.07 NA -0.20 0.11 -0.15 0.11 NA 
5a & 5b -0.19 0.07 NA -0.52 0.13 -0.50 0.15 -0.19 0.07 NA -0.52 0.12 -0.50 0.14 
6a & 6b NA -0.18 0.07 -0.52 0.13 -0.50 0.15 NA -0.18 0.06 -0.51 0.12 -0.49 0.14 
C.6.3 Random Selection with Replacement 
Scenario 
Development Validation 
Binary Continuous 
Categorical 
(Dummy 1) 
Categorical 
(Dummy 2) 
Binary Continuous 
Categorical 
(Dummy 1) 
Categorical 
(Dummy 2) 
                                                                                
1a & 1c -0.19 0.07 -0.18 0.07 -0.52 0.13 -0.50 0.15 -0.19 0.09 -0.19 0.09 -0.53 0.17 -0.51 0.21 
2a & 2b -0.19 0.07 -0.18 0.07 -0.52 0.13 -0.50 0.15 -0.19 0.09 -0.18 0.09 -0.52 0.17 -0.50 0.21 
3a & 3b -0.19 0.07 -0.18 0.07 -0.52 0.13 -0.50 0.15 -0.19 0.09 -0.18 0.09 -0.52 0.17 -0.50 0.21 
4a & 4c -0.19 0.07 -0.18 0.07 -0.52 0.13 -0.50 0.15 -0.19 0.07 -0.19 0.06 -0.52 0.12 -0.50 0.14 
5a & 5b -0.19 0.07 -0.19 0.07 -0.52 0.13 -0.50 0.15 -0.19 0.07 -0.19 0.06 -0.52 0.12 -0.50 0.14 
6a & 6b -0.19 0.07 -0.19 0.07 -0.52 0.13 -0.51 0.15 -0.19 0.07 -0.18 0.06 -0.52 0.12 -0.50 0.14 
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C.6.4 Single Imputation via Estimation 
Scenario 
Development Validation 
Binary Continuous 
Categorical 
(Dummy 1) 
Categorical 
(Dummy 2) 
Binary Continuous 
Categorical 
(Dummy 1) 
Categorical 
(Dummy 2) 
                                                                                
1a & 1c -0.19 0.07 -0.18 0.07 -0.52 0.13 -0.50 0.15 -0.19 0.09 -0.18 0.09 -0.52 0.17 -0.51 0.21 
2a & 2b -0.19 0.07 -0.18 0.07 -0.52 0.13 -0.50 0.15 -0.19 0.09 -0.19 0.09 -0.52 0.17 -0.51 0.21 
3a & 3b -0.19 0.07 -0.18 0.07 -0.52 0.13 -0.50 0.15 -0.19 0.09 -0.18 0.09 -0.52 0.17 -0.50 0.21 
4a & 4c -0.19 0.07 -0.18 0.07 -0.52 0.13 -0.50 0.15 -0.19 0.07 -0.19 0.06 -0.53 0.12 -0.50 0.14 
5a & 5b -0.19 0.07 -0.19 0.07 -0.52 0.13 -0.50 0.15 -0.19 0.07 -0.18 0.07 -0.52 0.12 -0.50 0.14 
6a & 6b -0.19 0.07 -0.19 0.07 -0.52 0.13 -0.51 0.15 -0.19 0.07 -0.18 0.06 -0.52 0.12 -0.50 0.14 
C.6.5 Hot Deck Imputation 
Scenario 
Development Validation 
Binary Continuous 
Categorical 
(Dummy 1) 
Categorical 
(Dummy 2) 
Binary Continuous 
Categorical 
(Dummy 1) 
Categorical 
(Dummy 2) 
                                                                                
1a & 1c -0.19 0.07 -0.18 0.07 -0.52 0.13 -0.50 0.15 -0.19 0.09 -0.19 0.09 -0.53 0.17 -0.51 0.21 
2a & 2b -0.19 0.07 -0.18 0.07 -0.52 0.13 -0.50 0.15 -0.19 0.09 -0.19 0.09 -0.52 0.17 -0.50 0.21 
3a & 3b -0.19 0.07 -0.18 0.07 -0.52 0.13 -0.50 0.15 -0.19 0.09 -0.18 0.09 -0.52 0.17 -0.50 0.21 
4a & 4c -0.19 0.07 -0.18 0.07 -0.52 0.13 -0.50 0.15 -0.19 0.07 -0.19 0.06 -0.52 0.12 -0.50 0.15 
5a & 5b -0.19 0.07 -0.19 0.07 -0.52 0.13 -0.50 0.15 -0.19 0.07 -0.18 0.07 -0.52 0.12 -0.50 0.14 
6a & 6b -0.19 0.07 -0.19 0.07 -0.52 0.13 -0.51 0.15 -0.19 0.07 -0.18 0.06 -0.52 0.12 -0.50 0.14 
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C.6.6 Random Selection with Replacement Multiple Times 
Scenario 
Development Validation 
Binary Continuous 
Categorical 
(Dummy 1) 
Categorical 
(Dummy 2) 
Binary Continuous 
Categorical 
(Dummy 1) 
Categorical 
(Dummy 2) 
                                                                                
1a & 1c -0.19 0.07 -0.18 0.07 -0.52 0.13 -0.50 0.15 -0.19 0.09 -0.18 0.09 -0.53 0.17 -0.50 0.21 
2a & 2b -0.19 0.07 -0.18 0.07 -0.52 0.13 -0.50 0.15 -0.19 0.09 -0.18 0.09 -0.53 0.17 -0.50 0.21 
3a & 3b -0.19 0.07 -0.18 0.07 -0.52 0.13 -0.50 0.15 -0.19 0.09 -0.18 0.09 -0.53 0.17 -0.50 0.21 
4a & 4c -0.19 0.07 -0.18 0.07 -0.52 0.13 -0.50 0.15 -0.19 0.07 -0.18 0.06 -0.53 0.12 -0.50 0.14 
5a & 5b -0.19 0.07 -0.18 0.07 -0.52 0.13 -0.50 0.15 -0.19 0.07 -0.18 0.06 -0.53 0.12 -0.50 0.14 
6a & 6b -0.19 0.07 -0.18 0.07 -0.52 0.13 -0.50 0.15 -0.19 0.07 -0.18 0.06 -0.52 0.12 -0.50 0.14 
C.7 Accuracy 
C.7.1 No missing data 
Scenario 
Binary Continuous 
Categorical 
(Dummy 1) 
Categorical 
(Dummy 2) 
Bias 
(%) 
MSE 
Coverage 
(%) 
Bias 
(%) 
MSE 
Coverage 
(%) 
Bias 
(%) 
MSE 
Coverage 
(%) 
Bias 
(%) 
MSE 
Coverage 
(%) 
1a & 1b -0.89 0.00 86.2 -5.62 0.00 88.7 -8.24 0.01 88.2 -14.13 0.01 88.3 
4a & 4b 6.24 0.01 80.8 3.08 0.01 80.1 -1.59 0.02 81.8 -2.42 0.03 83.4 
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C.7.2 Variable Matching  
Scenario 
Binary Continuous 
Categorical 
(Dummy 1) 
Categorical 
(Dummy 2) 
Bias 
(%) 
MSE 
Coverage 
(%) 
Bias 
(%) 
MSE 
Coverage 
(%) 
Bias 
(%) 
MSE 
Coverage 
(%) 
Bias 
(%) 
MSE 
Coverage 
(%) 
1a & 1c -30.30 -0.02 91.6 68.91 0.04 92.1 NA 
2a & 2b -2.36 0.00 88.1 NA -3.68 0.02 88.5 -7.50 0.02 88.5 
3a & 3b NA -1.40 0.00 89.8 -2.71 0.02 89.6 -2.00 0.03 87.8 
4a & 4c -33.85 -0.02 89.5 58.59 0.04 88.4 NA 
5a & 5b -0.88 0.00 81.7 NA -6.24 0.01 81.9 -5.89 0.02 82.6 
6a & 6b NA 6.77 0.01 82.3 -0.92 0.02 82.8 -0.83 0.03 83.6 
C.7.3 Random Selection with Replacement  
Scenario 
Binary Continuous 
Categorical 
(Dummy 1) 
Categorical 
(Dummy 2) 
Bias 
(%) 
MSE 
Coverage 
(%) 
Bias 
(%) 
MSE 
Coverage 
(%) 
Bias 
(%) 
MSE 
Coverage 
(%) 
Bias 
(%) 
MSE 
Coverage 
(%) 
1a & 1c 2.05 0.01 86.1 -4.92 0.00 88.9 -7.72 0.01 89.7 -10.24 0.02 88.9 
2a & 2b -3.95 0.00 88.2 -0.23 0.00 87.4 -3.05 0.02 87.9 -7.32 0.02 88.4 
3a & 3b 1.10 0.01 89.0 -1.67 0.00 89.8 -3.07 0.02 89.5 -2.79 0.03 87.8 
4a & 4c 0.14 0.01 82.4 -0.85 0.00 81.9 -6.31 0.01 81.6 -7.09 0.02 80.1 
5a & 5b -1.41 0.00 82.0 1.11 0.00 82.3 -5.95 0.01 80.9 -5.82 0.02 82.4 
6a & 6b -6.91 0.00 80.9 7.07 0.01 83.0 -0.39 0.02 83.4 -0.15 0.03 83.9 
 
  
  
 
3
6
5 
C.7.4 Single Imputation via Estimation  
Scenario 
Binary Continuous 
Categorical 
(Dummy 1) 
Categorical 
(Dummy 2) 
Bias 
(%) 
MSE 
Coverage 
(%) 
Bias 
(%) 
MSE 
Coverage 
(%) 
Bias 
(%) 
MSE 
Coverage 
(%) 
Bias 
(%) 
MSE 
Coverage 
(%) 
1a & 1c -0.41 0.00 86.9 -3.62 0.00 89.2 -2.35 0.02 88.1 -7.18 0.02 87.1 
2a & 2b -2.25 0.00 88.2 -8.09 0.00 88.7 -3.49 0.02 87.6 -8.00 0.02 87.9 
3a & 3b -5.15 0.00 88.4 -1.70 0.00 89.5 -2.23 0.02 89.3 -3.68 0.03 87.4 
4a & 4c 0.05 0.01 82.6 -1.03 0.00 82.9 -8.31 0.01 81.1 -6.18 0.02 83.4 
5a & 5b -1.32 0.00 81.5 3.58 0.01 83.1 -6.28 0.01 81.4 -5.14 0.02 83.1 
6a & 6b -3.10 0.00 81.2 7.67 0.01 82.6 -1.29 0.02 83.2 -0.93 0.03 83.4 
C.7.5 Hot Deck Imputation  
Scenario 
Binary Continuous 
Categorical 
(Dummy 1) 
Categorical 
(Dummy 2) 
Bias 
(%) 
MSE 
Coverage 
(%) 
Bias 
(%) 
MSE 
Coverage 
(%) 
Bias 
(%) 
MSE 
Coverage 
(%) 
Bias 
(%) 
MSE 
Coverage 
(%) 
1a & 1c -0.23 0.00 87.0 -5.83 0.00 89.4 -10.75 0.01 87.4 -8.79 0.02 87.9 
2a & 2b -2.93 0.00 87.3 -6.90 0.00 89.2 -4.04 0.02 88.1 -7.56 0.02 88.5 
3a & 3b -1.65 0.00 88.2 -1.00 0.00 90.1 -2.24 0.02 89.6 -2.43 0.03 87.9 
4a & 4c -0.49 0.00 81.9 -0.24 0.00 81.8 -4.17 0.02 81.3 -4.44 0.02 81.6 
5a & 5b -1.70 0.00 82.0 3.10 0.01 83.1 -6.55 0.01 81.9 -5.05 0.02 83.0 
6a & 6b -6.41 0.00 81.7 6.38 0.01 83.2 -0.94 0.02 83.0 -0.28 0.03 83.6 
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 C.7.6 Random Selection with Replacement Multiple Times 
Scenario 
Binary Continuous 
Categorical 
(Dummy 1) 
Categorical 
(Dummy 2) 
Bias 
(%) 
MSE 
Coverage 
(%) 
Bias 
(%) 
MSE 
Coverage 
(%) 
Bias 
(%) 
MSE 
Coverage 
(%) 
Bias 
(%) 
MSE 
Coverage 
(%) 
1a & 1c -1.14 0.00 100 -0.49 0.00 100 -3.97 0.01 100 -3.00 0.02 100 
2a & 2b 0.30 0.01 100 1.45 0.01 100 -2.25 0.01 100 -2.90 0.02 100 
3a & 3b -2.22 0.00 100 -1.05 0.00 100 -2.41 0.01 100 -3.08 0.02 100 
4a & 4c -0.31 0.00 100 0.11 0.00 100 -0.44 0.02 100 -0.59 0.02 100 
5a & 5b -0.10 0.01 100 0.17 0.00 100 -0.29 0.02 100 -0.58 0.02 100 
6a & 6b 0.07 0.01 100 -0.25 0.00 100 0.71 0.02 100 -0.19 0.02 100 
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Appendix D – Further Results from Chapter 9 
Table 54: Seizure recurrence risk in the next 12 months estimated from multivariable model at specific time points of seizure freedom. Estimates presented assume seizures not confined 
to sleep and no first degree relative with epilepsy. MESS (EEG/CT as 2 categories) & FIRST (random selection) 
 MESS FIRST 
Variable  Immediate Treatment Delayed Treatment   
Aetiology EEG 
CT/MRI 
scan results 
Months 
from 
index 
seizure 
Risk of seizure 
within next 12 
months 
(%, 95% CI) 
Months from 
index seizure 
until annual 
risk falls 
below 20% 
Risk of seizure 
within next 12 
months 
(%, 95% CI) 
Months from 
index seizure 
until annual 
risk falls 
below 20% 
Risk of 
seizure 
within next 
12 months 
(%, 95% CI) 
Months from 
index seizure 
until annual 
risk falls 
below 20% 
Risk of 
seizure 
within next 
12 months 
(%, 95% CI) 
Months from 
index seizure 
until annual 
risk falls 
below 20% 
Not remote 
symptomatic 
Normal Normal 
6 
12 
13 (10 to 16) 
7 (4 to 10) 
1.2 
16 (13 to 19) 
9 (6 to 12) 
3.2 
7 (2, 11) 
4 (0, 9) 
0.0 
14 (9, 18) 
10 (5, 14) 
0.6 
Not remote 
symptomatic 
Abnormal Normal 
6 
12 
19 (16 to 22) 
11 (8 to 13) 
5.3 
23 (20 to 26) 
13 (10 to 16) 
6.8 
10 (5, 14) 
7 (2, 11) 
0.0 
20 (16, 24) 
14 (10, 18) 
4.5 
Not remote 
symptomatic 
Normal Abnormal 
6 
12 
13 (10 to 17) 
7 (5 to 10) 
1.2 
16 (13 to 19) 
9 (6 to 12) 
3.3 
8 (3, 13) 
5 (1, 10) 
0.0 
16 (12, 21) 
11 (7, 15) 
2.2 
Not remote 
symptomatic 
Abnormal Abnormal 
6 
12 
19 (16 to 22) 
11 (8 to 14) 
5.5 
23 (20 to 26) 
13 (11 to 16) 
6.9 
11 (7, 16) 
8 (4, 12) 
0.0 
23 (20, 27) 
17 (13, 20) 
7.4 
Remote 
symptomatic 
Normal Normal 
6 
12 
18 (14 to 21) 
10 (7 to 13) 
4.0 
21 (18 to 24) 
12 (9 to 15) 
6.1 
10 (5, 15) 
7 (3, 11) 
0.0 
21 (17, 25) 
15 (11, 19) 
6.1 
Remote 
symptomatic 
Abnormal Normal 
6 
12 
25 (22 to 28) 
14 (12 to 17) 
8.7 
30 (27 to 33) 
17 (15 to 20) 
10.7 
15 (10, 19) 
10 (6, 14) 
0.8 
30 (26, 33) 
21 (18, 25) 
11.0 
Remote 
symptomatic 
Normal Abnormal 
6 
12 
18 (15 to 21) 
10 (7 to 13) 
4.0 
21 (18 to 24) 
12 (9 to 15) 
6.3 
12 (7, 17) 
8 (4, 12) 
0.0 
25 (21, 29) 
17 (14, 21) 
9.9 
Remote 
symptomatic 
Abnormal Abnormal 
6 
12 
26 (23 to 28) 
15 (12 to 17) 
8.7 
30 (28 to 33) 
18 (15 to 20) 
10.7 
18 (13, 22) 
12 (8, 16) 
2.5 
35 (31, 38) 
25 (21, 28) 
16.0 
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Table 55: Seizure recurrence risk in the next 12 months estimated from multivariable model at specific time 
points of seizure freedom. Estimates presented assume seizures not confined to sleep and no first degree 
relative with epilepsy. FIRST (single imputation) 
Variable  Immediate Treatment Delayed Treatment 
Aetiology EEG CT/MRI 
Months 
from 
index 
seizure 
Risk of 
seizure within 
next 12 
months 
(%, 95% CI) 
Months 
from 
index 
seizure 
until 
annual 
risk falls 
below 
20% 
Risk of seizure 
within next 12 
months 
(%, 95% CI) 
Months 
from 
index 
seizure 
until 
annual 
risk falls 
below 
20% 
Not remote 
symptomatic 
Normal Normal 
6 
12 
6 (2, 11) 
4 (0, 9) 
0.0 
14 (9, 18) 
10 (5, 14) 
0.6 
Not remote 
symptomatic 
Abnormal Normal 
6 
12 
10 (5, 14) 
7 (2, 11) 
0.0 
20 (16, 24) 
14 (10, 18) 
4.5 
Not remote 
symptomatic 
Normal Abnormal 
6 
12 
8 (3, 13) 
5 (1, 10) 
0.0 
16 (12, 21) 
11 (7, 15) 
2.2 
Not remote 
symptomatic 
Abnormal Abnormal 
6 
12 
11 (7, 16) 
8 (4, 12) 
0.0 
23 (19, 27) 
16 (13, 20) 
7.4 
Remote 
symptomatic 
Normal Normal 
6 
12 
10 (6, 15) 
7 (3, 11) 
0.0 
21 (17, 25) 
15 (11, 19) 
6.1 
Remote 
symptomatic 
Abnormal Normal 
6 
12 
15 (11, 19) 
10 (6, 14) 
0.8 
30 (27, 34) 
22 (18, 25) 
12.4 
Remote 
symptomatic 
Normal Abnormal 
6 
12 
12 (8, 17) 
8 (4, 13) 
0.0 
25 (21, 29) 
18 (14, 21) 
9.9 
Remote 
symptomatic 
Abnormal Abnormal 
6 
12 
18 (13, 22) 
12 (8, 16) 
2.5 
35 (32, 38) 
25 (22, 29) 
16.0 
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Table 56: Seizure recurrence risk in the next 12 months estimated from multivariable model at specific time 
points of seizure freedom. Estimates presented assume seizures not confined to sleep and no first degree 
relative with epilepsy. FIRST (hot deck imputation) 
Variable  Immediate Treatment Delayed Treatment 
Aetiology EEG CT/MRI 
Months 
from 
index 
seizure 
Risk of seizure 
within next 12 
months 
(%, 95% CI) 
Months 
from 
index 
seizure 
until 
annual 
risk falls 
below 
20% 
Risk of seizure 
within next 12 
months 
(%, 95% CI) 
Months 
from 
index 
seizure 
until 
annual 
risk falls 
below 
20% 
Not remote 
symptomatic 
Normal Normal 
6 
12 
7 (2, 12) 
5 (1, 9) 
0.0 
14 (10, 19) 
10 (6, 14) 
0.6 
Not remote 
symptomatic 
Abnormal Normal 
6 
12 
11 (6, 15) 
8 (4, 12) 
0.0 
22 (18, 26) 
16 (12, 20) 
7.1 
Not remote 
symptomatic 
Normal Abnormal 
6 
12 
7 (3, 12) 
5 (1, 9) 
0.0 
15 (11, 20) 
11 (7, 15) 
1.6 
Not remote 
symptomatic 
Abnormal Abnormal 
6 
12 
12 (7, 16) 
8 (4, 12) 
0.0 
24 (20, 28) 
17 (14, 21) 
9.9 
Remote 
symptomatic 
Normal Normal 
6 
12 
11 (6, 16) 
8 (4, 12) 
0.0 
23 (19, 27) 
16 (13, 20) 
7.1 
Remote 
symptomatic 
Abnormal Normal 
6 
12 
18 (13, 22) 
13 (9, 16) 
2.5 
34 (31, 38) 
25 (22, 29) 
16.8 
Remote 
symptomatic 
Normal Abnormal 
6 
12 
12 (8, 17) 
9 (5, 13) 
0.0 
25 (21, 29) 
18 (14, 22) 
10.2 
Remote 
symptomatic 
Abnormal Abnormal 
6 
12 
19 (15, 23) 
14 (10, 18) 
4.0 
37 (34, 40) 
28 (24, 31) 
16.8 
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Table 57: Seizure recurrence risk in the next 12 months estimated from multivariable model at specific time 
points of seizure freedom. Estimates presented assume seizures not confined to sleep and no first degree 
relative with epilepsy. FIRST (multiple imputation) 
Variable  Immediate Treatment Delayed Treatment 
Aetiology EEG CT/MRI 
Months 
from 
index 
seizure 
Risk of 
seizure within 
next 12 
months 
(%, 95% CI) 
Months 
from 
index 
seizure 
until 
annual 
risk falls 
below 
20% 
Risk of seizure 
within next 12 
months 
(%, 95% CI) 
Months 
from 
index 
seizure 
until 
annual 
risk falls 
below 
20% 
Not remote 
symptomatic 
Normal Normal 
6 
12 
6 (2, 11) 
4 (0, 9) 
0.0 
14 (9, 18) 
10 (5, 14) 
0.5 
Not remote 
symptomatic 
Abnormal Normal 
6 
12 
10 (5, 14) 
7 (2, 11) 
0.0 
20 (16, 24) 
14 (10, 18) 
4.8 
Not remote 
symptomatic 
Normal Abnormal 
6 
12 
8 (3, 12) 
5 (1, 10) 
0.0 
16 (12, 20) 
11 (7, 15) 
2.0 
Not remote 
symptomatic 
Abnormal Abnormal 
6 
12 
11 (7, 16) 
8 (4, 12) 
0.0 
23 (19, 27) 
16 (13, 20) 
7.4 
Remote 
symptomatic 
Normal Normal 
6 
12 
10 (6, 15) 
7 (3, 11) 
0.0 
21 (17, 25) 
15 (11, 19) 
6.6 
Remote 
symptomatic 
Abnormal Normal 
6 
12 
15 (11, 19) 
10 (6, 14) 
1.1 
30 (27, 34) 
22 (18, 25) 
12.1 
Remote 
symptomatic 
Normal Abnormal 
6 
12 
12 (7, 17) 
8 (4, 13) 
0.0 
25 (21, 29) 
17 (14, 21) 
9.9 
Remote 
symptomatic 
Abnormal Abnormal 
6 
12 
18 (13, 22) 
12 (8, 16) 
2.6 
35 (31, 38) 
25 (22, 29) 
15.7 
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